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Overview {#bph13348-sec-0003}
========

G protein‐coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term \"7TM receptor\" is commonly used interchangeably with \"GPCR\", although there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular N‐terminus, an intracellular C‐terminus and seven hydrophobic transmembrane domains (TM1‐TM7) linked by three extracellular loops (ECL1‐ECL3) and three intracellular loops (ICL1‐ICL3). About 800 GPCRs have been identified in man, of which about half have sensory functions, mediating olfaction ( 400), taste (33), light perception (10) and pheromone signalling (5) \[[1309](http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus)\]. The remaining  350 non‐sensory GPCRs mediate intersignalling by ligands that range in size from small molecules to peptide to large proteins; they are the targets for the majority of drugs in clinical usage \[[1451](http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus), [1560](http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus)\], although only a minority of these receptors are exploited therapeutically. The first classification scheme to be proposed for GPCRs \[[984](http://www.ncbi.nlm.nih.gov/pubmed/8081729?dopt=AbstractPlus)\] divided them, on the basic of sequence homology, into six classes. These classes and their prototype members were as follows: **Class A**(rhodopsin‐like), **Class B** (secretin receptor family), **Class C** (metabotropic glutamate), **Class D**(fungal mating pheromone receptors), Class E (cyclic AMP receptors) and **Class F** (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classification scheme \"GRAFS\" \[[1666](http://www.ncbi.nlm.nih.gov/pubmed/15862553?dopt=AbstractPlus)\] divides vertebrate GPCRs into five classes, overlapping with the A‐F nomenclature, *viz*:

**Glutamate family (class C)**, which includes metabotropic glutamate receptors, a calcium‐sensing receptor and GABA~B~ receptors, as well as three taste type 1 receptors \[[class C list](http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=C)\] and a family of pheromone receptors (V2 receptors) that are abundant in rodents but absent in man \[[1309](http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus)\].

**Rhodopsin family (class A),** which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2 receptors and five pheromone receptors (V1 receptors). \[[Class A list](http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=A)\]

**Adhesion family** GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N‐termini that are autoproteolytically cleaved from their 7TM domains at a conserved \"GPCR proteolysis site\" (GPS) which lies within a much larger ( 320 residue) \"GPCR autoproteolysis‐inducing\" (GAIN) domain, an evolutionary ancient mofif also found in polycystic kidney disease 1 (PKD1)‐like proteins, which has been suggested to be both required and sufficient for autoproteolysis \[[1538](http://www.ncbi.nlm.nih.gov/pubmed/23850273?dopt=AbstractPlus)\]. \[[Adhesion family list](http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=Adhesion)\].

**Frizzled family (class F)** consists of 10 Frizzled proteins (FZD(1‐10)) and Smoothened (SMO). \[[Frizzled family list](http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=Frizzled)\]. The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).

**Secretin family (class B),** encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27‐141 amino‐acid residues; nine of the mammalian receptors respond to ligands that are structurally related to one another (glucagon, glucagon‐like peptides (GLP‐1, GLP‐2), glucose‐dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase‐activating polypeptide (PACAP) and growth‐hormone‐releasing hormone (GHRH) \[[703](http://www.ncbi.nlm.nih.gov/pubmed/11790261?dopt=AbstractPlus)\].

GPCR families {#bph13348-sec-0004}
=============

**FamilyClass AClass B (Secretin)Class C (Glutamate)AdhesionFrizzledReceptors with known ligands**197^a^1512011**Orphans**87 (54)^a^‐8 (1)^a^26 (6)^a^0**Sensory (olfaction)**390^b,c^‐‐‐‐**Sensory (vision)**10^d^ opsins‐‐‐‐**Sensory (taste)**30^c^ taste 2‐3^c^ taste 1‐‐**Sensory (pheromone)**5^c^ vomeronasal 1‐‐‐‐**Total**71915223311

^a^Numbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\]; ^b^\[[1443](http://www.ncbi.nlm.nih.gov/pubmed/19129093?dopt=AbstractPlus)\]; ^c^\[[1309](http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus)\]; ^d^\[[1866](http://www.ncbi.nlm.nih.gov/pubmed/15774036?dopt=AbstractPlus)\].

Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the *β* ~2~ adrenoceptor, the latter culminating in the award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka \[[975](http://www.ncbi.nlm.nih.gov/pubmed/23650120?dopt=AbstractPlus), [1073](http://www.ncbi.nlm.nih.gov/pubmed/23650015?dopt=AbstractPlus)\].

Family structure {#bph13348-sec-0005}
================

[5746 Orphan and other 7TM receptors](#bph13348-sec-0006){ref-type="sec"}

[5746 Class A Orphans](#bph13348-sec-0007){ref-type="sec"}

[5756 Class C Orphans](#bph13348-sec-0009){ref-type="sec"}

[5756 Taste 1 receptors](#bph13348-sec-0010){ref-type="sec"}

[5757 Taste 2 receptors](#bph13348-sec-0013){ref-type="sec"}

[5758 Other 7TM proteins](#bph13348-sec-0015){ref-type="sec"}

[5759 5‐Hydroxytryptamine receptors](#bph13348-sec-0016){ref-type="sec"}

[5764 Acetylcholine receptors (muscarinic)](#bph13348-sec-0020){ref-type="sec"}

[5766 Adenosine receptors](#bph13348-sec-0024){ref-type="sec"}

[5768 Adhesion Class GPCRs](#bph13348-sec-0028){ref-type="sec"}

[5770 Adrenoceptors](#bph13348-sec-0030){ref-type="sec"}

[5774 Angiotensin receptors](#bph13348-sec-0040){ref-type="sec"}

[5775 Apelin receptor](#bph13348-sec-0044){ref-type="sec"}

[5777 Bile acid receptor](#bph13348-sec-0048){ref-type="sec"}

[5778 Bombesin receptors](#bph13348-sec-0052){ref-type="sec"}

[5780 Bradykinin receptors](#bph13348-sec-0056){ref-type="sec"}

[5781 Calcitonin receptors](#bph13348-sec-0059){ref-type="sec"}

[5783 Calcium‐sensing receptors](#bph13348-sec-0063){ref-type="sec"}

[5784 Cannabinoid receptors](#bph13348-sec-0067){ref-type="sec"}

[5785 Chemerin receptor](#bph13348-sec-0071){ref-type="sec"}

[5785 Chemokine receptors](#bph13348-sec-0073){ref-type="sec"}

[5791 Cholecystokinin receptors](#bph13348-sec-0077){ref-type="sec"}

[5792 Class Frizzled GPCRs](#bph13348-sec-0081){ref-type="sec"}

[5793 Complement peptide receptors](#bph13348-sec-0085){ref-type="sec"}

[5795 Corticotropin‐releasing factor receptors](#bph13348-sec-0089){ref-type="sec"}

[5796 Dopamine receptors](#bph13348-sec-0093){ref-type="sec"}

[5798 Endothelin receptors](#bph13348-sec-0097){ref-type="sec"}

[5799 G protein‐coupled estrogen receptor](#bph13348-sec-0101){ref-type="sec"}

[5800 Formylpeptide receptors](#bph13348-sec-0105){ref-type="sec"}

[5801 Free fatty acid receptors](#bph13348-sec-0109){ref-type="sec"}

[5803 GABA~B~ receptors](#bph13348-sec-0113){ref-type="sec"}

[5805 Galanin receptors](#bph13348-sec-0118){ref-type="sec"}

[5806 Ghrelin receptor](#bph13348-sec-0122){ref-type="sec"}

[5807 Glucagon receptor family](#bph13348-sec-0126){ref-type="sec"}

[5809 Glycoprotein hormone receptors](#bph13348-sec-0130){ref-type="sec"}

[5810 Gonadotrophin‐releasing hormone receptors](#bph13348-sec-0133){ref-type="sec"}

[5811 GPR18, GPR55 and GPR119](#bph13348-sec-0137){ref-type="sec"}

[5812 Histamine receptors](#bph13348-sec-0141){ref-type="sec"}

[5814 Hydroxycarboxylic acid receptors](#bph13348-sec-0145){ref-type="sec"}

[5815 Kisspeptin receptor](#bph13348-sec-0149){ref-type="sec"}

[5816 Leukotriene receptors](#bph13348-sec-0152){ref-type="sec"}

[5818 Lysophospholipid (LPA) receptors](#bph13348-sec-0156){ref-type="sec"}

[5819 Lysophospholipid (S1P) receptors](#bph13348-sec-0160){ref-type="sec"}

[5820 Melanin‐concentrating hormone receptors](#bph13348-sec-0164){ref-type="sec"}

[5821 Melanocortin receptors](#bph13348-sec-0168){ref-type="sec"}

[5822 Melatonin receptors](#bph13348-sec-0172){ref-type="sec"}

[5823 Metabotropic glutamate receptors](#bph13348-sec-0176){ref-type="sec"}

[5826 Motilin receptor](#bph13348-sec-0180){ref-type="sec"}

[5827 Neuromedin U receptors](#bph13348-sec-0184){ref-type="sec"}

[5828 Neuropeptide FF/neuropeptide AF receptors](#bph13348-sec-0188){ref-type="sec"}

[5829 Neuropeptide S receptor](#bph13348-sec-0192){ref-type="sec"}

[5829 Neuropeptide W/neuropeptide B receptors](#bph13348-sec-0196){ref-type="sec"}

[5830 Neuropeptide Y receptors](#bph13348-sec-0200){ref-type="sec"}

[5832 Neurotensin receptors](#bph13348-sec-0204){ref-type="sec"}

[5833 Opioid receptors](#bph13348-sec-0208){ref-type="sec"}

[5835 Orexin receptors](#bph13348-sec-0212){ref-type="sec"}

[5836 Oxoglutarate receptor](#bph13348-sec-0216){ref-type="sec"}

[5836 P2Y receptors](#bph13348-sec-0218){ref-type="sec"}

[5838 Parathyroid hormone receptors](#bph13348-sec-0222){ref-type="sec"}

[5839 Platelet‐activating factor receptor](#bph13348-sec-0226){ref-type="sec"}

[5840 Prokineticin receptors](#bph13348-sec-0230){ref-type="sec"}

[5841 Prolactin‐releasing peptide receptor](#bph13348-sec-0234){ref-type="sec"}

[5842 Prostanoid receptors](#bph13348-sec-0238){ref-type="sec"}

[5844 Proteinase‐activated receptors](#bph13348-sec-0242){ref-type="sec"}

[5846 QRFP receptor](#bph13348-sec-0246){ref-type="sec"}

[5846 Relaxin family peptide receptors](#bph13348-sec-0250){ref-type="sec"}

[5848 Somatostatin receptors](#bph13348-sec-0254){ref-type="sec"}

[5850 Succinate receptor](#bph13348-sec-0258){ref-type="sec"}

[5850 Tachykinin receptors](#bph13348-sec-0260){ref-type="sec"}

[5852 Thyrotropin‐releasing hormone receptors](#bph13348-sec-0264){ref-type="sec"}

[5852 Trace amine receptor](#bph13348-sec-0267){ref-type="sec"}

[5854 Urotensin receptor](#bph13348-sec-0271){ref-type="sec"}

[5854 Vasopressin and oxytocin receptors](#bph13348-sec-0275){ref-type="sec"}

[5856 VIP and PACAP receptors](#bph13348-sec-0279){ref-type="sec"}

[Orphan and other 7TM receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115) {#bph13348-sec-0006}
===========================================================================================================

[Class A Orphans](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=16) {#bph13348-sec-0007}
===========================================================================================

Overview {#bph13348-sec-0008}
--------

Table [1](#bph13348-tbl-0001){ref-type="table-wrap"} lists a number of putative GPCRs identified by [NC‐IUPHAR]{.ul}\[[**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)\], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\]. The GPCRs in Table [1](#bph13348-tbl-0001){ref-type="table-wrap"} are all Class A, rhodopsin‐like GPCRs. Class A orphan GPCRs not listed in Table [1](#bph13348-tbl-0001){ref-type="table-wrap"} are putative GPCRs with as‐yet unidentified endogenous ligands.

###### 

Class A orphan GPCRs with putative endogenous ligands

  ----------- ----------- ---------- --------- --------- --------- --------- ----------
  *GPR1*      *GPR3*      *GPR4*     *GPR6*    *GPR12*   *GPR15*   *GPR17*   *GPR20*
  *GPR22*     *GPR26*     *GPR31*    *GPR34*   *GPR35*   *GPR37*   *GPR39*   *GPR50*
  *GPR63*     *GRP65*     *GPR68*    *GPR75*   *GPR84*   *GPR87*   *GPR88*   *GPR132*
  *GPR149*    *GPR161*    *GPR183*   *LGR4*    *LGR5*    *LGR6*    *MAS1*    *MRGPRD*
  *MRGPRX1*   *MRGPRX2*   *P2RY10*   *TAAR2*                                 
  ----------- ----------- ---------- --------- --------- --------- --------- ----------

In addition the orphan receptors [*GPR18*](http://www.guidetopharmacology.org/GRAC/#89), [*GPR55*](http://www.guidetopharmacology.org/GRAC/#109) and [*GPR119*](http://www.guidetopharmacology.org/GRAC/#126) which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together ([GPR18, GPR55 and GPR119](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114)).

Nomenclature[*GPR1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=82)[*GPR3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=83)[*GPR4*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=84)[*GPR6*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=85)HGNC, UniProt[*GPR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4463), [P46091](http://www.uniprot.org/uniprot/P46091)[*GPR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4484), [P46089](http://www.uniprot.org/uniprot/P46089)[*GPR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4497), [P46093](http://www.uniprot.org/uniprot/P46093)[*GPR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4515), [P46095](http://www.uniprot.org/uniprot/P46095)Endogenous ligand----Protons--Endogenous agonists[chemerin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2945) ([*RARRES2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9868), [Q99969](http://www.uniprot.org/uniprot/Q99969)) (p*K* ~d~ 8.3) \[[95](http://www.ncbi.nlm.nih.gov/pubmed/18165312?dopt=AbstractPlus)\]------Agonists--[diphenyleneiodonium chloride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7802) (pEC~50~ 6) \[[2091](http://www.ncbi.nlm.nih.gov/pubmed/24633425?dopt=AbstractPlus)\]----CommentsReported to act as a co‐receptor for HIV \[[1724](http://www.ncbi.nlm.nih.gov/pubmed/10233994?dopt=AbstractPlus)\]. See review \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] for discussion of pairing with chemerin.[sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) was reported to be an endogenous agonist \[[1921](http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus)\], but this finding was not replicated in subsequent studies \[[2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\]. Reported to activate adenylyl cyclase constitutively through G~s~ \[[466](http://www.ncbi.nlm.nih.gov/pubmed/7639700?dopt=AbstractPlus)\]. Gene disruption results in premature ovarian ageing \[[1063](http://www.ncbi.nlm.nih.gov/pubmed/15956199?dopt=AbstractPlus)\], reduced *β*‐amyloid deposition \[[1868](http://www.ncbi.nlm.nih.gov/pubmed/19213921?dopt=AbstractPlus)\] and hypersensitivity to thermal pain \[[1615](http://www.ncbi.nlm.nih.gov/pubmed/21352831?dopt=AbstractPlus)\] in mice. First small molecule inverse agonist \[[860](http://www.ncbi.nlm.nih.gov/pubmed/25442311?dopt=AbstractPlus)\] and agonists identified \[[2091](http://www.ncbi.nlm.nih.gov/pubmed/24633425?dopt=AbstractPlus)\].An initial report suggesting activation by [lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508) and [sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[2131](http://www.ncbi.nlm.nih.gov/pubmed/11535583?dopt=AbstractPlus)\] has been retracted \[[2148](http://www.ncbi.nlm.nih.gov/pubmed/16498716?dopt=AbstractPlus)\]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus), [1704](http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus)\]. Gene disruption is associated with increased perinatal mortality and impaired vascular proliferation \[[2085](http://www.ncbi.nlm.nih.gov/pubmed/17145776?dopt=AbstractPlus)\]. Negative allosteric modulators of GPR4 have been reported \[[1889](http://www.ncbi.nlm.nih.gov/pubmed/26070068?dopt=AbstractPlus)\].An initial report that [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) (S1P) was a high‐affinity ligand (EC~50~ value of 39nM) \[[815](http://www.ncbi.nlm.nih.gov/pubmed/14592418?dopt=AbstractPlus), [1921](http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus)\] was not repeated by arrestin PathHunter\[TM\] assays \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus), [2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\]. Reported to activate adenylyl cyclase constitutively through G~s~ and to be located intracellularly \[[1453](http://www.ncbi.nlm.nih.gov/pubmed/19059244?dopt=AbstractPlus)\]. GPR6‐deficient mice showed reduced striatal cyclic AMP production *in vitro* and selected alterations in instrumental conditioning *in vivo*. \[[1134](http://www.ncbi.nlm.nih.gov/pubmed/17934457?dopt=AbstractPlus)\].

Nomenclature[*GPR12*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=86)[*GPR15*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=87)[*GPR17*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=88)[*GPR19*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=90)HGNC, UniProt[*GPR12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4466), [P47775](http://www.uniprot.org/uniprot/P47775)[*GPR15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4469), [P49685](http://www.uniprot.org/uniprot/P49685)[*GPR17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4471), [Q13304](http://www.uniprot.org/uniprot/Q13304)[*GPR19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4473), [Q15760](http://www.uniprot.org/uniprot/Q15760)Endogenous agonists----[UDP‐glucose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783) (pEC~50~ 5.9--9.5) \[[130](http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus), [344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\], [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354) (pEC~50~ 7.8--9.5) \[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\], [UDP‐galactose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1782) (pEC~50~ 6--8.9) \[[130](http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus), [344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\], [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) (pEC~50~ 6--8.8) \[[130](http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus), [344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\], [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) (pEC~50~ 8.1--8.4) \[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\]--CommentsReports that [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) is a ligand of GPR12 \[[814](http://www.ncbi.nlm.nih.gov/pubmed/12574419?dopt=AbstractPlus), [1921](http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus)\] have not been replicated in arrestin‐based assays \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus), [2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\]. Gene disruption results in dyslipidemia and obesity \[[154](http://www.ncbi.nlm.nih.gov/pubmed/16887097?dopt=AbstractPlus)\].Reported to act as a co‐receptor for HIV \[[462](http://www.ncbi.nlm.nih.gov/pubmed/9405683?dopt=AbstractPlus)\]. In an infection‐induced colitis model, *Gpr15* knockout mice were more prone to tissue damage and inflammatory cytokine expression \[[945](http://www.ncbi.nlm.nih.gov/pubmed/23661644?dopt=AbstractPlus)\].Reported to be a dual leukotriene and [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) receptor \[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\]. Another group instead proposed that GPR17 functions as a negative regulator of the CysLT~1~ receptor response to leukotriene D~4~ ([LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)). For further discussion, see \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\]. Reported to antagonize CysLT~1~ receptor signalling *in vivo*and *in vitro* \[[1175](http://www.ncbi.nlm.nih.gov/pubmed/19561298?dopt=AbstractPlus)\]. See reviews \[[250](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus)\] and \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].--

Nomenclature[*GPR20*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=91)[*GPR21*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=92)[*GPR22*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=93)[*GPR25*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=95)[*GPR26*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=96)HGNC, UniProt[*GPR20*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4475), [Q99678](http://www.uniprot.org/uniprot/Q99678)[*GPR21*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4476), [Q99679](http://www.uniprot.org/uniprot/Q99679)[*GPR22*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4477), [Q99680](http://www.uniprot.org/uniprot/Q99680)[*GPR25*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4480), [O00155](http://www.uniprot.org/uniprot/O00155)[*GPR26*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4481), [Q8NDV2](http://www.uniprot.org/uniprot/Q8NDV2)CommentsReported to inhibit adenylyl cyclase constitutively through G~i/o~ \[[708](http://www.ncbi.nlm.nih.gov/pubmed/18347022?dopt=AbstractPlus)\]. GPR20 deficient mice exhibit hyperactivity characterised by increased total distance travelled in an open field test \[207\].*Gpr21* knockout mice were resistant to diet‐induced obesity, exhibiting an increase in glucose tolerance and insulin sensitivity, as well as a modest lean phenotype \[[1448](http://www.ncbi.nlm.nih.gov/pubmed/22653059?dopt=AbstractPlus)\].Gene disruption results in increased severity of functional decompensation following aortic banding \[[10](http://www.ncbi.nlm.nih.gov/pubmed/18539757?dopt=AbstractPlus)\]. Identified as a susceptibility locus for osteoarthritis \[[494](http://www.ncbi.nlm.nih.gov/pubmed/21068099?dopt=AbstractPlus), [929](http://www.ncbi.nlm.nih.gov/pubmed/20112360?dopt=AbstractPlus), [1935](http://www.ncbi.nlm.nih.gov/pubmed/20090528?dopt=AbstractPlus)\].--Has been reported to activate adenylyl cyclase constitutively through G~s~ \[[880](http://www.ncbi.nlm.nih.gov/pubmed/17363172?dopt=AbstractPlus)\]. *Gpr26* knockout mice show increased levels of anxiety and depression‐like behaviours \[[2117](http://www.ncbi.nlm.nih.gov/pubmed/21924326?dopt=AbstractPlus)\].

Nomenclature[*GPR27*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=97)[*GPR31*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=98)[*GPR32*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=99)[*GPR33*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=100)[*GPR34*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=101)HGNC, UniProt[*GPR27*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4482), [Q9NS67](http://www.uniprot.org/uniprot/Q9NS67)[*GPR31*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4486), [O00270](http://www.uniprot.org/uniprot/O00270)[*GPR32*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4487), [O75388](http://www.uniprot.org/uniprot/O75388)[*GPR33*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4489), [Q49SQ1](http://www.uniprot.org/uniprot/Q49SQ1)[*GPR34*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4490), [Q9UPC5](http://www.uniprot.org/uniprot/Q9UPC5)Rank order of potency----[resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934)\>[LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034)----Endogenous agonists--[12S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404) (Selective) (pEC~50~ 9.6) \[[665](http://www.ncbi.nlm.nih.gov/pubmed/21712392?dopt=AbstractPlus)\] -- Mouse[resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934) (pEC~50~ 11.1) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\], [LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) (pEC~50~ 9.7) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\]--[lysophosphatidylserine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4064) (Selective) (pEC~50~ 6.6--6.9) \[[960](http://www.ncbi.nlm.nih.gov/pubmed/22343749?dopt=AbstractPlus), [1817](http://www.ncbi.nlm.nih.gov/pubmed/16460680?dopt=AbstractPlus)\]Labelled ligands----[\[^3^H\]resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4356) (Agonist) (p*K* ~d~ 9.7) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\]----CommentsKnockdown of Gpr27 reduces endogenous mouse insulin promotor activity and glucose‐stimulated insulin secretion \[[1012](http://www.ncbi.nlm.nih.gov/pubmed/22253604?dopt=AbstractPlus)\].See \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] for discussion of pairing.[resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934) has been demonstrated to activate GPR32 in two publications \[[316](http://www.ncbi.nlm.nih.gov/pubmed/22538616?dopt=AbstractPlus), [1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\]. The pairing was not replicated in a recent study based on arrestin recruitment \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]. *GPR32* is a pseudogene in mice and rats. See reviews \[[250](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus)\] and \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].*GPR33* is a pseudogene in most individuals, containing a premature stop codon within the coding sequence of the second intracellular loop \[[1621](http://www.ncbi.nlm.nih.gov/pubmed/15987686?dopt=AbstractPlus)\].Lysophosphatidylserine has been reported to be a ligand of GPR34 in several publications, but the pairing was not replicated in a recent study based on arrestin recruitment \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]. Fails to respond to a variety of lipid‐derived agents \[[2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\]. Gene disruption results in an enhanced immune response \[[1102](http://www.ncbi.nlm.nih.gov/pubmed/21097509?dopt=AbstractPlus)\]. Characterization of agonists at this receptor is discussed in \[[819](http://www.ncbi.nlm.nih.gov/pubmed/25970039?dopt=AbstractPlus)\] and \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].

Nomenclature[*GPR35*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=102)[*GPR37*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=103)[*GPR37L1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=104)[*GPR39*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=105)[*GPR42*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=228)HGNC, UniProt[*GPR35*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4492), [Q9HC97](http://www.uniprot.org/uniprot/Q9HC97)[*GPR37*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4494), [O15354](http://www.uniprot.org/uniprot/O15354)[*GPR37L1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14923), [O60883](http://www.uniprot.org/uniprot/O60883)[*GPR39*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4496), [O43194](http://www.uniprot.org/uniprot/O43194)[*GPR42*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4500), [O15529](http://www.uniprot.org/uniprot/O15529)Endogenous agonists[2‐oleoyl‐LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2936) (pEC~50~ 7.3--7.5) \[[1436](http://www.ncbi.nlm.nih.gov/pubmed/20361937?dopt=AbstractPlus)\], [kynurenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2918) (pEC~50~ 3.9--4.4) \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus), [1980](http://www.ncbi.nlm.nih.gov/pubmed/16754668?dopt=AbstractPlus)\]----[Zn^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566) \[[775](http://www.ncbi.nlm.nih.gov/pubmed/16959833?dopt=AbstractPlus)\]--Agonists--[neuropeptide head activator](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2496) (pEC~50~ 8--8.5) \[[1578](http://www.ncbi.nlm.nih.gov/pubmed/16443751?dopt=AbstractPlus)\]--[compound 1 \[PMID: 24900608\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7800) (pEC~50~ 4.9--7.2) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/24900608?dopt=AbstractPlus)\]--CommentsSeveral studies have shown that kynurenic acid is an agonist of GPR35 but it remains controversial whether the proposed endogenous ligand reaches sufficient tissue concentrations to activate the receptor \[[1015](http://www.ncbi.nlm.nih.gov/pubmed/18235993?dopt=AbstractPlus)\]. [2‐oleoyl‐LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2936) has also been proposed as an endogenous ligand \[[1436](http://www.ncbi.nlm.nih.gov/pubmed/20361937?dopt=AbstractPlus)\] but these results were not replicated in an arrestin assay \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]. The phosphodiesterase inhibitor [zaprinast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919) \[[1863](http://www.ncbi.nlm.nih.gov/pubmed/16934253?dopt=AbstractPlus)\] has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signalling \[[1863](http://www.ncbi.nlm.nih.gov/pubmed/16934253?dopt=AbstractPlus)\]. GPR35 is also activated by the pharmaceutical adjunct [pamoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2920) \[[2124](http://www.ncbi.nlm.nih.gov/pubmed/20826425?dopt=AbstractPlus)\]. See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[429](http://www.ncbi.nlm.nih.gov/pubmed/25805994?dopt=AbstractPlus)\].Reported to associate and regulate the dopamine transporter \[[1207](http://www.ncbi.nlm.nih.gov/pubmed/17519329?dopt=AbstractPlus)\] and to be a substrate for parkin \[[1205](http://www.ncbi.nlm.nih.gov/pubmed/19398891?dopt=AbstractPlus)\]. Gene disruption results in altered striatal signalling \[[1206](http://www.ncbi.nlm.nih.gov/pubmed/21372109?dopt=AbstractPlus)\]. The peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 \[[1264](http://www.ncbi.nlm.nih.gov/pubmed/23690594?dopt=AbstractPlus)\].The peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 \[[1264](http://www.ncbi.nlm.nih.gov/pubmed/23690594?dopt=AbstractPlus)\].Zn^2+^ has been reported to be a potent and efficacious agonist of human, mouse and rat GPR39 \[[2089](http://www.ncbi.nlm.nih.gov/pubmed/17214962?dopt=AbstractPlus)\]. [obestatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5336) ([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)), a fragment from the ghrelin precursor, was reported initially as an endogenous ligand, but subsequent studies failed to reproduce these findings. *GPR39* has been reported to be down‐regulated in adipose tissue in obesity‐related diabetes \[[273](http://www.ncbi.nlm.nih.gov/pubmed/17371481?dopt=AbstractPlus)\]. Gene disruption results in obesity and altered adipocyte metabolism \[[1497](http://www.ncbi.nlm.nih.gov/pubmed/21784784?dopt=AbstractPlus)\]. Reviewed in \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].--

Nomenclature[*GPR45*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=106)[*GPR50*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=107)[*GPR52*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=108)[*GPR61*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=110)HGNC, UniProt[*GPR45*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4503), [Q9Y5Y3](http://www.uniprot.org/uniprot/Q9Y5Y3)[*GPR50*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4506), [Q13585](http://www.uniprot.org/uniprot/Q13585)[*GPR52*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4508), [Q9Y2T5](http://www.uniprot.org/uniprot/Q9Y2T5)[*GPR61*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13300), [Q9BZJ8](http://www.uniprot.org/uniprot/Q9BZJ8)Comments--GPR50 is structurally related to MT~1~ and MT~2~ melatonin receptors, with which it heterodimerises constitutively and specifically \[[1089](http://www.ncbi.nlm.nih.gov/pubmed/16778767?dopt=AbstractPlus)\]. *Gpr50* knockout mice display abnormal thermoregulation and are much more likely than wild‐type mice to enter fasting‐induced torpor \[[111](http://www.ncbi.nlm.nih.gov/pubmed/22197240?dopt=AbstractPlus)\].First small molecule agonist reported \[[1703](http://www.ncbi.nlm.nih.gov/pubmed/24884590?dopt=AbstractPlus)\].GPR61 deficient mice exhibit obesity associated with hyperphagia \[[1363](http://www.ncbi.nlm.nih.gov/pubmed/21971119?dopt=AbstractPlus)\]. Although no endogenous ligands have been identified, 5‐(nonyloxy)tryptamine has been reported to be a low affinity inverse agonist \[[1852](http://www.ncbi.nlm.nih.gov/pubmed/15173198?dopt=AbstractPlus)\].

Nomenclature[*GPR62*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=111)[*GPR63*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=112)[*GPR65*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=113)[*GPR68*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=114)[*GPR75*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=115)HGNC, UniProt[*GPR62*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13301), [Q9BZJ7](http://www.uniprot.org/uniprot/Q9BZJ7)[*GPR63*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13302), [Q9BZJ6](http://www.uniprot.org/uniprot/Q9BZJ6)[*GPR65*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4517), [Q8IYL9](http://www.uniprot.org/uniprot/Q8IYL9)[*GPR68*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4519), [Q15743](http://www.uniprot.org/uniprot/Q15743)[*GPR75*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4526), [O95800](http://www.uniprot.org/uniprot/O95800)Endogenous ligand----ProtonsProtons--Comments--[sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) and [dioleoylphosphatidic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5512) have been reported to be low affinity agonists for GPR63 \[[1394](http://www.ncbi.nlm.nih.gov/pubmed/12618218?dopt=AbstractPlus)\] but this finding was not replicated in an arrestin‐based assay \[[2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\].GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus), [1704](http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus)\]. Reported to activate adenylyl cyclase; gene disruption leads to reduced eosinophilia in models of allergic airway disease \[[1000](http://www.ncbi.nlm.nih.gov/pubmed/19641187?dopt=AbstractPlus)\].GPR68 was previously identified as a receptor for [sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) (SPC) \[[2068](http://www.ncbi.nlm.nih.gov/pubmed/10806476?dopt=AbstractPlus)\], but the original publication has been retracted \[[2067](http://www.ncbi.nlm.nih.gov/pubmed/16508674?dopt=AbstractPlus)\]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus), [1704](http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus)\]. A family of 3,5‐disubstituted isoxazoles were identified as agonists of GPR68 \[[1617](http://www.ncbi.nlm.nih.gov/pubmed/22462679?dopt=AbstractPlus)\].[CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)) was reported to be an agonist of GPR75 \[[816](http://www.ncbi.nlm.nih.gov/pubmed/17001303?dopt=AbstractPlus)\], but the pairing could not be repeated in an arrestin assay \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\].

Nomenclature[*GPR78*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=116)[*GPR79*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=117)[*GPR82*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=118)[*GPR83*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=119)[*GPR84*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=120)HGNC, UniProt[*GPR78*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4528), [Q96P69](http://www.uniprot.org/uniprot/Q96P69)[*GPR79*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4529), --[*GPR82*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4533), [Q96P67](http://www.uniprot.org/uniprot/Q96P67)[*GPR83*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4523), [Q9NYM4](http://www.uniprot.org/uniprot/Q9NYM4)[*GPR84*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4535), [Q9NQS5](http://www.uniprot.org/uniprot/Q9NQS5)Agonists------[Zn^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566) (pEC~50~ 5) \[[1351](http://www.ncbi.nlm.nih.gov/pubmed/23335960?dopt=AbstractPlus)\] -- Mouse[decanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5532) (pEC~50~ 5--5.4) \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus), [1981](http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus)\], [undecanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5533) (pEC~50~ 5.1) \[[1981](http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus)\], [lauric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534) (pEC~50~ 5) \[[1981](http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus)\]CommentsGPR78 has been reported to be constitutively active, coupled to elevated cAMP production \[[880](http://www.ncbi.nlm.nih.gov/pubmed/17363172?dopt=AbstractPlus)\].--Mice with *Gpr82* knockout have a lower body weight and body fat content associated with reduced food intake, decreased serum triglyceride levels, as well as higher insulin sensitivity and glucose tolerance \[[479](http://www.ncbi.nlm.nih.gov/pubmed/22216272?dopt=AbstractPlus)\].One isoform has been implicated in the induction of CD4(+) CD25(+) regulatory T cells (Tregs) during inflammatory immune responses \[[696](http://www.ncbi.nlm.nih.gov/pubmed/20200545?dopt=AbstractPlus)\]. The extracellular N‐terminal domain is reported as an intramolecular inverse agonist \[[1352](http://www.ncbi.nlm.nih.gov/pubmed/25516095?dopt=AbstractPlus)\].Medium chain free fatty acids with carbon chain lengths of 9‐14 activate GPR84 \[[1828](http://www.ncbi.nlm.nih.gov/pubmed/23449982?dopt=AbstractPlus), [1981](http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus)\]. A surrogate ligand for GPR84, [6‐n‐octylaminouracil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5846) has also been proposed \[[1828](http://www.ncbi.nlm.nih.gov/pubmed/23449982?dopt=AbstractPlus)\]. See review \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] for discussion of classification. Mutational analysis and molecular modelling of GPR84 has been reported \[[1397](http://www.ncbi.nlm.nih.gov/pubmed/25425658?dopt=AbstractPlus)\].

Nomenclature[*GPR85*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=121)[*GPR87*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=122)[*GPR88*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=123)[*GPR101*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=125)HGNC, UniProt[*GPR85*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4536), [P60893](http://www.uniprot.org/uniprot/P60893)[*GPR87*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4538), [Q9BY21](http://www.uniprot.org/uniprot/Q9BY21)[*GPR88*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4539), [Q9GZN0](http://www.uniprot.org/uniprot/Q9GZN0)[*GPR101*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14963), [Q96P66](http://www.uniprot.org/uniprot/Q96P66)Endogenous agonists--[LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906) (pEC~50~ 7.4) \[[1344](http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus), [1836](http://www.ncbi.nlm.nih.gov/pubmed/17905198?dopt=AbstractPlus)\]----Agonists----[compound 2 \[PMID: 24793972\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7798) (pEC~50~ 6.2) \[[868](http://www.ncbi.nlm.nih.gov/pubmed/24793972?dopt=AbstractPlus)\]--CommentsProposed to regulate hippocampal neurogenesis in the adult, as well as neurogenesis‐dependent learning and memory \[[303](http://www.ncbi.nlm.nih.gov/pubmed/22697179?dopt=AbstractPlus)\].--Gene disruption results in altered striatal signalling \[[1137](http://www.ncbi.nlm.nih.gov/pubmed/19796684?dopt=AbstractPlus)\]. Small molecule agonists have been reported \[[147](http://www.ncbi.nlm.nih.gov/pubmed/25754495?dopt=AbstractPlus)\].Mutations in GPR101 have been linked to gigantism and acromegaly \[[1906](http://www.ncbi.nlm.nih.gov/pubmed/25470569?dopt=AbstractPlus)\].

Nomenclature[*GPR132*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=128)[*GPR135*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=129)[*GPR139*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=130)[*GPR141*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=131)[*GPR142*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=132)HGNC, UniProt[*GPR132*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17482), [Q9UNW8](http://www.uniprot.org/uniprot/Q9UNW8)[*GPR135*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19991), [Q8IZ08](http://www.uniprot.org/uniprot/Q8IZ08)[*GPR139*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19995), [Q6DWJ6](http://www.uniprot.org/uniprot/Q6DWJ6)[*GPR141*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19997), [Q7Z602](http://www.uniprot.org/uniprot/Q7Z602)[*GPR142*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20088), [Q7Z601](http://www.uniprot.org/uniprot/Q7Z601)Endogenous ligandProtons--------Agonists----[compound 1a \[PMID: 24900311\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7799) (pEC~50~ 7.4) \[[1721](http://www.ncbi.nlm.nih.gov/pubmed/24900311?dopt=AbstractPlus)\]----CommentsGPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus), [1704](http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus)\]. Reported to respond to [lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508) \[[891](http://www.ncbi.nlm.nih.gov/pubmed/11474113?dopt=AbstractPlus)\], but later retracted \[[2038](http://www.ncbi.nlm.nih.gov/pubmed/15653487?dopt=AbstractPlus)\].--Peptide agonists have been reported \[[828](http://www.ncbi.nlm.nih.gov/pubmed/24826842?dopt=AbstractPlus)\].--Small molecule agonists have been reported \[[1890](http://www.ncbi.nlm.nih.gov/pubmed/24900747?dopt=AbstractPlus), [2106](http://www.ncbi.nlm.nih.gov/pubmed/24900757?dopt=AbstractPlus)\].

Nomenclature[*GPR146*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=133)[*GPR148*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=134)[*GPR149*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=135)[*GPR150*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=136)[*GPR151*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=137)HGNC, UniProt[*GPR146*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21718), [Q96CH1](http://www.uniprot.org/uniprot/Q96CH1)[*GPR148*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23623), [Q8TDV2](http://www.uniprot.org/uniprot/Q8TDV2)[*GPR149*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23627), [Q86SP6](http://www.uniprot.org/uniprot/Q86SP6)[*GPR150*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23628), [Q8NGU9](http://www.uniprot.org/uniprot/Q8NGU9)[*GPR151*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23624), [Q8TDV0](http://www.uniprot.org/uniprot/Q8TDV0)CommentsYosten *et al*. demonstrated inhibition of [proinsulin C‐peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6145) ([*INS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6081), [P01308](http://www.uniprot.org/uniprot/P01308))‐induced stimulation of cFos expression folllowing knockdown of GPR146 in KATO III cells, suggesting proinsulin C‐peptide as an endogenous ligand of the receptor \[[2103](http://www.ncbi.nlm.nih.gov/pubmed/23759446?dopt=AbstractPlus)\].--*Gpr149* knockout mice displayed increased fertility and enhanced ovulation, with increased levels of FSH receptor and cyclin D2 mRNA levels \[[463](http://www.ncbi.nlm.nih.gov/pubmed/19887567?dopt=AbstractPlus)\].--GPR151 responded to galanin with an EC~50~ value of 2 *μ*M, suggesting that the endogenous ligand shares structural features with [galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592) ([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) \[[813](http://www.ncbi.nlm.nih.gov/pubmed/15111018?dopt=AbstractPlus)\].

Nomenclature[*GPR152*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=138)[*GPR153*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=139)[*GPR160*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=140)[*GPR161*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=141)[*GPR162*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=142)HGNC, UniProt[*GPR152*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23622), [Q8TDT2](http://www.uniprot.org/uniprot/Q8TDT2)[*GPR153*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23618), [Q6NV75](http://www.uniprot.org/uniprot/Q6NV75)[*GPR160*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23693), [Q9UJ42](http://www.uniprot.org/uniprot/Q9UJ42)[*GPR161*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23694), [Q8N6U8](http://www.uniprot.org/uniprot/Q8N6U8)[*GPR162*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16693), [Q16538](http://www.uniprot.org/uniprot/Q16538)Comments------A C‐terminal truncation (deletion) mutation in Gpr161 causes congenital cataracts and neural tube defects in the vacuolated lens (vl) mouse mutant \[[1226](http://www.ncbi.nlm.nih.gov/pubmed/18250320?dopt=AbstractPlus)\]. The mutated receptor is associated with cataract, spina bifida and white belly spot phenotypes in mice \[[994](http://www.ncbi.nlm.nih.gov/pubmed/18796533?dopt=AbstractPlus)\]. Gene disruption is associated with a failure of asymmetric embryonic development in zebrafish \[[1085](http://www.ncbi.nlm.nih.gov/pubmed/18755178?dopt=AbstractPlus)\].--

Nomenclature[*GPR171*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=143)[*GPR173*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=144)[*GPR174*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=145)[*GPR176*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=637)[*GPR182*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=146)HGNC, UniProt[*GPR171*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30057), [O14626](http://www.uniprot.org/uniprot/O14626)[*GPR173*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18186), [Q9NS66](http://www.uniprot.org/uniprot/Q9NS66)[*GPR174*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30245), [Q9BXC1](http://www.uniprot.org/uniprot/Q9BXC1)[*GPR176*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32370), [Q14439](http://www.uniprot.org/uniprot/Q14439)[*GPR182*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13708), [O15218](http://www.uniprot.org/uniprot/O15218)Endogenous agonists----[lysophosphatidylserine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4064) (pEC~50~ 7.1) \[[825](http://www.ncbi.nlm.nih.gov/pubmed/22983457?dopt=AbstractPlus)\]----CommentsGPR171 has been shown to be activated by the endogenous peptide [BigLEN](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6704) {Mouse}. This receptor‐peptide interaction is believed to be involved in regulating feeding and metabolism responses \[[621](http://www.ncbi.nlm.nih.gov/pubmed/24043826?dopt=AbstractPlus)\].--See \[[819](http://www.ncbi.nlm.nih.gov/pubmed/25970039?dopt=AbstractPlus)\] which discusses characterization of agonists at this receptor.--Rat GPR182 was first proposed as the adrenomedullin receptor \[[904](http://www.ncbi.nlm.nih.gov/pubmed/7592696?dopt=AbstractPlus)\]. However, it was later reported that rat and human GPR182 did not respond to adrenomedullin \[[927](http://www.ncbi.nlm.nih.gov/pubmed/9535752?dopt=AbstractPlus)\] and GPR182 is not currently considered to be a genuine adrenomedullin receptor \[[722](http://www.ncbi.nlm.nih.gov/pubmed/21051558?dopt=AbstractPlus)\].

Nomenclature[*GPR183*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=81)[*LGR4*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=147)[*LGR5*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=148)[*LGR6*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=149)[*MAS1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=150)HGNC, UniProt[*GPR183*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3128), [P32249](http://www.uniprot.org/uniprot/P32249)[*LGR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13299), [Q9BXB1](http://www.uniprot.org/uniprot/Q9BXB1)[*LGR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4504), [O75473](http://www.uniprot.org/uniprot/O75473)[*LGR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19719), [Q9HBX8](http://www.uniprot.org/uniprot/Q9HBX8)[*MAS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6899), [P04201](http://www.uniprot.org/uniprot/P04201)Endogenous agonists[7*α*,25‐dihydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4350) (Selective) (pEC~50~ 8.1--9.8) \[[694](http://www.ncbi.nlm.nih.gov/pubmed/21796212?dopt=AbstractPlus), [1125](http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus)\], [7*α*,27‐dihydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4353) (Selective) (pEC~50~ 8.9) \[[1125](http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus)\], [7*β*, 25‐dihydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4355) (Selective) (pEC~50~ 8.7) \[[1125](http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus)\], [7*β*, 27‐dihydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4354) (Selective) (pEC~50~ 7.3) \[[1125](http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus)\][R‐spondin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698) ([*RSPO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28583), [Q6UXX9](http://www.uniprot.org/uniprot/Q6UXX9)) (pEC~50~ 12.5) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697) ([*RSPO1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21679), [Q2MKA7](http://www.uniprot.org/uniprot/Q2MKA7)) (pEC~50~ 10.7) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699) ([*RSPO3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20866), [Q9BXY4](http://www.uniprot.org/uniprot/Q9BXY4)) (pEC~50~ 10.7) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700) ([*RSPO4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16175), [Q2I0M5](http://www.uniprot.org/uniprot/Q2I0M5)) (pEC~50~ 10.1) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\][R‐spondin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698) ([*RSPO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28583), [Q6UXX9](http://www.uniprot.org/uniprot/Q6UXX9)) (pEC~50~ 12) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697) ([*RSPO1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21679), [Q2MKA7](http://www.uniprot.org/uniprot/Q2MKA7)) (pEC~50~ 11.1) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699) ([*RSPO3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20866), [Q9BXY4](http://www.uniprot.org/uniprot/Q9BXY4)) (pEC~50~ 11) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\], [R‐spondin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700) ([*RSPO4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16175), [Q2I0M5](http://www.uniprot.org/uniprot/Q2I0M5)) (pEC~50~ 9.4) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus)\][R‐spondin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697) ([*RSPO1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21679), [Q2MKA7](http://www.uniprot.org/uniprot/Q2MKA7)) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\], [R‐spondin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698) ([*RSPO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28583), [Q6UXX9](http://www.uniprot.org/uniprot/Q6UXX9)) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\], [R‐spondin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699) ([*RSPO3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20866), [Q9BXY4](http://www.uniprot.org/uniprot/Q9BXY4)) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\], [R‐spondin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700) ([*RSPO4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16175), [Q2I0M5](http://www.uniprot.org/uniprot/Q2I0M5)) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\]--Agonists--------[angiotensin‐(1‐7)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) (p*K* ~i~ 7.3) \[[612](http://www.ncbi.nlm.nih.gov/pubmed/21670420?dopt=AbstractPlus)\] -- MouseCommentsTwo independent publications have shown that [7*α*,25‐dihydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4350) is an agonist of GPR183 and have demonstrated by mass spectrometry that this oxysterol is present endogenously in tissues \[[694](http://www.ncbi.nlm.nih.gov/pubmed/21796212?dopt=AbstractPlus), [1125](http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus)\]. Gpr183‐deficient mice show a reduction in the early antibody response to a T‐dependent antigen. GPR183‐deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre \[[923](http://www.ncbi.nlm.nih.gov/pubmed/21844396?dopt=AbstractPlus), [1488](http://www.ncbi.nlm.nih.gov/pubmed/19597478?dopt=AbstractPlus)\].LGR4 does not couple to heterotrimeric G proteins or recruit arrestins when stimulated by the R‐spondins, indicating a unique mechanism of action. R‐spondins bind to LGR4, which specifically associates with Frizzled and LDL receptor‐related proteins (LRPs) that are activated by the extracellular Wnt molecules and then trigger canonical Wnt signalling to increase gene expression \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [1612](http://www.ncbi.nlm.nih.gov/pubmed/22815884?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\]. Gene disruption leads to multiple developmental disorders \[[869](http://www.ncbi.nlm.nih.gov/pubmed/18487371?dopt=AbstractPlus), [1154](http://www.ncbi.nlm.nih.gov/pubmed/19605502?dopt=AbstractPlus), [1781](http://www.ncbi.nlm.nih.gov/pubmed/18955481?dopt=AbstractPlus), [2005](http://www.ncbi.nlm.nih.gov/pubmed/18424556?dopt=AbstractPlus)\].The four R‐spondins can bind to LGR4, LGR5, and LGR6, which specifically associate with Frizzled and LDL receptor‐related proteins (LRPs), proteins that are activated by extracellular Wnt molecules and which then trigger canonical Wnt signalling to increase gene expression \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus), [2140](http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus)\].----

Nomenclature[*MAS1L*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=151)[*MRGPRD*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=152)[*MRGPRE*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=153)[*MRGPRF*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=154)[*MRGPRG*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=155)HGNC, UniProt[*MAS1L*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13961), [P35410](http://www.uniprot.org/uniprot/P35410)[*MRGPRD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29626), [Q8TDS7](http://www.uniprot.org/uniprot/Q8TDS7)[*MRGPRE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30694), [Q86SM8](http://www.uniprot.org/uniprot/Q86SM8)[*MRGPRF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24828), [Q96AM1](http://www.uniprot.org/uniprot/Q96AM1)[*MRGPRG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24829), [Q86SM5](http://www.uniprot.org/uniprot/Q86SM5)Endogenous agonists--[*β*‐alanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365) (pEC~50~ 4.8) \[[1729](http://www.ncbi.nlm.nih.gov/pubmed/15037633?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]------Comments--An endogenous peptide with a high degree of sequence similarity to [angiotensin‐(1‐7)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)), [alamandine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6065) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333)), was shown to promote NO release in MRGPRD‐transfected cells. The binding of alamandine to MRGPRD to was shown to be blocked by D‐Pro^7^‐angiotensin‐(1‐7), [*β*‐alanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365) and [PD123319](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=597) \[[1045](http://www.ncbi.nlm.nih.gov/pubmed/23446738?dopt=AbstractPlus)\]. Genetic ablation of MRGPRD+ neurons of adult mice decreased behavioural sensitivity to mechanical stimuli but not to thermal stimuli \[[278](http://www.ncbi.nlm.nih.gov/pubmed/19451647?dopt=AbstractPlus)\]. See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].MRGPRF has been reported to respond to stimulation by angiotensin metabolites \[[589](http://www.ncbi.nlm.nih.gov/pubmed/18636314?dopt=AbstractPlus)\]. See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].

Nomenclature[*MRGPRX1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=156)[*MRGPRX2*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=157)[*MRGPRX3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=158)[*MRGPRX4*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=159)HGNC, UniProt[*MRGPRX1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17962), [Q96LB2](http://www.uniprot.org/uniprot/Q96LB2)[*MRGPRX2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17983), [Q96LB1](http://www.uniprot.org/uniprot/Q96LB1)[*MRGPRX3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17980), [Q96LB0](http://www.uniprot.org/uniprot/Q96LB0)[*MRGPRX4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17617), [Q96LA9](http://www.uniprot.org/uniprot/Q96LA9)Endogenous agonists[bovine adrenal medulla peptide 8‐22](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4058) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)) (Selective) (pEC~50~ 5.3--7.8) \[[299](http://www.ncbi.nlm.nih.gov/pubmed/15163697?dopt=AbstractPlus), [1080](http://www.ncbi.nlm.nih.gov/pubmed/11850634?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\][PAMP‐20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4057) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) (Selective) \[[899](http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus)\]----Agonists--[cortistatin‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2007) {Mouse, Rat} (pEC~50~ 6.9--7.6) \[[899](http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus), [1594](http://www.ncbi.nlm.nih.gov/pubmed/12915402?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]----Selective agonists--[PAMP‐12 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4056) (pEC~50~ 7.2--7.7) \[[899](http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus)\]----CommentsReported to mediate the sensation of itch \[[1131](http://www.ncbi.nlm.nih.gov/pubmed/20004959?dopt=AbstractPlus), [1739](http://www.ncbi.nlm.nih.gov/pubmed/21593341?dopt=AbstractPlus)\]. Reports that [bovine adrenal medulla peptide 8‐22](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4058) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)) was the most potent of a series of proenkephalin A‐derived peptides as an agonist of MRGPRX1 in assays of calcium mobilisation and radioligand binding \[[1080](http://www.ncbi.nlm.nih.gov/pubmed/11850634?dopt=AbstractPlus)\] were replicated in an independent study using an arrestin recruitment assay \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]. See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].A diverse range of substances has been reported to be agonists of MRGPRX2, with cortistatin 14 the highest potency agonist in assays of calcium mobilisation \[[1594](http://www.ncbi.nlm.nih.gov/pubmed/12915402?dopt=AbstractPlus)\], also confirmed in an independent study using an arrestin recruitment assay \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]. See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].--See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1779](http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus)\].

Nomenclature[*OPN3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=160)[*OPN4*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2758)[*OPN5*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=161)[*P2RY8*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=164)HGNC, UniProt[*OPN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14007), [Q9H1Y3](http://www.uniprot.org/uniprot/Q9H1Y3)[*OPN4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14449), [Q9UHM6](http://www.uniprot.org/uniprot/Q9UHM6)[*OPN5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19992), [Q6U736](http://www.uniprot.org/uniprot/Q6U736)[*P2RY8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15524), [Q86VZ1](http://www.uniprot.org/uniprot/Q86VZ1)Comments----Evidence indicates OPN5 triggers a UV‐sensitive G~i~‐mediated signalling pathway in mammalian tissues \[[982](http://www.ncbi.nlm.nih.gov/pubmed/22043319?dopt=AbstractPlus)\].--

Nomenclature[*P2RY10*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=165)[*TAAR2*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=167)[*TAAR3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=168)[*TAAR4P*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=169)HGNC, UniProt[*P2RY10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19906), [O00398](http://www.uniprot.org/uniprot/O00398)[*TAAR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4514), [Q9P1P5](http://www.uniprot.org/uniprot/Q9P1P5)[*TAAR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4513), [Q9P1P4](http://www.uniprot.org/uniprot/Q9P1P4)[*TAAR4P*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=31924), --Rank order of potency--[*β*‐phenylethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144)\>[tryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125) \[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\]----Endogenous agonists[sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) (Selective) (pEC~50~ 7.3) \[[1344](http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus)\], [LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906) (Selective) (pEC~50~ 6.9) \[[1344](http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus)\]------Comments--Probable pseudogene in 10‐15% of Asians due to a polymorphism (rs8192646) producing a premature stop codon at amino acid 168 \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].*TAAR3* is thought to be a pseudogene in man though functional in rodents \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].Pseudogene in man but functional in rodents \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\].

Nomenclature[*TAAR5*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=170)[*TAAR6*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=171)[*TAAR8*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=172)[*TAAR9*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=173)HGNC, UniProt[*TAAR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30236), [O14804](http://www.uniprot.org/uniprot/O14804)[*TAAR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20978), [Q96RI8](http://www.uniprot.org/uniprot/Q96RI8)[*TAAR8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14964), [Q969N4](http://www.uniprot.org/uniprot/Q969N4)[*TAAR9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20977), [Q96RI9](http://www.uniprot.org/uniprot/Q96RI9)CommentsTrimethylamine is reported as an agonist \[[1974](http://www.ncbi.nlm.nih.gov/pubmed/23393561?dopt=AbstractPlus)\] and 3‐iodothyronamine an inverse agonist \[[426](http://www.ncbi.nlm.nih.gov/pubmed/25706283?dopt=AbstractPlus)\].----*TAAR9* appears to be functional in most individuals but has a polymorphic premature stop codon at amino acid 61 (rs2842899) with an allele frequency of 10‐30% in different populations \[[1944](http://www.ncbi.nlm.nih.gov/pubmed/14559210?dopt=AbstractPlus)\].

[Class C Orphans](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=18) {#bph13348-sec-0009}
===========================================================================================

Nomenclature[*GPR156*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=209)[*GPR158*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=210)[*GPR179*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=211)[*GPRC5A*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=258)[*GPRC5B*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=259)[*GPRC5C*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=260)[*GPRC5D*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=261)HGNC, UniProt[*GPR156*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20844), [Q8NFN8](http://www.uniprot.org/uniprot/Q8NFN8)[*GPR158*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23689), [Q5T848](http://www.uniprot.org/uniprot/Q5T848)[*GPR179*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=31371), [Q6PRD1](http://www.uniprot.org/uniprot/Q6PRD1)[*GPRC5A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9836), [Q8NFJ5](http://www.uniprot.org/uniprot/Q8NFJ5)[*GPRC5B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13308), [Q9NZH0](http://www.uniprot.org/uniprot/Q9NZH0)[*GPRC5C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13309), [Q9NQ84](http://www.uniprot.org/uniprot/Q9NQ84)[*GPRC5D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13310), [Q9NZD1](http://www.uniprot.org/uniprot/Q9NZD1)

[Taste 1 receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=116) {#bph13348-sec-0010}
==============================================================================================

Overview {#bph13348-sec-0011}
--------

Whilst the taste of acid and salty foods appear to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R and T2R, which are similar in sequence and structure to Class C and Class A GPCR, respectively. Activation of taste receptors appears to involve gustducin‐ (G*α*t3) and G*α*14‐mediated signalling, although the precise mechanisms remain obscure. Gene disruption studies suggest the involvement of PLC*β*2 \[[2122](http://www.ncbi.nlm.nih.gov/pubmed/12581520?dopt=AbstractPlus)\], TRPM5 \[[2122](http://www.ncbi.nlm.nih.gov/pubmed/12581520?dopt=AbstractPlus)\] and IP3 \[[764](http://www.ncbi.nlm.nih.gov/pubmed/17925404?dopt=AbstractPlus)\] receptors in post‐receptor signalling of taste receptors. Although predominantly associated with the oral cavity, taste receptors are also located elsewhere, including further down the gastrointestinal system, in the lungs and in the brain.

[**Sweet/Umami**]{.ul} {#bph13348-sec-0012}
----------------------

T1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3 heterodimers respond to [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369) and may be positively allosterically modulated by 5\'‐nucleoside monophosphates, such as [5\'‐GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5123)\[[1096](http://www.ncbi.nlm.nih.gov/pubmed/12013525?dopt=AbstractPlus)\]. T1R2/T1R3 heterodimers respond to sugars, such as [sucrose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5411), and artificial sweeteners, such as [saccharin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5432)\[[1376](http://www.ncbi.nlm.nih.gov/pubmed/11509186?dopt=AbstractPlus)\].

Nomenclature[*TAS1R1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=656)[*TAS1R2*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=657)[*TAS1R3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=658)HGNC, UniProt[*TAS1R1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14448), [Q7RTX1](http://www.uniprot.org/uniprot/Q7RTX1)[*TAS1R2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14905), [Q8TE23](http://www.uniprot.org/uniprot/Q8TE23)[*TAS1R3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15661), [Q7RTX0](http://www.uniprot.org/uniprot/Q7RTX0)

[Taste 2 receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=117) {#bph13348-sec-0013}
==============================================================================================

[**Bitter**]{.ul} {#bph13348-sec-0014}
-----------------

The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand specificity or much broader responsiveness. For example, T2R5 responded to [cycloheximide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5433), but not 10 other bitter compounds \[[287](http://www.ncbi.nlm.nih.gov/pubmed/10761935?dopt=AbstractPlus)\], while T2R14 responded to at least eight different bitter tastants, including [(‐)‐*α*‐thujone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5344) and [picrotoxinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291)\[[119](http://www.ncbi.nlm.nih.gov/pubmed/15178431?dopt=AbstractPlus)\].

Specialist database [BitterDB](http://bitterdb.agri.huji.ac.il/dbbitter.php) contains additional information on bitter compounds and receptors \[[2023](http://www.ncbi.nlm.nih.gov/pubmed/21940398?dopt=AbstractPlus)\].

Nomenclature[*TAS2R1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=659)[*TAS2R3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=660)[*TAS2R4*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=661)[*TAS2R5*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=662)[*TAS2R7*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=663)[*TAS2R8*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=664)HGNC, UniProt[*TAS2R1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14909), [Q9NYW7](http://www.uniprot.org/uniprot/Q9NYW7)[*TAS2R3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14910), [Q9NYW6](http://www.uniprot.org/uniprot/Q9NYW6)[*TAS2R4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14911), [Q9NYW5](http://www.uniprot.org/uniprot/Q9NYW5)[*TAS2R5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14912), [Q9NYW4](http://www.uniprot.org/uniprot/Q9NYW4)[*TAS2R7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14913), [Q9NYW3](http://www.uniprot.org/uniprot/Q9NYW3)[*TAS2R8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14915), [Q9NYW2](http://www.uniprot.org/uniprot/Q9NYW2)

Nomenclature[*TAS2R9*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=665)[*TAS2R10*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=666)[*TAS2R13*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=667)[*TAS2R14*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=668)[*TAS2R16*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=669)[*TAS2R19*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=670)HGNC, UniProt[*TAS2R9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14917), [Q9NYW1](http://www.uniprot.org/uniprot/Q9NYW1)[*TAS2R10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14918), [Q9NYW0](http://www.uniprot.org/uniprot/Q9NYW0)[*TAS2R13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14919), [Q9NYV9](http://www.uniprot.org/uniprot/Q9NYV9)[*TAS2R14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14920), [Q9NYV8](http://www.uniprot.org/uniprot/Q9NYV8)[*TAS2R16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14921), [Q9NYV7](http://www.uniprot.org/uniprot/Q9NYV7)[*TAS2R19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19108), [P59542](http://www.uniprot.org/uniprot/P59542)

Nomenclature[*TAS2R20*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=671)[*TAS2R30*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=673)[*TAS2R31*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=674)[*TAS2R38*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=682)[*TAS2R39*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=675)[*TAS2R40*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=676)HGNC, UniProt[*TAS2R20*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19109), [P59543](http://www.uniprot.org/uniprot/P59543)[*TAS2R30*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19112), [P59541](http://www.uniprot.org/uniprot/P59541)[*TAS2R31*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19113), [P59538](http://www.uniprot.org/uniprot/P59538)[*TAS2R38*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9584), [P59533](http://www.uniprot.org/uniprot/P59533)[*TAS2R39*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18886), [P59534](http://www.uniprot.org/uniprot/P59534)[*TAS2R40*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18885), [P59535](http://www.uniprot.org/uniprot/P59535)

Nomenclature[*TAS2R41*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=680)[*TAS2R42*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=672)[*TAS2R43*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=678)[*TAS2R45*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2828)[*TAS2R46*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=679)[*TAS2R50*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=677)[*TAS2R60*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=681)HGNC, UniProt[*TAS2R41*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18883), [P59536](http://www.uniprot.org/uniprot/P59536)[*TAS2R42*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18888), [Q7RTR8](http://www.uniprot.org/uniprot/Q7RTR8)[*TAS2R43*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18875), [P59537](http://www.uniprot.org/uniprot/P59537)[*TAS2R45*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18876), [P59539](http://www.uniprot.org/uniprot/P59539)[*TAS2R46*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18877), [P59540](http://www.uniprot.org/uniprot/P59540)[*TAS2R50*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18882), [P59544](http://www.uniprot.org/uniprot/P59544)[*TAS2R60*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20639), [P59551](http://www.uniprot.org/uniprot/P59551)

[Other 7TM proteins](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=113) {#bph13348-sec-0015}
===============================================================================================

Nomenclature[*GPR107*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=651)[*GPR137*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=652)[*OR51E1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=653)[*TPRA1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=655)[*GPR143*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=203)[*GPR157*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=205)HGNC, UniProt[*GPR107*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17830), [Q5VW38](http://www.uniprot.org/uniprot/Q5VW38)[*GPR137*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24300), [Q96N19](http://www.uniprot.org/uniprot/Q96N19)[*OR51E1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15194), [Q8TCB6](http://www.uniprot.org/uniprot/Q8TCB6)[*TPRA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30413), [Q86W33](http://www.uniprot.org/uniprot/Q86W33)[*GPR143*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20145), [P51810](http://www.uniprot.org/uniprot/P51810)[*GPR157*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23687), [Q5UAW9](http://www.uniprot.org/uniprot/Q5UAW9)Endogenous agonists--------[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639) \[[1141](http://www.ncbi.nlm.nih.gov/pubmed/18828673?dopt=AbstractPlus)\]--CommentsGPR107 is a member of the LUSTR family of proteins found in both plants and animals, having similar topology to Gprotein‐coupled receptors \[[461](http://www.ncbi.nlm.nih.gov/pubmed/17454009?dopt=AbstractPlus)\]--OR51E1 is a putative olfactory receptor.TPRA1 shows no homology to known G protein‐coupled receptors.Loss‐of‐function mutations underlie ocular albinism type 1 \[[103](http://www.ncbi.nlm.nih.gov/pubmed/7647783?dopt=AbstractPlus)\].GPR157 has ambiguous sequence similarities to several different GPCR families (class A, class B and the slime mould cyclic AMP receptor). Because of its distant relationship to other GPCRs, it cannot be readily classified.

[5‐Hydroxytryptamine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1) {#bph13348-sec-0016}
========================================================================================================

Overview {#bph13348-sec-0017}
--------

5‐HT receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on 5‐HT receptors \[** [**789**](http://www.ncbi.nlm.nih.gov/pubmed/7938165?dopt=AbstractPlus) **\] and subsequently revised \[** [**707**](http://www.ncbi.nlm.nih.gov/pubmed/8936345?dopt=AbstractPlus) **\]**) are, with the exception of the ionotropic 5‐HT~3~ class, GPCR receptors where the endogenous agonist is [5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5). The diversity of metabotropic 5‐HT receptors is increased by alternative splicing that produces isoforms of the 5‐HT~2A~ (non‐functional), 5‐HT~2C~ (non‐functional), 5‐HT~4~, 5‐HT~6~ (non‐functional) and 5‐HT~7~ receptors. Unique amongst the GPCRs, RNA editing produces 5‐HT~2C~ receptor isoforms that differ in function, such as efficiency and specificity of coupling to G~q/11~ and also pharmacology \[[164](http://www.ncbi.nlm.nih.gov/pubmed/16896947?dopt=AbstractPlus), [2011](http://www.ncbi.nlm.nih.gov/pubmed/18554725?dopt=AbstractPlus)\]. Most 5‐HT receptors (except 5‐ht ~1e~ and 5‐ht ~5a/5b~) play specific roles mediating functional responses in different tissues (reviewed by \[[1554](http://www.ncbi.nlm.nih.gov/pubmed/19086344?dopt=AbstractPlus), [1957](http://www.ncbi.nlm.nih.gov/pubmed/17703282?dopt=AbstractPlus)\].

Nomenclature[5‐HT~1A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1)[5‐HT~1B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2)[5‐HT~1D~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3)[5‐ht~1e~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=4)[5‐HT~1F~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=5)HGNC, UniProt[*HTR1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5286), [P08908](http://www.uniprot.org/uniprot/P08908)[*HTR1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5287), [P28222](http://www.uniprot.org/uniprot/P28222)[*HTR1D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5289), [P28221](http://www.uniprot.org/uniprot/P28221)[*HTR1E*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5291), [P28566](http://www.uniprot.org/uniprot/P28566)[*HTR1F*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5292), [P30939](http://www.uniprot.org/uniprot/P30939)Agonists[U92016A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=30) (p*K* ~i~ 9.7) \[[1240](http://www.ncbi.nlm.nih.gov/pubmed/7965808?dopt=AbstractPlus)\], [vilazodone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427) (Partial agonist) (p*K* ~i~ 9.7) \[[402](http://www.ncbi.nlm.nih.gov/pubmed/19499624?dopt=AbstractPlus)\], [vortioxetine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351) (Partial agonist) (p*K* ~i~ 7.8) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus)\][L‐694,247](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15) (p*K* ~i~ 9.2) \[[637](http://www.ncbi.nlm.nih.gov/pubmed/10513577?dopt=AbstractPlus)\], [naratriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=45) (Partial agonist) (p*K* ~i~ 8.1) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [eletriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40) (p*K* ~i~ 8) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [frovatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7191) (p*K* ~i~ 8) \[[2069](http://www.ncbi.nlm.nih.gov/pubmed/9986723?dopt=AbstractPlus)\], [zolmitriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=60) (Partial agonist) (p*K* ~i~ 7.7) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [vortioxetine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351) (Partial agonist) (p*K* ~i~ 7.5) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus)\], [rizatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51) (Partial agonist) (p*K* ~i~ 6.9) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\][dihydroergotamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121) (p*K* ~i~ 9.2--9.9) \[[684](http://www.ncbi.nlm.nih.gov/pubmed/1652050?dopt=AbstractPlus), [1084](http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus), [1091](http://www.ncbi.nlm.nih.gov/pubmed/8967979?dopt=AbstractPlus)\], [ergotamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149) (p*K* ~i~ 9.1) \[[616](http://www.ncbi.nlm.nih.gov/pubmed/10715164?dopt=AbstractPlus)\], [L‐694,247](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15) (p*K* ~i~ 9) \[[2052](http://www.ncbi.nlm.nih.gov/pubmed/9855638?dopt=AbstractPlus)\], [naratriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=45) (p*K* ~i~ 8.4--9) \[[432](http://www.ncbi.nlm.nih.gov/pubmed/9303569?dopt=AbstractPlus), [1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus), [1577](http://www.ncbi.nlm.nih.gov/pubmed/7780656?dopt=AbstractPlus)\], [zolmitriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=60) (p*K* ~i~ 8.9) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [frovatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7191) (p*K* ~i~ 8.4) \[[2069](http://www.ncbi.nlm.nih.gov/pubmed/9986723?dopt=AbstractPlus)\], [rizatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51) (p*K* ~i~ 7.9) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\][BRL‐54443](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927) (p*K* ~i~ 8.7) \[227\][BRL‐54443](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927) (p*K* ~i~ 8.9) \[227\], [eletriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40) (p*K* ~i~ 8) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [sumatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54) (p*K* ~i~ 7.2--7.9) \[[11](http://www.ncbi.nlm.nih.gov/pubmed/9225282?dopt=AbstractPlus), [12](http://www.ncbi.nlm.nih.gov/pubmed/8380639?dopt=AbstractPlus), [1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus), [1968](http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus)\]Selective agonists[8‐OH‐DPAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7) (p*K* ~i~ 8.4--9.4) \[[406](http://www.ncbi.nlm.nih.gov/pubmed/9495870?dopt=AbstractPlus), [685](http://www.ncbi.nlm.nih.gov/pubmed/12527336?dopt=AbstractPlus), [896](http://www.ncbi.nlm.nih.gov/pubmed/15628665?dopt=AbstractPlus), [1079](http://www.ncbi.nlm.nih.gov/pubmed/9067310?dopt=AbstractPlus), [1280](http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus), [1386](http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus), [1388](http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus), [1389](http://www.ncbi.nlm.nih.gov/pubmed/1386736?dopt=AbstractPlus)\], [NLX‐101](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3924) (p*K* ~i~ 8.6) \[[1387](http://www.ncbi.nlm.nih.gov/pubmed/19154445?dopt=AbstractPlus)\][CP94253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3221) (p*K* ~i~ 8.7) \[976\][PNU109291](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3228) (p*K* ~i~ 9.1) \[[483](http://www.ncbi.nlm.nih.gov/pubmed/9632349?dopt=AbstractPlus)\] -- Gorilla, [eletriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40) (p*K* ~i~ 8.9) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\]--[lasmiditan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3928) (p*K* ~i~ 8.7) \[[1375](http://www.ncbi.nlm.nih.gov/pubmed/20855361?dopt=AbstractPlus)\], [LY334370](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=20) (p*K* ~i~ 8.7) \[[1968](http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus)\], [5‐BODMT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8422) (p*K* ~i~ 8.4) \[[966](http://www.ncbi.nlm.nih.gov/pubmed/21422162?dopt=AbstractPlus)\], [LY344864](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21) (p*K* ~i~ 8.2) \[[1502](http://www.ncbi.nlm.nih.gov/pubmed/9395253?dopt=AbstractPlus)\]Antagonists[(S)‐UH 301](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=61) (p*K* ~i~ 7.9) \[[1386](http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus)\]--------Selective antagonists[WAY‐100635](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=80) (p*K* ~i~ 7.9--9.2) \[[1386](http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus), [1388](http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus)\], [robalzotan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=72) (p*K* ~i~ 9.2) \[[872](http://www.ncbi.nlm.nih.gov/pubmed/9336327?dopt=AbstractPlus)\][SB 224289](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=130) (Inverse agonist) (p*K* ~i~ 8.2--8.6) \[[583](http://www.ncbi.nlm.nih.gov/pubmed/9548813?dopt=AbstractPlus), [1384](http://www.ncbi.nlm.nih.gov/pubmed/11040052?dopt=AbstractPlus), [1696](http://www.ncbi.nlm.nih.gov/pubmed/9776361?dopt=AbstractPlus)\], [SB236057](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3231) (Inverse agonist) (p*K* ~i~ 8.2) \[[1272](http://www.ncbi.nlm.nih.gov/pubmed/10443589?dopt=AbstractPlus)\], [GR‐55562](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=113) (p*K* ~B~ 7.4) \[[791](http://www.ncbi.nlm.nih.gov/pubmed/11888546?dopt=AbstractPlus)\][SB 714786](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=77) (p*K* ~i~ 9.1) \[[1987](http://www.ncbi.nlm.nih.gov/pubmed/15887956?dopt=AbstractPlus)\]----Nomenclature[5‐HT~1A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1)[5‐HT~1B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2)[5‐HT~1D~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3)[5‐ht~1e~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=4)[5‐HT~1F~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=5)Labelled ligands[\[^3^H\]robalzotan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=82) (Antagonist) (p*K* ~d~ 9.8) \[[861](http://www.ncbi.nlm.nih.gov/pubmed/9851589?dopt=AbstractPlus)\], [\[^3^H\]WAY100635](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3251) (Antagonist) (p*K* ~d~ 9.5) \[[933](http://www.ncbi.nlm.nih.gov/pubmed/9048968?dopt=AbstractPlus)\], [\[^3^H\]8‐OH‐DPAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=31) (Agonist) (p*K* ~d~ 6--9.4) \[[156](http://www.ncbi.nlm.nih.gov/pubmed/11101361?dopt=AbstractPlus), [896](http://www.ncbi.nlm.nih.gov/pubmed/15628665?dopt=AbstractPlus), [1385](http://www.ncbi.nlm.nih.gov/pubmed/10431754?dopt=AbstractPlus), [1388](http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus)\], [\[^3^H\]NLX‐112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3925) (Agonist) (p*K* ~d~ 8.9) \[[748](http://www.ncbi.nlm.nih.gov/pubmed/20799027?dopt=AbstractPlus)\], [\[^11^C\]WAY100635](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3252) (Antagonist) \[[1915](http://www.ncbi.nlm.nih.gov/pubmed/15689356?dopt=AbstractPlus)\], [p‐\[^18^F\]MPPF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3227) (Antagonist) \[[368](http://www.ncbi.nlm.nih.gov/pubmed/16330560?dopt=AbstractPlus)\][\[^3^H\]N‐methyl‐AZ10419369](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3219) (Agonist, Partial agonist) (p*K* ~d~ 9.4) \[[1182](http://www.ncbi.nlm.nih.gov/pubmed/19401496?dopt=AbstractPlus)\], [\[^3^H\]GR 125,743](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=131) (Selective Antagonist) (p*K* ~d~ 8.6--9.2) \[[637](http://www.ncbi.nlm.nih.gov/pubmed/10513577?dopt=AbstractPlus), [2061](http://www.ncbi.nlm.nih.gov/pubmed/10452531?dopt=AbstractPlus)\], [\[^3^H\]alniditan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=117) (Agonist) (p*K* ~d~ 8.6--9) \[[1084](http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus)\], [\[^125^I\]GTI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3250) (Agonist) (p*K* ~d~ 8.9) \[[193](http://www.ncbi.nlm.nih.gov/pubmed/1738002?dopt=AbstractPlus), [232](http://www.ncbi.nlm.nih.gov/pubmed/8361548?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]eletriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=118) (Agonist, Partial agonist) (p*K* ~d~ 8.5) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [\[^3^H\]sumatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=119) (Agonist, Partial agonist) (p*K* ~d~ 8) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [\[^11^C\]AZ10419369](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3926) (Agonist, Partial agonist) \[[1950](http://www.ncbi.nlm.nih.gov/pubmed/20424633?dopt=AbstractPlus)\][\[^3^H\]eletriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=118) (Agonist) (p*K* ~d~ 9.1) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\], [\[^3^H\]alniditan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=117) (Agonist) (p*K* ~d~ 8.8--8.9) \[[1084](http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus)\], [\[^125^I\]GTI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3250) (Selective Agonist) (p*K* ~d~ 8.9) \[[193](http://www.ncbi.nlm.nih.gov/pubmed/1738002?dopt=AbstractPlus), [232](http://www.ncbi.nlm.nih.gov/pubmed/8361548?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]GR 125,743](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=131) (Selective Antagonist) (p*K* ~d~ 8.6) \[[2061](http://www.ncbi.nlm.nih.gov/pubmed/10452531?dopt=AbstractPlus)\], [\[^3^H\]sumatriptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=119) (Agonist) (p*K* ~d~ 8.2) \[[1365](http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus)\][\[^3^H\]5‐HT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248) (Agonist) (p*K* ~d~ 8.1--8.2) \[[1237](http://www.ncbi.nlm.nih.gov/pubmed/1608964?dopt=AbstractPlus), [1463](http://www.ncbi.nlm.nih.gov/pubmed/8863519?dopt=AbstractPlus)\][\[^3^H\]LY334370](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=151) (Agonist) (p*K* ~d~ 9.4) \[[1968](http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus)\], [\[^125^I\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261) (Agonist) (p*K* ~d~ 9) \[[44](http://www.ncbi.nlm.nih.gov/pubmed/1328180?dopt=AbstractPlus)\] -- MouseComments--Wang *et al*. (2013) report X‐ray structures which reveal the binding modality of [ergotamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149) and [dihydroergotamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121) to the 5‐HT~1B~ receptor in comparison with the structure of the 5‐HT~2B~ receptor \[[1978](http://www.ncbi.nlm.nih.gov/pubmed/23519210?dopt=AbstractPlus)\].------

Nomenclature[5‐HT~2A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=6)[5‐HT~2B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7)[5‐HT~2C~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8)[5‐HT~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9)HGNC, UniProt[*HTR2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5293), [P28223](http://www.uniprot.org/uniprot/P28223)[*HTR2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5294), [P41595](http://www.uniprot.org/uniprot/P41595)[*HTR2C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5295), [P28335](http://www.uniprot.org/uniprot/P28335)[*HTR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5299), [Q13639](http://www.uniprot.org/uniprot/Q13639)Agonists[DOI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147) (p*K* ~i~ 7.4--9.2) \[[204](http://www.ncbi.nlm.nih.gov/pubmed/2233697?dopt=AbstractPlus), [1374](http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus), [1755](http://www.ncbi.nlm.nih.gov/pubmed/8534270?dopt=AbstractPlus)\][methysergide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134) (Partial agonist) (p*K* ~i~ 8--9.4) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1605](http://www.ncbi.nlm.nih.gov/pubmed/11104741?dopt=AbstractPlus), [1969](http://www.ncbi.nlm.nih.gov/pubmed/9459568?dopt=AbstractPlus)\], [DOI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147) (p*K* ~i~ 7.6--7.7) \[[1025](http://www.ncbi.nlm.nih.gov/pubmed/8078486?dopt=AbstractPlus), [1374](http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus), [1659](http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus)\][DOI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147) (p*K* ~i~ 7.2--8.6) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10611640?dopt=AbstractPlus), [1374](http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus), [1659](http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus)\], [Ro 60‐0175](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166) (p*K* ~i~ 7.7--8.2) \[[953](http://www.ncbi.nlm.nih.gov/pubmed/14709324?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\][cisapride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=240) (Partial agonist) (p*K* ~i~ 6.4--7.4) \[[77](http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus), [128](http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus), [597](http://www.ncbi.nlm.nih.gov/pubmed/7796807?dopt=AbstractPlus), [1266](http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus), [1267](http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus), [1941](http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus)\]Selective agonists--[BW723C86](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=161) (p*K* ~i~ 7.3--8.6) \[[108](http://www.ncbi.nlm.nih.gov/pubmed/15466450?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1659](http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus)\], [Ro 60‐0175](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166) (p*K* ~i~ 8.3) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\][WAY‐163909](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=229) (p*K* ~i~ 6.7--8) \[[454](http://www.ncbi.nlm.nih.gov/pubmed/15705738?dopt=AbstractPlus)\], [lorcaserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2941) (p*K* ~i~ 7.8) \[[1878](http://www.ncbi.nlm.nih.gov/pubmed/18252809?dopt=AbstractPlus)\][TD‐8954](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8426) (p*K* ~i~ 9.4) \[[1250](http://www.ncbi.nlm.nih.gov/pubmed/23756062?dopt=AbstractPlus)\], [ML 10302](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=235) (Partial agonist) (p*K* ~i~ 7.9--9) \[[136](http://www.ncbi.nlm.nih.gov/pubmed/12801225?dopt=AbstractPlus), [160](http://www.ncbi.nlm.nih.gov/pubmed/9603189?dopt=AbstractPlus), [1266](http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus), [1267](http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus), [1268](http://www.ncbi.nlm.nih.gov/pubmed/10821780?dopt=AbstractPlus)\], [RS67506](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3230) (pEC~50~ 8.8) \[[731](http://www.ncbi.nlm.nih.gov/pubmed/8903510?dopt=AbstractPlus)\] -- Rat, [relenopride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8427) (Partial agonist) (p*K* ~i~ 8.3) \[[607](http://www.ncbi.nlm.nih.gov/pubmed/25316608?dopt=AbstractPlus)\], [velusetrag](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8425) (p*K* ~i~ 7.7) \[[1139](http://www.ncbi.nlm.nih.gov/pubmed/22959244?dopt=AbstractPlus), [1763](http://www.ncbi.nlm.nih.gov/pubmed/18415081?dopt=AbstractPlus)\], [BIMU 8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=234) (p*K* ~i~ 7.3) \[[347](http://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus)\]Antagonists[risperidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96) (Inverse agonist) (p*K* ~i~ 9.3--10) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus)\], [mianserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135) (p*K* ~i~ 7.7--9.6) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1001](http://www.ncbi.nlm.nih.gov/pubmed/15107597?dopt=AbstractPlus), [1280](http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus)\], [ziprasidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59) (p*K* ~i~ 8.8--9.5) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus)\], [volinanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=185) (pIC~50~ 6.5--9.3) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1142](http://www.ncbi.nlm.nih.gov/pubmed/11562430?dopt=AbstractPlus), [1568](http://www.ncbi.nlm.nih.gov/pubmed/10188965?dopt=AbstractPlus)\], [blonanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670) (p*K* ~i~ 9.1) \[[1421](http://www.ncbi.nlm.nih.gov/pubmed/15686911?dopt=AbstractPlus)\], [clozapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38) (Inverse agonist) (p*K* ~i~ 7.6--9) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1277](http://www.ncbi.nlm.nih.gov/pubmed/9732398?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), [1943](http://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus)\], [olanzapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47) (p*K* ~i~ 8.6--8.9) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus)\], [nefazodone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7247) (p*K* ~i~ 8.2) \[[1698](http://www.ncbi.nlm.nih.gov/pubmed/21823597?dopt=AbstractPlus)\], [chlorpromazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=83) (Inverse agonist) (p*K* ~i~ 8.1) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [loxapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205) (Inverse agonist) (p*K* ~i~ 8.1) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [trifluoperazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214) (p*K* ~i~ 7.9) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [pimozide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90) (p*K* ~i~ 7.1--7.7) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [trazodone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=213) (p*K* ~i~ 7.4) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [haloperidol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86) (p*K* ~i~ 6.7--7.3) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1277](http://www.ncbi.nlm.nih.gov/pubmed/9732398?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus), [1943](http://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus)\], [mesoridazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7227) (p*K* ~i~ 7.3) \[[326](http://www.ncbi.nlm.nih.gov/pubmed/15357957?dopt=AbstractPlus)\], [mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241) (p*K* ~i~ 7.2) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus)\], [mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241) (p*K* ~i~ 7.2) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus)\], [quetiapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50) (p*K* ~i~ 6.4--7) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [molindone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=207) (p*K* ~i~ 6.5) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\][mianserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135) (p*K* ~i~ 7.9--8.8) \[[180](http://www.ncbi.nlm.nih.gov/pubmed/10455251?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1969](http://www.ncbi.nlm.nih.gov/pubmed/9459568?dopt=AbstractPlus)\][mianserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135) (Inverse agonist) (p*K* ~i~ 8.3--9.2) \[[524](http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1280](http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus)\], [methysergide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134) (p*K* ~i~ 8.6--9.1) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10611640?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [ziprasidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59) (Inverse agonist) (p*K* ~i~ 7.9--9) \[[743](http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus)\], [olanzapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47) (Inverse agonist) (p*K* ~i~ 8.1--8.4) \[[743](http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus)\], [loxapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205) (Inverse agonist) (p*K* ~i~ 7.8--8) \[[743](http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241) (p*K* ~i~ 7.4) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus)\], [mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241) (p*K* ~i~ 7.4) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus)\], [trazodone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=213) (p*K* ~i~ 6.6) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [trifluoperazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214) (p*K* ~i~ 6.4) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus)\], [agomelatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198) (p*K* ~i~ 6.2) \[[1276](http://www.ncbi.nlm.nih.gov/pubmed/12750432?dopt=AbstractPlus)\]--Selective antagonists[ketanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88) (p*K* ~i~ 8.1--9.7) \[[234](http://www.ncbi.nlm.nih.gov/pubmed/8845011?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1559](http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus)\], [pimavanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8423) (Inverse agonist) (p*K* ~i~ 9.3) \[[572](http://www.ncbi.nlm.nih.gov/pubmed/17519387?dopt=AbstractPlus), [1943](http://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus)\][BF‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8424) (p*K* ~i~ 10.1) \[[1671](http://www.ncbi.nlm.nih.gov/pubmed/25666387?dopt=AbstractPlus)\], [RS‐127445](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=188) (p*K* ~i~ 9--9.5) \[[180](http://www.ncbi.nlm.nih.gov/pubmed/10455251?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [EGIS‐7625](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=176) (p*K* ~i~ 9) \[[1001](http://www.ncbi.nlm.nih.gov/pubmed/15107597?dopt=AbstractPlus)\][FR260010](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3223) (p*K* ~i~ 9) \[[700](http://www.ncbi.nlm.nih.gov/pubmed/17074317?dopt=AbstractPlus)\], [SB 242084](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=193) (p*K* ~i~ 8.2--9) \[[928](http://www.ncbi.nlm.nih.gov/pubmed/9225286?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [RS‐102221](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=187) (p*K* ~i~ 8.3--8.4) \[[181](http://www.ncbi.nlm.nih.gov/pubmed/9225287?dopt=AbstractPlus), [970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\][RS 100235](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=250) (p*K* ~i~ 8.7--12.2) \[[347](http://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus), [1589](http://www.ncbi.nlm.nih.gov/pubmed/15351779?dopt=AbstractPlus)\], [SB 204070](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=256) (p*K* ~i~ 9.8--10.4) \[[128](http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus), [1266](http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus), [1267](http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus), [1941](http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus)\], [GR 113808](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=247) (p*K* ~i~ 9.3--10.3) \[[77](http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus), [128](http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus), [160](http://www.ncbi.nlm.nih.gov/pubmed/9603189?dopt=AbstractPlus), [347](http://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus), [1267](http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus), [1589](http://www.ncbi.nlm.nih.gov/pubmed/15351779?dopt=AbstractPlus), [1941](http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]fananserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3229) (Antagonist) (p*K* ~d~ 9.9) \[[1188](http://www.ncbi.nlm.nih.gov/pubmed/8472747?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]ketanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=197) (Antagonist) (p*K* ~d~ 8.6--9.7) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus), [1559](http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus)\], [\[^11^C\]volinanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3249) (Antagonist) \[[676](http://www.ncbi.nlm.nih.gov/pubmed/11044889?dopt=AbstractPlus)\], [\[^18^F\]altanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3242) (Antagonist) \[[1601](http://www.ncbi.nlm.nih.gov/pubmed/9027929?dopt=AbstractPlus)\][\[^3^H\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219) (Agonist) (p*K* ~d~ 8.7) \[[1559](http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus)\], [\[^3^H\]5‐HT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248) (Agonist) (p*K* ~d~ 8.1) \[[1967](http://www.ncbi.nlm.nih.gov/pubmed/8450835?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]mesulergine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=232) (Antagonist, Inverse agonist) (p*K* ~d~ 7.9) \[[970](http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus)\], [\[^125^I\]DOI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=169) (Agonist) (p*K* ~d~ 7.7--7.6)[\[^125^I\]DOI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=169) (Agonist) (p*K* ~d~ 8.7--9) \[[524](http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus)\], [\[^3^H\]mesulergine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=232) (Antagonist, Inverse agonist) (p*K* ~d~ 9.3--8.7) \[[524](http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus), [1559](http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus)\], [\[^3^H\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219) (Agonist)[\[^123^I\]SB 207710](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3243) (Antagonist) (p*K* ~d~ 10.1) \[228\] -- Pig, [\[^3^H\]GR 113808](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=259) (Antagonist) (p*K* ~d~ 10.3--9.7) \[[77](http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus), [128](http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus), [1268](http://www.ncbi.nlm.nih.gov/pubmed/10821780?dopt=AbstractPlus), [1941](http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus)\], [\[^3^H\]RS 57639](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=239) (Selective Antagonist) (p*K* ~d~ 9.7) \[[179](http://www.ncbi.nlm.nih.gov/pubmed/9225293?dopt=AbstractPlus)\] -- Guinea pig, [\[^11^C\]SB207145](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3244) (Antagonist) (p*K* ~d~ 8.6) \[[1169](http://www.ncbi.nlm.nih.gov/pubmed/21831646?dopt=AbstractPlus)\]Comments--LSD ([lysergic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=139)) and [ergotamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149) show a strong preference for arrestin recruitment over G protein coupling at the 5‐HT~2B~ receptor, with no such preference evident at 5‐HT~1B~ receptors, and they also antagonise 5‐HT~7A~ receptors \[[1963](http://www.ncbi.nlm.nih.gov/pubmed/23519215?dopt=AbstractPlus)\]. DHE ([dihydroergocryptine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=282)), [pergolide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=48) and [cabergoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=37) also show significant preference for arrestin recruitment over G protein coupling at 5‐HT~2B~ receptors \[[1963](http://www.ncbi.nlm.nih.gov/pubmed/23519215?dopt=AbstractPlus)\].The serotonin antagonist [mesulergine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206) was key to the discovery of the 5‐HT~2C~ receptor \[[1479](http://www.ncbi.nlm.nih.gov/pubmed/6519175?dopt=AbstractPlus)\].--

Nomenclature[5‐ht~5a~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=10)[5‐ht~5b~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=648)[5‐HT~6~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11)[5‐HT~7~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12)HGNC, UniProt[*HTR5A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5300), [P47898](http://www.uniprot.org/uniprot/P47898)[*HTR5BP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16291), --[*HTR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5301), [P50406](http://www.uniprot.org/uniprot/P50406)[*HTR7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5302), [P34969](http://www.uniprot.org/uniprot/P34969)Selective agonists----[WAY‐181187](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3240) (p*K* ~i~ 8.7) \[[1663](http://www.ncbi.nlm.nih.gov/pubmed/17625499?dopt=AbstractPlus)\], [E6801](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3217) (Partial agonist) (p*K* ~i~ 8.7) \[[769](http://www.ncbi.nlm.nih.gov/pubmed/15771424?dopt=AbstractPlus)\], [WAY‐208466](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8429) (p*K* ~i~ 8.3) \[[135](http://www.ncbi.nlm.nih.gov/pubmed/19523834?dopt=AbstractPlus)\], [EMD‐386088](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8428) (pIC~50~ 8.1) \[[1228](http://www.ncbi.nlm.nih.gov/pubmed/16055331?dopt=AbstractPlus)\][LP‐12](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8434) (p*K* ~i~ 9.9) \[[1082](http://www.ncbi.nlm.nih.gov/pubmed/17649988?dopt=AbstractPlus)\], [LP‐44](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8435) (p*K* ~i~ 9.7) \[[1082](http://www.ncbi.nlm.nih.gov/pubmed/17649988?dopt=AbstractPlus)\], [LP‐211](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8436) (p*K* ~i~ 9.2) \[[1083](http://www.ncbi.nlm.nih.gov/pubmed/18800769?dopt=AbstractPlus)\] -- Rat, [AS‐19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8433) (p*K* ~i~ 9.2) \[[947](http://www.ncbi.nlm.nih.gov/pubmed/23541835?dopt=AbstractPlus)\], [E55888](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3929) (p*K* ~i~ 8.6) \[[206](http://www.ncbi.nlm.nih.gov/pubmed/19118950?dopt=AbstractPlus)\]Antagonists------[lurasidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7461) (p*K* ~i~ 9.3) \[[829](http://www.ncbi.nlm.nih.gov/pubmed/20404009?dopt=AbstractPlus)\], [pimozide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90) (p*K* ~i~ 9.3) \[[1604](http://www.ncbi.nlm.nih.gov/pubmed/7908055?dopt=AbstractPlus)\] -- Rat, [vortioxetine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351) (p*K* ~i~ 6.3) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus)\]Selective antagonists[SB 699551](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=264) (p*K* ~i~ 8.2) \[[366](http://www.ncbi.nlm.nih.gov/pubmed/16002289?dopt=AbstractPlus)\]--[SB399885](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3241) (p*K* ~i~ 9) \[[763](http://www.ncbi.nlm.nih.gov/pubmed/17069795?dopt=AbstractPlus)\], [SB 271046](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=276) (p*K* ~i~ 8.9) \[[224](http://www.ncbi.nlm.nih.gov/pubmed/9925723?dopt=AbstractPlus)\], [cerlapirdine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7356) (p*K* ~i~ 8.9) \[358\], [SB357134](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3235) (p*K* ~i~ 8.5) \[[225](http://www.ncbi.nlm.nih.gov/pubmed/11140733?dopt=AbstractPlus)\], [Ro 63‐0563](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=275) (p*K* ~i~ 7.9--8.4) \[[168](http://www.ncbi.nlm.nih.gov/pubmed/9730917?dopt=AbstractPlus), [1754](http://www.ncbi.nlm.nih.gov/pubmed/9647481?dopt=AbstractPlus)\][SB269970](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3233) (p*K* ~i~ 8.6--8.9) \[[1874](http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus)\], [SB656104](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3237) (p*K* ~i~ 8.7) \[[531](http://www.ncbi.nlm.nih.gov/pubmed/12392747?dopt=AbstractPlus)\], [DR‐4004](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8431) (p*K* ~i~ 8.7) \[[615](http://www.ncbi.nlm.nih.gov/pubmed/12825922?dopt=AbstractPlus), [938](http://www.ncbi.nlm.nih.gov/pubmed/10052959?dopt=AbstractPlus)\], [JNJ‐18038683](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8432) (p*K* ~i~ 8.2) \[[177](http://www.ncbi.nlm.nih.gov/pubmed/22570363?dopt=AbstractPlus)\], [SB 258719](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=281) (Inverse agonist) (p*K* ~i~ 7.5) \[[1875](http://www.ncbi.nlm.nih.gov/pubmed/9720804?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261) (Agonist) (p*K* ~d~ 9.7) \[[636](http://www.ncbi.nlm.nih.gov/pubmed/11343685?dopt=AbstractPlus)\], [\[^3^H\]5‐CT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262) (Agonist) (p*K* ~d~ 8.6) \[[636](http://www.ncbi.nlm.nih.gov/pubmed/11343685?dopt=AbstractPlus)\][\[^125^I\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261) (Agonist) (p*K* ~d~ 9.3) \[[1227](http://www.ncbi.nlm.nih.gov/pubmed/8450829?dopt=AbstractPlus)\] -- Mouse, [\[^3^H\]5‐CT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262) (Agonist) \[[1965](http://www.ncbi.nlm.nih.gov/pubmed/9928243?dopt=AbstractPlus)\] -- Mouse[\[^11^C\]GSK215083](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8430) (Antagonist) (p*K* ~i~ 9.8) \[[1462](http://www.ncbi.nlm.nih.gov/pubmed/22223878?dopt=AbstractPlus)\], [\[^125^I\]SB258585](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3245) (Selective Antagonist) (p*K* ~d~ 9) \[[763](http://www.ncbi.nlm.nih.gov/pubmed/17069795?dopt=AbstractPlus)\], [\[^3^H\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219) (Agonist) (p*K* ~d~ 8.7) \[[167](http://www.ncbi.nlm.nih.gov/pubmed/9284367?dopt=AbstractPlus)\], [\[^3^H\]Ro 63‐0563](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3246) (Antagonist) (p*K* ~d~ 8.3) \[[168](http://www.ncbi.nlm.nih.gov/pubmed/9730917?dopt=AbstractPlus)\], [\[^3^H\]5‐CT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262) (Agonist)[\[^3^H\]5‐CT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262) (Agonist) (p*K* ~d~ 9.4) \[[1874](http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus)\], [\[^3^H\]5‐HT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248) (Agonist) (p*K* ~d~ 8.1--9) \[[93](http://www.ncbi.nlm.nih.gov/pubmed/8226867?dopt=AbstractPlus), [1793](http://www.ncbi.nlm.nih.gov/pubmed/9303561?dopt=AbstractPlus)\], [\[^3^H\]SB269970](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3247) (Selective Antagonist) (p*K* ~d~ 8.9) \[[1874](http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus)\], [\[^3^H\]LSD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219) (Agonist) (p*K* ~d~ 8.5--8.6) \[[1793](http://www.ncbi.nlm.nih.gov/pubmed/9303561?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0018}
--------

Tabulated *p* *K* ~i~ and *K* ~D~ values refer to binding to human 5‐HT receptors unless indicated otherwise. The nomenclature of 5‐HT~1B~/5‐HT~1D~ receptors has been revised \[[707](http://www.ncbi.nlm.nih.gov/pubmed/8936345?dopt=AbstractPlus)\]. Only the non‐rodent form of the receptor was previously called 5‐HT~1D~: the human 5‐HT~1B~ receptor (tabulated) displays a different pharmacology to the rodent forms of the receptor due to Thr335 of the human sequence being replaced by Asn in rodent receptors. [NAS181](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3226) is a selective antagonist of the rodent 5‐HT~1B~ receptor. [Fananserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5434) and [ketanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88) bind with high affinity to dopamine D4 and histamine H~1~ receptors respectively, and [ketanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88) is a potent *α*1 adrenoceptor antagonist, in addition to blocking 5‐HT~2A~ receptors. The human 5‐ht~5A~ receptor has been claimed to couple to several signal transduction pathways when stably expressed in C6 glioma cells \[[1404](http://www.ncbi.nlm.nih.gov/pubmed/12558985?dopt=AbstractPlus)\]. The human orthologue of the mouse 5‐ht~5b~ receptor is non‐functional due to interruption of the gene by stop codons. The 5‐ht~1e~ receptor appears not to have been cloned from mouse, or rat, impeding definition of its function. In addition to the receptors listed in the table, an \'orphan\' receptor, unofficially termed 5‐HT~1P~, has been described \[[600](http://www.ncbi.nlm.nih.gov/pubmed/10429737?dopt=AbstractPlus)\].
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[Acetylcholine receptors (muscarinic)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2) {#bph13348-sec-0020}
===============================================================================================================

Overview {#bph13348-sec-0021}
--------

Muscarinic acetylcholine receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Muscarinic Acetylcholine Receptors \[** [**275**](http://www.ncbi.nlm.nih.gov/pubmed/9647869?dopt=AbstractPlus) **\]**) are GPCRs of the Class A, rhodopsin‐like family where the endogenous agonist is [acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294). In addition to the agents listed in the table, [AC‐42](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=289), its structural analogues [AC‐260584](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=334) and [77‐LH‐28‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3271), [*N*‐desmethylclozapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=333), [TBPB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3258) and [LuAE51090](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5435) have been described as functionally selective agonists of the M~1~ receptor subtype *via* binding in a mode distinct from that utilized by non‐selective agonists \[[71](http://www.ncbi.nlm.nih.gov/pubmed/20413650?dopt=AbstractPlus), [878](http://www.ncbi.nlm.nih.gov/pubmed/18842902?dopt=AbstractPlus), [1040](http://www.ncbi.nlm.nih.gov/pubmed/18454168?dopt=AbstractPlus), [1041](http://www.ncbi.nlm.nih.gov/pubmed/16207821?dopt=AbstractPlus), [1232](http://www.ncbi.nlm.nih.gov/pubmed/17525129?dopt=AbstractPlus), [1635](http://www.ncbi.nlm.nih.gov/pubmed/20684563?dopt=AbstractPlus), [1786](http://www.ncbi.nlm.nih.gov/pubmed/16959945?dopt=AbstractPlus), [1787](http://www.ncbi.nlm.nih.gov/pubmed/12021390?dopt=AbstractPlus), [1825](http://www.ncbi.nlm.nih.gov/pubmed/14595031?dopt=AbstractPlus)\]. There are two pharmacologically characterised allosteric sites on muscarinic receptors, one defined by it binding [gallamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356), [strychnine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347) and [brucine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342), and the other defined by the binding of [KT 5720](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=337), [WIN 62,577](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=340), [WIN 51,708](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=339) and [staurosporine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=346)\[[1052](http://www.ncbi.nlm.nih.gov/pubmed/10860942?dopt=AbstractPlus), [1053](http://www.ncbi.nlm.nih.gov/pubmed/12435818?dopt=AbstractPlus)\].

Nomenclature[M~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=13)[M~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=14)HGNC, UniProt[*CHRM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1950), [P11229](http://www.uniprot.org/uniprot/P11229)[*CHRM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1951), [P08172](http://www.uniprot.org/uniprot/P08172)Agonists[carbachol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298) (p*K* ~i~ 3.2--5.3) \[[334](http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [2040](http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus)\], [pilocarpine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305) (Partial agonist) (p*K* ~i~ 5.1) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\], [bethanechol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297) (p*K* ~i~ 4) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\][bethanechol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297) (p*K* ~i~ 4) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\]Antagonists[glycopyrrolate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459) (pIC~50~ 9.9) \[[1801](http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus)\], [umeclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354) (p*K* ~i~ 9.8) \[[1035](http://www.ncbi.nlm.nih.gov/pubmed/19317446?dopt=AbstractPlus), [1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [AE9C90CB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586) (p*K* ~i~ 9.7) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [propantheline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329) (p*K* ~i~ 9.7) \[[797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus)\], [atropine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320) (p*K* ~i~ 8.5--9.6) \[[334](http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus), [552](http://www.ncbi.nlm.nih.gov/pubmed/16439611?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus), [1762](http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus)\], [tiotropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367) (p*K* ~i~ 9.6) \[[428](http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus)\], [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307) (p*K* ~i~ 9.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [dicyclomine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=355) (p*K* ~i~ 9.1) \[68\], [scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=330) (p*K* ~i~ 9) \[[797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus)\], [trihexyphenidyl](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7315) (p*K* ~i~ 8.9) \[68\], [tripitramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361) (p*K* ~i~ 8.8) \[[1176](http://www.ncbi.nlm.nih.gov/pubmed/7805774?dopt=AbstractPlus)\], [UH‐AH 37](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583) (p*K* ~i~ 8.6--8.7) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [tolterodine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360) (p*K* ~i~ 8.5--8.7) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [oxybutynin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359) (p*K* ~i~ 8.6) \[[410](http://www.ncbi.nlm.nih.gov/pubmed/22243489?dopt=AbstractPlus), [818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321) (p*K* ~i~ 7.5--8.3) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) (p*K* ~i~ 7.8--8.3) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [solifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7483) (p*K* ~i~ 7.6) \[[818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [AFDX384](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3264) (p*K* ~i~ 7.5) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [AQ‐RA 741](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8584) (p*K* ~i~ 7.2--7.5) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus)\], [methoctramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=327) (p*K* ~i~ 6.6--7.3) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [1762](http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus)\], [himbacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=324) (p*K* ~i~ 6.7--7.1) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1286](http://www.ncbi.nlm.nih.gov/pubmed/1331410?dopt=AbstractPlus)\], [muscarinic toxin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313) (p*K* ~i~ 7.1) \[[875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus)\], [otenzepad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309) (p*K* ~d~ 6.2) \[[493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus)\][tiotropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367) (p*K* ~i~ 9.9) \[[428](http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus)\], [umeclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354) (p*K* ~i~ 9.8) \[[1035](http://www.ncbi.nlm.nih.gov/pubmed/19317446?dopt=AbstractPlus), [1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [propantheline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329) (p*K* ~i~ 9.5) \[[797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus)\], [glycopyrrolate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459) (Full agonist) (pIC~50~ 9.3) \[[1801](http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus)\], [atropine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320) (p*K* ~i~ 7.8--9.2) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus), [1373](http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus), [1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus)\], [AE9C90CB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586) (p*K* ~i~ 8.6) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [tolterodine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360) (Inverse agonist) (p*K* ~i~ 8.4--8.6) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [1373](http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [AQ‐RA 741](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8584) (p*K* ~i~ 8.4) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus)\], [himbacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=324) (p*K* ~i~ 7.9--8.4) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus), [1286](http://www.ncbi.nlm.nih.gov/pubmed/1331410?dopt=AbstractPlus)\], [methoctramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=327) (p*K* ~i~ 7.3--8.4) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus), [1373](http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus)\], [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307) (p*K* ~i~ 8.3) \[[1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus)\], [AFDX384](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3264) (p*K* ~i~ 8.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [biperiden](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128) (p*K* ~d~ 8.2) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus)\], [oxybutynin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359) (p*K* ~i~ 7.7--8.1) \[[818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321) (Inverse agonist) (p*K* ~i~ 7--7.6) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1373](http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [UH‐AH 37](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583) (p*K* ~i~ 7.3--7.4) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [otenzepad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309) (p*K* ~i~ 6.7--7.2) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus)\], [solifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7483) (p*K* ~i~ 6.9--7.1) \[[818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) (p*K* ~i~ 6--6.7) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1002](http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus), [1373](http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [VU0255035](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3274) (p*K* ~i~ 6.2) \[[1717](http://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus)\], [muscarinic toxin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313) (p*K* ~i~\<6) \[[875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus)\], [guanylpirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276) (p*K* ~i~ 5.3) \[[1966](http://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus)\] -- Rat, [muscarinic toxin 7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314) (p*K* ~i~\<5) \[[1414](http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus)\]Selective antagonists[biperiden](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128) (p*K* ~d~ 9.3) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus)\], [VU0255035](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3274) (p*K* ~i~ 7.8) \[[1717](http://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus)\], [guanylpirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276) (p*K* ~i~ 7.3--7.6) \[[23](http://www.ncbi.nlm.nih.gov/pubmed/10323493?dopt=AbstractPlus), [1966](http://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus)\] -- Rat[tripitramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361) (p*K* ~i~ 9.6) \[[1176](http://www.ncbi.nlm.nih.gov/pubmed/7805774?dopt=AbstractPlus)\]Allosteric modulators[muscarinic toxin 7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314) (Negative) (p*K* ~i~ 11--11.1) \[[1414](http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus)\], [benzoquinazolinone 12](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8549) (Positive) (p*K* ~B~ 6.6) \[[4](http://www.ncbi.nlm.nih.gov/pubmed/25326383?dopt=AbstractPlus)\], [KT 5720](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=337) (Positive) (p*K* ~d~ 6.4) \[[1052](http://www.ncbi.nlm.nih.gov/pubmed/10860942?dopt=AbstractPlus)\], [brucine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342) (Positive) (p*K* ~d~ 4.5--5.8) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [1051](http://www.ncbi.nlm.nih.gov/pubmed/9495826?dopt=AbstractPlus)\], [BQCA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436) (Positive) (p*K* ~B~ 4--4.8) \[[4](http://www.ncbi.nlm.nih.gov/pubmed/25326383?dopt=AbstractPlus), [5](http://www.ncbi.nlm.nih.gov/pubmed/24443568?dopt=AbstractPlus), [261](http://www.ncbi.nlm.nih.gov/pubmed/22086918?dopt=AbstractPlus), [1161](http://www.ncbi.nlm.nih.gov/pubmed/19717450?dopt=AbstractPlus)\], [VU0029767](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3261) (Positive) \[[1208](http://www.ncbi.nlm.nih.gov/pubmed/19047481?dopt=AbstractPlus)\], [VU0090157](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3259) (Positive) \[[1208](http://www.ncbi.nlm.nih.gov/pubmed/19047481?dopt=AbstractPlus)\][W‐84](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=362) (Negative) (p*K* ~d~ 6--7.5) \[[1299](http://www.ncbi.nlm.nih.gov/pubmed/15163212?dopt=AbstractPlus), [1908](http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus)\], [C~7~/3‐phth](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7634) (Negative) (p*K* ~d~ 7.1) \[[335](http://www.ncbi.nlm.nih.gov/pubmed/9890565?dopt=AbstractPlus)\], [alcuronium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341) (Negative) (p*K* ~d~ 6.1--6.9) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [1908](http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus)\], [gallamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356) (Negative) (p*K* ~d~ 5.9--6.3) \[[348](http://www.ncbi.nlm.nih.gov/pubmed/990587?dopt=AbstractPlus), [1049](http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus)\], [LY2119620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6938) (Positive) (p*K* ~d~ 5.7) \[[383](http://www.ncbi.nlm.nih.gov/pubmed/24807965?dopt=AbstractPlus), [1010](http://www.ncbi.nlm.nih.gov/pubmed/24256733?dopt=AbstractPlus)\], [LY2033298](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262) (Positive) (p*K* ~d~ 4.4) \[[1933](http://www.ncbi.nlm.nih.gov/pubmed/21989256?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]QNB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318) (Antagonist) (p*K* ~d~ 10.6--10.8) \[[336](http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus), [1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus)\], [Cy3B‐telenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8598) (Antagonist) (p*K* ~d~ 10.5) \[[742](http://www.ncbi.nlm.nih.gov/pubmed/20133736?dopt=AbstractPlus)\], [\[^3^H\]N‐methyl scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317) (Antagonist) (p*K* ~d~ 9.4--10.3) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus), [334](http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus), [336](http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [847](http://www.ncbi.nlm.nih.gov/pubmed/16675658?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [932](http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus), [1049](http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus)\], [\[^3^H\](+)telenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8594) (Antagonist) (p*K* ~i~ 9.4) \[[500](http://www.ncbi.nlm.nih.gov/pubmed/2704371?dopt=AbstractPlus)\] -- Rat, [Alexa‐488‐telenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8600) (Antagonist) (p*K* ~d~ 9.3) \[[742](http://www.ncbi.nlm.nih.gov/pubmed/20133736?dopt=AbstractPlus)\], [\[^3^H\]pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3272) (Antagonist) (p*K* ~d~ 7.9) \[[1995](http://www.ncbi.nlm.nih.gov/pubmed/6546354?dopt=AbstractPlus)\], [BODIPY‐pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8604) (Antagonist) (p*K* ~i~ 7) \[[820](http://www.ncbi.nlm.nih.gov/pubmed/19451648?dopt=AbstractPlus)\], [\[^11^C\]butylthio‐TZTP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3268) (Agonist) \[[504](http://www.ncbi.nlm.nih.gov/pubmed/8835881?dopt=AbstractPlus)\], [\[^11^C\]xanomeline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3278) (Agonist) \[[504](http://www.ncbi.nlm.nih.gov/pubmed/8835881?dopt=AbstractPlus)\], [\[^18^F\](R,R)‐quinuclidinyl‐4‐fluoromethyl‐benzilate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3275) (Antagonist) \[[935](http://www.ncbi.nlm.nih.gov/pubmed/9313861?dopt=AbstractPlus)\] -- Rat[\[^3^H\]QNB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318) (Antagonist) (p*K* ~d~ 10.1--10.6) \[[1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus)\], [Cy3B‐telenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8598) (Antagonist) (p*K* ~i~ 10.4) \[[1380](http://www.ncbi.nlm.nih.gov/pubmed/23357106?dopt=AbstractPlus)\], [\[^3^H\]tiotropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8592) (Antagonist) (p*K* ~d~ 10.3) \[[1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [\[^3^H\]N‐methyl scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317) (Antagonist) (p*K* ~d~ 9.3--9.9) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus), [310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [847](http://www.ncbi.nlm.nih.gov/pubmed/16675658?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [932](http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus), [1049](http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus), [1985](http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus)\], [Alexa‐488‐telenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8600) (Antagonist) (p*K* ~i~ 8.8) \[[1380](http://www.ncbi.nlm.nih.gov/pubmed/23357106?dopt=AbstractPlus)\], [\[^3^H\]acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8593) (Agonist) (p*K* ~d~ 8.8) \[[1050](http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus)\], [\[^3^H\]oxotremorine‐M](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8595) (Agonist) (p*K* ~d~ 8.7) \[[137](http://www.ncbi.nlm.nih.gov/pubmed/6478115?dopt=AbstractPlus)\], [\[^3^H\]dimethyl‐W84](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=364) (Allosteric modulator, Positive) (p*K* ~d~ 8.5) \[[1908](http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus)\], [\[^18^F\]FP‐TZTP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3266) (Agonist) \[[845](http://www.ncbi.nlm.nih.gov/pubmed/12668051?dopt=AbstractPlus)\] -- Mouse

Nomenclature[M~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15)[M~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=16)[M~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17)HGNC, UniProt[*CHRM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1952), [P20309](http://www.uniprot.org/uniprot/P20309)[*CHRM4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1953), [P08173](http://www.uniprot.org/uniprot/P08173)[*CHRM5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1954), [P08912](http://www.uniprot.org/uniprot/P08912)Agonists[pilocarpine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305) (Partial agonist) (p*K* ~i~ 5.1) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\], [carbachol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298) (p*K* ~i~ 4--4.4) \[[310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [2040](http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus)\], [bethanechol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297) (p*K* ~i~ 4.2) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\][pilocarpine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305) (Partial agonist) (p*K* ~i~ 5.2) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\], [carbachol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298) (p*K* ~i~ 4.3--4.9) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [2040](http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus)\], [bethanechol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297) (p*K* ~i~ 4) \[[846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus)\][pilocarpine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305) (Partial agonist) (p*K* ~i~ 5) \[[639](http://www.ncbi.nlm.nih.gov/pubmed/16002459?dopt=AbstractPlus)\], [carbachol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298) (p*K* ~i~ 4.9) \[[2040](http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus)\]Antagonists[tiotropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367) (p*K* ~i~ 9.5--11.1) \[[428](http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus), [442](http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus)\], [umeclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354) (p*K* ~i~ 10.2) \[[1035](http://www.ncbi.nlm.nih.gov/pubmed/19317446?dopt=AbstractPlus), [1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [propantheline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329) (p*K* ~i~ 10) \[[797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus)\], [AE9C90CB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586) (p*K* ~i~ 9.9) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [atropine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320) (p*K* ~i~ 8.9--9.8) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [442](http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus), [1762](http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus)\], [ipratropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=325) (p*K* ~i~ 9.3--9.8) \[[442](http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus)\], [aclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7449) (pIC~50~ 9.8) \[[1530](http://www.ncbi.nlm.nih.gov/pubmed/19653626?dopt=AbstractPlus)\], [clidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=366) (p*K* ~i~ 9.6) \[[442](http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus)\], [glycopyrrolate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459) (pIC~50~ 9.6) \[[1801](http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus)\], [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307) (p*K* ~i~ 9.3) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321) (p*K* ~i~ 8.6--9.1) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [dicyclomine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=355) (p*K* ~i~ 9) \[68\], [oxybutynin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359) (p*K* ~i~ 8.8--8.9) \[[410](http://www.ncbi.nlm.nih.gov/pubmed/22243489?dopt=AbstractPlus), [818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [tolterodine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360) (p*K* ~i~ 8.4--8.5) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [biperiden](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128) (p*K* ~d~ 8.4) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus)\], [UH‐AH 37](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583) (p*K* ~i~ 8.1--8.2) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [solifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7483) (p*K* ~i~ 7.7--8) \[[818](http://www.ncbi.nlm.nih.gov/pubmed/12122494?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [tropicamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7319) (p*K* ~i~ 7.5) \[68\], [AQ‐RA 741](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8584) (p*K* ~i~ 7.2--7.3) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus)\], [AFDX384](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3264) (p*K* ~i~ 7.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [himbacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=324) (p*K* ~i~ 6.9--7.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1286](http://www.ncbi.nlm.nih.gov/pubmed/1331410?dopt=AbstractPlus)\], [methoctramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=327) (p*K* ~i~ 6.1--6.9) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [1762](http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus)\], [tripitramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361) (p*K* ~i~ 6.8) \[[1288](http://www.ncbi.nlm.nih.gov/pubmed/18595721?dopt=AbstractPlus)\], [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) (p*K* ~i~ 6.5--6.8) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [guanylpirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276) (p*K* ~i~ 6.2) \[[1966](http://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus)\] -- Rat, [VU0255035](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3274) (p*K* ~i~ 6.1) \[[1717](http://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus)\], [otenzepad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309) (p*K* ~i~ 6.1) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus)\], [muscarinic toxin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313) (p*K* ~i~\<6) \[[875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus)\], [muscarinic toxin 7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314) (p*K* ~i~\<5) \[[1414](http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus)\][umeclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354) (p*K* ~i~ 10.3) \[[1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [glycopyrrolate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459) (pIC~50~ 9.8) \[[1801](http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus)\], [AE9C90CB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586) (p*K* ~i~ 9.5) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307) (p*K* ~i~ 8.9) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [oxybutynin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359) (p*K* ~i~ 8.7) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [biperiden](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128) (p*K* ~d~ 8.6) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus)\], [UH‐AH 37](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583) (p*K* ~i~ 8.3--8.4) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [tolterodine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360) (p*K* ~i~ 8.3--8.4) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [AQ‐RA 741](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8584) (p*K* ~i~ 7.8--8.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus)\], [himbacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=324) (p*K* ~i~ 7.9--8.2) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1286](http://www.ncbi.nlm.nih.gov/pubmed/1331410?dopt=AbstractPlus)\], [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321) (p*K* ~i~ 7.3--8.1) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [AFDX384](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3264) (p*K* ~i~ 8) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [tripitramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361) (p*K* ~i~ 7.9) \[[1288](http://www.ncbi.nlm.nih.gov/pubmed/18595721?dopt=AbstractPlus)\], [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) (p*K* ~i~ 7--7.6) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [methoctramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=327) (p*K* ~i~ 6.6--7.5) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus)\], [otenzepad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309) (p*K* ~d~ 7) \[[493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus)\], [solifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7483) (p*K* ~i~ 6.8) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [guanylpirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276) (p*K* ~i~ 6.2) \[[1966](http://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus)\] -- Rat, [VU0255035](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3274) (p*K* ~i~ 5.9) \[[1717](http://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus)\], [muscarinic toxin 7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314) (p*K* ~i~\<5) \[[1414](http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus)\][umeclidinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354) (p*K* ~i~ 9.9) \[[1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [glycopyrrolate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459) (pIC~50~ 9.7) \[[1801](http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus)\], [AE9C90CB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586) (p*K* ~i~ 9.5) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307) (p*K* ~i~ 9) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [tolterodine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360) (p*K* ~i~ 8.5--8.8) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321) (p*K* ~i~ 7.9--8.6) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [UH‐AH 37](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583) (p*K* ~i~ 8.3) \[[609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [biperiden](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128) (p*K* ~d~ 8.2) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus)\], [oxybutynin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359) (p*K* ~i~ 7.9) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [AQ‐RA 741](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8584) (p*K* ~i~ 6.1--7.8) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [609](http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus)\], [tripitramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361) (p*K* ~i~ 7.5) \[[1176](http://www.ncbi.nlm.nih.gov/pubmed/7805774?dopt=AbstractPlus)\], [methoctramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=327) (p*K* ~i~ 6.3--7.2) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus), [458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [493](http://www.ncbi.nlm.nih.gov/pubmed/8759038?dopt=AbstractPlus), [730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus)\], [solifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7483) (p*K* ~i~ 7.2) \[[1749](http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus)\], [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) (p*K* ~i~ 6.8--7.1) \[[730](http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [2012](http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus)\], [guanylpirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276) (p*K* ~d~ 6.8) \[[514](http://www.ncbi.nlm.nih.gov/pubmed/7808421?dopt=AbstractPlus)\] -- Unknown, [himbacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=324) (p*K* ~i~ 5.4--6.5) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1286](http://www.ncbi.nlm.nih.gov/pubmed/1331410?dopt=AbstractPlus)\], [AFDX384](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3264) (p*K* ~i~ 6.3) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus)\], [muscarinic toxin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313) (p*K* ~i~\<6) \[[875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus)\], [otenzepad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309) (p*K* ~i~ 5.6) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus)\], [muscarinic toxin 7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314) (p*K* ~i~\<5) \[[1414](http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus)\]Selective antagonists----[ML381](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8591) (p*K* ~i~ 6.3) \[[593](http://www.ncbi.nlm.nih.gov/pubmed/24692176?dopt=AbstractPlus)\]Allosteric modulators[WIN 62,577](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=340) (Positive) (p*K* ~d~ 5.1) \[[1053](http://www.ncbi.nlm.nih.gov/pubmed/12435818?dopt=AbstractPlus)\], [N‐chloromethyl‐brucine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=344) (Positive) (p*K* ~d~ 3.3) \[[1051](http://www.ncbi.nlm.nih.gov/pubmed/9495826?dopt=AbstractPlus)\][muscarinic toxin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313) (Negative) (p*K* ~i~ 8.7) \[[875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [1444](http://www.ncbi.nlm.nih.gov/pubmed/9862767?dopt=AbstractPlus)\], [LY2119620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6938) (Positive) (p*K* ~d~ 5.7) \[[383](http://www.ncbi.nlm.nih.gov/pubmed/24807965?dopt=AbstractPlus)\], [thiochrome](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=348) (Positive) (p*K* ~d~ 4) \[[1050](http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus)\], [LY2033298](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262) (Positive) \[[286](http://www.ncbi.nlm.nih.gov/pubmed/18678919?dopt=AbstractPlus)\], [VU0152099](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3256) (Positive) \[[201](http://www.ncbi.nlm.nih.gov/pubmed/18772318?dopt=AbstractPlus)\], [VU0152100](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3263) (Positive) \[[201](http://www.ncbi.nlm.nih.gov/pubmed/18772318?dopt=AbstractPlus)\][ML380](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8687) (Positive) (pEC~50~ 6.7) \[[595](http://www.ncbi.nlm.nih.gov/pubmed/25147929?dopt=AbstractPlus)\]Selective allosteric modulators----[ML375](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7631) (Negative) (pIC~50~ 6.5) \[[594](http://www.ncbi.nlm.nih.gov/pubmed/24164599?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]tiotropium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8592) (Antagonist) (p*K* ~d~ 10.7) \[[1632](http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus)\], [\[^3^H\]QNB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318) (Antagonist) (p*K* ~d~ 10.4) \[[1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus)\], [\[^3^H\]N‐methyl scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317) (Antagonist) (p*K* ~d~ 9.7--10.2) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus), [310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [797](http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [932](http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus), [1049](http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus)\], [\[^3^H\]darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=319) (Antagonist) (p*K* ~d~ 9.5) \[[1762](http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus)\][\[^3^H\]QNB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318) (Antagonist) (p*K* ~d~ 9.7--10.5) \[[336](http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus), [1486](http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus)\], [\[^3^H\]N‐methyl scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317) (Antagonist) (p*K* ~d~ 9.9--10.2) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus), [310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [336](http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [846](http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [932](http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus), [1049](http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus), [1444](http://www.ncbi.nlm.nih.gov/pubmed/9862767?dopt=AbstractPlus), [1985](http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus)\], [\[^3^H\]acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8593) (Agonist) (p*K* ~d~ 8.2) \[[1050](http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus)\][\[^3^H\]QNB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318) (Antagonist) (p*K* ~d~ 10.2--10.7), [\[^3^H\]N‐methyl scopolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317) (Antagonist) (p*K* ~d~ 9.3--9.7) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus), [310](http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus), [759](http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus), [875](http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus), [932](http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus), [1985](http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0022}
--------

[LY2033298](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262) and [BQCA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436) have also been shown to directly activate the M~4~ and M~1~ receptors, respectively, via an allosteric site \[[1059](http://www.ncbi.nlm.nih.gov/pubmed/21300722?dopt=AbstractPlus), [1060](http://www.ncbi.nlm.nih.gov/pubmed/19940843?dopt=AbstractPlus), [1366](http://www.ncbi.nlm.nih.gov/pubmed/20406819?dopt=AbstractPlus), [1367](http://www.ncbi.nlm.nih.gov/pubmed/18628403?dopt=AbstractPlus)\]. The allosteric site for [gallamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356) and [strychnine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347) on M~2~ receptors can be labelled by [\[^3^H\]dimethyl‐W84](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=364)\[[1908](http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus)\]. [McN‐A‐343](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=290) is a functionally selective partial agonist that appears to interact in a bitopic mode with both the orthosteric and an allosteric site on the M~2~ muscarinic receptor \[[1934](http://www.ncbi.nlm.nih.gov/pubmed/18723515?dopt=AbstractPlus)\]. [THRX160209](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3255), hybrid 1 and hybrid 2, are multivalent (bitopic) ligands that also achieve selectivity for M~2~ receptors by binding both to the orthosteric and a nearby allosteric site \[[52](http://www.ncbi.nlm.nih.gov/pubmed/18842964?dopt=AbstractPlus), [1796](http://www.ncbi.nlm.nih.gov/pubmed/17478612?dopt=AbstractPlus)\].

Although numerous ligands for muscarinic acetylcholine receptors have been described, relatively few selective antagonists have been described, so it is common to assess the rank order of affinity of a number of antagonists of limited selectivity (*e.g.* [4‐DAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307), [darifenacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321), [pirenzepine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328)) in order to identify the involvement of particular subtypes. It should be noted that the measured affinities of antagonists (and agonists) in radioligand binding studies are sensitive to ionic strength and can increase over 10‐fold at low ionic strength compared to its value at physiological ionic strengths \[[151](http://www.ncbi.nlm.nih.gov/pubmed/497538?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0023}
---------------
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[Adenosine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=3) {#bph13348-sec-0024}
==============================================================================================

Overview {#bph13348-sec-0025}
--------

Adenosine receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Adenosine Receptors \[** [**541**](http://www.ncbi.nlm.nih.gov/pubmed/11734617?dopt=AbstractPlus) **\]**) are activated by the endogenous ligand [adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844)(potentially [inosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554) also at A~3~ receptors). Crystal structures for the antagonist‐bound and agonist‐bound A~2A~ adenosine receptors have been described \[[835](http://www.ncbi.nlm.nih.gov/pubmed/18832607?dopt=AbstractPlus), [2065](http://www.ncbi.nlm.nih.gov/pubmed/21393508?dopt=AbstractPlus)\].

Nomenclature[A~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18)[A~2A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=19)[A~2B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20)[A~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21)HGNC, UniProt[*ADORA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=262), [P30542](http://www.uniprot.org/uniprot/P30542)[*ADORA2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=263), [P29274](http://www.uniprot.org/uniprot/P29274)[*ADORA2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=264), [P29275](http://www.uniprot.org/uniprot/P29275)[*ADORA3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=268), [P0DMS8](http://www.uniprot.org/uniprot/P0DMS8)Agonists[cyclopentyladenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380) (p*K* ~i~ 6.5--9.4) \[[388](http://www.ncbi.nlm.nih.gov/pubmed/9827575?dopt=AbstractPlus), [570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus), [736](http://www.ncbi.nlm.nih.gov/pubmed/16444290?dopt=AbstractPlus), [839](http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus), [870](http://www.ncbi.nlm.nih.gov/pubmed/7798201?dopt=AbstractPlus), [1592](http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus), [2141](http://www.ncbi.nlm.nih.gov/pubmed/15740718?dopt=AbstractPlus)\]------(Sub)family‐selective agonists[NECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377) (p*K* ~i~ 5.3--8.2) \[[570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus), [870](http://www.ncbi.nlm.nih.gov/pubmed/7798201?dopt=AbstractPlus), [1592](http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus), [1903](http://www.ncbi.nlm.nih.gov/pubmed/8300561?dopt=AbstractPlus), [2077](http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus)\][NECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377) (p*K* ~i~ 6.9--8.7) \[[189](http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus), [427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), [570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus), [943](http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus), [1021](http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus), [2077](http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus)\][NECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377) (p*K* ~i~ 5.7--6.9) \[[146](http://www.ncbi.nlm.nih.gov/pubmed/11093773?dopt=AbstractPlus), [189](http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus), [862](http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus), [1113](http://www.ncbi.nlm.nih.gov/pubmed/10496952?dopt=AbstractPlus), [1798](http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus), [1945](http://www.ncbi.nlm.nih.gov/pubmed/16219300?dopt=AbstractPlus), [2077](http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus)\][NECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377) (p*K* ~i~ 7.5--8.4) \[[189](http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus), [570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus), [840](http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus), [1634](http://www.ncbi.nlm.nih.gov/pubmed/8234299?dopt=AbstractPlus), [1946](http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus), [2077](http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus)\]Selective agonists[5‐Cl‐5‐deoxy‐(±)‐ENBA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6560) (p*K* ~i~ 9.3) \[[536](http://www.ncbi.nlm.nih.gov/pubmed/19317449?dopt=AbstractPlus)\], [GR79236](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3288) (p*K* ~i~ 8.5) \[[839](http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus)\] -- Rat, [CCPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374) (p*K* ~i~ 7.7--8.1) \[[839](http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus), [1419](http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus)\][apadenoson](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290) (p*K* ~i~ 9.3) \[[1481](http://www.ncbi.nlm.nih.gov/pubmed/11406470?dopt=AbstractPlus)\], [UK‐432,097](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8420) (p*K* ~i~ 8.3) \[[2065](http://www.ncbi.nlm.nih.gov/pubmed/21393508?dopt=AbstractPlus)\], [CGS 21680](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375) (p*K* ~i~ 6.7--8.1) \[[189](http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus), [427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), [570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus), [839](http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus), [943](http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1021](http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus), [1419](http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus)\], [regadenoson](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5596) (p*K* ~i~ 6.5) \[[839](http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus)\][BAY 60‐6583](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289) (p*K* ~i~ 8--8.5) \[[460](http://www.ncbi.nlm.nih.gov/pubmed/17353435?dopt=AbstractPlus)\][IB‐MECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=422) (p*K* ~i~ 8.7--9.2) \[[511](http://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus), [561](http://www.ncbi.nlm.nih.gov/pubmed/8126704?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1946](http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus)\], [Cl‐IB‐MECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457) (p*K* ~i~ 8--8.9) \[[202](http://www.ncbi.nlm.nih.gov/pubmed/10731034?dopt=AbstractPlus), [840](http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus), [941](http://www.ncbi.nlm.nih.gov/pubmed/7932588?dopt=AbstractPlus)\], [MRS5698](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8421) (p*K* ~i~ 8.5) \[[1898](http://www.ncbi.nlm.nih.gov/pubmed/22559880?dopt=AbstractPlus)\]Antagonists[caffeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407) (p*K* ~i~ 4.3--5) \[[6](http://www.ncbi.nlm.nih.gov/pubmed/14563788?dopt=AbstractPlus), [409](http://www.ncbi.nlm.nih.gov/pubmed/8469419?dopt=AbstractPlus), 838\][SCH 58261](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=403) (p*K* ~i~ 8.3--9.2) \[[427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), [1021](http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus), [1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus)\], [theophylline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=413) (p*K* ~i~ 5.2--5.8) \[[427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), 838, [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1945](http://www.ncbi.nlm.nih.gov/pubmed/16219300?dopt=AbstractPlus)\], [caffeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407) (p*K* ~i~ 4.6--5.6) \[[6](http://www.ncbi.nlm.nih.gov/pubmed/14563788?dopt=AbstractPlus), 838, [1021](http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus)\][theophylline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=413) (p*K* ~i~ 4.1--5) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18404493?dopt=AbstractPlus), [511](http://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus), [944](http://www.ncbi.nlm.nih.gov/pubmed/12014951?dopt=AbstractPlus), [1945](http://www.ncbi.nlm.nih.gov/pubmed/16219300?dopt=AbstractPlus)\], [caffeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407) (p*K* ~i~ 4.5--5) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18404493?dopt=AbstractPlus), [188](http://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus), [944](http://www.ncbi.nlm.nih.gov/pubmed/12014951?dopt=AbstractPlus)\][caffeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407) (p*K* ~i~ 4.9) \[838\](Sub)family‐selective antagonists[CGS 15943](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384) (p*K* ~i~ 8.5) \[[1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus)\], [xanthine amine congener](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404) (p*K* ~d~ 7.5) \[[536](http://www.ncbi.nlm.nih.gov/pubmed/19317449?dopt=AbstractPlus)\][CGS 15943](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384) (p*K* ~i~ 7.7--9.4) \[[427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), [943](http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus)\], [xanthine amine congener](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404) (p*K* ~i~ 8.4--9) \[[427](http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus)\][xanthine amine congener](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404) (p*K* ~i~ 6.9--8.8) \[[146](http://www.ncbi.nlm.nih.gov/pubmed/11093773?dopt=AbstractPlus), [862](http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus), [863](http://www.ncbi.nlm.nih.gov/pubmed/10624567?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1113](http://www.ncbi.nlm.nih.gov/pubmed/10496952?dopt=AbstractPlus), [1798](http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus)\], [CGS 15943](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384) (p*K* ~i~ 6--8.1) \[[65](http://www.ncbi.nlm.nih.gov/pubmed/19141710?dopt=AbstractPlus), [862](http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus), [863](http://www.ncbi.nlm.nih.gov/pubmed/10624567?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus), [1798](http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus)\][CGS 15943](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384) (p*K* ~i~ 7--7.9) \[[949](http://www.ncbi.nlm.nih.gov/pubmed/8863790?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus), [1946](http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus)\], [xanthine amine congener](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404) (p*K* ~i~ 7--7.4) \[[968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1634](http://www.ncbi.nlm.nih.gov/pubmed/8234299?dopt=AbstractPlus), [1946](http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus)\]Selective antagonists[PSB36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3285) (p*K* ~i~ 9.9) \[[6](http://www.ncbi.nlm.nih.gov/pubmed/14563788?dopt=AbstractPlus)\] -- Rat, [DPCPX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386) (p*K* ~i~ 7.4--9.2) \[[826](http://www.ncbi.nlm.nih.gov/pubmed/8032613?dopt=AbstractPlus), [1419](http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus), [1592](http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus), [2015](http://www.ncbi.nlm.nih.gov/pubmed/16902942?dopt=AbstractPlus), [2141](http://www.ncbi.nlm.nih.gov/pubmed/15740718?dopt=AbstractPlus)\], [derenofylline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281) (p*K* ~i~ 9) \[[897](http://www.ncbi.nlm.nih.gov/pubmed/17558436?dopt=AbstractPlus)\], [WRC‐0571](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8419) (p*K* ~i~ 8.8) \[[1210](http://www.ncbi.nlm.nih.gov/pubmed/8632314?dopt=AbstractPlus)\][SCH442416](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3283) (p*K* ~i~ 8.4--10.3) \[[1728](http://www.ncbi.nlm.nih.gov/pubmed/20801028?dopt=AbstractPlus), [1891](http://www.ncbi.nlm.nih.gov/pubmed/11087559?dopt=AbstractPlus)\], [ZM‐241385](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=405) (p*K* ~i~ 8.8--9.1) \[[1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus)\][PSB‐0788](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6561) (p*K* ~i~ 9.4) \[[188](http://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus)\], [PSB603](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284) (p*K* ~i~ 9.3) \[[188](http://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus)\], [MRS1754](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=449) (p*K* ~i~ 8.8) \[[862](http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus), [948](http://www.ncbi.nlm.nih.gov/pubmed/10737749?dopt=AbstractPlus)\], [PSB1115](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3286) (p*K* ~i~ 7.3) \[[723](http://www.ncbi.nlm.nih.gov/pubmed/11906291?dopt=AbstractPlus)\][MRS1220](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=448) (p*K* ~i~ 8.2--9.2) \[[840](http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus), [949](http://www.ncbi.nlm.nih.gov/pubmed/8863790?dopt=AbstractPlus), [1818](http://www.ncbi.nlm.nih.gov/pubmed/11226132?dopt=AbstractPlus), [2090](http://www.ncbi.nlm.nih.gov/pubmed/16553647?dopt=AbstractPlus)\], [VUF5574](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3280) (p*K* ~i~ 8.4) \[[2143](http://www.ncbi.nlm.nih.gov/pubmed/10841801?dopt=AbstractPlus)\], [MRS1523](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=474) (p*K* ~i~ 7.7) \[[1092](http://www.ncbi.nlm.nih.gov/pubmed/9703464?dopt=AbstractPlus)\], [MRS1191](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=470) (p*K* ~i~ 7.5) \[[840](http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus), [866](http://www.ncbi.nlm.nih.gov/pubmed/8917655?dopt=AbstractPlus), 1097\]Labelled ligands[\[^3^H\]CCPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=379) (Agonist) (p*K* ~d~ 9.2) \[[968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1592](http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus)\], [\[^3^H\]DPCPX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=406) (Antagonist) (p*K* ~d~ 8.4--9.2) \[[388](http://www.ncbi.nlm.nih.gov/pubmed/9827575?dopt=AbstractPlus), [511](http://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus), [1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus), [1592](http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus), [1903](http://www.ncbi.nlm.nih.gov/pubmed/8300561?dopt=AbstractPlus)\][\[^3^H\]ZM 241385](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=455) (Antagonist) (p*K* ~d~ 8.7--9.1) \[[36](http://www.ncbi.nlm.nih.gov/pubmed/11164377?dopt=AbstractPlus), [569](http://www.ncbi.nlm.nih.gov/pubmed/10927024?dopt=AbstractPlus)\], [\[^3^H\]CGS 21680](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=424) (Agonist) (p*K* ~d~ 7.7--7.8) \[[852](http://www.ncbi.nlm.nih.gov/pubmed/2600819?dopt=AbstractPlus), [1976](http://www.ncbi.nlm.nih.gov/pubmed/2213023?dopt=AbstractPlus)\][\[^3^H\]MRS1754](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=453) (Antagonist) (p*K* ~d~ 8.8) \[[862](http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus)\][\[^125^I\]AB‐MECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=436) (Agonist) (p*K* ~d~ 9--9.1) \[[1445](http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus), [1946](http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0026}
--------

Adenosine inhibits many intracellular ATP‐utilising enzymes, including adenylyl cyclase (P‐site). A pseudogene exists for the A~2B~ adenosine receptor ([*ADORA2BP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=265)) with 79% identity to the A~2B~ adenosine receptor cDNA coding sequence, but which is unable to encode a functional receptor \[[841](http://www.ncbi.nlm.nih.gov/pubmed/7558011?dopt=AbstractPlus)\]. [DPCPX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386) also exhibits antagonism at A~2B~ receptors (p*K* ~i~ ca. 7,\[[34](http://www.ncbi.nlm.nih.gov/pubmed/8937736?dopt=AbstractPlus), [968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus)\]). Antagonists at A~3~ receptors exhibit marked species differences, such that only [MRS1523](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=474) and [MRS1191](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=470) are selective at the rat A~3~ receptor. In the absence of other adenosine receptors, [\[^3^H\]DPCPX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=406) and [\[^3^H\]ZM 241385](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=455) can also be used to label A~2B~ receptors (K~D~ *ca*. 30 and 60 nM respectively). [\[^125^I\]AB‐MECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=436) also binds to A~1~ receptors \[[968](http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus)\]. [\[^3^H\]CGS 21680](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=424) is relatively selective for A~2A~ receptors, but may also bind to other sites in cerebral cortex \[[384](http://www.ncbi.nlm.nih.gov/pubmed/8692280?dopt=AbstractPlus), [871](http://www.ncbi.nlm.nih.gov/pubmed/7566470?dopt=AbstractPlus)\]. [\[^3^H\]NECA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=425) binds to other non‐receptor elements, which also recognise adenosine \[[1143](http://www.ncbi.nlm.nih.gov/pubmed/8937447?dopt=AbstractPlus)\]. [XAC‐BY630](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3279) has been described as a fluorescent antagonist for labelling A~1~ adenosine receptors in living cells, although activity at other adenosine receptors was not examined \[[212](http://www.ncbi.nlm.nih.gov/pubmed/15070776?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0027}
---------------
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Mundell S *et al*. (2011) Adenosine receptor desensitization and trafficking. *Biochim. Biophys. Acta* **1808**: 1319‐28 [\[PMID:20550943\]](http://www.ncbi.nlm.nih.gov/pubmed/20550943?dopt=AbstractPlus)

Ponnoth DS *et al*. (2011) Adenosine receptors and vascular inflammation. *Biochim. Biophys. Acta* **1808**: 1429‐34 [\[PMID:20832387\]](http://www.ncbi.nlm.nih.gov/pubmed/20832387?dopt=AbstractPlus)

Wei CJ *et al*. (2011) Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. *Biochim. Biophys. Acta* **1808**: 1358‐79 [\[PMID:21185258\]](http://www.ncbi.nlm.nih.gov/pubmed/21185258?dopt=AbstractPlus)

[Adhesion Class GPCRs](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=17) {#bph13348-sec-0028}
================================================================================================

Overview {#bph13348-sec-0029}
--------

Adhesion GPCRs are structurally identified on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a \"stalk\" motif containing a GPCR proteolytic site. The N‐terminus often shares structural homology with proteins such as lectins and immunoglobulins, leading to the term adhesion GPCR \[[543](http://www.ncbi.nlm.nih.gov/pubmed/12761335?dopt=AbstractPlus), [2097](http://www.ncbi.nlm.nih.gov/pubmed/18789697?dopt=AbstractPlus)\]. **The nomenclature of these receptors was revised in 2015 as recommended by [NC‐IUPHAR]{.ul} and the [Adhesion GPCR Consortium]{.ul}** \[[683](http://www.ncbi.nlm.nih.gov/pubmed/25713288?dopt=AbstractPlus)\].

Nomenclature[ADGRA1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)[ADGRA2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=198)[ADGRA3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=199)[ADGRB1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=174)[ADGRB2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=175)HGNC, UniProt[*ADGRA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13838), [Q86SQ6](http://www.uniprot.org/uniprot/Q86SQ6)[*ADGRA2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17849), [Q96PE1](http://www.uniprot.org/uniprot/Q96PE1)[*ADGRA3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13839), [Q8IWK6](http://www.uniprot.org/uniprot/Q8IWK6)[*ADGRB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=943), [O14514](http://www.uniprot.org/uniprot/O14514)[*ADGRB2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=944), [O60241](http://www.uniprot.org/uniprot/O60241)Endogenous agonists------[phosphatidylserine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638) \[[1461](http://www.ncbi.nlm.nih.gov/pubmed/17960134?dopt=AbstractPlus)\]--Comments------ADGRB1 is reported to respond to [phosphatidylserine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638) \[[1461](http://www.ncbi.nlm.nih.gov/pubmed/17960134?dopt=AbstractPlus)\].--

Nomenclature[ADGRB3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=176)[*CELSR1*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=178)[*CELSR2*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=179)[*CELSR3*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=180)[ADGRD1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=202)HGNC, UniProt[*ADGRB3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=945), [O60242](http://www.uniprot.org/uniprot/O60242)[*CELSR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1850), [Q9NYQ6](http://www.uniprot.org/uniprot/Q9NYQ6)[*CELSR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3231), [Q9HCU4](http://www.uniprot.org/uniprot/Q9HCU4)[*CELSR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3230), [Q9NYQ7](http://www.uniprot.org/uniprot/Q9NYQ7)[*ADGRD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19893), [Q6QNK2](http://www.uniprot.org/uniprot/Q6QNK2)

Nomenclature[ADGRD2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=204)[ADGRE1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=182)[ADGRE2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=183)[ADGRE3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=184)[ADGRE4P](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=185)HGNC, UniProt[*ADGRD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18651), [Q7Z7M1](http://www.uniprot.org/uniprot/Q7Z7M1)[*ADGRE1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3336), [Q14246](http://www.uniprot.org/uniprot/Q14246)[*ADGRE2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3337), [Q9UHX3](http://www.uniprot.org/uniprot/Q9UHX3)[*ADGRE3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23647), [Q9BY15](http://www.uniprot.org/uniprot/Q9BY15)[*ADGRE4P*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19240), [Q86SQ3](http://www.uniprot.org/uniprot/Q86SQ3)

Nomenclature[ADGRE5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=177)[ADGRF1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=190)[ADGRF2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=191)[ADGRF3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=193)[ADGRF4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=195)HGNC, UniProt[*ADGRE5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1711), [P48960](http://www.uniprot.org/uniprot/P48960)[*ADGRF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18990), [Q5T601](http://www.uniprot.org/uniprot/Q5T601)[*ADGRF2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18991), [Q8IZF7](http://www.uniprot.org/uniprot/Q8IZF7)[*ADGRF3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18989), [Q8IZF5](http://www.uniprot.org/uniprot/Q8IZF5)[*ADGRF4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19011), [Q8IZF3](http://www.uniprot.org/uniprot/Q8IZF3)

Nomenclature[ADGRF5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=196)[ADGRG1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=186)[ADGRG2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=187)[ADGRG3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=188)[ADGRG4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=192)HGNC, UniProt[*ADGRF5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19030), [Q8IZF2](http://www.uniprot.org/uniprot/Q8IZF2)[*ADGRG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4512), [Q9Y653](http://www.uniprot.org/uniprot/Q9Y653)[*ADGRG2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4516), [Q8IZP9](http://www.uniprot.org/uniprot/Q8IZP9)[*ADGRG3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13728), [Q86Y34](http://www.uniprot.org/uniprot/Q86Y34)[*ADGRG4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18992), [Q8IZF6](http://www.uniprot.org/uniprot/Q8IZF6)Comments--Reported to bind tissue transglutaminase 2 \[[2066](http://www.ncbi.nlm.nih.gov/pubmed/16757564?dopt=AbstractPlus)\] and collagen, which activates the G~12/13~ pathway \[[1155](http://www.ncbi.nlm.nih.gov/pubmed/21768377?dopt=AbstractPlus)\].------

Nomenclature[ADGRG5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=194)[ADGRG6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=200)[ADGRG7](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=201)[ADGRL1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=206)HGNC, UniProt[*ADGRG5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19010), [Q8IZF4](http://www.uniprot.org/uniprot/Q8IZF4)[*ADGRG6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13841), [Q86SQ4](http://www.uniprot.org/uniprot/Q86SQ4)[*ADGRG7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19241), [Q96K78](http://www.uniprot.org/uniprot/Q96K78)[*ADGRL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20973), [O94910](http://www.uniprot.org/uniprot/O94910)

Nomenclature[ADGRL2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=207)[ADGRL3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=208)[ADGRL4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=181)[ADGRV1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=189)HGNC, UniProt[*ADGRL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18582), [O95490](http://www.uniprot.org/uniprot/O95490)[*ADGRL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20974), [Q9HAR2](http://www.uniprot.org/uniprot/Q9HAR2)[*ADGRL4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20822), [Q9HBW9](http://www.uniprot.org/uniprot/Q9HBW9)[*ADGRV1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17416), [Q8WXG9](http://www.uniprot.org/uniprot/Q8WXG9)Comments------Loss‐of‐function mutations are associated with Usher syndrome, a sensory deficit disorder \[[843](http://www.ncbi.nlm.nih.gov/pubmed/18463160?dopt=AbstractPlus)\].

[Adrenoceptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=4) {#bph13348-sec-0030}
========================================================================================

Overview {#bph13348-sec-0031}
--------

### **Adrenoceptors, *α*~1~** {#bph13348-sec-0032}

*α* ~1~‐Adrenoceptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Adrenoceptors \[** [**248**](http://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus) **\], see also \[** [**752**](http://www.ncbi.nlm.nih.gov/pubmed/7568329?dopt=AbstractPlus) **\]**) are activated by the endogenous agonists [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) and [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) with equal potency. [Phenylephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485), [methoxamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=483) and [cirazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=515) are agonists selective for *α* ~1~‐adrenoceptors relative to *α* ~2~‐adrenoceptors, while [prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503) (8.5‐10.5) and [corynanthine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5345)(6.5‐7.5) are antagonists considered selective for *α* ~1~‐adrenoceptors relative to *α* ~2~‐adrenoceptors. [\[^3^H\]prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5385)(0.25 nM) and [\[^125^I\]HEAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=482)(0.1 nM; also known as BE2254) are relatively selective radioligands. The *α* ~1A~‐adrenoceptor antagonist [S(+)‐niguldipine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=487) also has high affinity for L‐type Ca^2+^ channels. The conotoxin [rho‐TIA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=507) acts as a negative allosteric modulator at the *α* ~1B~‐adrenoceptor \[[1716](http://www.ncbi.nlm.nih.gov/pubmed/12824165?dopt=AbstractPlus)\], while the snake toxin [*ρ*‐Da1a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6663) acts as a selective non‐competitive antagonist at the *α* ~1A~‐adrenoceptor \[[1236](http://www.ncbi.nlm.nih.gov/pubmed/23935897?dopt=AbstractPlus), [1548](http://www.ncbi.nlm.nih.gov/pubmed/20015090?dopt=AbstractPlus)\]. Fluorescent derivatives of prazosin (Bodipy PL‐prazosin‐QAPB) are increasingly used to examine cellular localisation of *α* ~1~‐adrenoceptors. The vasoconstrictor effects of selective *α*1‐adrenoceptor agonists have led to their use as nasal decongestants; antagonists are used to treat hypertension ([doxazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170), [prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503)) and benign prostatic hyperplasia ([alfuzosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109), [tamsulosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488)). The combined *α* ~1~‐ and *β* ~2~‐adrenoceptor antagonist [carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) is widely used to treat congestive heart failure, although the contribution of *α* ~1~‐adrenoceptor blockade to the therapeutic effect is unclear. Several anti‐depressants and anti‐psychotic drugs possess *α* ~1~‐adrenoceptor blocking properties that are believed to contribute to side effects such as orthostatic hypotension and extrapyramidal effects.

Nomenclature[*α*~1A~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=22)[*α*~1B~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=23)[*α*~1D~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=24)HGNC, UniProt[*ADRA1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=277), [P35348](http://www.uniprot.org/uniprot/P35348)[*ADRA1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=278), [P35368](http://www.uniprot.org/uniprot/P35368)[*ADRA1D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=280), [P25100](http://www.uniprot.org/uniprot/P25100)Endogenous agonists----[(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) (p*K* ~i~ 7.2) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\]Agonists[oxymetazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124) (p*K* ~i~ 8--8.2) \[[780](http://www.ncbi.nlm.nih.gov/pubmed/8564227?dopt=AbstractPlus), [1420](http://www.ncbi.nlm.nih.gov/pubmed/8719417?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [1862](http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus)\], [phenylephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485) (p*K* ~i~ 5.2--5.4) \[[1862](http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus)\], [methoxamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=483) (p*K* ~i~ 5--5.2) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [1862](http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus)\][phenylephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485) (pIC~50~ 6.3--7.5) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1289](http://www.ncbi.nlm.nih.gov/pubmed/7969082?dopt=AbstractPlus)\]--Selective agonists[A61603](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=480) (pIC~50~ 7.8--8.4) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [969](http://www.ncbi.nlm.nih.gov/pubmed/7616455?dopt=AbstractPlus)\], [dabuzalgron](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3469) (p*K* ~i~ 7.4) \[[162](http://www.ncbi.nlm.nih.gov/pubmed/14678390?dopt=AbstractPlus)\]----Antagonists[prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503) (Inverse agonist) (p*K* ~i~ 9--9.9) \[[289](http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus), [389](http://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus), [532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [doxazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170) (p*K* ~i~ 9.3) \[689\], [terazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302) (p*K* ~i~ 8.7) \[[1263](http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus)\], [phentolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502) (p*K* ~i~ 8.6) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\], [alfuzosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109) (p*K* ~i~ 8.1) \[[750](http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus)\][prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503) (Inverse agonist) (p*K* ~i~ 9.6--9.9) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [tamsulosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488) (Inverse agonist) (p*K* ~i~ 9.5--9.7) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [doxazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170) (p*K* ~i~ 9.1) \[689\], [alfuzosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109) (p*K* ~i~ 8.6) \[[751](http://www.ncbi.nlm.nih.gov/pubmed/7658428?dopt=AbstractPlus)\], [terazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302) (p*K* ~i~ 8.6) \[[1263](http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus)\], [phentolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502) (p*K* ~i~ 7.5) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\][prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503) (Inverse agonist) (p*K* ~i~ 9.5--10.2) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [tamsulosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488) (p*K* ~i~ 9.8--10.2) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [doxazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170) (p*K* ~i~ 9.1) \[689\], [terazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302) (p*K* ~i~ 9.1) \[[1263](http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus)\], [alfuzosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109) (p*K* ~i~ 8.4) \[[750](http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus)\], [dapiprazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7155) (p*K* ~i~ 8.4) \[68\], [phentolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502) (Inverse agonist) (p*K* ~i~ 8.2) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\], [RS‐100329](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381) (p*K* ~i~ 7.9) \[[2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [labetalol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207) (p*K* ~i~ 6.6) \[68\]Selective antagonists[tamsulosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488) (p*K* ~i~ 10--10.7) \[[289](http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus), [389](http://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus), [532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus), [2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [silodosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=493) (p*K* ~i~ 10.4) \[[1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\], [S(+)‐niguldipine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=487) (p*K* ~i~ 9.1--10) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1722](http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus)\], [RS‐100329](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381) (p*K* ~i~ 9.6) \[[2029](http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus)\], [SNAP5089](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=498) (p*K* ~i~ 8.8--9.4) \[[750](http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus), [1081](http://www.ncbi.nlm.nih.gov/pubmed/9190863?dopt=AbstractPlus), [2014](http://www.ncbi.nlm.nih.gov/pubmed/7752182?dopt=AbstractPlus)\], [*ρ*‐Da1a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6663) (p*K* ~i~ 9.2--9.3) \[[1236](http://www.ncbi.nlm.nih.gov/pubmed/23935897?dopt=AbstractPlus), [1548](http://www.ncbi.nlm.nih.gov/pubmed/20015090?dopt=AbstractPlus)\], [RS‐17053](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=495) (p*K* ~i~ 9.2--9.3) \[[289](http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus), [389](http://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus), [529](http://www.ncbi.nlm.nih.gov/pubmed/8632751?dopt=AbstractPlus), [532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus)\][Rec 15/2615](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8459) (p*K* ~i~ 9.5) \[[1867](http://www.ncbi.nlm.nih.gov/pubmed/9190864?dopt=AbstractPlus)\], [L‐765314](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=506) (p*K* ~i~ 7.7) \[[1470](http://www.ncbi.nlm.nih.gov/pubmed/9548811?dopt=AbstractPlus)\], [AH 11110](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8461) (p*K* ~i~ 7.5) \[[1652](http://www.ncbi.nlm.nih.gov/pubmed/8764344?dopt=AbstractPlus)\][BMY‐7378](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9) (p*K* ~i~ 8.7--9.1) \[[268](http://www.ncbi.nlm.nih.gov/pubmed/11354357?dopt=AbstractPlus), [2102](http://www.ncbi.nlm.nih.gov/pubmed/11459121?dopt=AbstractPlus)\]

### **Adrenoceptors, *α*~2~** {#bph13348-sec-0033}

*α* ~2~‐Adrenoceptors (**nomenclature as agreed by [NC‐IUPHAR]{.ul} Subcommittee on Adrenoceptors; \[** [**248**](http://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus) **\]**) are activated by endogenous agonists with a relative potency of [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)\>[(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505). [Brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520) and [talipexole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5442) are agonists selective for *α* ~2~‐adrenoceptors relative to *α* ~1~‐adrenoceptors, [rauwolscine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136) and [yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102) are antagonists selective for *α* ~2~‐adrenoceptors relative to *α* ~1~‐adrenoceptors. [\[^3^H\]rauwolscine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=223)(1 nM), [\[^3^H\]brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5386)(5 nM) and [\[^3^H\]RX821002](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=528)(0.5 nM and 0.1 nM at *α* ~2C~) are relatively selective radioligands. There is species variation in the pharmacology of the *α* ~2A~‐adrenoceptor; for example, [yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102), [rauwolscine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136) and [oxymetazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124) have an  20‐fold higher affinity for the human *α* ~2A~‐adrenoceptor compared to the rat, mouse and bovine receptor. These *α* ~2A~ orthologues are sometimes referred to as *α* ~2D~‐adrenoceptors. Multiple mutations of *α* ~2~‐adrenoceptors have been described, some of which are associated with alterations in function. Presynaptic *α* ~2~‐adrenoceptors are widespread in the nervous system and regulate many functions, hence the multiplicity of actions. The effects of classical (not subtype selective) *α* ~2~‐adrenoceptor agonists such as [clonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516), [guanabenz](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443) and [brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520) on central baroreflex control (hypotension and bradycardia), as well as their ability to induce hypnotic effects and analgesia, and their ability to modulate seizure activity and platelet aggregation are mediated by *α* ~2A~‐adrenoceptors. [Clonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516) has been used as an anti‐hypertensive and also to counteract opioid withdrawal. Actions on imidazoline recognition sites may contribute to the pharmacological effects of clonidine. *α* ~2~‐Adrenoceptor agonists such as [dexmedetomidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521) have been widely used as sedatives and analgesics in veterinary medicine (also [xylazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=523)) and are now used frequently in humans. Dexmedetomidine also has analgesic, sympatholytic and anxiolytic properties but is notable for the production of sedation without respiratory depression. *α* ~2~‐Adrenoceptor antagonists are relatively little used therapeutically although [yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102) has been used to treat erectile dysfunction and several anti‐depressants (e.g. [Mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241)) that block *α* ~2~‐adrenoceptors may work through this mechanism. The roles of *α* ~2B~ and *α* ~2C~‐adrenoceptors are less clear but the *α* ~2B~ subtype appears to be involved in neurotransmission in the spinal cord and *α* ~2C~ in regulating catecholamine release from adrenal chromaffin cells.

Nomenclature[*α*~2A~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=25)[*α*~2B~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=26)[*α*~2C~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=27)HGNC, UniProt[*ADRA2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=281), [P08913](http://www.uniprot.org/uniprot/P08913)[*ADRA2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=282), [P18089](http://www.uniprot.org/uniprot/P18089)[*ADRA2C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=283), [P18825](http://www.uniprot.org/uniprot/P18825)Endogenous agonists[(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) (p*K* ~i~ 5.6--8.3) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\][(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) (Partial agonist) (p*K* ~i~ 5.6--9.1) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\][(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) (p*K* ~i~ 5.9--8.7) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\]Agonists[dexmedetomidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521) (Partial agonist) (p*K* ~i~ 7.6--9.6) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1163](http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [clonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516) (Partial agonist) (p*K* ~i~ 7.2--9.2) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520) (p*K* ~i~ 6.7--8.7) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1163](http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [apraclonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7117) (p*K* ~i~ 8.5) \[[1343](http://www.ncbi.nlm.nih.gov/pubmed/8784451?dopt=AbstractPlus)\], [guanabenz](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443) (pIC~50~ 7.4) \[68\], [guanfacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522) (Partial agonist) (p*K* ~i~ 7.1--7.3) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1165](http://www.ncbi.nlm.nih.gov/pubmed/9283709?dopt=AbstractPlus)\][dexmedetomidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521) (p*K* ~i~ 7.5--9.7) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1163](http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [clonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516) (Partial agonist) (p*K* ~i~ 6.7--9.5) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520) (Partial agonist) (p*K* ~i~ 6--8.3) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [guanabenz](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443) (pIC~50~ 6.8) \[68\], [guanfacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522) (p*K* ~i~ 5.8--6.5) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus)\][dexmedetomidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521) (p*K* ~i~ 7--9.3) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [brimonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520) (Partial agonist) (p*K* ~i~ 5.7--7.6) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1163](http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus), [1484](http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus), [1503](http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus)\], [apraclonidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7117) (p*K* ~i~ 7.5) \[[1343](http://www.ncbi.nlm.nih.gov/pubmed/8784451?dopt=AbstractPlus)\], [guanfacine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522) (Partial agonist) (p*K* ~i~ 5.4--6.2) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus)\], [guanabenz](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443) (pIC~50~ 6) \[68\]Selective agonists[oxymetazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124) (Partial agonist) (p*K* ~i~ 8--8.6) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus), [1163](http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus), [1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\]----Antagonists[yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102) (p*K* ~i~ 8.5--9.5) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus), [416](http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus), [1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\], [WB 4101](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499) (p*K* ~i~ 8.4--9.4) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus), [416](http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus), [1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\], [spiroxatrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53) (p*K* ~i~ 9) \[[1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\], [mirtazapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241) (p*K* ~i~ 7.7) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus)\], [tolazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7310) (p*K* ~i~ 5.4) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus)\][yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102) (p*K* ~i~ 8.4--9.2) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus), [416](http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus), [1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\][yohimbine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102) (p*K* ~i~ 7.9--8.9) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus), [416](http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus), [1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\], [phenoxybenzamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7268) (p*K* ~i~ 8.5) \[[2002](http://www.ncbi.nlm.nih.gov/pubmed/1834671?dopt=AbstractPlus)\], [tolazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7310) (p*K* ~i~ 5.5) \[[854](http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus)\]Selective antagonists[BRL 44408](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=525) (p*K* ~i~ 8.2--8.8) \[[1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus), [2104](http://www.ncbi.nlm.nih.gov/pubmed/2573535?dopt=AbstractPlus)\][imiloxan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3470) (p*K* ~i~ 7.3) \[[1269](http://www.ncbi.nlm.nih.gov/pubmed/1970500?dopt=AbstractPlus)\] -- Rat[JP1302](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3930) (p*K* ~B~ 7.8) \[[1631](http://www.ncbi.nlm.nih.gov/pubmed/17220913?dopt=AbstractPlus)\]Labelled ligands----[\[^3^H\]MK‐912](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=527) (Antagonist) (p*K* ~d~ 10.1) \[[1922](http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus)\]

### **Adrenoceptors, *β*** {#bph13348-sec-0034}

*β*‐Adrenoceptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Adrenoceptors, \[** [**248**](http://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus) **\]**) are activated by the endogenous agonists [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) and [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505). [Isoprenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=536) is a synthetic agonist selective for *β*‐adrenoceptors relative to *α* ~1~‐ and *α* ~2~‐adrenoceptors, while for *β* ~1~ and *β* ~2~ adrenoceptors, [propranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564)(pK~i~8.2‐9.2) and [cyanopindolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132)(pK~i~ 10.0‐11.0) are relatively selective antagonists. [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505), [xamoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=538) and [(‐)‐Ro 363](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5571) are agonists that show selectivity for *β* ~1~‐ relative to *β* ~2~‐adrenoceptors. Pharmacological differences exist between human and mouse *β* ~3~‐adrenoceptors, and the \'rodent selective\' agonists [BRL 37344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567) and [CL316243](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462) have low efficacy at the human *β* ~3~‐adrenoceptor whereas [CGP 12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532) and [L 755507](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931) activate human *β* ~3~‐adrenoceptors \[[1649](http://www.ncbi.nlm.nih.gov/pubmed/17717109?dopt=AbstractPlus)\]. *β* ~3~‐Adrenoceptors are relatively resistant to blockade by [propranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564)(pK~i~5.8‐7.0), but can be blocked by high concentrations of [bupranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550)(pK~i~8.65 \[[1650](http://www.ncbi.nlm.nih.gov/pubmed/18684840?dopt=AbstractPlus)\]). [SR59230A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547) has reasonably high affinity at *β* ~3~‐adrenoceptors \[[1197](http://www.ncbi.nlm.nih.gov/pubmed/8821531?dopt=AbstractPlus)\], but does not discriminate well between the three *β*‐adrenoceptor subtypes \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\] and has been reported to have lower affinity for the *β* ~3~‐adrenoceptor in some circumstances \[[913](http://www.ncbi.nlm.nih.gov/pubmed/8864547?dopt=AbstractPlus)\]. [L‐748337](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3932) is the most selective antagonist for *β* ~3~ adrenoceptors. \[^125^I\]‐[cyanopindolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132), \[^125^I\]‐hydroxybenzylpindolol and \[^3^H\]‐[alprenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=563) are high affinity radioligands widely used to label *β* ~1~‐ and *β* ~2~‐adrenoceptors and *β* ~3~‐adrenoceptors can be labelled with higher concentrations (nM) of \[^125^I\]‐cyanopindolol in the presence of appropriate concentrations of *β* ~1~‐ and *β* ~2~‐adrenoceptor antagonists. \[^3^H\]L‐748337 is a *β* ~3~‐selective radioligand. Fluorescent ligands such as BODIPY‐TMR‐CGP12177 are also increasingly being used to track *β*‐adrenoceptors at the cellular level \[[86](http://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus)\]. Somewhat selective *β* ~1~‐adrenoceptor selective agonists ([denopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=534), [dobutamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=535)) are used short‐term to treat cardiogenic shock but, in the longer term, reduce survival. *β* ~1~‐Adrenoceptor‐preferring antagonists are used to treat hypertension ([atenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548), [betaxolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=549), [bisoprolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7129), [metoprolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553) and [nebivolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7246)), cardiac arrhythmias ([atenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548), bisoprolol, [esmolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7178)) and cardiac failure ([metoprolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553), nebivolol). Cardiac failure is also succesfully treated with [carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) which blocks both *β* ~1~‐ and *β* ~2~‐adrenoceptors, as well as *α* ~1~‐adrenoceptors. *β* ~2~‐Adrenoceptor‐selective agonists are powerful bronchodilators widely used to treat respiratory disorders. There are both short ([salbutamol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=558), [terbutaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=560)) and long acting drugs ([formoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3465), [salmeterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=559)). Although many first generation *β*‐adrenoceptor antagonists ([propranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564)) block both *β* ~1~‐ and *β* ~2~‐adrenoceptors there are no *β* ~2~‐adrenoceptor‐selective antagonists used therapeutically. The *β* ~3~‐adrenoceptor agonist [mirabegron](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445) is used to control overactive bladder syndrome.

Nomenclature[*β*~1~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=28)[*β*~2~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29)[*β*~3~‐adrenoceptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30)HGNC, UniProt[*ADRB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=285), [P08588](http://www.uniprot.org/uniprot/P08588)[*ADRB2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=286), [P07550](http://www.uniprot.org/uniprot/P07550)[*ADRB3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=288), [P13945](http://www.uniprot.org/uniprot/P13945)Rank order of potency[(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505)\>[(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)[(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)\>[(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505)[(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) = [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)Endogenous agonists[noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=484) (p*K* ~i~ 6) \[[549](http://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus)\]----Agonists[pindolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91) (Partial agonist) (p*K* ~i~ 9.3) \[[1011](http://www.ncbi.nlm.nih.gov/pubmed/17804228?dopt=AbstractPlus)\], [isoprenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=536) (p*K* ~i~ 6.6--7) \[[549](http://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus), [1651](http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus)\], [dobutamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=535) (Partial agonist) (p*K* ~i~ 5.5) \[[831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus)\][pindolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91) (Partial agonist) (p*K* ~i~ 9.4) \[[1011](http://www.ncbi.nlm.nih.gov/pubmed/17804228?dopt=AbstractPlus)\], [arformoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7479) (p*K* ~i~ 8.6) \[[37](http://www.ncbi.nlm.nih.gov/pubmed/15324892?dopt=AbstractPlus)\], [isoprenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=536) (p*K* ~i~ 6.4) \[[1651](http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus)\], [dobutamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=535) (Partial agonist) (p*K* ~i~ 6.2) \[[1100](http://www.ncbi.nlm.nih.gov/pubmed/15102946?dopt=AbstractPlus)\], [ephedrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=556) (Partial agonist) (p*K* ~i~ 5.6) \[[851](http://www.ncbi.nlm.nih.gov/pubmed/9295336?dopt=AbstractPlus)\][carazolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=569) (p*K* ~i~ 8.7) \[[1256](http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus)\]Selective agonists[(‐)‐Ro 363](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5571) (p*K* ~i~ 8) \[[1301](http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus)\], [xamoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=538) (Partial agonist) (p*K* ~i~ 7) \[[831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus)\], [denopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=534) (Partial agonist) (p*K* ~i~ 5.8) \[[831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus), [1830](http://www.ncbi.nlm.nih.gov/pubmed/7902433?dopt=AbstractPlus)\][formoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3465) (pEC~50~ 10.1) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\], [salmeterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=559) (pEC~50~ 9.9) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\], [zinterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3466) (pEC~50~ 9.5) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\], [vilanterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353) (pEC~50~ 9.4) \[[1534](http://www.ncbi.nlm.nih.gov/pubmed/20462258?dopt=AbstractPlus)\], [procaterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3464) (pEC~50~ 8.4) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\], [indacaterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7455) (p*K* ~i~ 7.8) \[[107](http://www.ncbi.nlm.nih.gov/pubmed/22932315?dopt=AbstractPlus)\], [fenoterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=557) (p*K* ~i~ 6.9) \[[55](http://www.ncbi.nlm.nih.gov/pubmed/24454993?dopt=AbstractPlus)\], [salbutamol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=558) (Partial agonist) (p*K* ~i~ 5.8--6.1) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus)\], [terbutaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=560) (Partial agonist) (p*K* ~i~ 5.6) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus)\], [orciprenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7250) (p*K* ~d~ 5.3) \[[1784](http://www.ncbi.nlm.nih.gov/pubmed/19168263?dopt=AbstractPlus)\][L 755507](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931) (pEC~50~ 10.1) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\], [L742791](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3467) (pEC~50~ 8.8) \[[2000](http://www.ncbi.nlm.nih.gov/pubmed/9873496?dopt=AbstractPlus)\], [mirabegron](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445) (pEC~50~ 7.7) \[[1849](http://www.ncbi.nlm.nih.gov/pubmed/17293563?dopt=AbstractPlus)\], [CGP 12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532) (Partial agonist) (p*K* ~i~ 6.1--7.3) \[[159](http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1256](http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus), [1301](http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus)\], [SB251023](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3468) (pEC~50~ 7.1) \[[810](http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus)\] -- Mouse, [BRL 37344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567) (p*K* ~i~ 6.4--7) \[[159](http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus), [431](http://www.ncbi.nlm.nih.gov/pubmed/7912272?dopt=AbstractPlus), [768](http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus), [1256](http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus)\], [CL316243](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462) (p*K* ~i~ 5.2) \[[2080](http://www.ncbi.nlm.nih.gov/pubmed/11249148?dopt=AbstractPlus)\]Antagonists[carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) (p*K* ~i~ 9.5) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [bupranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550) (p*K* ~i~ 7.3--9) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [levobunolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570) (p*K* ~i~ 8.4) \[68\], [labetalol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207) (p*K* ~i~ 8.2) \[68\], [metoprolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553) (p*K* ~i~ 7--7.6) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [768](http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [esmolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7178) (p*K* ~i~ 6.9) \[68\], [nadolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=554) (p*K* ~i~ 6.9) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [practolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=555) (p*K* ~i~ 6.1--6.8) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [propafenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561) (p*K* ~i~ 6.7) \[68\], [sotalol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7297) (p*K* ~i~ 6.1) \[68\][carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) (p*K* ~i~ 9.4--9.9) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [timolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=565) (p*K* ~i~ 9.7) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus)\], [propranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564) (p*K* ~i~ 9.1--9.5) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [86](http://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus), [831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [levobunolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570) (p*K* ~i~ 9.3) \[68\], [bupranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550) (p*K* ~i~ 8.3--9.1) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [alprenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=563) (p*K* ~i~ 9) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus)\], [nadolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=554) (p*K* ~i~ 7--8.6) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [labetalol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207) (p*K* ~i~ 8) \[68\], [propafenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561) (p*K* ~i~ 7.4) \[68\], [sotalol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7297) (p*K* ~i~ 6.5) \[68\][carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) (p*K* ~i~ 9.4) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [bupranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550) (p*K* ~i~ 6.8--7.3) \[[159](http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus), [262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1256](http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus)\], [propranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564) (p*K* ~i~ 6.3--7.2) \[[1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1517](http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus)\], [levobunolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570) (p*K* ~i~ 6.8) \[[1517](http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus)\]Selective antagonists[CGP 20712A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=541) (p*K* ~i~ 8.5--9.2) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [levobetaxolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8035) (p*K* ~i~ 9.1) \[[1715](http://www.ncbi.nlm.nih.gov/pubmed/11572462?dopt=AbstractPlus)\], [betaxolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=549) (p*K* ~i~ 8.8) \[[1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [nebivolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7246) (pIC~50~ 8.1--8.7) \[[1476](http://www.ncbi.nlm.nih.gov/pubmed/2462161?dopt=AbstractPlus)\] -- Rabbit, [atenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548) (p*K* ~i~ 6.7--7.6) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [886](http://www.ncbi.nlm.nih.gov/pubmed/15060759?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\], [acebutolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7107) (p*K* ~i~ 6.4) \[68\][ICI 118551](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=543) (Inverse agonist) (p*K* ~i~ 9.2--9.5) \[[83](http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus), [86](http://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus)\][L‐748337](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3932) (p*K* ~i~ 8.4) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\], [SR59230A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547) (p*K* ~i~ 6.9--8.4) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus), [405](http://www.ncbi.nlm.nih.gov/pubmed/8730727?dopt=AbstractPlus), [768](http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus)\], [L748328](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3463) (p*K* ~i~ 8.4) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562) (Selective Antagonist) (p*K* ~d~ 10.4--11.3) \[[831](http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus), [1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1651](http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus)\][\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562) (Antagonist) (p*K* ~d~ 11.1) \[[1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1651](http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus)\][\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562) (Agonist, Partial agonist) (p*K* ~d~ 9.2--9.8) \[[1144](http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus), [1301](http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus), [1517](http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus), [1651](http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus), [1806](http://www.ncbi.nlm.nih.gov/pubmed/9131260?dopt=AbstractPlus)\]CommentsThe agonists indicated have less than two orders of magnitude selectivity \[[81](http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus)\].--Agonist [SB251023](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3468) has a pEC50 of 6.9 for the splice variant of the mouse *β* ~3~ receptor, *β* ~3b~ \[[810](http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0035}
--------

### **Adrenoceptors, *α*~1~** {#bph13348-sec-0036}

The clone originally called the *α* ~1C~‐adrenoceptor corresponds to the pharmacologically defined *α* ~1A~‐adrenoceptor \[[752](http://www.ncbi.nlm.nih.gov/pubmed/7568329?dopt=AbstractPlus)\]. Some tissues possess *α* ~1A~‐adrenoceptors (termed *α* ~1L~‐adrenoceptors \[[532](http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus), [1329](http://www.ncbi.nlm.nih.gov/pubmed/17162094?dopt=AbstractPlus)\]) that display relatively low affinity in functional and binding assays for [prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503)(p*K~i~*\< 9) indicative of different receptor states or locations. *α* ~1A~‐adrenoceptor C‐terminal splice variants form homo‐ and heterodimers, but fail to generate a functional *α* ~1L~‐adrenoceptor \[[1557](http://www.ncbi.nlm.nih.gov/pubmed/15266013?dopt=AbstractPlus)\]. *α* ~1D~‐Adrenoceptors form heterodimers with *α* ~1B~‐ or *β* ~2~‐adrenoceptors that show increased cell‐surface expression \[[1917](http://www.ncbi.nlm.nih.gov/pubmed/15615865?dopt=AbstractPlus)\]. Recombinant *α* ~1D~‐adrenoceptors have been shown in some heterologous systems to be mainly located intracellularly but cell‐surface localization is attained by truncation of the N‐terminus, or by co‐expression of *α* ~1B~‐ or *β* ~2~‐adrenoceptors to form heterodimers \[[670](http://www.ncbi.nlm.nih.gov/pubmed/14718583?dopt=AbstractPlus), [1917](http://www.ncbi.nlm.nih.gov/pubmed/15615865?dopt=AbstractPlus)\]. In smooth muscle of native blood vessels all three *α* ~1‐~adrenoceptor subtypes are located on the surface and intracellularly \[[1260](http://www.ncbi.nlm.nih.gov/pubmed/19572943?dopt=AbstractPlus), [1261](http://www.ncbi.nlm.nih.gov/pubmed/19888965?dopt=AbstractPlus)\].

Signalling is predominantly via G~q/11~ but *α* ~1~‐adrenoceptors also couple to G~i/o~, G~s~ and G~12/13~. Several ligands activating *α* ~1A~‐adrenoceptors display ligand directed signalling bias relative to noradrenaline. For example, [oxymetazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124) is a full agonist for extracellular acidification rate (ECAR) and a partial agonist for Ca^2+^ release but does not stimulate cAMP production. [Phenylephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485) is biased toward ECAR versus Ca^2+^ release or cAMP accumulation but not between Ca^2+^ release and cAMP accumulation \[[495](http://www.ncbi.nlm.nih.gov/pubmed/20978120?dopt=AbstractPlus)\]. There are also differences between subtypes in coupling efficiency to different pathways‐ *e.g.* in some systems coupling efficiency to Ca^2+^ signalling is *α* ~1A~\>*α* ~1B~\>*α* ~1D~, but for MAP kinase signalling is *α* ~1D~\>*α* ~1A~\>*α* ~1B~. In vascular smooth muscle, the potency of agonists is related to the predominant subtype, *α* ~1D~‐ conveying greater agonist sensitivity than *α* ~1A~‐adrenoceptors \[[526](http://www.ncbi.nlm.nih.gov/pubmed/23373597?dopt=AbstractPlus)\].

### **Adrenoceptors, *α*~2~** {#bph13348-sec-0037}

[ARC‐239](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=524)(pK~i~ 8.0) and [prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503)(pK~i~ 7.5) show selectivity for *α* ~2B~‐ and *α* ~2C~‐adrenoceptors over *α* ~2A~‐adrenoceptors.[Oxymetazoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124) is a reduced efficacy agonist and is one of many *α* ~2~‐adrenoceptor agonists that are imidazolines or closely related compounds. Other binding sites for imidazolines, distinct from *α* ~2~‐adrenoceptors, and structurally distinct from the 7TM adrenoceptors, have been identified and classified as I~1~, I~2~ and I~3~sites \[[390](http://www.ncbi.nlm.nih.gov/pubmed/15224384?dopt=AbstractPlus)\]; catecholamines have a low affinity, while rilmenidine and moxonidine are selective ligands for these sites, evoking hypotensive effects *in vivo*. I~1~‐imidazoline receptors are involved in central inhibition of sympathetic tone, I~2~‐imidazoline receptors are an allosteric binding site on monoamine oxidase B, and I~3~‐imidazoline receptors regulate insulin secretion from pancreatic *β*‐cells. *α* ~2A~‐adrenoceptor stimulation reduces insulin secretion from *β*‐islets \[[2083](http://www.ncbi.nlm.nih.gov/pubmed/22645144?dopt=AbstractPlus)\], with a polymorphism in the 5\'‐UTR of the ADRA2A gene being associated with increased receptor expression in *β*‐islets and heightened susceptibility to diabetes \[[1599](http://www.ncbi.nlm.nih.gov/pubmed/19965390?dopt=AbstractPlus)\].

*α* ~2A~‐ and *α* ~2C~‐adrenoceptors form homodimers \[[1758](http://www.ncbi.nlm.nih.gov/pubmed/16605244?dopt=AbstractPlus)\]. Heterodimers between *α* ~2A~‐ and either the *α* ~2c~‐adrenoceptor or *μ* opioid peptide receptor exhibit altered signalling and trafficking properties compared to the individual receptors \[[1758](http://www.ncbi.nlm.nih.gov/pubmed/16605244?dopt=AbstractPlus), [1858](http://www.ncbi.nlm.nih.gov/pubmed/19126537?dopt=AbstractPlus), [1956](http://www.ncbi.nlm.nih.gov/pubmed/18193048?dopt=AbstractPlus)\]. Signalling by *α* ~2~‐adrenoceptors is primarily via G~i/o~, however the *α* ~2A~‐adrenoceptor also couples to G~s~\[[459](http://www.ncbi.nlm.nih.gov/pubmed/7559592?dopt=AbstractPlus)\]. Imidazoline compounds display bias relative to each other at the *α* ~2A~‐adrenoceptor when assayed by \[^35^S\] GTP*γ*S binding compared to inhibition of cAMP accumulation \[[1477](http://www.ncbi.nlm.nih.gov/pubmed/12649300?dopt=AbstractPlus)\]. The noradrenaline reuptake inhibitor desipramine acts directly on the *α* ~2A~‐adrenoceptor, promoting internalisation *via* recruitment of arrestin without activating G proteins \[[371](http://www.ncbi.nlm.nih.gov/pubmed/21859713?dopt=AbstractPlus)\].

### **Adrenoceptors, *β*** {#bph13348-sec-0038}

Radioligand binding with [\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562) can be used to define *β* ~1~‐ or *β* ~2~‐adrenoceptors when conducted in the presence of a \'saturating\' concentration of either a *β* ~1~‐ or *β* ~2~‐adrenoceptor‐selective antagonist. [\[^3^H\]CGP12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5387) or [\[^3^H\]dihydroalprenolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5388) can be used in place of [\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562). Binding of a fluorescent analogue of [CGP 12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532) to *β* ~2~‐adrenoceptors in living cells has been described \[[84](http://www.ncbi.nlm.nih.gov/pubmed/12770928?dopt=AbstractPlus)\]. [\[^125^I\]ICYP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562) at higher (nM) concentrations can be used to label *β* ~3~‐adrenoceptors in systems where there are few if any other *β*‐adrenoceptor subtypes. Pharmacological differences exist between human and mouse *β* ~3~‐adrenoceptors, and the \'rodent selective\' agonists [BRL 37344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567) and [CL316243](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462) are partial agonists at the human *β* ~3~‐adrenoceptor whereas [CGP 12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532) and [L 755507](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931) activate human *β*3‐adrenoceptors with greater potency \[[1650](http://www.ncbi.nlm.nih.gov/pubmed/18684840?dopt=AbstractPlus)\]. The *β* ~3~‐adrenoceptor has an intron in the coding region, but splice variants have only been described for the mouse \[[496](http://www.ncbi.nlm.nih.gov/pubmed/10455305?dopt=AbstractPlus)\], where the isoforms display different signalling characteristics \[[810](http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus)\]. There are 3 *β*‐adrenoceptors in turkey (termed the t*β*, t*β*3c and t*β*4c) that have a pharmacology that differs from the human *β*‐adrenoceptors \[[82](http://www.ncbi.nlm.nih.gov/pubmed/21152092?dopt=AbstractPlus)\]. Numerous polymorphisms have been described for the three *β*‐adrenoceptors; some are associated with alterations in agonist‐evoked signalling and trafficking, altered susceptibility to disease and/or altered responses to pharmacotherapy \[[1103](http://www.ncbi.nlm.nih.gov/pubmed/15090197?dopt=AbstractPlus)\].

All *β*‐adrenoceptors couple to G~s~(activating adenylyl cyclase and elevating cAMP levels), but it is also clear that they activate other G proteins such as G~i~ and many other G protein‐independent signalling pathways, including arrestin‐mediated signalling, which may in turn lead to activation of MAP kinases. Many antagonists at *β* ~1~‐ and *β* ~2~‐adrenoceptors are agonists at *β* ~3~‐adrenoceptors ([CL316243](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462), [CGP 12177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532) and [carazolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=569)). Many 'antagonists' that block agonist‐stimulated cAMP accumulation, for example [carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) and bucindolol, are able to activate MAP kinase pathways \[[85](http://www.ncbi.nlm.nih.gov/pubmed/14645666?dopt=AbstractPlus), [497](http://www.ncbi.nlm.nih.gov/pubmed/20132209?dopt=AbstractPlus), [559](http://www.ncbi.nlm.nih.gov/pubmed/16901982?dopt=AbstractPlus), [560](http://www.ncbi.nlm.nih.gov/pubmed/18403719?dopt=AbstractPlus), [1649](http://www.ncbi.nlm.nih.gov/pubmed/17717109?dopt=AbstractPlus), [1650](http://www.ncbi.nlm.nih.gov/pubmed/18684840?dopt=AbstractPlus)\] and thus display \'protean agonism\'. [Bupranolol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550) appears to act as a neutral antagonist in most systems so far examined. Agonists also display biased signalling at the *β* ~2~‐adrenoceptor via G~s~ or arrestins \[[443](http://www.ncbi.nlm.nih.gov/pubmed/18086673?dopt=AbstractPlus)\].

The X‐ray crystal structures have been described of the agonist bound \[[1988](http://www.ncbi.nlm.nih.gov/pubmed/21228877?dopt=AbstractPlus)\] and antagonist bound forms of the *β* ~1~‐ \[[1989](http://www.ncbi.nlm.nih.gov/pubmed/18594507?dopt=AbstractPlus)\], agonist‐bound \[[313](http://www.ncbi.nlm.nih.gov/pubmed/17962520?dopt=AbstractPlus)\] and antagonist‐bound forms of the *β* ~2~‐adrenoceptor \[[1561](http://www.ncbi.nlm.nih.gov/pubmed/21228869?dopt=AbstractPlus), [1598](http://www.ncbi.nlm.nih.gov/pubmed/21228876?dopt=AbstractPlus)\], as well as a fully active agonist‐bound, G~s~ protein‐coupled *β* ~2~‐adrenoceptor \[[1562](http://www.ncbi.nlm.nih.gov/pubmed/21772288?dopt=AbstractPlus)\]. [Carvedilol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551) and bucindolol bind to an extended site of the *β* ~1~‐adrenoceptor involving contacts in TM2, 3, and 7 and extracellular loop 2 that may facilitate coupling to arrestins \[[1989](http://www.ncbi.nlm.nih.gov/pubmed/18594507?dopt=AbstractPlus)\]. Compounds displaying arrestin‐biased signalling at the *β* ~2~‐adrenoceptor also have a greater effect on the conformation of TM7, whereas full agonists for G~s~ coupling promote movement of TM5 and TM6 \[[1127](http://www.ncbi.nlm.nih.gov/pubmed/22267580?dopt=AbstractPlus)\]. Recent studies using NMR spectroscopy have demonstrated significant conformational flexibility in the *β* ~2~‐adrenoceptor which is stabilized by both agonist and G proteins highlighting the dynamic nature of interactions with both ligand and downstream signalling partners \[[946](http://www.ncbi.nlm.nih.gov/pubmed/23721409?dopt=AbstractPlus), [1199](http://www.ncbi.nlm.nih.gov/pubmed/25981665?dopt=AbstractPlus), [1413](http://www.ncbi.nlm.nih.gov/pubmed/23374348?dopt=AbstractPlus)\]. Such flexibility will likely have consequences for our understanding of biased agonism, and for the future therapeutic exploitation of this phenomenon.
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[Angiotensin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=6) {#bph13348-sec-0040}
================================================================================================

Overview {#bph13348-sec-0041}
--------

The actions of [angiotensin II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) (Ang II) are mediated by AT~1~ and AT~2~ receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Angiotensin Receptors \[** [**2137**](http://www.ncbi.nlm.nih.gov/pubmed/10977869?dopt=AbstractPlus) **\]**), which have around 30% sequence similarity. Endogenous ligands are [angiotensin II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504)([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) and [angiotensin III](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=585)([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) (Ang III), while [angiotensin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=583)([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) is weakly active in some systems.

Nomenclature[AT~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34)[AT~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=35)HGNC, UniProt[*AGTR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=336), [P30556](http://www.uniprot.org/uniprot/P30556)[*AGTR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=338), [P50052](http://www.uniprot.org/uniprot/P50052)Selective agonists[L‐162,313](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3936) (pIC~50~ 7.8--7.9) \[[1490](http://www.ncbi.nlm.nih.gov/pubmed/7829475?dopt=AbstractPlus)\][CGP42112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3944) (pIC~50~ 9.6) \[[190](http://www.ncbi.nlm.nih.gov/pubmed/21542804?dopt=AbstractPlus)\], [\[p‐aminoPhe6\]ang II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=595) (p*K* ~d~ 9.1--9.4) \[[1789](http://www.ncbi.nlm.nih.gov/pubmed/2194459?dopt=AbstractPlus), 2139\] -- RatAntagonists[telmisartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=592) (pIC~50~ 8.4) \[[1241](http://www.ncbi.nlm.nih.gov/pubmed/9878991?dopt=AbstractPlus)\], [olmesartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=591) (pIC~50~ 8.1) \[[981](http://www.ncbi.nlm.nih.gov/pubmed/11451212?dopt=AbstractPlus)\]--Selective antagonists[candesartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=587) (pIC~50~ 9.5--9.7) \[[1942](http://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus)\], [EXP3174](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=586) (pIC~50~ 7.4--9.5) \[[1887](http://www.ncbi.nlm.nih.gov/pubmed/8372104?dopt=AbstractPlus), [1942](http://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus)\], [eprosartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=588) (pIC~50~ 8.4--8.8) \[[464](http://www.ncbi.nlm.nih.gov/pubmed/1309870?dopt=AbstractPlus)\], [irbesartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=589) (pIC~50~ 8.7--8.8) \[[1942](http://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus)\], [losartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590) (pIC~50~ 7.4--8.7) \[[1887](http://www.ncbi.nlm.nih.gov/pubmed/8372104?dopt=AbstractPlus), 2139\], [valsartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3937) (pIC~50~ 8.6) \[[2138](http://www.ncbi.nlm.nih.gov/pubmed/8577935?dopt=AbstractPlus)\], [azilsartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6901) (pIC~50~ 8.1--8.1) \[[1551](http://www.ncbi.nlm.nih.gov/pubmed/24742498?dopt=AbstractPlus), [1844](http://www.ncbi.nlm.nih.gov/pubmed/24739538?dopt=AbstractPlus)\][PD123177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=596) (pIC~50~ 8.5--9.5) \[[291](http://www.ncbi.nlm.nih.gov/pubmed/2314387?dopt=AbstractPlus), [321](http://www.ncbi.nlm.nih.gov/pubmed/2590220?dopt=AbstractPlus), [450](http://www.ncbi.nlm.nih.gov/pubmed/8469774?dopt=AbstractPlus)\] -- Rat, [EMA401](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8374) (pIC~50~ 8.5--9.3) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/24507378?dopt=AbstractPlus), [1582](http://www.ncbi.nlm.nih.gov/pubmed/24507377?dopt=AbstractPlus), [1767](http://www.ncbi.nlm.nih.gov/pubmed/23489258?dopt=AbstractPlus)\], [PD123319](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=597) (p*K* ~d~ 8.7--9.2) \[[449](http://www.ncbi.nlm.nih.gov/pubmed/2402226?dopt=AbstractPlus), [2025](http://www.ncbi.nlm.nih.gov/pubmed/1709220?dopt=AbstractPlus), 2139\]Labelled ligands[\[^3^H\]A81988](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3938) (Antagonist) (p*K* ~d~ 9.2) \[[690](http://www.ncbi.nlm.nih.gov/pubmed/8206129?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]L158809](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3939) (Antagonist) (p*K* ~d~ 9.2) \[[305](http://www.ncbi.nlm.nih.gov/pubmed/1480133?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]eprosartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3940) (Antagonist) (p*K* ~d~ 9.1) \[[21](http://www.ncbi.nlm.nih.gov/pubmed/8463997?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]valsartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=593) (Antagonist) (pIC~50~ 8.8--9) \[[1954](http://www.ncbi.nlm.nih.gov/pubmed/11206708?dopt=AbstractPlus)\], [\[^125^I\]EXP985](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3942) (Antagonist) (p*K* ~d~ 8.8) \[[322](http://www.ncbi.nlm.nih.gov/pubmed/1445340?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]losartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3941) (Antagonist) (p*K* ~d~ 8.2) \[[294](http://www.ncbi.nlm.nih.gov/pubmed/8282008?dopt=AbstractPlus)\] -- Rat[\[^125^I\]CGP42112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=594) (Agonist) (p*K* ~d~ 10.6) \[[2017](http://www.ncbi.nlm.nih.gov/pubmed/2775266?dopt=AbstractPlus), [2018](http://www.ncbi.nlm.nih.gov/pubmed/1764088?dopt=AbstractPlus), 2139\]

Comments {#bph13348-sec-0042}
--------

AT~1~ receptors are predominantly coupled to Gq~/11~, however they are also linked to arrestin recruitment and stimulate G protein‐independent arrestin signalling \[[1156](http://www.ncbi.nlm.nih.gov/pubmed/20427692?dopt=AbstractPlus)\]. Most species express a single *AGTR1* gene, but two related *agtr1a* and a*gtr1b* receptor genes are expressed in rodents. The AT~2~ receptor counteracts several of the growth responses initiated by the AT~1~ receptors. The AT~2~ receptor is much less abundant than the AT~1~ receptor in adult tissues and is upregulated in pathological conditions. AT~1~ receptor antagonists bearing substituted 4‐phenylquinoline moieties have been synthesized, which bind to AT~1~ receptors with nanomolar affinity and are slightly more potent than [losartan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590) in functional studies \[[264](http://www.ncbi.nlm.nih.gov/pubmed/15115399?dopt=AbstractPlus)\]. The antagonist activity of [CGP42112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3944) at the AT~2~ receptor has also been reported \[[2147](http://www.ncbi.nlm.nih.gov/pubmed/3071214?dopt=AbstractPlus)\].

The AT~1~ and bradykinin B2 receptors have been proposed to form a heterodimeric complex \[[3](http://www.ncbi.nlm.nih.gov/pubmed/10993080?dopt=AbstractPlus)\].

There is also evidence for an AT~4~ receptor that specifically binds [angiotensin IV](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5368) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) and is located in the brain and kidney. An additional putative endogenous ligand for the AT~4~ receptor has been described ([LVV‐hemorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5353)([*HBB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4827), [P68871](http://www.uniprot.org/uniprot/P68871)), a globin decapeptide) \[[1296](http://www.ncbi.nlm.nih.gov/pubmed/9166749?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0043}
---------------
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Zhang H *et al*. (2015) Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. *Cell* **161**: 833‐44 [\[PMID:25913193\]](http://www.ncbi.nlm.nih.gov/pubmed/25913193?dopt=AbstractPlus)
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[Apelin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=7) {#bph13348-sec-0044}
==========================================================================================

Overview {#bph13348-sec-0045}
--------

The apelin receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the apelin receptor \[** [**1510**](http://www.ncbi.nlm.nih.gov/pubmed/20605969?dopt=AbstractPlus) **\]**) responds to apelin, a 36 amino‐acid peptide derived initially from bovine stomach. [Apelin‐36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606)([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)), [apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605)([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) and [\[Pyr^1^\]apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599)([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) are the predominant endogenous ligands which are cleaved from a 77 amino‐acid precursor peptide ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) by a so far unidentified enzymatic pathway \[[1864](http://www.ncbi.nlm.nih.gov/pubmed/9792798?dopt=AbstractPlus)\]. A second family of peptides discovered independently and named Elabela \[[323](http://www.ncbi.nlm.nih.gov/pubmed/24316148?dopt=AbstractPlus)\] or Toddler, that has little sequence similarity to apelin, has been proposed as a second endogenous apelin receptor ligand \[[1475](http://www.ncbi.nlm.nih.gov/pubmed/24407481?dopt=AbstractPlus)\].

Nomenclature[apelin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=36)HGNC, UniProt[*APLNR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=339), [P35414](http://www.uniprot.org/uniprot/P35414)Rank order of potency[\[Pyr^1^\]apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) ≥[apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) \>[apelin‐36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) \[[503](http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus), [1864](http://www.ncbi.nlm.nih.gov/pubmed/9792798?dopt=AbstractPlus)\]Endogenous agonists[apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) (Selective) (pIC~50~ 8.8--9.5) \[[503](http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus), [785](http://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus), [1254](http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus)\], [apelin receptor early endogenous ligand](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7930) ([*APELA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=48925), [P0DMC3](http://www.uniprot.org/uniprot/P0DMC3)) (Selective) (p*K* ~d~ 9.3) \[[412](http://www.ncbi.nlm.nih.gov/pubmed/25995451?dopt=AbstractPlus)\], [apelin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3556) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) (Selective) (pIC~50~ 7.9--9) \[[468](http://www.ncbi.nlm.nih.gov/pubmed/15341513?dopt=AbstractPlus), [1254](http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus)\], [\[Pyr^1^\]apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) (Selective) (pIC~50~ 7--8.8) \[[918](http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus), [1254](http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus)\], [Elabela/Toddler‐21](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8525) ([*APELA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=48925), [P0DMC3](http://www.uniprot.org/uniprot/P0DMC3)) (pIC~50~ 8.7) \[2086\], [Elabela/Toddler‐32](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8524) ([*APELA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=48925), [P0DMC3](http://www.uniprot.org/uniprot/P0DMC3)) (pIC~50~ 8.7) \[2086\], [apelin‐36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606) ([*APLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16665), [Q9ULZ1](http://www.uniprot.org/uniprot/Q9ULZ1)) (Selective) (pIC~50~ 8.2--8.6) \[[503](http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus), [785](http://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus), [918](http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus), [1254](http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus)\], [Elabela/Toddler‐11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8526) ([*APELA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=48925), [P0DMC3](http://www.uniprot.org/uniprot/P0DMC3)) (pIC~50~ 7.2) \[2086\]Selective agonists[MM07](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8523) (Biased agonist) (pEC~50~ 9.5) \[[203](http://www.ncbi.nlm.nih.gov/pubmed/25712721?dopt=AbstractPlus)\]Antagonists[MM54](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6186) (p*K* ~i~ 8.2) \[[1166](http://www.ncbi.nlm.nih.gov/pubmed/21560248?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]\[Nle^75^,Tyr^77^\]apelin‐36 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=603) (Agonist) (p*K* ~d~ 11.2) \[[918](http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus)\], [\[^125^I\]\[Glp^65^Nle^75^,Tyr^77^\]apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3761) (Agonist) (p*K* ~d~ 10.7) \[[785](http://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus)\], [\[^125^I\](Pyr^1^)apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=601) (Agonist) (p*K* ~d~ 9.5) \[[911](http://www.ncbi.nlm.nih.gov/pubmed/11250876?dopt=AbstractPlus)\], [\[^125^I\]apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=602) (Agonist) (p*K* ~d~ 9.2) \[[503](http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus)\], [\[^3^H\](Pyr^1^)\[Met(0)11\]‐apelin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=604) (Agonist) (p*K* ~d~ 8.6) \[[1254](http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0046}
--------

Potency order determined for heterologously expressed human apelin receptor (p*D* ~2~ values range from 9.5 to 8.6). The apelin receptor may also act as a co‐receptor with CD4 for isolates of human immunodeficiency virus, with apelin blocking this function \[[279](http://www.ncbi.nlm.nih.gov/pubmed/11090199?dopt=AbstractPlus)\]. A modified apelin‐13 peptide, [apelin‐13(F13A)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5354) was reported to block the hypotensive response to apelin in rat *in vivo*\[[1067](http://www.ncbi.nlm.nih.gov/pubmed/15486224?dopt=AbstractPlus)\], however, this peptide exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin receptor \[[503](http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0047}
---------------
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[Bile acid receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=8) {#bph13348-sec-0048}
=============================================================================================

Overview {#bph13348-sec-0049}
--------

The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718). Selective agonists are promising drugs for the treatment of metabolic disorders, such as type II diabetes, obesity and atherosclerosis.

Nomenclature[GPBA receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=37)HGNC, UniProt[*GPBAR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19680), [Q8TDU6](http://www.uniprot.org/uniprot/Q8TDU6)Rank order of potency[lithocholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611)\>[deoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610)\>[chenodeoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=608), [cholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=609) (Unknown) \[[917](http://www.ncbi.nlm.nih.gov/pubmed/12524422?dopt=AbstractPlus), [1214](http://www.ncbi.nlm.nih.gov/pubmed/12419312?dopt=AbstractPlus)\]Selective agonists[betulinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3945) (pEC~50~ 6) \[[590](http://www.ncbi.nlm.nih.gov/pubmed/19911773?dopt=AbstractPlus)\], [oleanolic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3306) (pEC~50~ 5.7) \[[1648](http://www.ncbi.nlm.nih.gov/pubmed/17825251?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0050}
--------

The triterpenoid natural product [betulinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3945) has also been reported to inhibit inflammatory signalling through the NF*κ*B pathway \[[1842](http://www.ncbi.nlm.nih.gov/pubmed/12960358?dopt=AbstractPlus)\]. Disruption of GPBA expression is reported to protect from cholesterol gallstone formation \[[1951](http://www.ncbi.nlm.nih.gov/pubmed/16724960?dopt=AbstractPlus)\]. A new series of 5‐phenoxy‐1,3‐dimethyl‐1H‐pyrazole‐4‐carboxamides have been reported as highly potent agonists \[[1138](http://www.ncbi.nlm.nih.gov/pubmed/23337601?dopt=AbstractPlus)\].
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---------------
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[Bombesin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=9) {#bph13348-sec-0052}
=============================================================================================

Overview {#bph13348-sec-0053}
--------

Bombesin receptors (**nomenclature recommended by the NC‐IUPHAR Subcommittee on bombesin receptors, \[** [**857**](http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus) **\]**) are activated by the endogenous ligands [gastrin‐releasing peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=612)([*GRP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4605), [P07492](http://www.uniprot.org/uniprot/P07492)) (GRP), [neuromedin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=613)([*NMB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7842), [P08949](http://www.uniprot.org/uniprot/P08949)) (NMB) and [GRP‐(18‐27)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3582)([*GRP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4605), [P07492](http://www.uniprot.org/uniprot/P07492)) (previously named neuromedin C). [Bombesin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=616) is a tetradecapeptide, originally derived from amphibians, and is an agonist at BB~1~ and BB~2~ receptors. These receptors couple primarily to the G~q/11~ family of G proteins (but see also \[[857](http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus)\]). Each of these receptors is widely distributed in the CNS and peripheral tissues \[[625](http://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus), [857](http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus), [1556](http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus), [1642](http://www.ncbi.nlm.nih.gov/pubmed/15203211?dopt=AbstractPlus)\]. Activation of BB~1~ and BB~2~ receptors causes a wide range of physiological actions, including the stimulation of normal and neoplastic tissue growth, smooth‐muscle contraction, appetite and feeding behavior, secretion and many central nervous system effects \[[857](http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus), 858, 859, [1185](http://www.ncbi.nlm.nih.gov/pubmed/21042212?dopt=AbstractPlus), [1317](http://www.ncbi.nlm.nih.gov/pubmed/15134870?dopt=AbstractPlus), [1556](http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus)\]. A physiological role for the BB~3~ receptor has yet to be fully defined although recently studies using receptor knockout mice and newly described agonists/antagonists suggest an important role in glucose and insulin regulation, metabolic homeostasis, feeding and other CNS behaviors and growth of normal/neoplastic tissues \[[625](http://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus), [1186](http://www.ncbi.nlm.nih.gov/pubmed/22157398?dopt=AbstractPlus), [1430](http://www.ncbi.nlm.nih.gov/pubmed/9367152?dopt=AbstractPlus)\].

Nomenclature[BB~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38)[BB~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=39)[BB~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=40)HGNC, UniProt[*NMBR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7843), [P28336](http://www.uniprot.org/uniprot/P28336)[*GRPR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4609), [P30550](http://www.uniprot.org/uniprot/P30550)[*BRS3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1113), [P32247](http://www.uniprot.org/uniprot/P32247)Endogenous agonists[neuromedin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=613) ([*NMB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7842), [P08949](http://www.uniprot.org/uniprot/P08949)) (Selective) (p*K* ~i~ 8.1--10.3) \[[857](http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus), [1556](http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus), [1919](http://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus)\][neuromedin C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6178) (pIC~50~ 9.9) \[[1919](http://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus)\], [gastrin releasing peptide(14‐27) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6175) (Selective) (pIC~50~ 9.7--9.8) \[[1919](http://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus)\]--Selective agonists----[compound 8a \[PMID: 24900283\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8503) (pIC~50~ 8.9) \[[1129](http://www.ncbi.nlm.nih.gov/pubmed/24900283?dopt=AbstractPlus)\], [compound 9g \[PMID: 24412111\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8509) (pEC~50~ 8.8) \[[1220](http://www.ncbi.nlm.nih.gov/pubmed/24412111?dopt=AbstractPlus)\], [MK‐7725](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8502) (pIC~50~ 8.5) \[[324](http://www.ncbi.nlm.nih.gov/pubmed/24900461?dopt=AbstractPlus)\], [MK‐5046](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6170) (p*K* ~i~ 7.7--8.4) \[[1321](http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus), [1689](http://www.ncbi.nlm.nih.gov/pubmed/24900253?dopt=AbstractPlus)\], [\[D‐Tyr^6^,Apa‐4Cl^11^,Phe^13^,Nle^14^\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946) (p*K* ~i~ 8.1) \[[1202](http://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus)\], [compound 17c \[PMID: 25497965\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8507) (pEC~50~ 7.9) \[[1219](http://www.ncbi.nlm.nih.gov/pubmed/25497965?dopt=AbstractPlus)\], [compound 9f \[PMID: 24412111\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8508) (pEC~50~ 7.8) \[[1220](http://www.ncbi.nlm.nih.gov/pubmed/24412111?dopt=AbstractPlus)\], [bag‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6188) (pIC~50~ 7.7) \[[659](http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus)\], [compound 22e \[PMID: 20167483\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8504) (pIC~50~ 7.6) \[[727](http://www.ncbi.nlm.nih.gov/pubmed/20167483?dopt=AbstractPlus)\], [bag‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6189) (pIC~50~ 7) \[[659](http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus)\]Antagonists[D‐Nal‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Nal‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=635) (pIC~50~ 6.2--6.6) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\]----Selective antagonists[PD 176252](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=626) (pIC~50~ 9.3--9.8) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\], [PD 168368](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=621) (pIC~50~ 9.3--9.6) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\], [dNal‐*cyc*(Cys‐Tyr‐dTrp‐Orn‐Val)‐Nal‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3871)[\[D‐Phe^6^, Leu^13^, Cpa^14^,*ψ*13‐14\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3840) (p*K* ~i~ 9.8) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\], [JMV641](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3889) (pIC~50~ 9.3) \[[1892](http://www.ncbi.nlm.nih.gov/pubmed/11463790?dopt=AbstractPlus)\] -- Mouse, [\[(3‐Ph‐Pr^6^), His^7^,D‐Ala^11^,D‐Pro^13^,*ψ*13‐14),Phe^14^\] bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627) (pIC~50~ 9.2) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus), [1062](http://www.ncbi.nlm.nih.gov/pubmed/8446610?dopt=AbstractPlus)\], [\[D‐Tpi^6^, Leu^13^*ψ*(CH~2~NH)‐Leu^14^\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6183) (pIC~50~ 8.9) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\], [Ac‐GRP‐(20‐26)‐methylester](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=625) (pIC~50~ 8.7) \[[624](http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus)\], [JMV594](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=624) (pIC~50~ 8.7--8.7) \[[1133](http://www.ncbi.nlm.nih.gov/pubmed/10231715?dopt=AbstractPlus), [1892](http://www.ncbi.nlm.nih.gov/pubmed/11463790?dopt=AbstractPlus)\] -- Mouse[bantag‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6176) (pIC~50~ 8.6--8.7) \[[659](http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus), [1321](http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus)\], [ML‐18](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8505) (pIC~50~ 5.3) \[[1316](http://www.ncbi.nlm.nih.gov/pubmed/25554218?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]BH‐NMB (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3771) (Agonist), [\[^125^I\]\[Tyr^4^\]bombesin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623) (Agonist)[\[^125^I\]\[D‐Tyr^6^\]bombesin‐(6‐13)‐methyl ester](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=628) (Selective Antagonist) (p*K* ~d~ 9.3) \[[1201](http://www.ncbi.nlm.nih.gov/pubmed/7684815?dopt=AbstractPlus)\] -- Mouse, [\[^125^I\]\[Tyr^4^\]bombesin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623) (Agonist) (p*K* ~d~ 8.2) \[[131](http://www.ncbi.nlm.nih.gov/pubmed/7838118?dopt=AbstractPlus)\], [\[^125^I\]GRP (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3788) (Agonist)[\[^3^H\]bag‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8506) (Agonist) (p*K* ~d~ 8.6) \[[659](http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus)\] -- Mouse, [\[^125^I\]\[D‐Tyr^6^,*β*‐Ala^11^,Phe^13^,Nle^14^\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631) (Agonist) (p*K* ~d~ 8--8.4) \[[1203](http://www.ncbi.nlm.nih.gov/pubmed/9325344?dopt=AbstractPlus), [1321](http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0054}
--------

All three subtypes may be activated by [\[D‐Phe^6^,*β*‐Ala^11^,Phe^13^,Nle^14^\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632)\[[1203](http://www.ncbi.nlm.nih.gov/pubmed/9325344?dopt=AbstractPlus)\]. [\[D‐Tyr^6^,Apa‐4Cl^11^,Phe^13^,Nle^14^\]bombesin‐(6‐14)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946) has more than 200‐fold selectivity for BB~3~ receptors over BB~1~ and BB~2~\[[1202](http://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus)\].
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[Bradykinin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=10) {#bph13348-sec-0056}
================================================================================================

Overview {#bph13348-sec-0057}
--------

Bradykinin (or kinin) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on Bradykinin (kinin) Receptors \[** [**1072**](http://www.ncbi.nlm.nih.gov/pubmed/15734727?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides [bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) (BK), [\[des‐Arg^9^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)), Lys‐BK ([kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042))), [\[des‐Arg^10^\]kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)), [T‐kinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=639)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) (Ile‐Ser‐BK), [\[Hyp^3^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3578)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) and [Lys‐\[Hyp^3^\]‐bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3580)([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)). The variation in affinity or inactivity of B~2~ receptor antagonists could reflect the existence of species homologues of B~2~ receptors.

Nomenclature[B~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=41)[B~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=42)HGNC, UniProt[*BDKRB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1029), [P46663](http://www.uniprot.org/uniprot/P46663)[*BDKRB2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1030), [P30411](http://www.uniprot.org/uniprot/P30411)Rank order of potency[\[des‐Arg^10^\]kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) \>[\[des‐Arg^9^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) = [kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) \>[bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042))[kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) \>[bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) ≫[\[des‐Arg^9^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)), [\[des‐Arg^10^\]kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042))Endogenous agonists[\[des‐Arg^10^\]kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644) ([*KNG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6383), [P01042](http://www.uniprot.org/uniprot/P01042)) (Selective) (p*K* ~i~ 9.6--10) \[[69](http://www.ncbi.nlm.nih.gov/pubmed/9111052?dopt=AbstractPlus), [104](http://www.ncbi.nlm.nih.gov/pubmed/9313952?dopt=AbstractPlus), [876](http://www.ncbi.nlm.nih.gov/pubmed/10422787?dopt=AbstractPlus)\]--Selective agonists[\[Sar,D‐Phe^8^,des‐Arg^9^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=643) (p*K* ~i~ 5.7) \[[876](http://www.ncbi.nlm.nih.gov/pubmed/10422787?dopt=AbstractPlus)\][\[Hyp^3^,Tyr(Me)^8^\]BK](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3841), [\[Phe^8^,*ψ*(CH~2~‐NH)Arg^9^\]BK](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846)Antagonists[\[Leu^9^,des‐Arg^10^\]kallidin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=642) (p*K* ~i~ 9.1--9.3) \[[69](http://www.ncbi.nlm.nih.gov/pubmed/9111052?dopt=AbstractPlus), [104](http://www.ncbi.nlm.nih.gov/pubmed/9313952?dopt=AbstractPlus)\]--Selective antagonists[B‐9958](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=655) (p*K* ~i~ 9.2--10.3) \[[596](http://www.ncbi.nlm.nih.gov/pubmed/16368899?dopt=AbstractPlus), [1570](http://www.ncbi.nlm.nih.gov/pubmed/9650825?dopt=AbstractPlus)\], [R‐914](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3906) (pA~2~ 8.6) \[[617](http://www.ncbi.nlm.nih.gov/pubmed/10082494?dopt=AbstractPlus)\], [R‐715](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=661) (pA~2~ 8.5) \[[618](http://www.ncbi.nlm.nih.gov/pubmed/8901831?dopt=AbstractPlus)\][icatibant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=667) (p*K* ~i~ 10.2) \[[39](http://www.ncbi.nlm.nih.gov/pubmed/10514288?dopt=AbstractPlus)\], [FR173657](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=674) (pA~2~ 8.2) \[[1593](http://www.ncbi.nlm.nih.gov/pubmed/9095082?dopt=AbstractPlus)\], [anatibant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=679) (p*K* ~i~ 8.2) \[[1537](http://www.ncbi.nlm.nih.gov/pubmed/10596852?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]Hpp‐desArg^10^HOE140](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3791) (p*K* ~d~ 10), [\[^3^H\]Lys‐\[des‐Arg^9^\]BK](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3825) (Agonist) (p*K* ~d~ 9.4), [\[^3^H\]Lys‐\[Leu^8^\]\[des‐Arg^9^\]BK](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3826) (Antagonist)[\[^3^H\]BK (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3812) (Agonist) (p*K* ~d~ 9.4) \[[2034](http://www.ncbi.nlm.nih.gov/pubmed/9333122?dopt=AbstractPlus)\] -- Mouse, [\[^3^H\]NPC17731](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3831) (Antagonist) (p*K* ~d~ 9.1--9.4) \[[2119](http://www.ncbi.nlm.nih.gov/pubmed/9651119?dopt=AbstractPlus), [2120](http://www.ncbi.nlm.nih.gov/pubmed/11379050?dopt=AbstractPlus)\], [\[^125^I\]\[Tyr^8^\]bradykinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3765) (Agonist)
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[Calcitonin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=11) {#bph13348-sec-0059}
================================================================================================

Overview {#bph13348-sec-0060}
--------

This receptor family comprises a group of receptors for the calcitonin/CGRP family of peptides. The calcitonin (CT), amylin (AMY), calcitonin gene‐related peptide (CGRP) and adrenomedullin (AM) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on CGRP, AM, AMY, and CT receptors \[** [**721**](http://www.ncbi.nlm.nih.gov/pubmed/18552275?dopt=AbstractPlus) **,** [**1528**](http://www.ncbi.nlm.nih.gov/pubmed/12037140?dopt=AbstractPlus) **\]**) are generated by the genes [*CALCR*](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:1440) (which codes for the CT receptor (CTR)) and [*CALCRL*](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:16709)(which codes for the calcitonin receptor‐like receptor, CLR, previously known as CRLR). Their function and pharmacology are altered in the presence of RAMPs (receptor activity‐modifying proteins), which are single TM domain proteins of *ca.* 130 amino acids, identified as a family of three members; RAMP1, RAMP2 and RAMP3. There are splice variants of CTR; these in turn produce variants of the AMY receptor \[[1528](http://www.ncbi.nlm.nih.gov/pubmed/12037140?dopt=AbstractPlus)\], some of which can be potently activated by CGRP. The endogenous agonists are the peptides [calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685)([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)), [*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681)([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) (formerly known as CGRP‐I), [*β*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682)([*CALCB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1438), [P10092](http://www.uniprot.org/uniprot/P10092)) (formerly known as CGRP‐II), [amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687)([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) (occasionally called islet‐amyloid polypeptide, diabetes‐associated polypeptide), [adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683)([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) and [adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)). There are species differences in peptide sequences, particularly for the CTs. [CTR‐stimulating peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5369) {Pig} (CRSP) is another member of the family with selectivity for the CTR but it is not expressed in humans \[[907](http://www.ncbi.nlm.nih.gov/pubmed/12556539?dopt=AbstractPlus)\]. [Olcegepant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702) (also known as BIBN4096BS, *p*Ki 10.5) and [telcagepant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703)(also known as MK0974, *p*Ki 9) are the most selective antagonists available, having a high selectivity for CGRP receptors, with a particular preference for those of primate origin.

CLR by itself binds no known endogenous ligand, but in the presence of RAMPs it gives receptors for CGRP, adrenomedullin and adrenomedullin 2/intermedin.

Nomenclature[CT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43)[AMY~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=44)[AMY~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=45)[AMY~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=46)HGNC, UniProt[*CALCR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1440), [P30988](http://www.uniprot.org/uniprot/P30988)------Subunits--[RAMP1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=51) (Accessory protein), [CT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43)[CT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43), [RAMP2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52) (Accessory protein)[CT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43), [RAMP3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=53) (Accessory protein)Rank order of potency[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)≥[calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)) ≥[amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)), [*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) \>[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)), [adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4))[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)≥[amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) ≥[*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) \>[adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)) ≥[calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)) \>[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318))Poorly defined[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)≥[amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) \>[*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) ≥[adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)) ≥[calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)) \>[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318))Endogenous agonists[calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)) (Selective) (pEC~50~ 9--11.2) \[[32](http://www.ncbi.nlm.nih.gov/pubmed/7588285?dopt=AbstractPlus), [58](http://www.ncbi.nlm.nih.gov/pubmed/11033437?dopt=AbstractPlus), [718](http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus), [1027](http://www.ncbi.nlm.nih.gov/pubmed/12565884?dopt=AbstractPlus), [1087](http://www.ncbi.nlm.nih.gov/pubmed/11023820?dopt=AbstractPlus), [1341](http://www.ncbi.nlm.nih.gov/pubmed/10342886?dopt=AbstractPlus)\][amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) (pEC~50~ 9--9.7) \[[610](http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus)\][amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) (pEC~50~ 8.3--9.1) \[[610](http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus)\][amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) (pEC~50~ 8.9--9.6) \[[610](http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]CT (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3776) (Agonist) (p*K* ~d~ 9--10), [\[^125^I\]CT (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3777) (Agonist) (p*K* ~d~ 10)[\[^125^I\]BH‐AMY (rat, mouse)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist) (p*K* ~d~ 9--10)[\[^125^I\]BH‐AMY (rat, mouse)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist) (p*K* ~d~ 9--10)[\[^125^I\]BH‐AMY (rat, mouse)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist) (p*K* ~d~ 9--10)

Nomenclature[calcitonin receptor‐like receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47)[CGRP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=48)[AM~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=49)[AM~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=50)HGNC, UniProt[*CALCRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16709), [Q16602](http://www.uniprot.org/uniprot/Q16602)------Subunits--[calcitonin receptor‐like receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47), [RAMP1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=51) (Accessory protein)[calcitonin receptor‐like receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47), [RAMP2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52) (Accessory protein)[calcitonin receptor‐like receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47), [RAMP3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=53) (Accessory protein)Rank order of potency--[*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) \>[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) ≥[adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)) \>[amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) ≥[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) \>[adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)) \>[*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)), [amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) \>[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)[adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) ≥[adrenomedullin 2/intermedin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684) ([*ADM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28898), [Q7Z4H4](http://www.uniprot.org/uniprot/Q7Z4H4)) ≥[*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) \>[amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687) ([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) \>[calcitonin (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)Endogenous agonists--[*β*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682) ([*CALCB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1438), [P10092](http://www.uniprot.org/uniprot/P10092)) (p*K* ~i~ 9.9--11) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus), [1251](http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus)\], [*α*‐CGRP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681) ([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P06881](http://www.uniprot.org/uniprot/P06881)) (p*K* ~i~ 9.7--10) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus), [1251](http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus)\][adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) (p*K* ~i~ 8.3--9.2) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus), [1251](http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus)\][adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683) ([*ADM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=259), [P35318](http://www.uniprot.org/uniprot/P35318)) (p*K* ~i~ 8.3--9) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus), [539](http://www.ncbi.nlm.nih.gov/pubmed/10347248?dopt=AbstractPlus)\]Antagonists--[olcegepant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702) (p*K* ~i~ 10.2--10.7) \[[435](http://www.ncbi.nlm.nih.gov/pubmed/10711339?dopt=AbstractPlus), [719](http://www.ncbi.nlm.nih.gov/pubmed/16959943?dopt=AbstractPlus), [720](http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus), [1194](http://www.ncbi.nlm.nih.gov/pubmed/11847213?dopt=AbstractPlus)\], [telcagepant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703) (p*K* ~i~ 9.1) \[[1633](http://www.ncbi.nlm.nih.gov/pubmed/18039958?dopt=AbstractPlus)\]----Selective antagonists----[AM‐(22‐52) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=706) (p*K* ~i~ 7--7.8) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus), [720](http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus), [1251](http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus)\]--Labelled ligands--[\[^125^I\]*α*CGRP (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3766) (Agonist) (p*K* ~d~ 10), [\[^125^I\]*α*CGRP (mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6567) (Agonist)[\[^125^I\]AM (rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3768) (Agonist) (p*K* ~d~ 10--9)[\[^125^I\]AM (rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3768) (Agonist) (p*K* ~d~ 9--10)

Comments {#bph13348-sec-0061}
--------

It is important to note that a complication with the interpretation of pharmacological studies with AMY receptors in transfected cells is that most of this work has likely used a mixed population of receptors, encompassing RAMP‐coupled CTR as well as CTR alone. This means that although in binding assays human [calcitonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685)([*CALCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1437), [P01258](http://www.uniprot.org/uniprot/P01258)) has low affinity for ^125^I‐AMY binding sites, cells transfected with CTR and RAMPs can display potent CT functional responses. Transfection of human CTR with any RAMP can generate receptors with a high affinity for both salmon CT and AMY and varying affinity for different antagonists \[[337](http://www.ncbi.nlm.nih.gov/pubmed/10385705?dopt=AbstractPlus), [718](http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus), [719](http://www.ncbi.nlm.nih.gov/pubmed/16959943?dopt=AbstractPlus)\]. The major human CTR splice variant (hCT~(a)~, which does not contain an insert) with RAMP1 (*i.e.* the AMY~1(a)~ receptor) has a high affinity for CGRP, unlike hCT~(a)~‐RAMP3 (*i.e*. AMY~3(a)~ receptor) \[[337](http://www.ncbi.nlm.nih.gov/pubmed/10385705?dopt=AbstractPlus), [718](http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus)\]. However, the AMY receptor phenotype is RAMP‐type, splice variant and cell‐line‐dependent \[[1886](http://www.ncbi.nlm.nih.gov/pubmed/10871296?dopt=AbstractPlus)\]. In particular, CGRP is a more potent agonist than [amylin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687)([*IAPP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5329), [P10997](http://www.uniprot.org/uniprot/P10997)) at increasing cAMP at the delta 47 hCT(a) receptor, when transfected with RAMP1 (to give the corresponding AMY1(a) receptor) in Cos 7 cells \[[1543](http://www.ncbi.nlm.nih.gov/pubmed/22946511?dopt=AbstractPlus)\].

The ligands described represent the best available but their selectivity is limited. For example, adrenomedullin has appreciable affinity for CGRP receptors. CGRP can show significant cross‐reactivity at AMY receptors and AM~2~ receptors. Adrenomedullin 2/intermedin also has high affinity for the AM~2~ receptor \[[779](http://www.ncbi.nlm.nih.gov/pubmed/21658025?dopt=AbstractPlus)\]. CGRP‐(8‐37) acts as an antagonist of CGRP (*p*K~i~ 8) and inhibits some AM and AMY responses (*p*K~i~ 6‐7). It is weak at CT receptors. Salmon CT‐(8‐32) is an antagonist at both AMY and CT receptors. [AC187](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=689), a salmon CT analogue, is also an antagonist at AMY and CT receptors. Human AM‐(22‐52) has some selectivity towards AM receptors, but with modest potency (*p*K~i~  7), limiting its use \[[720](http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus)\]. AM‐(22‐52) is slightly more effective at AM~1~ than AM~2~ receptors but this difference is not sufficient for this peptide to be a useful discriminator of the AM receptor subtypes. [Olcegepant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702) shows the greatest selectivity between receptors but still has significant affinity for AMY~1~ receptors \[[1973](http://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus)\].

Ligand responsiveness at CT and AMY receptors can be affected by receptor splice variation and can depend on the pathway being measured. Particularly for AMY receptors, relative potency can vary with the type and level of RAMP present and can be influenced by other factors such as G proteins \[[1324](http://www.ncbi.nlm.nih.gov/pubmed/18599553?dopt=AbstractPlus), [1886](http://www.ncbi.nlm.nih.gov/pubmed/10871296?dopt=AbstractPlus)\].

G~s~ is a prominent route for effector coupling for CLR and CTR but other pathways (*e.g.* Ca^2+^, ERK, Akt), and G proteins can be activated \[[1972](http://www.ncbi.nlm.nih.gov/pubmed/20633935?dopt=AbstractPlus)\]. There is evidence that CGRP‐RCP (a 148 amino‐acid hydrophilic protein, [*ASL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=746)([P04424](http://www.uniprot.org/uniprot/P04424)) is important for the coupling of CLR to adenylyl cyclase \[[498](http://www.ncbi.nlm.nih.gov/pubmed/10903324?dopt=AbstractPlus)\]. \[^125^I\]‐Salmon CT is the most common radioligand for CT receptors but it has high affinity for AMY receptors and is also poorly reversible. \[^125^I\]‐Tyr^0^‐CGRP is widely used as a radioligand for CGRP receptors.

Some early literature distinguished between *CGRP~1~* and *CGRP~2~* receptors. It is now clear that the complex of *CALCRL* and *RAMP1* represents the *CGRP~1~* subtype and is now known simply as the CGRP receptor \[[721](http://www.ncbi.nlm.nih.gov/pubmed/18552275?dopt=AbstractPlus)\]. The *CGRP~2~* receptor is now considered to have arisen from the actions of CGRP at AM~2~ and AMY receptors. This term should not be used \[[721](http://www.ncbi.nlm.nih.gov/pubmed/18552275?dopt=AbstractPlus)\].
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[Calcium‐sensing receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=12) {#bph13348-sec-0063}
=====================================================================================================

Overview {#bph13348-sec-0064}
--------

The calcium‐sensing receptor (CaS, **provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) responds to extracellular calcium and magnesium in the millimolar range and to gadolinium and some polycations in the micromolar range \[[229](http://www.ncbi.nlm.nih.gov/pubmed/8255296?dopt=AbstractPlus)\]. The sensitivity of CaS to primary agonists can be increased by aromatic L‐amino acids \[[362](http://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus)\] and also by elevated extracellular pH \[[1544](http://www.ncbi.nlm.nih.gov/pubmed/15201280?dopt=AbstractPlus)\] or decreased extracellular ionic strength \[[1545](http://www.ncbi.nlm.nih.gov/pubmed/9677383?dopt=AbstractPlus)\]. This receptor bears no sequence or structural relation to the plant calcium receptor, also called CaS.

Nomenclature[CaS receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=54)[GPRC6 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=55)HGNC, UniProt[*CASR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1514), [P41180](http://www.uniprot.org/uniprot/P41180)[*GPRC6A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18510), [Q5T6X5](http://www.uniprot.org/uniprot/Q5T6X5)Amino‐acid rank order of potency[L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313), [L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717), [L‐histidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310)\>[L‐alanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720)\>[L‐serine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726), [L‐proline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314), [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369)\>[L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309) (not L‐lysine, L‐arginine, L‐leucine and L‐isoleucine) \[[362](http://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus)\]--Cation rank order of potency[Gd^3+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426)\>[Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707)\>[Mg^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708) \[[229](http://www.ncbi.nlm.nih.gov/pubmed/8255296?dopt=AbstractPlus)\]--Polyamine rank order of potency[spermine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710)\>[spermidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390)\>[putrescine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388) \[[1546](http://www.ncbi.nlm.nih.gov/pubmed/9357776?dopt=AbstractPlus)\]--Allosteric modulators[AC265347](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3947) (Positive) (pEC~50~ 7.6--8.1) \[[1160](http://www.ncbi.nlm.nih.gov/pubmed/21239511?dopt=AbstractPlus)\], [NPS 2143](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=716) (Negative) (pIC~50~ 7.1--7.4) \[[1377](http://www.ncbi.nlm.nih.gov/pubmed/11561095?dopt=AbstractPlus), [2087](http://www.ncbi.nlm.nih.gov/pubmed/15686947?dopt=AbstractPlus)\], [cinacalcet](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3308) (Positive) (pEC~50~ 7.3) \[[1378](http://www.ncbi.nlm.nih.gov/pubmed/14593085?dopt=AbstractPlus)\], [calindol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=719) (Positive) (pEC~50~ 6.5) \[[1499](http://www.ncbi.nlm.nih.gov/pubmed/14976203?dopt=AbstractPlus)\], [calindol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=719) (Positive) (p*K* ~d~ 6--6.5) \[[930](http://www.ncbi.nlm.nih.gov/pubmed/15149704?dopt=AbstractPlus)\], [tecalcet](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=718) (Positive) (p*K* ~d~ 6.5) \[[1379](http://www.ncbi.nlm.nih.gov/pubmed/9520489?dopt=AbstractPlus)\], [calhex 231](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=714) (Negative) (pIC~50~ 6.4) \[[1500](http://www.ncbi.nlm.nih.gov/pubmed/14506236?dopt=AbstractPlus)\]--Comments2‐benzylpyrrolidine derivatives of NPS 2143 are also negative allosteric modulators of the calcium sensing receptor \[[2087](http://www.ncbi.nlm.nih.gov/pubmed/15686947?dopt=AbstractPlus)\]. [etelcalcetide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8375) is a novel peptide agonist of the receptor \[[1975](http://www.ncbi.nlm.nih.gov/pubmed/23674604?dopt=AbstractPlus)\].GPRC6 is a related G~q~‐coupled receptor which responds to basic amino acids \[[2004](http://www.ncbi.nlm.nih.gov/pubmed/15576628?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0065}
--------

Positive allosteric modulators of CaS are termed Type II calcimimetics and can suppress parathyroid hormone ([PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785)([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270))) secretion \[[1379](http://www.ncbi.nlm.nih.gov/pubmed/9520489?dopt=AbstractPlus)\]. Negative allosteric modulators are called calcilytics and can act to increase [PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785)([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270)) secretion \[[1377](http://www.ncbi.nlm.nih.gov/pubmed/11561095?dopt=AbstractPlus)\].

The central role of CaS in the maintenance of extracellular calcium homeostasis is seen most clearly in patients with loss‐of‐function CaS mutations who develop familial hypocalciuric hypercalcaemia (heterozygous mutation) or neonatal severe hyperparathyroidism (homozygous mutation) and in CaS null mice \[[293](http://www.ncbi.nlm.nih.gov/pubmed/18765830?dopt=AbstractPlus), [765](http://www.ncbi.nlm.nih.gov/pubmed/7493018?dopt=AbstractPlus)\], which exhibit similar increases in PTH secretion and blood [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707) levels. A gain‐of‐function mutation in the CaS gene is associated with autosomal dominant hypocalcaemia.
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[Cannabinoid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=13) {#bph13348-sec-0067}
=================================================================================================

Overview {#bph13348-sec-0068}
--------

Cannabinoid receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Cannabinoid Receptors \[** [**1494**](http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus) **\]**) are activated by endogenous ligands that include N‐arachidonoylethanolamine ([anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364)), [N‐homo‐*γ*‐linolenoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5444), [N‐docosatetra‐7,10,13,16‐enoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5445) and [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729). Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion \[[35](http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus)\].

Nomenclature[CB~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56)[CB~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57)HGNC, UniProt[*CNR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2159), [P21554](http://www.uniprot.org/uniprot/P21554)[*CNR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2160), [P34972](http://www.uniprot.org/uniprot/P34972)(Sub)family‐selective agonists[HU‐210](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731) (p*K* ~i~ 9.1--10.2) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [CP55940](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=730) (p*K* ~i~ 8.3--9.2) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [WIN55212‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733) (p*K* ~i~ 6.9--8.7) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1730](http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [*Δ*^9^‐tetrahydrocannabinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424) (Partial agonist) (p*K* ~i~ 7.3--7.4) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\][HU‐210](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731) (p*K* ~i~ 9.3--9.8) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1579](http://www.ncbi.nlm.nih.gov/pubmed/9379442?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [WIN55212‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733) (p*K* ~i~ 8.4--9.6) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1730](http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [CP55940](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=730) (p*K* ~i~ 8.6--9.2) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [*Δ*^9^‐tetrahydrocannabinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424) (Partial agonist) (p*K* ~i~ 7.1--7.5) \[[106](http://www.ncbi.nlm.nih.gov/pubmed/8626625?dopt=AbstractPlus), [509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1579](http://www.ncbi.nlm.nih.gov/pubmed/9379442?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\]Selective agonists[arachidonyl‐2‐chloroethylamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=738) (p*K* ~i~ 8.9) \[[755](http://www.ncbi.nlm.nih.gov/pubmed/10336536?dopt=AbstractPlus)\] -- Rat, [arachidonylcyclopropylamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=739) (p*K* ~i~ 8.7) \[[755](http://www.ncbi.nlm.nih.gov/pubmed/10336536?dopt=AbstractPlus)\] -- Rat, [O‐1812](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=732) (p*K* ~i~ 8.5) \[[420](http://www.ncbi.nlm.nih.gov/pubmed/11181068?dopt=AbstractPlus)\] -- Rat, [*R*‐(+)‐methanandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2506) (p*K* ~i~ 7.7) \[[931](http://www.ncbi.nlm.nih.gov/pubmed/8893848?dopt=AbstractPlus)\] -- Rat[JWH‐133](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=747) (p*K* ~i~ 8.5) \[[804](http://www.ncbi.nlm.nih.gov/pubmed/10658595?dopt=AbstractPlus), [1493](http://www.ncbi.nlm.nih.gov/pubmed/11060760?dopt=AbstractPlus)\], [L‐759,633](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=748) (p*K* ~i~ 7.7--8.2) \[576, [1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus)\], [AM1241](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3316) (p*K* ~i~ 8.1) \[[2088](http://www.ncbi.nlm.nih.gov/pubmed/16894349?dopt=AbstractPlus)\], [L‐759,656](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=749) (p*K* ~i~ 7.7--7.9) \[576, [1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus)\], [HU‐308](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=746) (p*K* ~i~ 7.6) \[[699](http://www.ncbi.nlm.nih.gov/pubmed/10588688?dopt=AbstractPlus)\]Selective antagonists[rimonabant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=743) (p*K* ~i~ 7.9--8.7) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9435190?dopt=AbstractPlus), [509](http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus), [1586](http://www.ncbi.nlm.nih.gov/pubmed/8070571?dopt=AbstractPlus), [1613](http://www.ncbi.nlm.nih.gov/pubmed/12663689?dopt=AbstractPlus), [1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\], [AM251](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317) (p*K* ~i~ 8.1) \[[1038](http://www.ncbi.nlm.nih.gov/pubmed/10052983?dopt=AbstractPlus)\] -- Rat, [AM281](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=741) (p*K* ~i~ 7.9) \[[1037](http://www.ncbi.nlm.nih.gov/pubmed/11741201?dopt=AbstractPlus)\] -- Rat, [LY320135](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=742) (p*K* ~i~ 6.9) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9435190?dopt=AbstractPlus)\][SR144528](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=751) (p*K* ~i~ 8.3--9.2) \[[1587](http://www.ncbi.nlm.nih.gov/pubmed/9454810?dopt=AbstractPlus), [1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus)\], [AM‐630](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=750) (p*K* ~i~ 7.5) \[[1602](http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]rimonabant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=745) (Antagonist) (p*K* ~d~ 8.9--10) \[[205](http://www.ncbi.nlm.nih.gov/pubmed/9316881?dopt=AbstractPlus), [761](http://www.ncbi.nlm.nih.gov/pubmed/8981483?dopt=AbstractPlus), [889](http://www.ncbi.nlm.nih.gov/pubmed/8978752?dopt=AbstractPlus), [1498](http://www.ncbi.nlm.nih.gov/pubmed/8733746?dopt=AbstractPlus), [1588](http://www.ncbi.nlm.nih.gov/pubmed/8614277?dopt=AbstractPlus), [1742](http://www.ncbi.nlm.nih.gov/pubmed/8987831?dopt=AbstractPlus), [1873](http://www.ncbi.nlm.nih.gov/pubmed/9536023?dopt=AbstractPlus)\] -- Rat--

Comments {#bph13348-sec-0069}
--------

Both CB~1~ and CB~2~ receptors may be labelled with [\[^3^H\]CP55940](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=734)(0.5 nM; \[[1733](http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus)\]) and [\[^3^H\]WIN55212‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=736)(2‐2.4 nM; \[[1756](http://www.ncbi.nlm.nih.gov/pubmed/7651369?dopt=AbstractPlus), [1783](http://www.ncbi.nlm.nih.gov/pubmed/8622639?dopt=AbstractPlus)\]). [Anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) is also an agonist at vanilloid receptors ([TRPV1](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=78#show_object_507)) and [PPARs](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86)\[[1418](http://www.ncbi.nlm.nih.gov/pubmed/17704824?dopt=AbstractPlus), [2135](http://www.ncbi.nlm.nih.gov/pubmed/10440374?dopt=AbstractPlus)\]. There is evidence for an allosteric site on the CB~1~ receptor \[[1532](http://www.ncbi.nlm.nih.gov/pubmed/16113085?dopt=AbstractPlus)\]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems \[[1494](http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus)\]. Moreover, [GPR18, GPR55 and GPR119](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114), although showing little structural similarity to CB~1~ and CB~2~receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands \[[1494](http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus)\].
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[Chemerin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=338) {#bph13348-sec-0071}
==============================================================================================

Overview {#bph13348-sec-0072}
--------

The chemerin receptor (**nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **\]**) is activated by chemerin \[1148, 1253, 2108\] and the lipid‐derived, anti‐inflammatory ligand [resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333) (RvE1), which is the result of sequential metabolism of [EPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362) by aspirin‐modified cyclooxygenase and lipoxygenase \[[56](http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus), [57](http://www.ncbi.nlm.nih.gov/pubmed/17339491?dopt=AbstractPlus)\]. In addition, two GPCRs for [resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934) (RvD1) have been identified, FPR2/ALX, the lipoxin A~4~ receptor, and GPR32, an orphan receptor \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\].

Nomenclature[chemerin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=79)HGNC, UniProt[*CMKLR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2121), [Q99788](http://www.uniprot.org/uniprot/Q99788)Rank order of potency[resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333)\>[chemerin C‐terminal peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3422)\>[18R‐HEPE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3400)\>[EPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362) \[[56](http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus)\]Selective agonists[resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333)Labelled ligands[\[^3^H\]resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2901) (Agonist) (p*K* ~d~ 8) \[[56](http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus), [57](http://www.ncbi.nlm.nih.gov/pubmed/17339491?dopt=AbstractPlus)\]

[Chemokine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=14) {#bph13348-sec-0073}
===============================================================================================

Overview {#bph13348-sec-0074}
--------

Chemokine receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Chemokine Receptors \[** [**78**](http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus) **,** [**1346**](http://www.ncbi.nlm.nih.gov/pubmed/12037138?dopt=AbstractPlus) **,** [**1347**](http://www.ncbi.nlm.nih.gov/pubmed/10699158?dopt=AbstractPlus) **\]**) comprise a large subfamily of 7TM proteins that bind one or more chemokines, a large family of small cytokines typically possessing chemotactic activity for leukocytes. Chemokine receptors can be divided by function into two main groups: G protein‐coupled chemokine receptors, which mediate leukocyte trafficking, and "Atypical chemokine receptors", which may signal through non‐G protein‐coupled mechanisms and act as chemokine scavengers to downregulate inflammation or shape chemokine gradients \[[78](http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus)\].

Chemokines in turn can be divided by structure into four subclasses by the number and arrangement of conserved cysteines. CC (also known as *β*‐chemokines; *n*= 28), CXC (also known as *α*‐chemokines; *n*= 17) and CX3C (*n*= 1) chemokines all have four conserved cysteines, with zero, one and three amino acids separating the first two cysteines respectively. C chemokines (*n*= 2) have only the second and fourth cysteines found in other chemokines. Chemokines can also be classified by function into homeostatic and inflammatory subgroups. Most chemokine receptors are able to bind multiple high‐affinity chemokine ligands, but the ligands for a given receptor are almost always restricted to the same structural subclass. Most chemokines bind to more than one receptor subtype. Receptors for inflammatory chemokines are typically highly promiscuous with regard to ligand specificity, and may lack a selective endogenous ligand. G protein‐coupled chemokine receptors are named acccording to the class of chemokines bound, whereas ACKR is the root acronym for atypical chemokine receptors \[[79](http://www.ncbi.nlm.nih.gov/pubmed/25958743?dopt=AbstractPlus)\]. Listed are those human agonists with EC~50~ values \<50 nM in either Ca^2+^ flux or chemotaxis assays at human recombinant G protein‐coupled chemokine receptors expressed in mammalian cell lines. There can be substantial cross‐species differences in the sequences of both chemokines and chemokine receptors, and in the pharmacology and biology of chemokine receptors. Endogenous and microbial non‐chemokine ligands have also been identified for chemokine receptors. Many chemokine receptors function as HIV co‐receptors, but CCR5 is the only one demonstrated to play an essential role in HIV/AIDS pathogenesis. The tables include both standard chemokine receptor names \[[2101](http://www.ncbi.nlm.nih.gov/pubmed/10714678?dopt=AbstractPlus)\] and the most commonly used aliases. Numerical data quoted are typically p*K* ~i~ or pIC~50~ values from radioligand binding to heterologously expressed receptors.

Nomenclature[CCR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=58)[CCR2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59)[CCR3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60)HGNC, UniProt[*CCR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1602), [P32246](http://www.uniprot.org/uniprot/P32246)[*CCR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1603), [P41597](http://www.uniprot.org/uniprot/P41597)[*CCR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1604), [P51677](http://www.uniprot.org/uniprot/P51677)Endogenous agonists[CCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756) ([*CCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10627), [P10147](http://www.uniprot.org/uniprot/P10147)) (p*K* ~i~ 7.8--10.2) \[[328](http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus), [357](http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus), [747](http://www.ncbi.nlm.nih.gov/pubmed/9624164?dopt=AbstractPlus), [2134](http://www.ncbi.nlm.nih.gov/pubmed/11170631?dopt=AbstractPlus)\], [CCL23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=755) ([*CCL23*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10622), [P55773](http://www.uniprot.org/uniprot/P55773)) (Selective) (p*K* ~i~ 8.9) \[[328](http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus)\], [CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)) (p*K* ~i~ 6.8--8.2) \[[357](http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus), [747](http://www.ncbi.nlm.nih.gov/pubmed/9624164?dopt=AbstractPlus)\], [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)) (p*K* ~i~ 8.1) \[[328](http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus), [667](http://www.ncbi.nlm.nih.gov/pubmed/11994538?dopt=AbstractPlus)\], [CCL15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=754) ([*CCL15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10613), [Q16663](http://www.uniprot.org/uniprot/Q16663)) (Selective) (pIC~50~ 7.9) \[[373](http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus)\], [CCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753) ([*CCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10612), [Q16627](http://www.uniprot.org/uniprot/Q16627)) (p*K* ~i~ 7.4) \[[328](http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus)\], [CCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770) ([*CCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10611), [Q99616](http://www.uniprot.org/uniprot/Q99616)), [CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772) ([*CCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10635), [P80075](http://www.uniprot.org/uniprot/P80075))[CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771) ([*CCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10618), [P13500](http://www.uniprot.org/uniprot/P13500)) (pIC~50~ 9.3--10.2) \[[373](http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus), [1159](http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus), [1291](http://www.ncbi.nlm.nih.gov/pubmed/10770925?dopt=AbstractPlus), [1465](http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus), [1920](http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus)\], [CCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770) ([*CCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10611), [Q99616](http://www.uniprot.org/uniprot/Q99616)) (pIC~50~ 8.6--8.7) \[[1159](http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus), [1920](http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus)\], [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)) (pIC~50~ 8.4--8.7) \[[373](http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus), [1159](http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus), [1920](http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus)\], [CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)) (Partial agonist) (pIC~50~ 7.1--7.7) \[[1159](http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus), [1465](http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus)\], [CCL16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1272) ([*CCL16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10614), [O15467](http://www.uniprot.org/uniprot/O15467))[CCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770) ([*CCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10611), [Q99616](http://www.uniprot.org/uniprot/Q99616)) (pIC~50~ 8.7--10.3) \[[1332](http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus), [1920](http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus)\], [CCL24](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=775) ([*CCL24*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10623), [O00175](http://www.uniprot.org/uniprot/O00175)) (Selective) (pIC~50~ 8--9.4) \[[1332](http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus), [1465](http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus)\], [CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)) (p*K* ~i~ 8.5--9.3) \[[391](http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus)\], [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)) (p*K* ~i~ 8.6--9.2) \[[391](http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus)\], [CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)) (Selective) (pIC~50~ 8.7--9) \[[452](http://www.ncbi.nlm.nih.gov/pubmed/12761559?dopt=AbstractPlus), [961](http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus), [1332](http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus), [1625](http://www.ncbi.nlm.nih.gov/pubmed/10854442?dopt=AbstractPlus), [1920](http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus)\], [CCL26](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=776) ([*CCL26*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10625), [Q9Y258](http://www.uniprot.org/uniprot/Q9Y258)) (Selective) (pIC~50~ 7.9--8.9) \[[961](http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus), [1332](http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus), [1465](http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus)\], [CCL15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=754) ([*CCL15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10613), [Q16663](http://www.uniprot.org/uniprot/Q16663)) (pIC~50~ 8.6) \[[373](http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus)\], [CCL28](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3649) ([*CCL28*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17700), [Q9NRJ3](http://www.uniprot.org/uniprot/Q9NRJ3)), [CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772) ([*CCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10635), [P80075](http://www.uniprot.org/uniprot/P80075))Agonists----[CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=787) {Mouse} (p*K* ~i~ 9.5--10) \[[391](http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus)\]Endogenous antagonists[CCL4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757) ([*CCL4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10630), [P13236](http://www.uniprot.org/uniprot/P13236)) (Selective) (p*K* ~i~ 7.1--7.8) \[[328](http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus), [357](http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus)\][CCL26](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=776) ([*CCL26*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10625), [Q9Y258](http://www.uniprot.org/uniprot/Q9Y258)) (Selective) (pIC~50~ 8.5) \[[1465](http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus)\][CXCL10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=835) ([*CXCL10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10637), [P02778](http://www.uniprot.org/uniprot/P02778)) (Selective), [CXCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836) ([*CXCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10638), [O14625](http://www.uniprot.org/uniprot/O14625)) (Selective), [CXCL9](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=837) ([*CXCL9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7098), [Q07325](http://www.uniprot.org/uniprot/Q07325)) (Selective)Antagonists------Selective antagonists[BX 471](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=767) (p*K* ~i~ 8.2--9) \[[1098](http://www.ncbi.nlm.nih.gov/pubmed/10748002?dopt=AbstractPlus)\], [compound 2b‐1 \[PMID: 12614873\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3696) (pIC~50~ 8.7) \[[1368](http://www.ncbi.nlm.nih.gov/pubmed/12614873?dopt=AbstractPlus)\], [CP‐481,715](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3497) (p*K* ~d~ 8) \[[614](http://www.ncbi.nlm.nih.gov/pubmed/12909630?dopt=AbstractPlus)\], [UCB35625](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3536) (pIC~50~ 8) \[[1625](http://www.ncbi.nlm.nih.gov/pubmed/10854442?dopt=AbstractPlus)\][GSK Compound 34](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3502) (p*K* ~i~ 7.6)[banyu (I)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=796) (Inverse agonist) (p*K* ~i~ 8.5) \[[1977](http://www.ncbi.nlm.nih.gov/pubmed/12450563?dopt=AbstractPlus)\], [SB328437](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3530) (p*K* ~i~ 8.4), [BMS compound 87b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3492) (p*K* ~i~ 8.1) \[[1964](http://www.ncbi.nlm.nih.gov/pubmed/12067561?dopt=AbstractPlus)\]Antibodies------Labelled ligands[\[^125^I\]CCL7 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist) (p*K* ~d~ 9.2) \[[127](http://www.ncbi.nlm.nih.gov/pubmed/7545673?dopt=AbstractPlus)\], [\[^125^I\]CCL3 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=763) (Agonist) (p*K* ~d~ 8--8.8) \[[127](http://www.ncbi.nlm.nih.gov/pubmed/7545673?dopt=AbstractPlus), [623](http://www.ncbi.nlm.nih.gov/pubmed/9115216?dopt=AbstractPlus), [1646](http://www.ncbi.nlm.nih.gov/pubmed/9336350?dopt=AbstractPlus)\], [\[^125^I\]CCL5 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist) (p*K* ~d~ 8.2) \[[1646](http://www.ncbi.nlm.nih.gov/pubmed/9336350?dopt=AbstractPlus)\][\[^125^I\]CCL2 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=762) (Agonist), [\[^125^I\]CCL7 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist)[\[^125^I\]CCL11 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=794) (Antagonist) (p*K* ~d~ 8.3) \[[1977](http://www.ncbi.nlm.nih.gov/pubmed/12450563?dopt=AbstractPlus)\], [\[^125^I\]CCL5 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist), [\[^125^I\]CCL7 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist)

Nomenclature[CCR4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61)[CCR5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=62)HGNC, UniProt[*CCR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1605), [P51679](http://www.uniprot.org/uniprot/P51679)[*CCR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1606), [P51681](http://www.uniprot.org/uniprot/P51681)Endogenous agonists[CCL22](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=798) ([*CCL22*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10621), [O00626](http://www.uniprot.org/uniprot/O00626)) (Selective) (pIC~50~ 9.2) \[[822](http://www.ncbi.nlm.nih.gov/pubmed/9430724?dopt=AbstractPlus)\], [CCL17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797) ([*CCL17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10615), [Q92583](http://www.uniprot.org/uniprot/Q92583)) (Selective) (pIC~50~ 8.7) \[[822](http://www.ncbi.nlm.nih.gov/pubmed/9430724?dopt=AbstractPlus)\][CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)) (p*K* ~i~ 9.2--9.7) \[[75](http://www.ncbi.nlm.nih.gov/pubmed/10318947?dopt=AbstractPlus), [1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus), [1611](http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus)\], [CCL4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757) ([*CCL4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10630), [P13236](http://www.uniprot.org/uniprot/P13236)) (Selective) (p*K* ~i~ 9.4--9.6) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus), [1611](http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus)\], [CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772) ([*CCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10635), [P80075](http://www.uniprot.org/uniprot/P80075)) (p*K* ~i~ 9.3) \[[1611](http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus)\], [CCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756) ([*CCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10627), [P10147](http://www.uniprot.org/uniprot/P10147)) (p*K* ~i~ 8--8.9) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus), [1611](http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus), [2134](http://www.ncbi.nlm.nih.gov/pubmed/11170631?dopt=AbstractPlus)\], [CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)) (pIC~50~ 7.7) \[[157](http://www.ncbi.nlm.nih.gov/pubmed/10477718?dopt=AbstractPlus)\], [CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771) ([*CCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10618), [P13500](http://www.uniprot.org/uniprot/P13500)) (p*K* ~i~ 7.5) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus)\], [CCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753) ([*CCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10612), [Q16627](http://www.uniprot.org/uniprot/Q16627)) (p*K* ~i~ 7.2) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus)\], [CCL16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1272) ([*CCL16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10614), [O15467](http://www.uniprot.org/uniprot/O15467))Agonists[vMIP‐III](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4359)[R5‐HIV‐1 gp120](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3910)Endogenous antagonists--[CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)) (Selective) (p*K* ~i~ 7.5) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus)\]Antagonists--[vicriviroc](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=807) (p*K* ~i~ 9.1) \[[1805](http://www.ncbi.nlm.nih.gov/pubmed/16304152?dopt=AbstractPlus)\], [ancriviroc](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=804) (p*K* ~i~ 7.8--8.7) \[[1173](http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus), [1455](http://www.ncbi.nlm.nih.gov/pubmed/11585437?dopt=AbstractPlus), [1805](http://www.ncbi.nlm.nih.gov/pubmed/16304152?dopt=AbstractPlus)\]Selective antagonists--[E913](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3500) (pIC~50~ 8.7) \[[1174](http://www.ncbi.nlm.nih.gov/pubmed/11454872?dopt=AbstractPlus)\], [aplaviroc](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=805) (p*K* ~i~ 8.5) \[[1173](http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus)\], [maraviroc](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=806) (pIC~50~ 8.1) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus)\], [TAK‐779](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=783) (p*K* ~i~ 7.5) \[[1173](http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus)\], [MRK‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3651) \[[1023](http://www.ncbi.nlm.nih.gov/pubmed/12604693?dopt=AbstractPlus)\] -- RatAntibodies[mogamulizumab](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6477) (Inhibition) \[[51](http://www.ncbi.nlm.nih.gov/pubmed/21154168?dopt=AbstractPlus), 1731\]--Labelled ligands[\[^125^I\]CCL17 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3652) (Agonist), [\[^125^I\]CCL27 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3653) (Agonist)[\[^125^I\]CCL4 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=799) (Agonist) (p*K* ~d~ 9.6) \[[1364](http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus)\], [\[^125^I\]CCL3 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=763) (Agonist), [\[^125^I\]CCL5 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist), [\[^125^I\]CCL8 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=766) (Agonist)

Nomenclature[CCR6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=63)[CCR7](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=64)[CCR8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=65)[CCR9](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=66)[CCR10](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=67)HGNC, UniProt[*CCR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1607), [P51684](http://www.uniprot.org/uniprot/P51684)[*CCR7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1608), [P32248](http://www.uniprot.org/uniprot/P32248)[*CCR8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1609), [P51685](http://www.uniprot.org/uniprot/P51685)[*CCR9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1610), [P51686](http://www.uniprot.org/uniprot/P51686)[*CCR10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4474), [P46092](http://www.uniprot.org/uniprot/P46092)Endogenous agonists[CCL20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=808) ([*CCL20*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10619), [P78556](http://www.uniprot.org/uniprot/P78556)) (pIC~50~ 7.9--8.5) \[[18](http://www.ncbi.nlm.nih.gov/pubmed/12081481?dopt=AbstractPlus), [74](http://www.ncbi.nlm.nih.gov/pubmed/9169459?dopt=AbstractPlus), [1526](http://www.ncbi.nlm.nih.gov/pubmed/9294137?dopt=AbstractPlus)\], [beta‐defensin 4A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3648) ([*DEFB4A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2767) [*DEFB4B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30193), [O15263](http://www.uniprot.org/uniprot/O15263)) (Selective) \[[2081](http://www.ncbi.nlm.nih.gov/pubmed/10521347?dopt=AbstractPlus)\][CCL21](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=811) ([*CCL21*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10620), [O00585](http://www.uniprot.org/uniprot/O00585)) (Selective) (pIC~50~ 9.3) \[[2099](http://www.ncbi.nlm.nih.gov/pubmed/9507024?dopt=AbstractPlus)\], [CCL19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810) ([*CCL19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10617), [Q99731](http://www.uniprot.org/uniprot/Q99731)) (Selective) (pIC~50~ 7.7--9, median 8.6) \[[1449](http://www.ncbi.nlm.nih.gov/pubmed/16904643?dopt=AbstractPlus), [2098](http://www.ncbi.nlm.nih.gov/pubmed/9153236?dopt=AbstractPlus), [2099](http://www.ncbi.nlm.nih.gov/pubmed/9507024?dopt=AbstractPlus)\][CCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=812) ([*CCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10609), [P22362](http://www.uniprot.org/uniprot/P22362)) (Selective) (pIC~50~ 8.5--9.8) \[[387](http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus), [710](http://www.ncbi.nlm.nih.gov/pubmed/16221874?dopt=AbstractPlus), [824](http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus)\], [CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4415) {Mouse} -- Mouse[CCL25](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=817) ([*CCL25*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10624), [O15444](http://www.uniprot.org/uniprot/O15444)) (Selective)[CCL27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3646) ([*CCL27*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10626), [Q9Y4X3](http://www.uniprot.org/uniprot/Q9Y4X3)) (Selective), [CCL28](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3649) ([*CCL28*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17700), [Q9NRJ3](http://www.uniprot.org/uniprot/Q9NRJ3)) (Selective)Agonists----[vMIP‐I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=815) (pIC~50~ 8.9--9.9) \[[387](http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus), [824](http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus)\]----Selective antagonists----[vMCC‐I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=816) (pIC~50~ 9.4) \[[387](http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus)\]----Labelled ligands[\[^125^I\]CCL20 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3654) (Agonist) (p*K* ~d~∼10) \[[641](http://www.ncbi.nlm.nih.gov/pubmed/9294138?dopt=AbstractPlus)\][\[^125^I\]CCL19 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3655) (Agonist), [\[^125^I\]CCL21 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3656) (Agonist) \[[856](http://www.ncbi.nlm.nih.gov/pubmed/10201891?dopt=AbstractPlus)\][\[^125^I\]CCL1 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=814) (Agonist) (p*K* ~d~ 8.9--9.7) \[[824](http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus), [1597](http://www.ncbi.nlm.nih.gov/pubmed/9211859?dopt=AbstractPlus)\][\[^125^I\]CCL25 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3657) (Agonist)--

Nomenclature[CXCR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=68)[CXCR2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=69)[CXCR3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=70)HGNC, UniProt[*CXCR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6026), [P25024](http://www.uniprot.org/uniprot/P25024)[*CXCR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6027), [P25025](http://www.uniprot.org/uniprot/P25025)[*CXCR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4540), [P49682](http://www.uniprot.org/uniprot/P49682)Endogenous agonists[CXCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821) ([*CXCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6025), [P10145](http://www.uniprot.org/uniprot/P10145)) (p*K* ~i~ 8.8--9.5) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus), [675](http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus), [1068](http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus), [2032](http://www.ncbi.nlm.nih.gov/pubmed/15946947?dopt=AbstractPlus), [2049](http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus)\], [CXCL6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820) ([*CXCL6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10643), [P80162](http://www.uniprot.org/uniprot/P80162)) (p*K* ~i~ 7) \[[2053](http://www.ncbi.nlm.nih.gov/pubmed/9692902?dopt=AbstractPlus)\][CXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=819) ([*CXCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4602), [P09341](http://www.uniprot.org/uniprot/P09341)) (Selective) (p*K* ~i~ 8.4--9.7) \[[675](http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus), [1068](http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus), [2049](http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus)\], [CXCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821) ([*CXCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6025), [P10145](http://www.uniprot.org/uniprot/P10145)) (p*K* ~i~ 8.8--9.5) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus), [675](http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus), [1068](http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus), [2032](http://www.ncbi.nlm.nih.gov/pubmed/15946947?dopt=AbstractPlus), [2049](http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus)\], [CXCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=830) ([*PPBP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9240), [P02775](http://www.uniprot.org/uniprot/P02775)) (Selective) (pIC~50~ 6.3--9.3) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus)\], [CXCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=828) ([*CXCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4604), [P19876](http://www.uniprot.org/uniprot/P19876)) (Selective) (pIC~50~ 7.8--9.2) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus)\], [CXCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=827) ([*CXCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4603), [P19875](http://www.uniprot.org/uniprot/P19875)) (Selective) (pIC~50~ 7--9.1) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus)\], [CXCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=829) ([*CXCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10642), [P42830](http://www.uniprot.org/uniprot/P42830)) (Selective) (pIC~50~ 6.9--9) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus)\], [CXCL6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820) ([*CXCL6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10643), [P80162](http://www.uniprot.org/uniprot/P80162)) (p*K* ~d~ 7) \[[2053](http://www.ncbi.nlm.nih.gov/pubmed/9692902?dopt=AbstractPlus)\][CXCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836) ([*CXCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10638), [O14625](http://www.uniprot.org/uniprot/O14625)) (Selective) (p*K* ~i~ 10.4--10.5) \[[734](http://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus)\], [CXCL10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=835) ([*CXCL10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10637), [P02778](http://www.uniprot.org/uniprot/P02778)) (Selective) (p*K* ~i~ 7.8--9.8) \[[734](http://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus), [2006](http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus)\], [CXCL9](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=837) ([*CXCL9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7098), [Q07325](http://www.uniprot.org/uniprot/Q07325)) (Selective) (p*K* ~i~ 7.3--8.3) \[[734](http://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus), [2006](http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus)\]Agonists[vCXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8496) (pIC~50~ 7.4) \[[1158](http://www.ncbi.nlm.nih.gov/pubmed/20044480?dopt=AbstractPlus)\], [HIV‐1 matrix protein p17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8495) (p*K* ~d~ 5.7) \[[602](http://www.ncbi.nlm.nih.gov/pubmed/22262769?dopt=AbstractPlus)\][vCXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8496) (pIC~50~ 8.2) \[[1158](http://www.ncbi.nlm.nih.gov/pubmed/20044480?dopt=AbstractPlus)\], [HIV‐1 matrix protein p17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8495) (p*K* ~d~ 6.9) \[[602](http://www.ncbi.nlm.nih.gov/pubmed/22262769?dopt=AbstractPlus)\]--Selective agonists------Endogenous antagonists----[CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)) (Selective) (p*K* ~i~ 7.2) \[[2006](http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus)\], [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)) (Selective) (p*K* ~i~ 6.6) \[[2006](http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus)\]Antagonists------Selective antagonists--[navarixin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8497) (pIC~50~ 10.3) \[[78](http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus), [456](http://www.ncbi.nlm.nih.gov/pubmed/17181143?dopt=AbstractPlus)\], [danirixin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8500) (pIC~50~ 7.9) \[[1285](http://www.ncbi.nlm.nih.gov/pubmed/26092545?dopt=AbstractPlus)\], [SB 225002](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=833) (pIC~50~ 7.7) \[[2016](http://www.ncbi.nlm.nih.gov/pubmed/9553055?dopt=AbstractPlus)\], [elubirixin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8499) (pIC~50~ 7.7) \[[78](http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus)\], [SX‐517](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8501) (pIC~50~ 7.2) \[[1172](http://www.ncbi.nlm.nih.gov/pubmed/25254640?dopt=AbstractPlus)\]--Allosteric modulators[reparixin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8498) (Negative) (pIC~50~ 9) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus)\][reparixin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8498) (Negative) (pIC~50~ 6.4) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]CXCL8 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=822) (Agonist) (p*K* ~d~ 8.9--9.6) \[[675](http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus), [1584](http://www.ncbi.nlm.nih.gov/pubmed/12626541?dopt=AbstractPlus)\][\[^125^I\]CXCL8 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=822) (Agonist) (p*K* ~d~ 9--9.4) \[[675](http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus), [1584](http://www.ncbi.nlm.nih.gov/pubmed/12626541?dopt=AbstractPlus)\], [\[^125^I\]CXCL1 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3677) (Agonist), [\[^125^I\]CXCL5 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3659) (Agonist), [\[^125^I\]CXCL7 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3658) (Agonist)[\[^125^I\]CXCL10 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3660) (Agonist), [\[^125^I\]CXCL11 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3661) (Agonist)CommentsReports on the expression of native CXCR1 by mouse leukocytes are not conclusive. There are reports on the existence of mouse *Cxcr1* and on *Cxcr1* knockout mice, but the distinct function of the gene and of its knockout phenotype are unclear \[[118](http://www.ncbi.nlm.nih.gov/pubmed/17289163?dopt=AbstractPlus), [351](http://www.ncbi.nlm.nih.gov/pubmed/21254176?dopt=AbstractPlus), [1297](http://www.ncbi.nlm.nih.gov/pubmed/16084593?dopt=AbstractPlus), [1628](http://www.ncbi.nlm.nih.gov/pubmed/21693308?dopt=AbstractPlus), [1794](http://www.ncbi.nlm.nih.gov/pubmed/23026400?dopt=AbstractPlus)\].----

Nomenclature[CXCR4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71)[CXCR5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=72)[CXCR6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=73)HGNC, UniProt[*CXCR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2561), [P61073](http://www.uniprot.org/uniprot/P61073)[*CXCR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1060), [P32302](http://www.uniprot.org/uniprot/P32302)[*CXCR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16647), [O00574](http://www.uniprot.org/uniprot/O00574)Endogenous agonists[CXCL12*α*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4358) ([*CXCL12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10672), [P48061](http://www.uniprot.org/uniprot/P48061)) (Selective) (p*K* ~d~ 7.7--8.2) \[[746](http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus), [1136](http://www.ncbi.nlm.nih.gov/pubmed/9712844?dopt=AbstractPlus)\], [CXCL12*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=845) ([*CXCL12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10672), [P48061](http://www.uniprot.org/uniprot/P48061)) (Selective) (p*K* ~d~ 7.9) \[[746](http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus)\][CXCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3645) ([*CXCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10639), [O43927](http://www.uniprot.org/uniprot/O43927)) (Selective) (p*K* ~d~ 7.3) \[[97](http://www.ncbi.nlm.nih.gov/pubmed/22913878?dopt=AbstractPlus)\][CXCL16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=855) ([*CXCL16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16642), [Q9H2A7](http://www.uniprot.org/uniprot/Q9H2A7)) (Selective) (p*K* ~d~ 9) \[[2026](http://www.ncbi.nlm.nih.gov/pubmed/11290797?dopt=AbstractPlus)\]Agonists----Selective agonists[ALX40‐4C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=607) (Partial agonist) (pIC~50~ 6.1) \[[2121](http://www.ncbi.nlm.nih.gov/pubmed/11923301?dopt=AbstractPlus)\], [X4‐HIV‐1 gp120](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3919)--Endogenous antagonists----Antagonists[plerixafor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844) (p*K* ~i~ 7) \[[2121](http://www.ncbi.nlm.nih.gov/pubmed/11923301?dopt=AbstractPlus)\]--Selective antagonists[T134](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=852) (pIC~50~ 8.4) \[[1856](http://www.ncbi.nlm.nih.gov/pubmed/9918823?dopt=AbstractPlus)\], [AMD070](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8580) (pIC~50~ 7.9) \[[1750](http://www.ncbi.nlm.nih.gov/pubmed/20297846?dopt=AbstractPlus)\], [HIV‐Tat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=773)--Allosteric modulators----Labelled ligands[\[^125^I\]CXCL12*α* (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=849) (Agonist) (p*K* ~d~ 8.1--8.4) \[[421](http://www.ncbi.nlm.nih.gov/pubmed/11104827?dopt=AbstractPlus), [746](http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus)\][\[^125^I\]CXCL13 (mouse)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8631) (Agonist) \[[222](http://www.ncbi.nlm.nih.gov/pubmed/24190631?dopt=AbstractPlus)\] -- Mouse[\[^125^I\]CXCL16 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3662) (Agonist)Comments------

Nomenclature[CX~3~CR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=74)[XCR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=75)[ACKR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=316)[ACKR2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=314)HGNC, UniProt[*CX3CR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2558), [P49238](http://www.uniprot.org/uniprot/P49238)[*XCR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1625), [P46094](http://www.uniprot.org/uniprot/P46094)[*ACKR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4035), [Q16570](http://www.uniprot.org/uniprot/Q16570)[*ACKR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1565), [O00590](http://www.uniprot.org/uniprot/O00590)Endogenous ligands----[CXCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=829) ([*CXCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10642), [P42830](http://www.uniprot.org/uniprot/P42830)), [CXCL6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820) ([*CXCL6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10643), [P80162](http://www.uniprot.org/uniprot/P80162)), [CXCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821) ([*CXCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6025), [P10145](http://www.uniprot.org/uniprot/P10145)), [CXCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836) ([*CXCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10638), [O14625](http://www.uniprot.org/uniprot/O14625)), [CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771) ([*CCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10618), [P13500](http://www.uniprot.org/uniprot/P13500)), [CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)), [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)), [CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)), [CCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753) ([*CCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10612), [Q16627](http://www.uniprot.org/uniprot/Q16627)), [CCL17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797) ([*CCL17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10615), [Q92583](http://www.uniprot.org/uniprot/Q92583))[CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771) ([*CCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10618), [P13500](http://www.uniprot.org/uniprot/P13500)), [CCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756) ([*CCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10627), [P10147](http://www.uniprot.org/uniprot/P10147)), [CCL4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757) ([*CCL4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10630), [P13236](http://www.uniprot.org/uniprot/P13236)), [CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758) ([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501)), [CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759) ([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098)), [CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772) ([*CCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10635), [P80075](http://www.uniprot.org/uniprot/P80075)), [CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769) ([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671)), [CCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770) ([*CCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10611), [Q99616](http://www.uniprot.org/uniprot/Q99616)), [CCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753) ([*CCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10612), [Q16627](http://www.uniprot.org/uniprot/Q16627)), [CCL17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797) ([*CCL17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10615), [Q92583](http://www.uniprot.org/uniprot/Q92583)), [CCL22](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=798) ([*CCL22*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10621), [O00626](http://www.uniprot.org/uniprot/O00626))Endogenous agonists[CX~3~CL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=856) ([*CX3CL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10647), [P78423](http://www.uniprot.org/uniprot/P78423)) (Selective) (pIC~50~ 8.9) \[[577](http://www.ncbi.nlm.nih.gov/pubmed/14607932?dopt=AbstractPlus)\][XCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3647) ([*XCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10645), [P47992](http://www.uniprot.org/uniprot/P47992)) (Selective), [XCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4370) ([*XCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10646), [Q9UBD3](http://www.uniprot.org/uniprot/Q9UBD3)) (Selective)----Labelled ligands[\[^125^I\]CX~3~CL1 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3664) (Agonist)----Comments--When fused with secreted alkaline phophatase (SEAP), XCL1 functions as a probe at XCR1ACKR1 is used by *Plasmodium vivax* and *Plasmodium knowlsei* for entering erythrocytes.

Nomenclature[ACKR3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=80)[ACKR4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=315)[CCRL2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=78)HGNC, UniProt[*ACKR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23692), [P25106](http://www.uniprot.org/uniprot/P25106)[*ACKR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1611), [Q9NPB9](http://www.uniprot.org/uniprot/Q9NPB9)[*CCRL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1612), [O00421](http://www.uniprot.org/uniprot/O00421)Endogenous ligands----[chemerin C‐terminal peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3422), [CCL19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810) ([*CCL19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10617), [Q99731](http://www.uniprot.org/uniprot/Q99731)) \[[95](http://www.ncbi.nlm.nih.gov/pubmed/18165312?dopt=AbstractPlus)\]Endogenous agonists[CXCL12*α*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4358) ([*CXCL12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10672), [P48061](http://www.uniprot.org/uniprot/P48061)) (pEC~50~ 7.5--7.9) \[[640](http://www.ncbi.nlm.nih.gov/pubmed/20956518?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\], [CXCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836) ([*CXCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10638), [O14625](http://www.uniprot.org/uniprot/O14625)), [adrenomedullin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3589) {Mouse} \[[965](http://www.ncbi.nlm.nih.gov/pubmed/25203207?dopt=AbstractPlus)\] -- Mouse[CCL19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810) ([*CCL19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10617), [Q99731](http://www.uniprot.org/uniprot/Q99731)) (p*K* ~i~ 8.4) \[[1997](http://www.ncbi.nlm.nih.gov/pubmed/23341447?dopt=AbstractPlus)\], [CCL25](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=817) ([*CCL25*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10624), [O15444](http://www.uniprot.org/uniprot/O15444)) (p*K* ~i~ 7.6) \[[1997](http://www.ncbi.nlm.nih.gov/pubmed/23341447?dopt=AbstractPlus)\], [CCL21](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=811) ([*CCL21*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10620), [O00585](http://www.uniprot.org/uniprot/O00585)) (p*K* ~i~ 6.9) \[[1997](http://www.ncbi.nlm.nih.gov/pubmed/23341447?dopt=AbstractPlus)\]--

Comments {#bph13348-sec-0075}
--------

Mouse Cxcr binds iodinated mouse KC ([CXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4423){Mouse}) and mouse MIP‐2 ([CXCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4424){Mouse}) with high affinity (mouse KC and MIP‐2 are homologues of human [CXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=819)([*CXCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4602), [P09341](http://www.uniprot.org/uniprot/P09341)), [CXCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=827)([*CXCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4603), [P19875](http://www.uniprot.org/uniprot/P19875)) and [CXCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=828)([*CXCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4604), [P19876](http://www.uniprot.org/uniprot/P19876))), but shows low affinity for human IL‐8 ([CXCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821)([*CXCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6025), [P10145](http://www.uniprot.org/uniprot/P10145))).

Specific chemokine receptors facilitate cell entry by microbes, such as ACKR1 for *Plasmodium vivax*, and CCR5 for HIV‐1. Virally encoded chemokine receptors are known (*e.g.* US28, a homologue of CCR1 from human cytomegalovirus and ORF74, which encodes a homolog of CXCR2 in *Herpesvirus saimiri* and Herpesvirus‐68), but their role in viral life cycles is not established. Viruses can exploit or subvert the chemokine system by producing chemokine antagonists and scavengers.

The CC chemokine family (CCL1‐28) includes I309 ([CCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=812)([*CCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10609), [P22362](http://www.uniprot.org/uniprot/P22362))), MCP‐1 ([CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771)([*CCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10618), [P13500](http://www.uniprot.org/uniprot/P13500))), MIP‐1*α*([CCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756)([*CCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10627), [P10147](http://www.uniprot.org/uniprot/P10147))), MIP‐1*β*([CCL4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757)([*CCL4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10630), [P13236](http://www.uniprot.org/uniprot/P13236))), RANTES ([CCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758)([*CCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10632), [P13501](http://www.uniprot.org/uniprot/P13501))), MCP‐3 ([CCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759)([*CCL7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10634), [P80098](http://www.uniprot.org/uniprot/P80098))), MCP‐2 ([CCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772)([*CCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10635), [P80075](http://www.uniprot.org/uniprot/P80075))), eotaxin ([CCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769)([*CCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10610), [P51671](http://www.uniprot.org/uniprot/P51671))), MCP‐4 ([CCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770)([*CCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10611), [Q99616](http://www.uniprot.org/uniprot/Q99616))), HCC‐1 ([CCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753)([*CCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10612), [Q16627](http://www.uniprot.org/uniprot/Q16627))), Lkn‐1/HCC‐2 ([CCL15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=754)([*CCL15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10613), [Q16663](http://www.uniprot.org/uniprot/Q16663))), TARC ([CCL17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797)([*CCL17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10615), [Q92583](http://www.uniprot.org/uniprot/Q92583))), ELC ([CCL19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810)([*CCL19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10617), [Q99731](http://www.uniprot.org/uniprot/Q99731))), LARC ([CCL20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=808)([*CCL20*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10619), [P78556](http://www.uniprot.org/uniprot/P78556))), SLC ([CCL21](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=811)([*CCL21*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10620), [O00585](http://www.uniprot.org/uniprot/O00585))), MDC ([CCL22](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=798)([*CCL22*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10621), [O00626](http://www.uniprot.org/uniprot/O00626))), MPIF‐1 ([CCL23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=755)([*CCL23*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10622), [P55773](http://www.uniprot.org/uniprot/P55773))), eotaxin‐2 ([CCL24](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=775)([*CCL24*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10623), [O00175](http://www.uniprot.org/uniprot/O00175))), TECK ([CCL25](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=817)([*CCL25*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10624), [O15444](http://www.uniprot.org/uniprot/O15444))), eotaxin ([CCL26](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=776)([*CCL26*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10625), [Q9Y258](http://www.uniprot.org/uniprot/Q9Y258))), eskine/CTACK ([CCL27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3646)([*CCL27*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10626), [Q9Y4X3](http://www.uniprot.org/uniprot/Q9Y4X3))) and MEC ([CCL28](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3649)([*CCL28*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17700), [Q9NRJ3](http://www.uniprot.org/uniprot/Q9NRJ3))). The CXC chemokine family (CXCL1‐17) includes GRO*α*([CXCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=819)([*CXCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4602), [P09341](http://www.uniprot.org/uniprot/P09341))), GRO*β*([CXCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=827)([*CXCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4603), [P19875](http://www.uniprot.org/uniprot/P19875))), GRO*γ*([CXCL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=828)([*CXCL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4604), [P19876](http://www.uniprot.org/uniprot/P19876))), platelet factor 4 ([CXCL4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3685)([*PF4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8861), [P02776](http://www.uniprot.org/uniprot/P02776))), ENA78 ([CXCL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=829)([*CXCL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10642), [P42830](http://www.uniprot.org/uniprot/P42830))), GCP‐2 ([CXCL6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820)([*CXCL6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10643), [P80162](http://www.uniprot.org/uniprot/P80162))), NAP‐2 ([CXCL7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=830)([*PPBP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9240), [P02775](http://www.uniprot.org/uniprot/P02775))), IL‐8 ([CXCL8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821)([*CXCL8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6025), [P10145](http://www.uniprot.org/uniprot/P10145))), MIG ([CXCL9](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=837)([*CXCL9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7098), [Q07325](http://www.uniprot.org/uniprot/Q07325))), IP10 ([CXCL10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=835)([*CXCL10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10637), [P02778](http://www.uniprot.org/uniprot/P02778))), I‐TAC ([CXCL11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836)([*CXCL11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10638), [O14625](http://www.uniprot.org/uniprot/O14625))), SDF‐1 (CXCL12, *i.e.* [CXCL12*α*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4358)([*CXCL12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10672), [P48061](http://www.uniprot.org/uniprot/P48061)) and [CXCL12*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=845)([*CXCL12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10672), [P48061](http://www.uniprot.org/uniprot/P48061))), BLC ([CXCL13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3645)([*CXCL13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10639), [O43927](http://www.uniprot.org/uniprot/O43927))), BRAK ([CXCL14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3680)([*CXCL14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10640), [O95715](http://www.uniprot.org/uniprot/O95715))), mouse lungkine ([CXCL15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3862) {Mouse}) SR‐PSOX ([CXCL16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=855)([*CXCL16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16642), [Q9H2A7](http://www.uniprot.org/uniprot/Q9H2A7))) and [CXCL17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6479)([*CXCL17*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19232), [Q6UXB2](http://www.uniprot.org/uniprot/Q6UXB2)). The CX~3~C chemokine ([CX~3~CL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=856)([*CX3CL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10647), [P78423](http://www.uniprot.org/uniprot/P78423))) is also known as fractalkine (neurotactin in the mouse). Like [CXCL16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=855)([*CXCL16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16642), [Q9H2A7](http://www.uniprot.org/uniprot/Q9H2A7)), and unlike other chemokines, [CX~3~CL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=856)([*CX3CL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10647), [P78423](http://www.uniprot.org/uniprot/P78423)) is multimodular containing a chemokine domain, an elongated mucin‐like stalk, a transmembrane domain and a cytoplasmic tail. Both plasma membrane‐associated and shed forms have been identified. The C chemokine ([XCL1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3647)([*XCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10645), [P47992](http://www.uniprot.org/uniprot/P47992))) is also known as lymphotactin.

Two chemokine receptor antagonists have now been approved by the FDA: the CCR5 antagonist [maraviroc](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=806) (Pfizer) for treatment of HIV/AIDS in patients with CCR5‐using strains; and the CXCR4 antagonist [plerixafor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844) (Sanofi) for hematopoietic stem cell mobilization with [G‐CSF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4934)([*CSF3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2438), [P09919](http://www.uniprot.org/uniprot/P09919)) in patients undergoing transplantation in the context of chemotherapy for lymphoma and multiple myeloma.

Further Reading {#bph13348-sec-0076}
---------------

Bachelerie F *et al*. (2015) An atypical addition to the chemokine receptor nomenclature: IUPHAR Review \~15\~. *Br. J. Pharmacol.* [\[PMID:25958743\]](http://www.ncbi.nlm.nih.gov/pubmed/25958743?dopt=AbstractPlus)

Koelink PJ *et al*. (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. *Pharmacol. Ther.* **133**: 1‐18 [\[PMID:21839114\]](http://www.ncbi.nlm.nih.gov/pubmed/21839114?dopt=AbstractPlus)

Murphy PM. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. *Pharmacol. Rev.* **54**: 227‐9 [\[PMID:12037138\]](http://www.ncbi.nlm.nih.gov/pubmed/12037138?dopt=AbstractPlus)

Murphy PM *et al*. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol. Rev.* **52**: 145‐176 [\[PMID:10699158\]](http://www.ncbi.nlm.nih.gov/pubmed/10699158?dopt=AbstractPlus)

Muñoz LM *et al*. (2011) Receptor oligomerization: a pivotal mechanism for regulating chemokine function. *Pharmacol. Ther.* **131**: 351‐8 [\[PMID:21600920\]](http://www.ncbi.nlm.nih.gov/pubmed/21600920?dopt=AbstractPlus)

Scholten DJ *et al*. (2012) Pharmacological modulation of chemokine receptor function. *Br. J. Pharmacol.* **165**: 1617‐43 [\[PMID:21699506\]](http://www.ncbi.nlm.nih.gov/pubmed/21699506?dopt=AbstractPlus)

Szpakowska M *et al*. (2012) Function, diversity and therapeutic potential of the N‐terminal domain of human chemokine receptors. *Biochem. Pharmacol.* **84**: 1366‐80 [\[PMID:22935450\]](http://www.ncbi.nlm.nih.gov/pubmed/22935450?dopt=AbstractPlus)

White GE *et al*. (2013) CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. *Pharmacol. Rev.* **65**: 47‐89 [\[PMID:23300131\]](http://www.ncbi.nlm.nih.gov/pubmed/23300131?dopt=AbstractPlus)

[Cholecystokinin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=15) {#bph13348-sec-0077}
=====================================================================================================

Overview {#bph13348-sec-0078}
--------

Cholecystokinin receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on CCK receptors \[** [**1403**](http://www.ncbi.nlm.nih.gov/pubmed/10581329?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides cholecystokinin‐8 ([CCK‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864)([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307))), [CCK‐33](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=860)([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307)), [CCK‐58](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3552)([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307)) and gastrin ([gastrin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559)([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350))). There are only two distinct subtypes of CCK receptors, CCK~1~ and CCK~2~ receptors \[[992](http://www.ncbi.nlm.nih.gov/pubmed/1373504?dopt=AbstractPlus), [1986](http://www.ncbi.nlm.nih.gov/pubmed/1313582?dopt=AbstractPlus)\], with some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are distinguished by their peptide selectivity, with the CCK~1~ receptor requiring the carboxyl‐terminal heptapeptide‐amide that includes a sulfated tyrosine for high affinity and potency, while the CCK~2~ receptor requires only the carboxyl‐terminal tetrapeptide shared by both CCK and gastrin peptides. These receptors have characteristic and distinct distributions, with both present in both the central nervous system and peripheral tissues.

Nomenclature[CCK~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76)[CCK~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77)HGNC, UniProt[*CCKAR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1570), [P32238](http://www.uniprot.org/uniprot/P32238)[*CCKBR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1571), [P32239](http://www.uniprot.org/uniprot/P32239)Rank order of potency[CCK‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864) ([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307)) ≫[gastrin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [desulfated cholecystokinin‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725)\>[CCK‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861) ([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307))[CCK‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864) ([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307)) ≥[gastrin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [desulfated cholecystokinin‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725), [CCK‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861) ([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307))Endogenous agonists--[desulfated cholecystokinin‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725) (pIC~50~ 8.3--8.7) \[[1071](http://www.ncbi.nlm.nih.gov/pubmed/7681836?dopt=AbstractPlus)\], [gastrin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)) (Selective) (pIC~50~ 8.3) \[[805](http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus)\] -- Mouse, [CCK‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861) ([*CCK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569), [P06307](http://www.uniprot.org/uniprot/P06307)) (pIC~50~ 7.5) \[[832](http://www.ncbi.nlm.nih.gov/pubmed/8349705?dopt=AbstractPlus)\], [desulfated gastrin‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3558) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [desulfated gastrin‐17](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8408) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [desulfated gastrin‐34](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8409) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [desulfated gastrin‐71](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8410) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [gastrin‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8411) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [gastrin‐34](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3562) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350)), [gastrin‐71](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3566) ([*GAST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4164), [P01350](http://www.uniprot.org/uniprot/P01350))Selective agonists[A‐71623](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=858) (pIC~50~ 8.4) \[[63](http://www.ncbi.nlm.nih.gov/pubmed/1636779?dopt=AbstractPlus)\] -- Rat, [JMV180](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3888) (pIC~50~ 8.3) \[[926](http://www.ncbi.nlm.nih.gov/pubmed/7654246?dopt=AbstractPlus)\], [GW‐5823](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=865) (pIC~50~ 7.6) \[[737](http://www.ncbi.nlm.nih.gov/pubmed/9276016?dopt=AbstractPlus)\][RB‐400](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=900) (p*K* ~i~ 9.1) \[[123](http://www.ncbi.nlm.nih.gov/pubmed/14698161?dopt=AbstractPlus)\] -- Rat, [PBC‐264](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3948) (pIC~50~ 9.1) \[[844](http://www.ncbi.nlm.nih.gov/pubmed/8720482?dopt=AbstractPlus)\] -- RatAntagonists[lintitript](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=890) (pIC~50~ 8.3) \[[632](http://www.ncbi.nlm.nih.gov/pubmed/10988332?dopt=AbstractPlus)\]--Selective antagonists[devazepide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=878) (pIC~50~ 9.7) \[[805](http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus)\] -- Rat, [T‐0632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=884) (pIC~50~ 9.6) \[[1861](http://www.ncbi.nlm.nih.gov/pubmed/8813597?dopt=AbstractPlus)\] -- Rat, [PD‐140548](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=904) (pIC~50~ 8.6) \[[1748](http://www.ncbi.nlm.nih.gov/pubmed/8605955?dopt=AbstractPlus)\] -- Rat, [lorglumide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=891) (pIC~50~ 6.7--8.2) \[[805](http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus), [834](http://www.ncbi.nlm.nih.gov/pubmed/2437574?dopt=AbstractPlus)\] -- Rat[YF‐476](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=887) (pIC~50~ 9.7) \[[196](http://www.ncbi.nlm.nih.gov/pubmed/22607579?dopt=AbstractPlus), [1854](http://www.ncbi.nlm.nih.gov/pubmed/9042983?dopt=AbstractPlus)\], [GV150013](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3503) (pIC~50~ 9.4) \[[1930](http://www.ncbi.nlm.nih.gov/pubmed/11020274?dopt=AbstractPlus)\], [L‐740093](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=881) (pIC~50~ 9.2) \[[1398](http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus)\], [YM‐022](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=888) (pIC~50~ 9.2) \[[1398](http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus)\], [JNJ‐26070109](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6665) (pIC~50~ 8.5) \[[1336](http://www.ncbi.nlm.nih.gov/pubmed/21493750?dopt=AbstractPlus)\], [L‐365260](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=879) (pIC~50~ 8.4) \[[1071](http://www.ncbi.nlm.nih.gov/pubmed/7681836?dopt=AbstractPlus)\], [RP73870](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3523) (pIC~50~ 8) \[[1115](http://www.ncbi.nlm.nih.gov/pubmed/10385255?dopt=AbstractPlus)\] -- Rat, [LY262691](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3509) (pIC~50~ 7.5) \[[1561](http://www.ncbi.nlm.nih.gov/pubmed/21228869?dopt=AbstractPlus)\] -- RatLabelled ligands[\[^3^H\]devazepide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3476) (Antagonist) (p*K* ~d~ 9.7) \[[292](http://www.ncbi.nlm.nih.gov/pubmed/3018478?dopt=AbstractPlus)\], [\[^125^I\]DTyr‐Gly‐\[(Nle28,31)CCK‐26‐33](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6666) (Agonist) (pIC~50~ 9) \[[1527](http://www.ncbi.nlm.nih.gov/pubmed/3410633?dopt=AbstractPlus)\][\[^3^H\]PD140376](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3478) (Antagonist) (p*K* ~i~ 9.7--10) \[[809](http://www.ncbi.nlm.nih.gov/pubmed/8474432?dopt=AbstractPlus)\] -- Guinea pig, [\[^125^I\]PD142308](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3472) (Antagonist) (p*K* ~d~ 9.6) \[781\] -- Guinea pig, [\[^125^I\]DTyr‐Gly‐\[(Nle28,31)CCK‐26‐33](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6666) (Agonist) (pIC~50~ 9) \[[1527](http://www.ncbi.nlm.nih.gov/pubmed/3410633?dopt=AbstractPlus)\], [\[^125^I\]gastrin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3781) (Agonist) (pIC~50~ 9), [\[^3^H\]gastrin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3821) (Agonist) (pIC~50~ 9), [\[^3^H\]L365260](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3477) (Antagonist) (p*K* ~d~ 8.2--8.5) \[[1398](http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus)\], [\[^125^I\]‐BDZ~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6667) (Antagonist) (p*K* ~i~ 8.4) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19271701?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0079}
--------

While a cancer‐specific CCK receptor has been postulated to exist, which also might be responsive to incompletely processed forms of CCK (Gly‐extended forms), this has never been isolated. An alternatively spliced form of the CCK~2~ receptor in which intron 4 is retained, adding 69 amino acids to the intracellular loop 3 (ICL3) region, has been described to be present particularly in certain neoplasms where mRNA mis‐splicing has been commonly observed \[[1764](http://www.ncbi.nlm.nih.gov/pubmed/12429993?dopt=AbstractPlus)\], but it is not clear that this receptor splice form plays a special role in carcinogenesis. Another alternative splicing event for the CCK~2~ receptor was reported \[[1782](http://www.ncbi.nlm.nih.gov/pubmed/8415658?dopt=AbstractPlus)\], with alternative donor sites in exon 4 resulting in long (452 amino acids) and short (447 amino acids) forms of the receptor differing by five residues in ICL3, however, no clear functional differences have been observed.
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---------------
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[Class Frizzled GPCRs](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=25) {#bph13348-sec-0081}
================================================================================================

Overview {#bph13348-sec-0082}
--------

Receptors of the Class Frizzled (FZD, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on the Class Frizzled GPCRs \[** [**1676**](http://www.ncbi.nlm.nih.gov/pubmed/21079039?dopt=AbstractPlus) **\]**), are GPCRs originally identified in*Drosophila* \[[285](http://www.ncbi.nlm.nih.gov/pubmed/1334084?dopt=AbstractPlus)\], which are highly conserved across species. FZDs are activated by WNTs, which are cysteine‐rich lipoglycoproteins with fundamental functions in ontogeny and tissue homeostatis. FZD signalling was initially divided into two pathways, being either dependent on the accumulation of the transcription regulator [*β*‐catenin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5371)([*CTNNB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2514), [P35222](http://www.uniprot.org/uniprot/P35222)) or being *β*‐catenin‐independent (often referred to as canonical *vs.* non‐canonical WNT/FZD signalling, respectively). WNT stimulation of FZDs can, in cooperation with the low density lipoprotein receptors [*LRP5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6697) ([O75197](http://www.uniprot.org/uniprot/O75197)) and [*LRP6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6698)([O75581](http://www.uniprot.org/uniprot/O75581)), lead to the inhibition of a constitutively active destruction complex, which results in the accumulation of *β*‐catenin and subsequently its translocation to the nucleus. *β*‐Catenin, in turn, modifies gene transcription by interacting with TCF/LEF transcription factors. *β*‐Catenin‐independent FZD signalling is far more complex with regard to the diversity of the activated pathways. WNT/FZD signalling can lead to the activation of pertussis toxin‐sensitive heterotrimeric G proteins \[[939](http://www.ncbi.nlm.nih.gov/pubmed/21070854?dopt=AbstractPlus)\], the elevation of intracellular calcium \[[1757](http://www.ncbi.nlm.nih.gov/pubmed/9389482?dopt=AbstractPlus)\], activation of cGMP‐specific PDE6 \[[17](http://www.ncbi.nlm.nih.gov/pubmed/12471263?dopt=AbstractPlus)\] and elevation of cAMP as well as RAC‐1, JNK, Rho and Rho kinase signalling \[[695](http://www.ncbi.nlm.nih.gov/pubmed/19651774?dopt=AbstractPlus)\]. Furthermore, the phosphoprotein Disheveled constitutes a key player in WNT/FZD signalling. As with other GPCRs, members of the Frizzled family are functionally dependent on the arrestin scaffolding protein for internalization \[[306](http://www.ncbi.nlm.nih.gov/pubmed/12958365?dopt=AbstractPlus)\], as well as for *β*‐catenin‐dependent \[[235](http://www.ncbi.nlm.nih.gov/pubmed/17426148?dopt=AbstractPlus)\] and ‐independent \[[236](http://www.ncbi.nlm.nih.gov/pubmed/18953287?dopt=AbstractPlus), [940](http://www.ncbi.nlm.nih.gov/pubmed/17476309?dopt=AbstractPlus)\] signalling. The pattern of cell signalling is complicated by the presence of additional ligands, which can enhance or inhibit FZD signalling (secreted Frizzled‐related proteins (sFRP), [Wnt‐inhibitory factor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5372)([*WIF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18081), [Q9Y5W5](http://www.uniprot.org/uniprot/Q9Y5W5)) (WIF), [sclerostin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3704)([*SOST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13771), [Q9BQB4](http://www.uniprot.org/uniprot/Q9BQB4)) or Dickkopf (DKK)), as well as modulatory (co)‐receptors with [Ryk](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#TypeXVRTKs:RYK), [ROR1](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#TypeVIIIRTKs:ROR1), [ROR2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#TypeVIIIRTKs:ROR2) and Kremen, which may also function as independent signalling proteins.

Nomenclature[FZD~1~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=229)[FZD~2~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=230)[FZD~3~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=231)[FZD~4~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=232)[FZD~5~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=233)HGNC, UniProt[*FZD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4038), [Q9UP38](http://www.uniprot.org/uniprot/Q9UP38)[*FZD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4040), [Q14332](http://www.uniprot.org/uniprot/Q14332)[*FZD3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4041), [Q9NPG1](http://www.uniprot.org/uniprot/Q9NPG1)[*FZD4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4042), [Q9ULV1](http://www.uniprot.org/uniprot/Q9ULV1)[*FZD5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4043), [Q13467](http://www.uniprot.org/uniprot/Q13467)

Nomenclature[FZD~6~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=234)[FZD~7~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=235)[FZD~8~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=236)[FZD~9~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=237)[FZD~10~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=238)HGNC, UniProt[*FZD6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4044), [O60353](http://www.uniprot.org/uniprot/O60353)[*FZD7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4045), [O75084](http://www.uniprot.org/uniprot/O75084)[*FZD8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4046), [Q9H461](http://www.uniprot.org/uniprot/Q9H461)[*FZD9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4047), [O00144](http://www.uniprot.org/uniprot/O00144)[*FZD10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4039), [Q9ULW2](http://www.uniprot.org/uniprot/Q9ULW2)

Nomenclature[SMO](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239)HGNC, UniProt[*SMO*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11119), [Q99835](http://www.uniprot.org/uniprot/Q99835)Antagonists[saridegib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8198) (pIC~50~ 8.9) \[[1904](http://www.ncbi.nlm.nih.gov/pubmed/19522463?dopt=AbstractPlus)\], [glasdegib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8201) (pIC~50~ 8.3) \[[1342](http://www.ncbi.nlm.nih.gov/pubmed/24900436?dopt=AbstractPlus)\], [erismodegib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8199) (p*K* ~i~ 8.2) \[[1979](http://www.ncbi.nlm.nih.gov/pubmed/23063522?dopt=AbstractPlus)\]Selective antagonists[vismodegib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6975) (p*K* ~i~ 7.8) \[[1979](http://www.ncbi.nlm.nih.gov/pubmed/23063522?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0083}
--------

There is limited knowledge about WNT/FZD specificity and which molecular entities determine the signalling outcome of a specific WNT/FZD pair. Understanding of the coupling to G proteins is incomplete (see \[[423](http://www.ncbi.nlm.nih.gov/pubmed/24032637?dopt=AbstractPlus)\]). There is also a scarcity of information on basic pharmacological characteristics of FZDs, such as binding constants, ligand specificity or concentration‐response relationships \[[937](http://www.ncbi.nlm.nih.gov/pubmed/19208479?dopt=AbstractPlus)\].

**Ligands associated with FZD signalling**

***WNTs***: [Wnt‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3672)([*WNT1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12774), [P04628](http://www.uniprot.org/uniprot/P04628)), [Wnt‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3673)([*WNT2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12780), [P09544](http://www.uniprot.org/uniprot/P09544)) (also known as Int‐1‐related protein), [Wnt‐2b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3674)([*WNT2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12781), [Q93097](http://www.uniprot.org/uniprot/Q93097)) (also known as WNT‐13), [Wnt‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3675)([*WNT3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12782), [P56703](http://www.uniprot.org/uniprot/P56703)) , [Wnt‐3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3549)([*WNT3A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15983), [P56704](http://www.uniprot.org/uniprot/P56704)), [Wnt‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3547)([*WNT4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12783), [P56705](http://www.uniprot.org/uniprot/P56705)), [Wnt‐5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3548)([*WNT5A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12784), [P41221](http://www.uniprot.org/uniprot/P41221)) , [Wnt‐5b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3676)([*WNT5B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16265), [Q9H1J7](http://www.uniprot.org/uniprot/Q9H1J7)), [Wnt‐6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3678)([*WNT6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12785), [Q9Y6F9](http://www.uniprot.org/uniprot/Q9Y6F9)), [Wnt‐7a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3679)([*WNT7A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12786), [O00755](http://www.uniprot.org/uniprot/O00755)), [Wnt‐7b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3681)([*WNT7B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12787), [P56706](http://www.uniprot.org/uniprot/P56706)), [Wnt‐8a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3682)([*WNT8A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12788), [Q9H1J5](http://www.uniprot.org/uniprot/Q9H1J5)), [Wnt‐8b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3683)([*WNT8B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12789), [Q93098](http://www.uniprot.org/uniprot/Q93098)), [Wnt‐9a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3684)([*WNT9A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12778), [O14904](http://www.uniprot.org/uniprot/O14904)) (also known as WNT‐14), [Wnt‐9b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3686)([*WNT9B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12779), [O14905](http://www.uniprot.org/uniprot/O14905)) (also known as WNT‐15 or WNT‐14b), [Wnt‐10a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3687)([*WNT10A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13829), [Q9GZT5](http://www.uniprot.org/uniprot/Q9GZT5)), [Wnt‐10b](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3688)([*WNT10B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12775), [O00744](http://www.uniprot.org/uniprot/O00744)) (also known as WNT‐12), [Wnt‐11](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3689)([*WNT11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12776), [O96014](http://www.uniprot.org/uniprot/O96014)) and [Wnt‐16](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3690)([*WNT16*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16267), [Q9UBV4](http://www.uniprot.org/uniprot/Q9UBV4)).

***Extracellular proteins that interact with FZDs**:* [norrin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1063)([*NDP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7678), [Q00604](http://www.uniprot.org/uniprot/Q00604)), [R‐spondin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697)([*RSPO1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21679), [Q2MKA7](http://www.uniprot.org/uniprot/Q2MKA7)), [R‐spondin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698)([*RSPO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28583), [Q6UXX9](http://www.uniprot.org/uniprot/Q6UXX9)) , [R‐spondin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699)([*RSPO3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20866), [Q9BXY4](http://www.uniprot.org/uniprot/Q9BXY4)), [R‐spondin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700)([*RSPO4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16175), [Q2I0M5](http://www.uniprot.org/uniprot/Q2I0M5)), [sFRP‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3691)([*SFRP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10776), [Q8N474](http://www.uniprot.org/uniprot/Q8N474)), [sFRP‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3692)([*SFRP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10777), [Q96HF1](http://www.uniprot.org/uniprot/Q96HF1)), [sFRP‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3693)([*FRZB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3959), [Q92765](http://www.uniprot.org/uniprot/Q92765)), [sFRP‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3694)([*SFRP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10778), [Q6FHJ7](http://www.uniprot.org/uniprot/Q6FHJ7)), [sFRP‐5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3695)([*SFRP5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10779), [Q6FHJ7](http://www.uniprot.org/uniprot/Q6FHJ7)).

***Extracellular proteins that interact with WNTs or LRPs:*** [Dickkopf 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3701)([*DKK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2891), [O94907](http://www.uniprot.org/uniprot/O94907)), [*WIF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18081) ([Q9Y5W5](http://www.uniprot.org/uniprot/Q9Y5W5)), [sclerostin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3704)([*SOST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13771), [Q9BQB4](http://www.uniprot.org/uniprot/Q9BQB4)), [kremen 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3702)([*KREMEN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17550), [Q96MU8](http://www.uniprot.org/uniprot/Q96MU8)) and [kremen 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3703) ([*KREMEN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18797), [Q8NCW0](http://www.uniprot.org/uniprot/Q8NCW0))

***Small exogenous ligands:*** Foxy‐5 \[[1835](http://www.ncbi.nlm.nih.gov/pubmed/18927296?dopt=AbstractPlus)\], Box‐5, UM206 \[[1031](http://www.ncbi.nlm.nih.gov/pubmed/21931076?dopt=AbstractPlus)\], and XWnt8 ([P28026](http://www.uniprot.org/uniprot/P28026)) also known as mini‐Wnt8.
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---------------
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[Complement peptide receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=5) {#bph13348-sec-0085}
=======================================================================================================

Overview {#bph13348-sec-0086}
--------

Complement peptide receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on Complement peptide receptors \[** [**967**](http://www.ncbi.nlm.nih.gov/pubmed/23383423?dopt=AbstractPlus) **\]**) are activated by the endogenous  75 amino‐acid anaphylatoxin polypeptides [C3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640)([*C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1318), [P01024](http://www.uniprot.org/uniprot/P01024)). [C4a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6547)([*C4A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1323), [P0C0L4](http://www.uniprot.org/uniprot/P0C0L4)) and [C5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573)([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331), [P01031](http://www.uniprot.org/uniprot/P01031)), generated upon stimulation of the complement cascade.

Nomenclature[C3a receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=31)[C5a~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32)[C5a~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=33)HGNC, UniProt[*C3AR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1319), [Q16581](http://www.uniprot.org/uniprot/Q16581)[*C5AR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1338), [P21730](http://www.uniprot.org/uniprot/P21730)[*C5AR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4527), [Q9P296](http://www.uniprot.org/uniprot/Q9P296)Rank order of potency[C3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640) ([*C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1318), [P01024](http://www.uniprot.org/uniprot/P01024)) \>[C5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573) ([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331), [P01031](http://www.uniprot.org/uniprot/P01031)) \[[41](http://www.ncbi.nlm.nih.gov/pubmed/8898085?dopt=AbstractPlus)\][C5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573) ([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331), [P01031](http://www.uniprot.org/uniprot/P01031)), [C5a des‐Arg](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=574) ([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331)) \>[C3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640) ([*C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1318), [P01024](http://www.uniprot.org/uniprot/P01024)) \[[41](http://www.ncbi.nlm.nih.gov/pubmed/8898085?dopt=AbstractPlus)\]--Endogenous agonists--[ribosomal protein S19](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3728) ([*RPS19*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10402), [P39019](http://www.uniprot.org/uniprot/P39019)) \[[2071](http://www.ncbi.nlm.nih.gov/pubmed/11107061?dopt=AbstractPlus)\]--Agonists[E7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3915) (pEC~50~ 8.7) \[[43](http://www.ncbi.nlm.nih.gov/pubmed/9476119?dopt=AbstractPlus)\], [compound 21 \[PMID: 25259874\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8381) (pEC~50~ 7.7) \[[1571](http://www.ncbi.nlm.nih.gov/pubmed/25259874?dopt=AbstractPlus)\], [SQ007‐5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8379) (Partial agonist) (pEC~50~ 6.7) \[[124](http://www.ncbi.nlm.nih.gov/pubmed/22500977?dopt=AbstractPlus)\], [Ac‐RHYPLWR](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8380) (pEC~50~ 6) \[[672](http://www.ncbi.nlm.nih.gov/pubmed/25446428?dopt=AbstractPlus)\][*N*‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Cha‐D‐Arg‐CO~2~H](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=572) (pIC~50~ 7.6) \[[916](http://www.ncbi.nlm.nih.gov/pubmed/1732540?dopt=AbstractPlus), [989](http://www.ncbi.nlm.nih.gov/pubmed/7930622?dopt=AbstractPlus)\]--Antagonists[SB290157](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3529) (pIC~50~ 7.6) \[[40](http://www.ncbi.nlm.nih.gov/pubmed/11342658?dopt=AbstractPlus)\], [compound 4 \[PMID: 25259874\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8384) (pIC~50~ 5.9) \[[1571](http://www.ncbi.nlm.nih.gov/pubmed/25259874?dopt=AbstractPlus)\][CHIPS](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3724) (p*K* ~d~ 9) \[[1522](http://www.ncbi.nlm.nih.gov/pubmed/15153520?dopt=AbstractPlus)\], [W54011](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=581) (p*K* ~i~ 8.7) \[[1819](http://www.ncbi.nlm.nih.gov/pubmed/12384495?dopt=AbstractPlus)\], [AcPhe‐Orn‐Pro‐D‐Cha‐Trp‐Arg](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3853) (pIC~50~ 7.9) \[[2039](http://www.ncbi.nlm.nih.gov/pubmed/9719594?dopt=AbstractPlus)\], [*N*‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Trp‐D‐Arg‐CO~2~H](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=576) (pIC~50~ 7.2) \[[989](http://www.ncbi.nlm.nih.gov/pubmed/7930622?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]C3a (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3773) (Agonist) (p*K* ~d~ 8.4) \[[296](http://www.ncbi.nlm.nih.gov/pubmed/10092660?dopt=AbstractPlus)\][\[^125^I\]C5a (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3774) (Agonist) (p*K* ~d~ 8.7) \[[803](http://www.ncbi.nlm.nih.gov/pubmed/4020139?dopt=AbstractPlus)\][\[^125^I\]C5a (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3774) (Agonist)Comments----Binds C5a complement factor, but appears to lack G protein signalling and has been termed a decoy receptor \[[1684](http://www.ncbi.nlm.nih.gov/pubmed/19100624?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0087}
--------

[SB290157](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3529) has also been reported to have agonist properties at the C3a receptor \[[1218](http://www.ncbi.nlm.nih.gov/pubmed/16154494?dopt=AbstractPlus)\]. The putative chemoattractant receptor termed C5a~2~ (also known as GPR77, C5L2) binds \[^125^I\]C5a with no clear signalling function, but has a putative role opposing inflammatory responses \[[257](http://www.ncbi.nlm.nih.gov/pubmed/11773063?dopt=AbstractPlus), [568](http://www.ncbi.nlm.nih.gov/pubmed/15784721?dopt=AbstractPlus), [585](http://www.ncbi.nlm.nih.gov/pubmed/15715664?dopt=AbstractPlus)\]. Binding to this site may be displaced with the rank order [C5a des‐Arg](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=574)([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331))\>[C5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573)([*C5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1331), [P01031](http://www.uniprot.org/uniprot/P01031)) \[[257](http://www.ncbi.nlm.nih.gov/pubmed/11773063?dopt=AbstractPlus), [1440](http://www.ncbi.nlm.nih.gov/pubmed/12899627?dopt=AbstractPlus)\] while there is controversy over the ability of [C3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640)([*C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1318), [P01024](http://www.uniprot.org/uniprot/P01024)) and [C3a des Arg](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5367)([*C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1318), [P01024](http://www.uniprot.org/uniprot/P01024)) to compete \[[778](http://www.ncbi.nlm.nih.gov/pubmed/15990859?dopt=AbstractPlus), [894](http://www.ncbi.nlm.nih.gov/pubmed/12540846?dopt=AbstractPlus), [895](http://www.ncbi.nlm.nih.gov/pubmed/15833747?dopt=AbstractPlus), [1440](http://www.ncbi.nlm.nih.gov/pubmed/12899627?dopt=AbstractPlus)\]. C5a~2~ appears to lack G protein signalling and has been termed a decoy receptor \[[1684](http://www.ncbi.nlm.nih.gov/pubmed/19100624?dopt=AbstractPlus)\]. However, C5a~2~ does recruit arrestin after ligand binding, which might provide a signaling pathway for this receptor \[[89](http://www.ncbi.nlm.nih.gov/pubmed/20044484?dopt=AbstractPlus), [1937](http://www.ncbi.nlm.nih.gov/pubmed/19641221?dopt=AbstractPlus)\], and forms heteromers with C5a~1~. C5a, but not C5a‐des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2 \[[380](http://www.ncbi.nlm.nih.gov/pubmed/24060963?dopt=AbstractPlus)\]. There are also reports of pro‐inflammatory activity of C5a~2~, mediated by HMGB1, but the signaling pathway that underlies this is currently unclear (reviewed in \[[1095](http://www.ncbi.nlm.nih.gov/pubmed/23239822?dopt=AbstractPlus)\]).
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[Corticotropin‐releasing factor receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=19) {#bph13348-sec-0089}
====================================================================================================================

Overview {#bph13348-sec-0090}
--------

Corticotropin‐releasing factor (CRF, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on Corticotropin‐releasing Factor Receptors \[** [**716**](http://www.ncbi.nlm.nih.gov/pubmed/12615952?dopt=AbstractPlus) **\]**) receptors are activated by the endogenous peptides [corticotrophin‐releasing hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912) ([*CRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2355), [P06850](http://www.uniprot.org/uniprot/P06850)), a 41 amino‐acid peptide, [urocortin 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919)([*UCN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12516), [P55089](http://www.uniprot.org/uniprot/P55089)), 40 amino‐acids, [urocortin 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=921) ([*UCN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18414), [Q96RP3](http://www.uniprot.org/uniprot/Q96RP3)), 38 amino‐acids and [urocortin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=928) ([*UCN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17781), [Q969E3](http://www.uniprot.org/uniprot/Q969E3)), 38 amino‐acids. CRF~1~ and CRF~2~ receptors are activated non‐selectively by [corticotrophin‐releasing hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912) ([*CRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2355), [P06850](http://www.uniprot.org/uniprot/P06850)) and [urocortin 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919) ([*UCN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12516), [P55089](http://www.uniprot.org/uniprot/P55089)). Binding to CRF receptors can be conducted using \[^125^I\]Tyr^0^‐CRF or [\[^125^I\]Tyr^0^‐sauvagine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5389) with *K* ~d~ values of 0.1‐0.4 nM. CRF~1~ and CRF~2~ receptors are non‐selectively antagonized by [*α*‐helical CRF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=923), [D‐Phe‐CRF‐(12‐41)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3865) and [astressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=925).

Nomenclature[CRF~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212)[CRF~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=213)HGNC, UniProt[*CRHR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2357), [P34998](http://www.uniprot.org/uniprot/P34998)[*CRHR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2358), [Q13324](http://www.uniprot.org/uniprot/Q13324)Endogenous agonists--[urocortin 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=921) ([*UCN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18414), [Q96RP3](http://www.uniprot.org/uniprot/Q96RP3)) (Selective) (p*K* ~d~ 8.5--8.6) \[[392](http://www.ncbi.nlm.nih.gov/pubmed/15450949?dopt=AbstractPlus)\], [urocortin 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=928) ([*UCN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17781), [Q969E3](http://www.uniprot.org/uniprot/Q969E3)) (Selective) (p*K* ~d~ 7.9--8) \[[392](http://www.ncbi.nlm.nih.gov/pubmed/15450949?dopt=AbstractPlus)\]Antagonists[SSR125543A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3533) (p*K* ~i~ 8.7) \[[663](http://www.ncbi.nlm.nih.gov/pubmed/11907190?dopt=AbstractPlus)\]--Selective antagonists[CP 154,526](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3495) (pIC~50~ 9.3--10.4) \[[1153](http://www.ncbi.nlm.nih.gov/pubmed/8874139?dopt=AbstractPlus)\] -- Rat, [DMP696](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3499) (p*K* ~i~ 8.3--9) \[[726](http://www.ncbi.nlm.nih.gov/pubmed/10669572?dopt=AbstractPlus)\], [NBI27914](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3512) (p*K* ~i~ 8.3--9) \[[298](http://www.ncbi.nlm.nih.gov/pubmed/8893829?dopt=AbstractPlus)\], [R121919](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3520) (p*K* ~i~ 8.3--9) \[[2133](http://www.ncbi.nlm.nih.gov/pubmed/10867111?dopt=AbstractPlus)\], [antalarmin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3489) (p*K* ~i~ 8.3--9) \[[2001](http://www.ncbi.nlm.nih.gov/pubmed/8940412?dopt=AbstractPlus)\], [CP376395](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3496) (pIC~50~ 8.3) \[[307](http://www.ncbi.nlm.nih.gov/pubmed/18288792?dopt=AbstractPlus)\] -- Rat, [CRA1000](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3498) (pIC~50~ 6.4--7.1) \[[284](http://www.ncbi.nlm.nih.gov/pubmed/10357258?dopt=AbstractPlus)\][antisauvagine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=931) (p*K* ~d~ 8.8--9.6) \[[394](http://www.ncbi.nlm.nih.gov/pubmed/11123370?dopt=AbstractPlus)\], [K41498](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3891) (p*K* ~i~ 9.2) \[[1048](http://www.ncbi.nlm.nih.gov/pubmed/12110614?dopt=AbstractPlus)\], [K31440](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3890) (p*K* ~i~ 8.7--8.8) \[[1622](http://www.ncbi.nlm.nih.gov/pubmed/11835994?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0091}
--------

A CRF binding protein has been identified ([*CRHBP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2356), [P24387](http://www.uniprot.org/uniprot/P24387)) to which both [corticotrophin‐releasing hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912)([*CRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2355), [P06850](http://www.uniprot.org/uniprot/P06850)) and [urocortin 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919)([*UCN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12516), [P55089](http://www.uniprot.org/uniprot/P55089)) bind with high affinities, which has been suggested to bind and inactivate circulating [corticotrophin‐releasing hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912)([*CRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2355), [P06850](http://www.uniprot.org/uniprot/P06850)) \[[1489](http://www.ncbi.nlm.nih.gov/pubmed/7595134?dopt=AbstractPlus)\].
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[Dopamine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=20) {#bph13348-sec-0093}
==============================================================================================

Overview {#bph13348-sec-0094}
--------

Dopamine receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Dopamine Receptors \[1677\]**) are commonly divided into D~1~‐like (D~1~ and D~5~) and D~2~‐like (D~2~, D~3~ and D~4~) families, where the endogenous agonist is [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940).

Nomenclature[D~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=214)[D~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215)HGNC, UniProt[*DRD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3020), [P21728](http://www.uniprot.org/uniprot/P21728)[*DRD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3023), [P14416](http://www.uniprot.org/uniprot/P14416)Endogenous agonists[dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) (p*K* ~i~ 4.3--5.6) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus), [1884](http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus)\][dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) (p*K* ~i~ 4.7--7.2) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\]Agonists[fenoldopam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=939) (p*K* ~i~ 6.5--7.9) \[[1884](http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus)\][rotigotine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=941) (p*K* ~i~ 10.2) \[[424](http://www.ncbi.nlm.nih.gov/pubmed/12086487?dopt=AbstractPlus)\], [cabergoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=37) (Partial agonist) (p*K* ~i~ 9--9.2) \[[1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus)\], [aripiprazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=34) (Partial agonist) (p*K* ~i~ 9.1) \[[2111](http://www.ncbi.nlm.nih.gov/pubmed/23279866?dopt=AbstractPlus)\], [bromocriptine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=35) (p*K* ~i~ 7.3--8.3) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\], [MLS1547](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8369) (Biased agonist) (p*K* ~i~ 8.2) \[[544](http://www.ncbi.nlm.nih.gov/pubmed/24755247?dopt=AbstractPlus)\], [ropinirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7295) (p*K* ~i~ 8.1) \[[732](http://www.ncbi.nlm.nih.gov/pubmed/9057850?dopt=AbstractPlus)\], [apomorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33) (Partial agonist) (p*K* ~i~ 5.7--7.5) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [pramipexole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=953) (p*K* ~i~ 5.1--7.4) \[[1273](http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\], [benzquinamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7124) (p*K* ~i~ 5.4) \[[643](http://www.ncbi.nlm.nih.gov/pubmed/22711801?dopt=AbstractPlus)\](Sub)family‐selective agonists[A68930](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6077) (pEC~50~ 6.8) \[[1381](http://www.ncbi.nlm.nih.gov/pubmed/16318870?dopt=AbstractPlus)\], [SKF‐38393](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=935) (Partial agonist) (p*K* ~i~ 6.2--6.8) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus), [1884](http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus)\][quinpirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2) (p*K* ~i~ 4.9--7.7) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [1273](http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus), [1473](http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1778](http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus), [1940](http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus)\]Selective agonists[SKF‐83959](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8443) (Biased agonist) (pEC~50~ 9.7) \[[364](http://www.ncbi.nlm.nih.gov/pubmed/25660762?dopt=AbstractPlus)\], [SKF‐81297](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=938) (p*K* ~i~ 8.7) \[[46](http://www.ncbi.nlm.nih.gov/pubmed/1973652?dopt=AbstractPlus)\] -- Rat[sumanirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3949) (p*K* ~i~ 8.1) \[[1239](http://www.ncbi.nlm.nih.gov/pubmed/15980060?dopt=AbstractPlus)\]Antagonists[flupentixol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948) (p*K* ~i~ 7--8.4) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus), [1884](http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus)\][blonanserin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670) (p*K* ~i~ 9.9) \[[1421](http://www.ncbi.nlm.nih.gov/pubmed/15686911?dopt=AbstractPlus)\], [pipotiazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7557) (p*K* ~i~ 9.7) \[[1777](http://www.ncbi.nlm.nih.gov/pubmed/1586393?dopt=AbstractPlus)\], [perphenazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209) (p*K* ~i~ 8.9--9.6) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), 1691\], [risperidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96) (p*K* ~i~ 9.4) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus)\], [perospirone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556) (p*K* ~i~ 9.2) \[[1692](http://www.ncbi.nlm.nih.gov/pubmed/1060115?dopt=AbstractPlus)\], [trifluoperazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214) (p*K* ~i~ 8.9--9) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1693](http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus)\], [asenapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=22) (p*K* ~i~ 8.9) \[[1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus)\], [sertindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98) (p*K* ~i~ 8--8.9) \[[986](http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus), [1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), 1691\], [fluphenazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204) (p*K* ~i~ 8.8) \[[1647](http://www.ncbi.nlm.nih.gov/pubmed/17826096?dopt=AbstractPlus)\], [flupentixol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948) (p*K* ~i~ 8.8) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus)\], [pimozide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90) (p*K* ~i~ 7--8.8) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [olanzapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47) (p*K* ~i~ 8.7) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus)\], [mesoridazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7227) (p*K* ~i~ 8.7) \[[326](http://www.ncbi.nlm.nih.gov/pubmed/15357957?dopt=AbstractPlus)\], [ziprasidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59) (p*K* ~i~ 8.6) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus)\], [prochlorperazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279) (p*K* ~i~ 8.4) \[68\], [loxapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205) (p*K* ~i~ 7.9--8.3) \[[1008](http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus), [1693](http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus)\], [(‐)‐sulpiride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=958) (p*K* ~i~ 6.3--8) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1860](http://www.ncbi.nlm.nih.gov/pubmed/8301592?dopt=AbstractPlus)\], [amisulpride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=963) (p*K* ~i~ 7.9--8) \[[1195](http://www.ncbi.nlm.nih.gov/pubmed/8099194?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [metoclopramide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=241) (p*K* ~i~ 7.5) \[[1221](http://www.ncbi.nlm.nih.gov/pubmed/9808703?dopt=AbstractPlus)\] -- Mouse, [quetiapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50) (p*K* ~i~ 7.2) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus)\], [*trans*‐flupenthixol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=968) (p*K* ~i~ 6.9) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus)\], [clozapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38) (p*K* ~i~ 5.8--6.9) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1164](http://www.ncbi.nlm.nih.gov/pubmed/7907989?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1860](http://www.ncbi.nlm.nih.gov/pubmed/8301592?dopt=AbstractPlus)\], [promazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7281) (p*K* ~i~ 6.5) \[[246](http://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus)\](Sub)family‐selective antagonists[SCH‐23390](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943) (p*K* ~i~ 7.4--9.5) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus), [1884](http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus)\], [SKF‐83556](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944) (p*K* ~i~ 9.5) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus)\], [ecopipam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3304) (p*K* ~i~ 8.3) \[[1885](http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus)\][haloperidol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86) (p*K* ~i~ 7.4--8.8) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1164](http://www.ncbi.nlm.nih.gov/pubmed/7907989?dopt=AbstractPlus), [1273](http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1885](http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus)\]Selective antagonists--[L‐741,626](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=177) (p*K* ~i~ 7.9--8.5) \[[655](http://www.ncbi.nlm.nih.gov/pubmed/17095222?dopt=AbstractPlus), [1020](http://www.ncbi.nlm.nih.gov/pubmed/8642550?dopt=AbstractPlus)\], [domperidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965) (p*K* ~i~ 7.9--8.4) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [raclopride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94) (p*K* ~i~ 8) \[[1281](http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus)\], [ML321](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8368) (p*K* ~i~ 7) \[[2058](http://www.ncbi.nlm.nih.gov/pubmed/24260782?dopt=AbstractPlus), [2059](http://www.ncbi.nlm.nih.gov/pubmed/24666157?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]SCH‐23390](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=946) (Antagonist) (p*K* ~d~ 9.5) \[[2127](http://www.ncbi.nlm.nih.gov/pubmed/2168520?dopt=AbstractPlus)\][\[^3^H\]spiperone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300) (Antagonist) (p*K* ~d~ 10.2) \[[239](http://www.ncbi.nlm.nih.gov/pubmed/2974511?dopt=AbstractPlus), [767](http://www.ncbi.nlm.nih.gov/pubmed/10882389?dopt=AbstractPlus), [2125](http://www.ncbi.nlm.nih.gov/pubmed/20122961?dopt=AbstractPlus)\] -- RatLabelled ligands[\[^125^I\]SCH23982](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=945) (Antagonist) (p*K* ~d~ 9.5) \[[408](http://www.ncbi.nlm.nih.gov/pubmed/2144334?dopt=AbstractPlus)\][\[^3^H\]raclopride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3299) (Antagonist) (p*K* ~d~ 8.9) \[[1028](http://www.ncbi.nlm.nih.gov/pubmed/4015674?dopt=AbstractPlus)\] -- Rat

Nomenclature[D~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=216)[D~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217)[D~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=218)HGNC, UniProt[*DRD3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3024), [P35462](http://www.uniprot.org/uniprot/P35462)[*DRD4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3025), [P21917](http://www.uniprot.org/uniprot/P21917)[*DRD5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3026), [P21918](http://www.uniprot.org/uniprot/P21918)Endogenous agonists[dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) (p*K* ~i~ 6.4--7.3) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus), [1778](http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus)\][dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) (p*K* ~i~ 7.6) \[[1940](http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus)\][dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) (p*K* ~i~ 6.6) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus)\]Agonists[pramipexole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=953) (p*K* ~i~ 8.4--8.7) \[[1273](http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\], [bromocriptine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=35) (Partial agonist) (p*K* ~i~ 7.1--8.2) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\], [ropinirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7295) (p*K* ~i~ 7.7) \[[732](http://www.ncbi.nlm.nih.gov/pubmed/9057850?dopt=AbstractPlus)\], [apomorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33) (Partial agonist) (p*K* ~i~ 6.1--7.6) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\][apomorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33) (Partial agonist) (p*K* ~i~ 8.4) \[[1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus)\]--(Sub)family‐selective agonists[quinpirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2) (p*K* ~i~ 6.4--8) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus), [1273](http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus), [1281](http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus), [1473](http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1778](http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus), [1940](http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus)\][quinpirole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2) (p*K* ~i~ 7.5) \[[1279](http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus), [1473](http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus), [1940](http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus)\][A68930](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6077) (pEC~50~ 6.6) \[[1381](http://www.ncbi.nlm.nih.gov/pubmed/16318870?dopt=AbstractPlus)\]Selective agonists[PD 128907](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=952) (p*K* ~i~ 7.6--7.7) \[[1539](http://www.ncbi.nlm.nih.gov/pubmed/8531103?dopt=AbstractPlus), [1653](http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus)\][PD168,077](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=975) (Partial agonist) (p*K* ~i~ 8.8) \[[995](http://www.ncbi.nlm.nih.gov/pubmed/15448188?dopt=AbstractPlus)\] -- Rat, [A412997](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3301) (p*K* ~i~ 8.1) \[[1319](http://www.ncbi.nlm.nih.gov/pubmed/16153699?dopt=AbstractPlus)\] -- Rat, [A412997](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3301) (p*K* ~i~ 8.1) \[[1319](http://www.ncbi.nlm.nih.gov/pubmed/16153699?dopt=AbstractPlus)\]--Antagonists[perospirone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556) (p*K* ~i~ 9.6) \[[1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [sertindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98) (p*K* ~i~ 8--8.8) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), 1691\], [prochlorperazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279) (p*K* ~i~ 8.4) \[68\], [(‐)‐sulpiride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=958) (p*K* ~i~ 6.7--7.7) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1860](http://www.ncbi.nlm.nih.gov/pubmed/8301592?dopt=AbstractPlus)\], [loxapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205) (p*K* ~i~ 7.7) \[1691\], [domperidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965) (p*K* ~i~ 7.1--7.6) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus)\], [promazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7281) (p*K* ~i~ 6.8) \[[246](http://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus)\][perospirone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556) (p*K* ~i~ 10.1) \[[1694](http://www.ncbi.nlm.nih.gov/pubmed/9577836?dopt=AbstractPlus)\], [sertindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98) (p*K* ~i~ 7.8--9.1) \[[246](http://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus), 1691, [1693](http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus), [1694](http://www.ncbi.nlm.nih.gov/pubmed/9577836?dopt=AbstractPlus)\], [sonepiprazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=980) (p*K* ~i~ 8.9) \[[1668](http://www.ncbi.nlm.nih.gov/pubmed/9098699?dopt=AbstractPlus)\], [loxapine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205) (p*K* ~i~ 8.1) \[[1693](http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus)\]--(Sub)family‐selective antagonists[haloperidol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86) (p*K* ~i~ 7.5--8.6) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus), [1776](http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus), [1885](http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus)\][haloperidol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86) (p*K* ~i~ 8.7--8.8) \[[1033](http://www.ncbi.nlm.nih.gov/pubmed/8102973?dopt=AbstractPlus), [1711](http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus), [1885](http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus)\][SCH‐23390](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943) (p*K* ~i~ 7.5--9.5) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus)\], [SKF‐83556](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944) (p*K* ~i~ 9.4) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus)\], [ecopipam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3304) (p*K* ~i~ 8.3) \[[1823](http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus)\]Selective antagonists[S33084](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=129) (p*K* ~i~ 9.6) \[[1278](http://www.ncbi.nlm.nih.gov/pubmed/10869410?dopt=AbstractPlus)\], [nafadotride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=44) (p*K* ~i~ 9.5) \[[1654](http://www.ncbi.nlm.nih.gov/pubmed/8531087?dopt=AbstractPlus)\], [PG01037](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6675) (p*K* ~i~ 9.2) \[[656](http://www.ncbi.nlm.nih.gov/pubmed/17672446?dopt=AbstractPlus)\], [NGB 2904](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6674) (p*K* ~i~ 8.8) \[[2055](http://www.ncbi.nlm.nih.gov/pubmed/17627675?dopt=AbstractPlus)\], [SB 277011‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=143) (p*K* ~i~ 8) \[[1569](http://www.ncbi.nlm.nih.gov/pubmed/10945872?dopt=AbstractPlus)\], [(+)‐S‐14297](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=955) (p*K* ~i~ 6.9--7.9) \[[1275](http://www.ncbi.nlm.nih.gov/pubmed/7988633?dopt=AbstractPlus), [1281](http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus)\][L745870](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3303) (p*K* ~i~ 9.4) \[[1020](http://www.ncbi.nlm.nih.gov/pubmed/8642550?dopt=AbstractPlus)\], [A‐381393](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8441) (p*K* ~i~ 8.8) \[[1361](http://www.ncbi.nlm.nih.gov/pubmed/15992586?dopt=AbstractPlus)\], [L741742](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3302) (p*K* ~i~ 8.5) \[[1609](http://www.ncbi.nlm.nih.gov/pubmed/8642551?dopt=AbstractPlus)\], [ML398](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8440) (p*K* ~i~ 7.4) \[[138](http://www.ncbi.nlm.nih.gov/pubmed/25221667?dopt=AbstractPlus)\]--Selective allosteric modulators[SB269652](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7694) (Negative) (p*K* ~i~∼9) \[[558](http://www.ncbi.nlm.nih.gov/pubmed/25583363?dopt=AbstractPlus)\]----Labelled ligands--[\[^3^H\]spiperone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300) (Antagonist) (p*K* ~d~ 9.5) \[[749](http://www.ncbi.nlm.nih.gov/pubmed/7777184?dopt=AbstractPlus), [1940](http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus)\][\[^3^H\]SCH‐23390](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=946) (Antagonist) (p*K* ~d~ 9.2) \[[1580](http://www.ncbi.nlm.nih.gov/pubmed/8051291?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]spiperone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300) (Antagonist) (p*K* ~d~ 9.9) \[[767](http://www.ncbi.nlm.nih.gov/pubmed/10882389?dopt=AbstractPlus), [2125](http://www.ncbi.nlm.nih.gov/pubmed/20122961?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]7‐OH‐DPAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3296) (Agonist) (p*K* ~d~ 9.6) \[[1581](http://www.ncbi.nlm.nih.gov/pubmed/7759603?dopt=AbstractPlus)\], [\[^3^H\]PD128907](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3298) (Agonist) (p*K* ~d~ 9) \[[27](http://www.ncbi.nlm.nih.gov/pubmed/7674830?dopt=AbstractPlus)\][\[^125^I\]L750667](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3295) (Antagonist) (p*K* ~d~ 9.8) \[[1473](http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus)\], [\[^3^H\]NGD941](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3297) (Antagonist) (p*K* ~d~ 8.3) \[[1533](http://www.ncbi.nlm.nih.gov/pubmed/9262371?dopt=AbstractPlus)\][\[^125^I\]SCH23982](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=945) (Antagonist) (p*K* ~d~ 9.1) -- Unknown

Comments {#bph13348-sec-0095}
--------

The selectivity of many of these agents is less than two orders of magnitude. [\[^3^H\]raclopride](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3299) exhibits similar high affinity for D~2~ and D~3~ receptors (low affinity for D~4~), but has been used to label D~2~ receptors in the presence of a D~3~‐selective antagonist. [\[^3^H\]7‐OH‐DPAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3296) has similar affinity for D~2~ and D~3~ receptors, but labels only D~3~ receptors in the absence of divalent cations. The pharmacological profile of the D~5~ receptor is similar to, yet distinct from, that of the D~1~ receptor. The splice variants of the D~2~ receptor are commonly termed D~2S~ and D~2L~ (short and long). The *DRD4* gene encoding the D~4~ receptor is highly polymorphic in humans, with allelic variations of the protein from amino acid 387 to 515.
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[Endothelin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=21) {#bph13348-sec-0097}
================================================================================================

Overview {#bph13348-sec-0098}
--------

Endothelin receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Endothelin Receptors \[** [**395**](http://www.ncbi.nlm.nih.gov/pubmed/12037137?dopt=AbstractPlus) **\]**) are activated by the endogenous 21 amino‐acid peptides endothelins 1‐3 ([endothelin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989)([*EDN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3176), [P05305](http://www.uniprot.org/uniprot/P05305)), [endothelin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990)([*EDN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3177), [P20800](http://www.uniprot.org/uniprot/P20800)) and [endothelin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004)([*EDN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3178), [P14138](http://www.uniprot.org/uniprot/P14138))).

Nomenclature[ET~A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219)[ET~B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220)HGNC, UniProt[*EDNRA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3179), [P25101](http://www.uniprot.org/uniprot/P25101)[*EDNRB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3180), [P24530](http://www.uniprot.org/uniprot/P24530)Family selective agonists[endothelin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989) ([*EDN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3176), [P05305](http://www.uniprot.org/uniprot/P05305)) = [endothelin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990) ([*EDN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3177), [P20800](http://www.uniprot.org/uniprot/P20800)) \>[endothelin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004) ([*EDN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3178), [P14138](http://www.uniprot.org/uniprot/P14138)) \[[1178](http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus)\][endothelin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989) ([*EDN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3176), [P05305](http://www.uniprot.org/uniprot/P05305)) = [endothelin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990) ([*EDN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3177), [P20800](http://www.uniprot.org/uniprot/P20800)), [endothelin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004) ([*EDN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3178), [P14138](http://www.uniprot.org/uniprot/P14138))Selective agonists--[sarafotoxin S6c](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1008) (p*K* ~d~ 8.8--9.8) \[[1016](http://www.ncbi.nlm.nih.gov/pubmed/8587419?dopt=AbstractPlus), [1616](http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus)\], [BQ 3020](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3859) (p*K* ~i~ 9.7) \[[1576](http://www.ncbi.nlm.nih.gov/pubmed/7733918?dopt=AbstractPlus)\], [\[Ala^1,3,11,15^\]ET‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3837) (p*K* ~d~ 8.7--9.2) \[[1300](http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus)\], [IRL 1620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3886) (p*K* ~i~ 8.7) \[[1991](http://www.ncbi.nlm.nih.gov/pubmed/1320877?dopt=AbstractPlus)\](Sub)family‐selective antagonists[SB209670](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3528) (p*K* ~B~ 9.4) \[[474](http://www.ncbi.nlm.nih.gov/pubmed/8201588?dopt=AbstractPlus)\] -- Rat, [TAK 044](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3913) (pA~2~ 8.4) \[[1993](http://www.ncbi.nlm.nih.gov/pubmed/7780649?dopt=AbstractPlus)\] -- Rat, [bosentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494) (pA~2~ 7.2) \[[354](http://www.ncbi.nlm.nih.gov/pubmed/8035319?dopt=AbstractPlus)\] -- Rat[SB209670](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3528) (p*K* ~B~ 9.4) \[[474](http://www.ncbi.nlm.nih.gov/pubmed/8201588?dopt=AbstractPlus)\] -- Rat, [TAK 044](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3913) (pA~2~ 8.4) \[[1993](http://www.ncbi.nlm.nih.gov/pubmed/7780649?dopt=AbstractPlus)\] -- Rat, [bosentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494) (p*K* ~i~ 7.1) \[[1349](http://www.ncbi.nlm.nih.gov/pubmed/12502366?dopt=AbstractPlus)\]Selective antagonists[atrasentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3487) (pA~2~ 9.2--10.5) \[[1446](http://www.ncbi.nlm.nih.gov/pubmed/8632312?dopt=AbstractPlus)\], [PD‐156707](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=999) (p*K* ~d~ 9--9.8) \[[1180](http://www.ncbi.nlm.nih.gov/pubmed/9023329?dopt=AbstractPlus)\], [macitentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7352) (pIC~50~ 9.3) \[[174](http://www.ncbi.nlm.nih.gov/pubmed/22862294?dopt=AbstractPlus)\], [sitaxsentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3950) (pA~2~ 8) \[[2047](http://www.ncbi.nlm.nih.gov/pubmed/9171878?dopt=AbstractPlus)\], [FR139317](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=998) (Inverse agonist) (pIC~50~ 7.3--7.9) \[[1178](http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus)\], [ambrisentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3951) (pIC~50~ 7.7) \[[175](http://www.ncbi.nlm.nih.gov/pubmed/15139756?dopt=AbstractPlus)\], [BQ123](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=997) (pA~2~ 6.9--7.4) \[[1178](http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus)\], [avosentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8260) (pIC~50~ 7.3) \[210\], [ambrisentan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3951) (pA~2~ 7.1) \[[175](http://www.ncbi.nlm.nih.gov/pubmed/15139756?dopt=AbstractPlus)\][A192621](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1009) (p*K* ~d~ 8.1) \[[2145](http://www.ncbi.nlm.nih.gov/pubmed/10479298?dopt=AbstractPlus)\], [BQ788](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1010) (p*K* ~d~ 7.9--8) \[[1616](http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus)\], [IRL 2500](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3887) (p*K* ~d~ 7.2) \[[1616](http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus)\], [Ro 46‐8443](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1011) (pIC~50~ 7.2) \[[209](http://www.ncbi.nlm.nih.gov/pubmed/8612786?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]PD164333](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1002) (Antagonist) (p*K* ~d~ 9.6--9.8) \[[398](http://www.ncbi.nlm.nih.gov/pubmed/9489609?dopt=AbstractPlus)\], [\[^3^H\]S0139](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3479) (Antagonist) (p*K* ~d~ 9.2), [\[^125^I\]PD151242](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1001) (Antagonist) (p*K* ~d~ 9--9.1) \[[399](http://www.ncbi.nlm.nih.gov/pubmed/8012722?dopt=AbstractPlus)\], [\[^3^H\]BQ123](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1003) (Antagonist) (p*K* ~d~ 8.5) \[[817](http://www.ncbi.nlm.nih.gov/pubmed/7768260?dopt=AbstractPlus)\][\[^125^I\]IRL1620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1007) (Agonist) (p*K* ~d~ 9.9--10.1) \[[1362](http://www.ncbi.nlm.nih.gov/pubmed/8301559?dopt=AbstractPlus)\], [\[^125^I\]BQ3020](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1005) (Agonist) (p*K* ~d~ 8.3--10) \[[702](http://www.ncbi.nlm.nih.gov/pubmed/8587429?dopt=AbstractPlus), [1300](http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus), [1495](http://www.ncbi.nlm.nih.gov/pubmed/7881728?dopt=AbstractPlus)\], [\[^125^I\]\[Ala^1,3,11,15^\]ET‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3760) (Agonist) (p*K* ~d~ 9.7) \[[1300](http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0099}
--------

Splice variants of the ET~A~ receptor have been identified in rat pituitary cells; one of these, ET~A~R‐C13, appeared to show loss of function with comparable plasma membrane expression to wild type receptor \[[713](http://www.ncbi.nlm.nih.gov/pubmed/17312275?dopt=AbstractPlus)\]. Subtypes of the ET~B~ receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists \[[1295](http://www.ncbi.nlm.nih.gov/pubmed/9113361?dopt=AbstractPlus)\].
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[G protein‐coupled estrogen receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=22) {#bph13348-sec-0101}
===============================================================================================================

Overview {#bph13348-sec-0102}
--------

The G protein‐coupled estrogen receptor (GPER, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the G protein‐coupled estrogen receptor \[** [**1536**](http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus) **\]**) was identified following observations of estrogen‐evoked [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) signalling in breast cancer cells \[[61](http://www.ncbi.nlm.nih.gov/pubmed/8078914?dopt=AbstractPlus)\], which mirrored the differential expression of an orphan 7‐transmembrane receptor GPR30 \[[265](http://www.ncbi.nlm.nih.gov/pubmed/9367686?dopt=AbstractPlus)\]. There are observations of both cell‐surface and intracellular expression of the GPER receptor \[[1573](http://www.ncbi.nlm.nih.gov/pubmed/15705806?dopt=AbstractPlus), [1877](http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus)\].

Nomenclature[GPER](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=221)HGNC, UniProt[*GPER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4485), [Q99527](http://www.uniprot.org/uniprot/Q99527)Selective agonists[G1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1014) (p*K* ~i~ 8) \[[176](http://www.ncbi.nlm.nih.gov/pubmed/16520733?dopt=AbstractPlus)\]Selective antagonists[G36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6480) (pIC~50~ 6.8--6.9) \[[414](http://www.ncbi.nlm.nih.gov/pubmed/21782022?dopt=AbstractPlus)\], [G15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3320) (pIC~50~ 6.7) \[[413](http://www.ncbi.nlm.nih.gov/pubmed/19430488?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]17*β*‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1012) (Agonist) (p*K* ~d~ 8.5--8.6) \[[1877](http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0103}
--------

Antagonists at the nuclear estrogen receptor, such as [fulvestrant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015) and [tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016)\[[515](http://www.ncbi.nlm.nih.gov/pubmed/11043579?dopt=AbstractPlus)\], as well as the flavonoid 'phytoestrogens' [genistein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826) and [quercetin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5346)\[[1177](http://www.ncbi.nlm.nih.gov/pubmed/15090535?dopt=AbstractPlus)\], are agonists at GPER receptors.
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---------------
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Prossnitz ER *et al*. (2014) Estrogen biology: new insights into GPER function and clinical opportunities. *Mol. Cell. Endocrinol.* **389**: 71‐83 [\[PMID:24530924\]](http://www.ncbi.nlm.nih.gov/pubmed/24530924?dopt=AbstractPlus)

[Formylpeptide receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23) {#bph13348-sec-0105}
===================================================================================================

Overview {#bph13348-sec-0106}
--------

The [formylpeptide receptors](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00510000502765) (**nomenclature agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the formyl peptide receptor family \[** [**2092**](http://www.ncbi.nlm.nih.gov/pubmed/19498085?dopt=AbstractPlus) **\]**) respond to exogenous ligands such as the bacterial product [fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022) (fMLP) and endogenous ligands such as [annexin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031)([*ANXA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=533), [P04083](http://www.uniprot.org/uniprot/P04083)) , [cathepsin G](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570)([*CTSG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2532), [P08311](http://www.uniprot.org/uniprot/P08311)), amyloid *β*42, serum amyloid A and [spinorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1026), derived from [*β*‐haemoglobin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5370)([*HBB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4827), [P68871](http://www.uniprot.org/uniprot/P68871)).

Nomenclature[FPR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=222)[FPR2/ALX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223)[FPR3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=224)HGNC, UniProt[*FPR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3826), [P21462](http://www.uniprot.org/uniprot/P21462)[*FPR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3827), [P25090](http://www.uniprot.org/uniprot/P25090)[*FPR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3828), [P25089](http://www.uniprot.org/uniprot/P25089)Rank order of potency[fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022)\>[cathepsin G](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570) ([*CTSG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2532), [P08311](http://www.uniprot.org/uniprot/P08311)) \>[annexin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031) ([*ANXA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=533), [P04083](http://www.uniprot.org/uniprot/P04083)) \[[1058](http://www.ncbi.nlm.nih.gov/pubmed/12401407?dopt=AbstractPlus), [1821](http://www.ncbi.nlm.nih.gov/pubmed/15210802?dopt=AbstractPlus)\][LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034)=[aspirin triggered lipoxin A4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933)=[ATLa2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383)\>[LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354)=[LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)≫[15‐deoxy‐LXA4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3402)≫[fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022) \[[352](http://www.ncbi.nlm.nih.gov/pubmed/10393980?dopt=AbstractPlus), [519](http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus), [521](http://www.ncbi.nlm.nih.gov/pubmed/8527441?dopt=AbstractPlus), [651](http://www.ncbi.nlm.nih.gov/pubmed/11141472?dopt=AbstractPlus), [1846](http://www.ncbi.nlm.nih.gov/pubmed/9151906?dopt=AbstractPlus)\]--Endogenous agonists--[LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) (Selective) (pEC~50~∼12) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\], [resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934) (Selective) (pEC~50~∼11.9) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\], [aspirin triggered lipoxin A4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933) (Selective)[F2L](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3935) ([*HEBP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17176), [Q9NRV9](http://www.uniprot.org/uniprot/Q9NRV9)) (Selective) (pEC~50~ 8--8.2) \[[1274](http://www.ncbi.nlm.nih.gov/pubmed/15623572?dopt=AbstractPlus)\]Agonists[fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022) (pEC~50~ 10.1--10.2) \[[546](http://www.ncbi.nlm.nih.gov/pubmed/7387981?dopt=AbstractPlus), [1734](http://www.ncbi.nlm.nih.gov/pubmed/1262785?dopt=AbstractPlus)\]----Selective agonists--[ATLa2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383) \[[662](http://www.ncbi.nlm.nih.gov/pubmed/15056011?dopt=AbstractPlus)\]--Endogenous antagonists[spinorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1026) (Selective) (pIC~50~ 4.3) \[[1099](http://www.ncbi.nlm.nih.gov/pubmed/11714831?dopt=AbstractPlus), [1348](http://www.ncbi.nlm.nih.gov/pubmed/1373134?dopt=AbstractPlus)\]----Antagonists[t‐Boc‐FLFLF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1030) (p*K* ~i~ 6--6.5) \[[2008](http://www.ncbi.nlm.nih.gov/pubmed/8387097?dopt=AbstractPlus)\]----Selective antagonists[cyclosporin H](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1025) (p*K* ~i~ 6.1--7.1) \[[2008](http://www.ncbi.nlm.nih.gov/pubmed/8387097?dopt=AbstractPlus), [2078](http://www.ncbi.nlm.nih.gov/pubmed/17082621?dopt=AbstractPlus)\]----Labelled ligands[\[^3^H\]fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1018) (Agonist) (p*K* ~d~ 7.6--9.3) \[[990](http://www.ncbi.nlm.nih.gov/pubmed/6285921?dopt=AbstractPlus)\][\[^3^H\]LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3411) (Agonist) (p*K* ~d~ 9.2--9.3) \[[519](http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus), [520](http://www.ncbi.nlm.nih.gov/pubmed/1322894?dopt=AbstractPlus)\]--CommentsA FITC‐conjugated fMLP analogue has been used for binding to the mouse recombinant receptor \[[724](http://www.ncbi.nlm.nih.gov/pubmed/23160941?dopt=AbstractPlus)\].The agonist activity of the lipid mediators described has been questioned \[[697](http://www.ncbi.nlm.nih.gov/pubmed/23643932?dopt=AbstractPlus), [1513](http://www.ncbi.nlm.nih.gov/pubmed/23607720?dopt=AbstractPlus)\], which may derive from batch‐to‐batch differences, partial agonism or biased agonism. Recent results from Cooray *et al.* (2013) \[[365](http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus)\] have addressed this issue and the role of homodimers and heterodimers in the intracellular signaling .--

Comments {#bph13348-sec-0107}
--------

Note that the data for FPR2/ALX are also reproduced on the [leukotriene](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35) receptor page.

Further Reading {#bph13348-sec-0108}
---------------
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Yazid S *et al*. (2012) Anti‐inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti‐inflammatory system. *Prostaglandins Other Lipid Mediat.* **98**: 94‐100 [\[PMID:22123264\]](http://www.ncbi.nlm.nih.gov/pubmed/22123264?dopt=AbstractPlus)

Ye RD *et al*. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. *Pharmacol. Rev.* **61**: 119‐61 [\[PMID:19498085\]](http://www.ncbi.nlm.nih.gov/pubmed/19498085?dopt=AbstractPlus)

[Free fatty acid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=24) {#bph13348-sec-0109}
=====================================================================================================

Overview {#bph13348-sec-0110}
--------

Free fatty acid receptors (FFA, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on free fatty acid receptors \[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **,** [**1803**](http://www.ncbi.nlm.nih.gov/pubmed/19047536?dopt=AbstractPlus) **\]**) are activated by free fatty acids. Long‐chain saturated and unsaturated fatty acids (C14.0 ([myristic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806)), C16:0 ([palmitic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055)), C18:1 ([oleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054)), C18:2 ([linoleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052)), C18:3, ([*α*‐linolenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049)), C20:4 ([arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391)), C20:5,n‐3 ([EPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362)), C22:6,n‐3 ([docosahexaenoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051))) activate FFA1 \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus), [998](http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus)\] and FFA4 receptors \[[757](http://www.ncbi.nlm.nih.gov/pubmed/15619630?dopt=AbstractPlus), [812](http://www.ncbi.nlm.nih.gov/pubmed/22343897?dopt=AbstractPlus), [1427](http://www.ncbi.nlm.nih.gov/pubmed/20813258?dopt=AbstractPlus)\], while short chain fatty acids (C2 ([acetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058)), C3 ([propanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062)), C4 ([butyric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059)) and C5 ([pentanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1061))) activate FFA2 \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1399](http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus)\] and FFA3 \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus)\] receptors. In addition, thiazolidinedione PPAR*γ* agonists such as [rosiglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056) activate FFA1 (pEC~50~ 5.2; \[[999](http://www.ncbi.nlm.nih.gov/pubmed/14675457?dopt=AbstractPlus), [1768](http://www.ncbi.nlm.nih.gov/pubmed/19398560?dopt=AbstractPlus), [1802](http://www.ncbi.nlm.nih.gov/pubmed/17200419?dopt=AbstractPlus)\]) and small molecule allosteric modulators, such as [4‐CMTB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5500), have recently been characterised for FFA2 \[[801](http://www.ncbi.nlm.nih.gov/pubmed/23066016?dopt=AbstractPlus), [1070](http://www.ncbi.nlm.nih.gov/pubmed/18818303?dopt=AbstractPlus), [1769](http://www.ncbi.nlm.nih.gov/pubmed/21498659?dopt=AbstractPlus)\].

Nomenclature[FFA1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225)[FFA2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226)[FFA3 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=227)[FFA4 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=127)[*GPR42*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=228)HGNC, UniProt[*FFAR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4498), [O14842](http://www.uniprot.org/uniprot/O14842)[*FFAR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4501), [O15552](http://www.uniprot.org/uniprot/O15552)[*FFAR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4499), [O14843](http://www.uniprot.org/uniprot/O14843)[*FFAR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19061), [Q5NUL3](http://www.uniprot.org/uniprot/Q5NUL3)[*GPR42*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4500), [O15529](http://www.uniprot.org/uniprot/O15529)Endogenous agonists[docosahexaenoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051) (pEC~50~ 5.4--6) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus)\]----[*α*‐linolenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049) (pEC~50~ 5.5) \[[1727](http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus)\]--Agonists[fasiglifam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6484) (pEC~50~ 7.1) \[[893](http://www.ncbi.nlm.nih.gov/pubmed/25787200?dopt=AbstractPlus), [1791](http://www.ncbi.nlm.nih.gov/pubmed/25043059?dopt=AbstractPlus), [1909](http://www.ncbi.nlm.nih.gov/pubmed/21752941?dopt=AbstractPlus)\]--------(Sub)family‐selective agonists[*α*‐linolenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049) (pEC~50~ 4.6--5.7) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus), [998](http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus)\], [oleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054) (pEC~50~ 3.9--5.7) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus), [998](http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus)\], [myristic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806) (pEC~50~ 4.5--5.1) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus), [998](http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus)\][propanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062) (pEC~50~ 3--4.9) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1399](http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\], [acetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058) (pEC~50~ 3.1--4.6) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1399](http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\], [butyric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059) (pEC~50~ 2.9--4.6) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1399](http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\], [*trans*‐2‐methylcrotonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6499) (pEC~50~ 3.8) \[[1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\], [1‐methylcyclopropanecarboxylic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6500) (pEC~50~ 2.6) \[[1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\][propanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062) (pEC~50~ 3.9--5.7) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus), [2063](http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus)\], [butyric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059) (pEC~50~ 3.8--4.9) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus), [2063](http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus)\], [1‐methylcyclopropanecarboxylic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6500) (pEC~50~ 3.9) \[[1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus)\], [acetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058) (pEC~50~ 2.8--3.9) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus), [1057](http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus), [1670](http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus), [2063](http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus)\][myristic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806) (pEC~50~ 5.2) \[[1996](http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus)\], [oleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054) (pEC~50~ 4.7) \[[1996](http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus)\]--Selective agonists[AMG‐837](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6485) (pEC~50~ 8.5) \[[1110](http://www.ncbi.nlm.nih.gov/pubmed/22859723?dopt=AbstractPlus)\], [TUG‐770](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6483) (pEC~50~ 8.2) \[[332](http://www.ncbi.nlm.nih.gov/pubmed/23687558?dopt=AbstractPlus)\], [GW9508](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1050) (pEC~50~ 7.3) \[[217](http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus)\], [linoleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052) (pEC~50~ 4.4--5.7) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus), [833](http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus), [998](http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus)\][compound 1 \[PMID: 23589301\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6488) (pEC~50~ 7.1) \[[800](http://www.ncbi.nlm.nih.gov/pubmed/23589301?dopt=AbstractPlus)\] -- Rat, [(S)‐4‐CMTB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3420) (pEC~50~ 6.4) \[[801](http://www.ncbi.nlm.nih.gov/pubmed/23066016?dopt=AbstractPlus), [1070](http://www.ncbi.nlm.nih.gov/pubmed/18818303?dopt=AbstractPlus)\]--[compound A \[PMID 24997608\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8418) (pEC~50~ 7.6) \[[1428](http://www.ncbi.nlm.nih.gov/pubmed/24997608?dopt=AbstractPlus)\], [TUG‐891](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6490) (pEC~50~ 7) \[[1727](http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus)\] -- Unknown, [NCG21](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5587) (pEC~50~ 5.9) \[[1829](http://www.ncbi.nlm.nih.gov/pubmed/19007110?dopt=AbstractPlus)\]--Selective antagonists[GW1100](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1057) (pIC~50~ 6) \[[217](http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus)\][GLPG0974](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8417) (pIC~50~ 8.1) \[[1512](http://www.ncbi.nlm.nih.gov/pubmed/25380412?dopt=AbstractPlus)\], [CATPB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6487) (pIC~50~ 6.5) \[[801](http://www.ncbi.nlm.nih.gov/pubmed/23066016?dopt=AbstractPlus)\]------CommentsAntagonist [GW1100](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1057) has been shown to reduce \[^35^S\]GTP*γ*S binding in *FFAR1*‐expressing cells \[[1802](http://www.ncbi.nlm.nih.gov/pubmed/17200419?dopt=AbstractPlus)\]. GW1100 is also an oxytocin receptor antagonist \[[217](http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus)\]. TUG‐770 and [GW9508](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1050) are both approximately 100 fold selective for FFA1 over FFA4 \[[217](http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus), [332](http://www.ncbi.nlm.nih.gov/pubmed/23687558?dopt=AbstractPlus)\]. AMG‐837 and the related analogue AM6331 have been suggested to have an allosteric mechanism of action at FFA1, with respect to the orthosteric fatty acid binding site \[[1110](http://www.ncbi.nlm.nih.gov/pubmed/22859723?dopt=AbstractPlus), [2064](http://www.ncbi.nlm.nih.gov/pubmed/23403053?dopt=AbstractPlus)\].--Beta‐hydroxybutyrate has been reported to antagonise FFA3 responses to short chain fatty acids \[[951](http://www.ncbi.nlm.nih.gov/pubmed/21518883?dopt=AbstractPlus)\]. A range of FFA3 selective molecules with agonist and antagonist properties, but which bind at sites distinct from the short chain fatty acid binding site, have recently been described \[[799](http://www.ncbi.nlm.nih.gov/pubmed/24870406?dopt=AbstractPlus)\].[compound A \[PMID 24997608\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8418) exhibits more than 1000 fold selectivity \[[1428](http://www.ncbi.nlm.nih.gov/pubmed/24997608?dopt=AbstractPlus)\], and [TUG‐891](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6490) 50‐1000 fold selectivity for FFA4 over FFA1 \[[1727](http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus)\], dependent on the assay. NGC21 exhibits approximately 15 fold selectivity for FFA4 over FFA1 \[[1820](http://www.ncbi.nlm.nih.gov/pubmed/20685848?dopt=AbstractPlus)\].--

Comments {#bph13348-sec-0111}
--------

Short (361 amino acids) and long (377 amino acids) splice variants of human FFA4 have been reported \[[1318](http://www.ncbi.nlm.nih.gov/pubmed/19723586?dopt=AbstractPlus)\], which differ by a 16 amino acid insertion in intracellular loop 3, and exhibit differences in intracellular signalling properties in recombinant systems \[[1996](http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus)\]. The long FFA4 splice variant has not been identified in other primates or rodents to date \[[757](http://www.ncbi.nlm.nih.gov/pubmed/15619630?dopt=AbstractPlus), [1318](http://www.ncbi.nlm.nih.gov/pubmed/19723586?dopt=AbstractPlus)\].

[*GPR42*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4500) was originally described as a pseudogene within the family ([ENSFM00250000002583](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000002583)), but the recent discovery of several polymorphisms suggests that some versions of GPR42 may be functional \[[1101](http://www.ncbi.nlm.nih.gov/pubmed/19630535?dopt=AbstractPlus)\]. [*GPR84*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4535) is a structurally‐unrelated G protein‐coupled receptor which has been found to respond to medium chain fatty acids \[[1981](http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0112}
---------------

Mancini AD *et al*. (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? *Trends Endocrinol. Metab.* **24**: 398‐407 [\[PMID:23631851\]](http://www.ncbi.nlm.nih.gov/pubmed/23631851?dopt=AbstractPlus)

Maslowski KM *et al*. (2011) Diet, gut microbiota and immune responses. *Nat. Immunol.* **12**: 5‐9 [\[PMID:21169997\]](http://www.ncbi.nlm.nih.gov/pubmed/21169997?dopt=AbstractPlus)

Milligan G *et al*. (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. *Br. J. Pharmacol.* **158**: 146‐53 [\[PMID:19719777\]](http://www.ncbi.nlm.nih.gov/pubmed/19719777?dopt=AbstractPlus)

Reimann F *et al*. (2012) G‐protein‐coupled receptors in intestinal chemosensation. *Cell Metab.* **15**: 421‐31 [\[PMID:22482725\]](http://www.ncbi.nlm.nih.gov/pubmed/22482725?dopt=AbstractPlus)

Stoddart LA *et al*. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, ‐2, and ‐3: pharmacology and pathophysiological functions. *Pharmacol. Rev.* **60**: 405‐17 [\[PMID:19047536\]](http://www.ncbi.nlm.nih.gov/pubmed/19047536?dopt=AbstractPlus)

Talukdar S *et al*. (2011) Targeting GPR120 and other fatty acid‐sensing GPCRs ameliorates insulin resistance and inflammatory diseases. *Trends Pharmacol. Sci.* **32**: 543‐50 [\[PMID:21663979\]](http://www.ncbi.nlm.nih.gov/pubmed/21663979?dopt=AbstractPlus)

Watterson KR *et al*. (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. *Front Endocrinol (Lausanne)* **5**: 137 [\[PMID:25221541\]](http://www.ncbi.nlm.nih.gov/pubmed/25221541?dopt=AbstractPlus)

[GABA~B~ receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=26) {#bph13348-sec-0113}
=============================================================================================

Overview {#bph13348-sec-0114}
--------

Functional GABA~B~ receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on GABA~B~ receptors \[** [**194**](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus) **,** [**1507**](http://www.ncbi.nlm.nih.gov/pubmed/17329545?dopt=AbstractPlus) **\]**) are formed from the heterodimerization of two similar 7TM subunits termed GABA~B1~ and GABA~B2~\[[194](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus), [478](http://www.ncbi.nlm.nih.gov/pubmed/17499108?dopt=AbstractPlus), [1506](http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus), [1507](http://www.ncbi.nlm.nih.gov/pubmed/17329545?dopt=AbstractPlus), [1926](http://www.ncbi.nlm.nih.gov/pubmed/17433877?dopt=AbstractPlus)\]. GABA~B~ receptors are widespread in the CNS and regulate both pre‐ and postsynaptic activity. The GABA~B1~ subunit, when expressed alone, binds both antagonists and agonists, but the affinity of the latter is generally 10‐100‐fold less than for the native receptor. The GABA~B1~ subunit when expressed alone is not transported to the cell membrane and is non‐functional. However, Richer *et al.*. (2008) report that GABA~B1~ alone can control ERK/MAPK pathway activity \[[1585](http://www.ncbi.nlm.nih.gov/pubmed/19052921?dopt=AbstractPlus)\]. Co‐expression of GABA~B1~ and GABA~B2~ subunits allows transport of GABA~B1~ to the cell surface and generates a functional receptor that can couple to signal transduction pathways such as high‐voltage‐activated Ca^2+^ channels (Ca~v~2.1, Ca~v~2.2), or inwardly rectifying potassium channels (Kir3) \[[144](http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus), [194](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus), [195](http://www.ncbi.nlm.nih.gov/pubmed/10604925?dopt=AbstractPlus)\]. The GABA~B2~subunit also determines the rate of internalisation of the dimeric GABA~B~ receptor \[[693](http://www.ncbi.nlm.nih.gov/pubmed/21724853?dopt=AbstractPlus)\]. The GABA~B1~ subunit harbours the GABA (orthosteric)‐binding site within an extracellular domain (ECD) venus flytrap module (VTM), whereas the GABA~B2~ subunit mediates G protein‐coupled signalling \[[194](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus), [591](http://www.ncbi.nlm.nih.gov/pubmed/24305054?dopt=AbstractPlus), [592](http://www.ncbi.nlm.nih.gov/pubmed/22660477?dopt=AbstractPlus), [1506](http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus)\]. The two subunits interact by direct allosteric coupling \[[1313](http://www.ncbi.nlm.nih.gov/pubmed/21063387?dopt=AbstractPlus)\], such that GABA~B2~ increases the affinity of GABA~B1~ for agonists and reciprocally GABA~B1~ facilitates the coupling of GABA~B2~ to G proteins \[[591](http://www.ncbi.nlm.nih.gov/pubmed/24305054?dopt=AbstractPlus), [1013](http://www.ncbi.nlm.nih.gov/pubmed/15922585?dopt=AbstractPlus), [1506](http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus)\]. GABA~B1~ and GABA~B2~ subunits assemble in a 1:1 stoichiometry by means of a coiled‐coil interaction between *α*‐helices within their carboxy‐termini that masks an endoplasmic reticulum retention motif (RXRR) within the GABA~B1~ subunit but other domains of the proteins also contribute to their heteromerization \[[144](http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus), [243](http://www.ncbi.nlm.nih.gov/pubmed/24778228?dopt=AbstractPlus), [1506](http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus)\]. Recent evidence indicates that higher order assemblies of GABA~B~receptor comprising dimers of heterodimers occur in recombinant expression systems and *in vivo* and that such complexes exhibit negative functional cooperativity between heterodimers \[[361](http://www.ncbi.nlm.nih.gov/pubmed/21552208?dopt=AbstractPlus), [1505](http://www.ncbi.nlm.nih.gov/pubmed/19723778?dopt=AbstractPlus)\]. Adding further complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16 associate as tetramers with the carboxy terminus of the GABA~B2~ subunit to impart altered signalling kinetics and agonist potency to the receptor complex \[[102](http://www.ncbi.nlm.nih.gov/pubmed/20406808?dopt=AbstractPlus), [1680](http://www.ncbi.nlm.nih.gov/pubmed/20400944?dopt=AbstractPlus), [1914](http://www.ncbi.nlm.nih.gov/pubmed/24836506?dopt=AbstractPlus)\] and reviewed by \[[1508](http://www.ncbi.nlm.nih.gov/pubmed/20655485?dopt=AbstractPlus)\]. Four isoforms of the human GABA~B1~ subunit have been cloned. The predominant GABA~B1(a)~ and GABA~B1(b)~ isoforms, which are most prevalent in neonatal and adult brain tissue respectively, differ in their ECD sequences as a result of the use of alternative transcription initiation sites. GABA~B1(a)~‐containing heterodimers localise to distal axons and mediate inhibition of glutamate release in the CA3‐CA1 terminals, and GABA release onto the layer 5 pyramidal neurons, whereas GABA~B1(b)~‐containing receptors occur within dendritic spines and mediate slow postsynaptic inhibition \[[1541](http://www.ncbi.nlm.nih.gov/pubmed/16701210?dopt=AbstractPlus), [1955](http://www.ncbi.nlm.nih.gov/pubmed/16701209?dopt=AbstractPlus)\]. Isoforms generated by alternative splicing are GABA~B1(c)~ that differs in the ECD, and GABA~B1(e)~, which is a truncated protein that can heterodimerize with the GABA~B2~ subunit but does not constitute a functional receptor. Only the 1a and 1b variants are identified as components of native receptors \[[194](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus)\]. Additional GABA~B1~ subunit isoforms have been described in rodents and humans \[[1065](http://www.ncbi.nlm.nih.gov/pubmed/21124972?dopt=AbstractPlus)\] and reviewed by \[[144](http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus)\].

Nomenclature[GABA~B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242)Subunits[kcdt12b](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1919) (Accessory protein), [KCTD16](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1920) (Accessory protein), [KCTD12](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1918) (Accessory protein), [GABA~B2~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241), [GABA~B1~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=240), [KCTD8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1917) (Accessory protein)Agonists[CGP 44532](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1082) (pIC~50~ 8.6) \[551\] -- Rat, [(‐)‐baclofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1064) (pIC~50~ 8.5) \[551\] -- Rat, [3‐APPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1081) (p*K* ~i~ 5.2--7.2) \[[762](http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus)\], [baclofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1084) (p*K* ~i~ 4.3--6.2) \[[762](http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus), [2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\], [3‐APMPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1080) (p*K* ~i~ 5.1) \[[2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\]Antagonists[CGP 62349](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1072) (p*K* ~i~ 8.5--8.9) \[[762](http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus), [2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\], [CGP 55845](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088) (p*K* ~i~ 7.8) \[[2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\], [SCH 50911](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1075) (p*K* ~i~ 5.5--6) \[[762](http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus), [2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\], [CGP 35348](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1069) (p*K* ~i~ 4.4) \[[2041](http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus)\], [2‐hydroxy‐saclofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1068) (pIC~50~ 4.1) \[[914](http://www.ncbi.nlm.nih.gov/pubmed/9069281?dopt=AbstractPlus)\] -- RatLabelled ligands[\[^3^H\]CGP 54626](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1090) (Antagonist) (p*K* ~i~ 9.1) \[[879](http://www.ncbi.nlm.nih.gov/pubmed/9872315?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]CGP 62349](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3429) (Antagonist) (p*K* ~d~ 9.1) \[[922](http://www.ncbi.nlm.nih.gov/pubmed/10521582?dopt=AbstractPlus)\] -- Rat, [\[^125^I\]CGP 64213](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1076) (Antagonist) (p*K* ~d~ 9) \[[563](http://www.ncbi.nlm.nih.gov/pubmed/10692480?dopt=AbstractPlus)\] -- Rat, [\[^125^I\]CGP 71872](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1077) (Antagonist) (p*K* ~d~ 9) \[[914](http://www.ncbi.nlm.nih.gov/pubmed/9069281?dopt=AbstractPlus)\] -- Rat, [\[^3^H\](R)‐(‐)‐baclofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3428) (Agonist)

Subunits {#bph13348-sec-0115}
--------

Nomenclature[GABA~B1~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=240)[GABA~B2~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241)HGNC, UniProt[*GABBR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4070), [Q9UBS5](http://www.uniprot.org/uniprot/Q9UBS5)[*GABBR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4507), [O75899](http://www.uniprot.org/uniprot/O75899)

Comments {#bph13348-sec-0116}
--------

Potencies of agonists and antagonists listed in the table, quantified as IC~50~ values for the inhibition of [\[^3^H\]CGP27492](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5381) binding to rat cerebral cortex membranes, are from \[[194](http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus), [550](http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus), 551\]. Radioligand *K* ~D~ values relate to binding to rat brain membranes. [CGP 71872](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1074) is a photoaffinity ligand for the GABA~B1~ subunit \[[122](http://www.ncbi.nlm.nih.gov/pubmed/10658574?dopt=AbstractPlus)\]. CGP27492 ([3‐APPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1081)), CGP35024 ([3‐APMPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1080)) and [CGP 44532](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1082) act as antagonists at human GABA~A~ *ρ*1 receptors, with potencies in the low micromolar range \[[550](http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus)\]. In addition to the ligands listed in the table, [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707) binds to the VTM of the GABA~B1~ subunit to act as a positive allosteric modulator of [GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067)\[[563](http://www.ncbi.nlm.nih.gov/pubmed/10692480?dopt=AbstractPlus)\]. In cerebellar Purkinje neurones, the interaction of [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707) with the GABA~B~ receptor enhances the activity of mGlu~1~, through functional cross‐talk involving G‐protein G*β* *γ* subunits \[[1590](http://www.ncbi.nlm.nih.gov/pubmed/19590495?dopt=AbstractPlus), [1837](http://www.ncbi.nlm.nih.gov/pubmed/15550547?dopt=AbstractPlus)\]. Synthetic positive allosteric modulators with low, or no, intrinsic activity include [CGP7930](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079), [GS39783](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446), [BHF‐177](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5503) and [(+)‐BHFF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5504)\[[9](http://www.ncbi.nlm.nih.gov/pubmed/17894647?dopt=AbstractPlus), [144](http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus), [150](http://www.ncbi.nlm.nih.gov/pubmed/15126507?dopt=AbstractPlus), [550](http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus)\]. The site of action of [CGP7930](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079) and [GS39783](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446) appears to be on the heptahelical domain of the GABA~B2~ subunit \[[455](http://www.ncbi.nlm.nih.gov/pubmed/16966477?dopt=AbstractPlus), [1506](http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus)\]. In the presence of [CGP7930](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079) or [GS39783](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446), [CGP 35348](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1069) and [2‐hydroxy‐saclofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1068) behave as partial agonists \[[550](http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus)\]. A negative allosteric modulator of GABA~B~ activity has been reported \[[302](http://www.ncbi.nlm.nih.gov/pubmed/25050158?dopt=AbstractPlus)\]. Knock‐out of the GABA~B1~ subunit in C57B mice causes the development of severe tonic‐clonic convulsions that prove fatal within a month of birth, whereas $\text{GABA}_{\text{B1}}^{\quad\; - \text{/} -}$ BALB/c mice, although also displaying spontaneous epileptiform activity, are viable. The phenotype of the latter animals additionally includes hyperalgesia, hyperlocomotion (in a novel, but not familiar, environment), hyperdopaminergia, memory impairment and behaviours indicative of anxiety \[[482](http://www.ncbi.nlm.nih.gov/pubmed/15451397?dopt=AbstractPlus), [1932](http://www.ncbi.nlm.nih.gov/pubmed/16606363?dopt=AbstractPlus)\]. A similar phenotype has been found for $\text{GABA}_{\text{B2}}^{\quad\; - \text{/} -}$ BALB/c mice \[[582](http://www.ncbi.nlm.nih.gov/pubmed/15240800?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0117}
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[Galanin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=27) {#bph13348-sec-0118}
=============================================================================================

Overview {#bph13348-sec-0119}
--------

Galanin receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides [galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592)([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) and [galanin‐like peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594)([*GALP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24840), [Q9UBC7](http://www.uniprot.org/uniprot/Q9UBC7)). Human [galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592)([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) is a 30 amino‐acid non‐amidated peptide \[[499](http://www.ncbi.nlm.nih.gov/pubmed/1714839?dopt=AbstractPlus)\]; in other species, it is 29 amino acids long and C‐terminally amidated. Amino acids 1‐14 of galanin are highly conserved in mammals, birds, reptiles, amphibia and fish. Shorter peptide species (*e.g*. human galanin‐1‐19 \[[139](http://www.ncbi.nlm.nih.gov/pubmed/1710578?dopt=AbstractPlus)\] and porcine galanin‐5‐29 \[[1740](http://www.ncbi.nlm.nih.gov/pubmed/1283627?dopt=AbstractPlus)\]) and N‐terminally extended forms (*e.g.* N‐terminally seven and nine residue elongated forms of porcine galanin \[[140](http://www.ncbi.nlm.nih.gov/pubmed/1718731?dopt=AbstractPlus), [1740](http://www.ncbi.nlm.nih.gov/pubmed/1283627?dopt=AbstractPlus)\]) have been reported.

Nomenclature[GAL~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=243)[GAL~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=244)[GAL~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=245)HGNC, UniProt[*GALR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4132), [P47211](http://www.uniprot.org/uniprot/P47211)[*GALR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4133), [O43603](http://www.uniprot.org/uniprot/O43603)[*GALR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4134), [O60755](http://www.uniprot.org/uniprot/O60755)Rank order of potency[galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592) ([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) \>[galanin‐like peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594) ([*GALP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24840), [Q9UBC7](http://www.uniprot.org/uniprot/Q9UBC7)) \[[1433](http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus)\][galanin‐like peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594) ([*GALP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24840), [Q9UBC7](http://www.uniprot.org/uniprot/Q9UBC7)) ≥[galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592) ([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) \[[1433](http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus)\][galanin‐like peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594) ([*GALP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24840), [Q9UBC7](http://www.uniprot.org/uniprot/Q9UBC7)) \>[galanin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592) ([*GAL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4114), [P22466](http://www.uniprot.org/uniprot/P22466)) \[[1039](http://www.ncbi.nlm.nih.gov/pubmed/15944009?dopt=AbstractPlus)\]Agonists--[galanin(2‐29) (rat/mouse)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3876) (p*K* ~i~ 7.2--8.7) \[[1457](http://www.ncbi.nlm.nih.gov/pubmed/9832122?dopt=AbstractPlus), [1982](http://www.ncbi.nlm.nih.gov/pubmed/9742938?dopt=AbstractPlus), [1983](http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus), [1984](http://www.ncbi.nlm.nih.gov/pubmed/9405385?dopt=AbstractPlus)\] -- Rat--Selective agonists--[\[D‐Trp^2^\]galanin‐(1‐29)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3866) (p*K* ~i~ 8.1) \[[1765](http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus)\] -- Rat--Selective antagonists[2,3‐dihydro‐1,4‐dithiin‐1,1,4,4‐tetroxide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3486) (pIC~50~ 5.6) \[[1688](http://www.ncbi.nlm.nih.gov/pubmed/10896115?dopt=AbstractPlus)\][M871](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3900) (p*K* ~i~ 7.9) \[1780\][SNAP 398299](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6125) (p*K* ~i~ 8.3) \[[987](http://www.ncbi.nlm.nih.gov/pubmed/16789730?dopt=AbstractPlus), [988](http://www.ncbi.nlm.nih.gov/pubmed/16730981?dopt=AbstractPlus), [1833](http://www.ncbi.nlm.nih.gov/pubmed/16287967?dopt=AbstractPlus)\], [SNAP 37889](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6126) (p*K* ~i~ 7.8--7.8) \[[987](http://www.ncbi.nlm.nih.gov/pubmed/16789730?dopt=AbstractPlus), [988](http://www.ncbi.nlm.nih.gov/pubmed/16730981?dopt=AbstractPlus), [1833](http://www.ncbi.nlm.nih.gov/pubmed/16287967?dopt=AbstractPlus)\]Selective allosteric modulators--[CYM2503](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8547) (Positive) (pEC~50~ 9.2) \[[1147](http://www.ncbi.nlm.nih.gov/pubmed/20660766?dopt=AbstractPlus)\] -- Rat--Labelled ligands[\[^125^I\]\[Tyr^26^\]galanin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391) (Agonist) (p*K* ~d~ 10.3) \[[525](http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus)\], [\[^125^I\]\[Tyr^26^\]galanin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391) (Agonist) (p*K* ~d~ 7.8) \[[525](http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus)\][\[^125^I\]\[Tyr^26^\]galanin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391) (Agonist) (p*K* ~d~ 9.2) \[[1983](http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus)\] -- Rat[\[^125^I\]\[Tyr^26^\]galanin (pig)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6117) (Agonist) (p*K* ~d~ 8.6) \[[187](http://www.ncbi.nlm.nih.gov/pubmed/9880084?dopt=AbstractPlus), [1766](http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus)\]Comments--The CYM2503 PAM potentiates the anticonvulsant activity of endogenous galanin in mouse seizure models \[[1147](http://www.ncbi.nlm.nih.gov/pubmed/20660766?dopt=AbstractPlus)\].--

Comments {#bph13348-sec-0120}
--------

[galanin‐(1‐11)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5356) is a high‐affinity agonist at GAL~1~/GAL~2~(p*K* ~i~ 9), and [galanin(2‐11)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5357) is selective for GAL~2~ and GAL~3~ compared with GAL~1~\[[1146](http://www.ncbi.nlm.nih.gov/pubmed/15944007?dopt=AbstractPlus)\]. \[^125^I\]‐\[Tyr^26^\]galanin binds to all three subtypes with *K* ~d~ values generally reported to range from 0.05 to 1 nM, depending on the assay conditions used \[[525](http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus), [1752](http://www.ncbi.nlm.nih.gov/pubmed/2436195?dopt=AbstractPlus), [1765](http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus), [1766](http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus), [1983](http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus)\]. Porcine galanin‐(3‐29) does not bind to cloned GAL~1~, GAL~2~ or GAL~3~ receptors, but a receptor that is functionally activated by porcine galanin‐(3‐29) has been reported in pituitary and gastric smooth muscle cells \[[658](http://www.ncbi.nlm.nih.gov/pubmed/7529309?dopt=AbstractPlus), [2054](http://www.ncbi.nlm.nih.gov/pubmed/7683428?dopt=AbstractPlus)\]. Additional galanin receptor subtypes are also suggested from studies with chimeric peptides (*e.g*. [M15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3896), [M35](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3898) and [M40](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3899)), which act as antagonists in functional assays in the cardiovascular system \[[1924](http://www.ncbi.nlm.nih.gov/pubmed/7693918?dopt=AbstractPlus)\], spinal cord \[[2024](http://www.ncbi.nlm.nih.gov/pubmed/1373497?dopt=AbstractPlus)\], locus coeruleus, hippocampus \[[100](http://www.ncbi.nlm.nih.gov/pubmed/1720557?dopt=AbstractPlus)\] and hypothalamus \[[101](http://www.ncbi.nlm.nih.gov/pubmed/7504301?dopt=AbstractPlus), [1078](http://www.ncbi.nlm.nih.gov/pubmed/1283559?dopt=AbstractPlus)\], but exhibit agonist activity at some peripheral sites \[[101](http://www.ncbi.nlm.nih.gov/pubmed/7504301?dopt=AbstractPlus), [658](http://www.ncbi.nlm.nih.gov/pubmed/7529309?dopt=AbstractPlus)\]. The chimeric peptides [M15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3896), [M32](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3897), [M35](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3898), [M40](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3899) and [C7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3861) are agonists at GAL~1~ receptors expressed endogenously in Bowes human melanoma cells \[[1433](http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus)\], and at heterologously expressed recombinant GAL~1~, GAL~2~ and GAL~3~ receptors \[[525](http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus), [1765](http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus), [1766](http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus)\]. Recent studies have described the synthesis of a series of novel, systemically‐active, galanin analogues, with modest preferential binding at the GAL~2~ receptor. Specific chemical modifications to the galanin backbone increased brain levels of these peptides after *i.v.* injection and several of these peptides exerted a potent antidepressant‐like effect in mouse models of depression \[[1623](http://www.ncbi.nlm.nih.gov/pubmed/23600864?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0121}
---------------

Foord SM *et al*. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. *Pharmacol Rev* **57**: 279‐288 [\[PMID:15914470\]](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)

Lang R *et al*. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. *Pharmacol. Rev.* **67**: 118‐75 [\[PMID:25428932\]](http://www.ncbi.nlm.nih.gov/pubmed/25428932?dopt=AbstractPlus)

Lang R *et al*. (2011) The galanin peptide family in inflammation. *Neuropeptides* **45**: 1‐8 [\[PMID:21087790\]](http://www.ncbi.nlm.nih.gov/pubmed/21087790?dopt=AbstractPlus)

Lawrence C *et al*. (2011) Galanin‐like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. *Front Neuroendocrinol* **32**: 1‐9 [\[PMID:20558195\]](http://www.ncbi.nlm.nih.gov/pubmed/20558195?dopt=AbstractPlus)

Webling KE *et al*. (2012) Galanin receptors and ligands. *Front Endocrinol (Lausanne)* **3**: 146 [\[PMID:23233848\]](http://www.ncbi.nlm.nih.gov/pubmed/23233848?dopt=AbstractPlus)

[Ghrelin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=28) {#bph13348-sec-0122}
============================================================================================

Overview {#bph13348-sec-0123}
--------

The ghrelin receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee for the Ghrelin receptor \[** [**397**](http://www.ncbi.nlm.nih.gov/pubmed/16382107?dopt=AbstractPlus) **\]**) is activated by a 28 amino‐acid peptide originally isolated from rat stomach, where it is cleaved from a 117 amino‐acid precursor ([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)). The human gene encoding the precursor peptide has 83% sequence homology to rat prepro‐ghrelin, although the mature peptides from rat and human differ by only two amino acids \[[1222](http://www.ncbi.nlm.nih.gov/pubmed/11549267?dopt=AbstractPlus)\]. Alternative splicing results in the formation of a second peptide, [\[des‐Gln^14^\]ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3600)([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) with equipotent biological activity \[[783](http://www.ncbi.nlm.nih.gov/pubmed/10801861?dopt=AbstractPlus)\]. A unique post‐translational modification (octanoylation of Ser^3^, catalysed by ghrelin *O*‐acyltransferase ([*MBOAT4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32311), [Q96T53](http://www.uniprot.org/uniprot/Q96T53)) \[[2082](http://www.ncbi.nlm.nih.gov/pubmed/18267071?dopt=AbstractPlus)\] occurs in both peptides, essential for full activity in binding to ghrelin receptors in the hypothalamus and pituitary, and for the release of growth hormone from the pituitary \[[983](http://www.ncbi.nlm.nih.gov/pubmed/10604470?dopt=AbstractPlus)\]. Structure activity studies showed the first five N‐terminal amino acids to be the minimum required for binding \[[116](http://www.ncbi.nlm.nih.gov/pubmed/11087562?dopt=AbstractPlus)\], and receptor mutagenesis has indicated overlap of the ghrelin binding site with those for small molecule agonists and allosteric modulators of [ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099)([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) function \[[776](http://www.ncbi.nlm.nih.gov/pubmed/18923064?dopt=AbstractPlus)\]. In cell systems, the ghrelin receptor is constitutively active \[[777](http://www.ncbi.nlm.nih.gov/pubmed/15383539?dopt=AbstractPlus)\], but this is abolished by a naturally occurring mutation (A204E) that results in decreased cell surface receptor expression and is associated with familial short stature \[[1458](http://www.ncbi.nlm.nih.gov/pubmed/16511605?dopt=AbstractPlus)\].

Nomenclature[ghrelin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246)HGNC, UniProt[*GHSR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4267), [Q92847](http://www.uniprot.org/uniprot/Q92847)Rank order of potency[ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099) ([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) = [\[des‐Gln^14^\]ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3600) ([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) \[[115](http://www.ncbi.nlm.nih.gov/pubmed/12969753?dopt=AbstractPlus), [1222](http://www.ncbi.nlm.nih.gov/pubmed/11549267?dopt=AbstractPlus)\]Selective antagonists[GSK1614343](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870) (pIC~50~ 8.4) \[[1624](http://www.ncbi.nlm.nih.gov/pubmed/20593439?dopt=AbstractPlus)\], [GSK1614343](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870) (p*K* ~B~ 8) \[[1487](http://www.ncbi.nlm.nih.gov/pubmed/21034740?dopt=AbstractPlus)\] -- RatLabelled ligands[\[^125^I\]\[His^9^\]ghrelin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1094) (Agonist) (p*K* ~d~ 9.4) \[[912](http://www.ncbi.nlm.nih.gov/pubmed/11522606?dopt=AbstractPlus)\], [\[^125^I\]\[Tyr^4^\]ghrelin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1096) (Agonist) (p*K* ~d~ 9.4) \[[1339](http://www.ncbi.nlm.nih.gov/pubmed/11314756?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0124}
--------

[\[des‐octanoyl\]ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1098)([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) has been shown to bind (as [\[^125^I\]Tyr^4^‐des‐octanoyl‐ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3810)) and have effects in the cardiovascular system \[[115](http://www.ncbi.nlm.nih.gov/pubmed/12969753?dopt=AbstractPlus)\], which raises the possible existence of different receptor subtypes in peripheral tissues and the central nervous system. A potent inverse agonist has been identified ([\[D‐Arg^1^,D‐Phe^5^,D‐Trp^7,9^,Leu^11^\]substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1102), p*D* ~2~ 8.3; \[[774](http://www.ncbi.nlm.nih.gov/pubmed/12907757?dopt=AbstractPlus)\]). [Ulimorelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3535), described as a ghrelin receptor agonist (p*K* ~i~ 7.8 and p*D* ~2~ 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of [ghrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099)([*GHRL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18129), [Q9UBU3](http://www.uniprot.org/uniprot/Q9UBU3)) from the release of growth hormone \[[538](http://www.ncbi.nlm.nih.gov/pubmed/18719021?dopt=AbstractPlus)\]. A number of selective antagonists have been reported, including peptidomimetic \[[1338](http://www.ncbi.nlm.nih.gov/pubmed/22798076?dopt=AbstractPlus)\] and non‐peptide small molecules including [GSK1614343](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870)\[[1487](http://www.ncbi.nlm.nih.gov/pubmed/21034740?dopt=AbstractPlus), [1624](http://www.ncbi.nlm.nih.gov/pubmed/20593439?dopt=AbstractPlus)\].
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[Glucagon receptor family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=29) {#bph13348-sec-0126}
====================================================================================================

Overview {#bph13348-sec-0127}
--------

The glucagon family of receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the Glucagon receptor family \[** [**1234**](http://www.ncbi.nlm.nih.gov/pubmed/12615957?dopt=AbstractPlus) **\]**) are activated by the endogenous peptide (27‐44 aa) hormones [glucagon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136)([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)), [glucagon‐like peptide 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194)([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)), [glucagon‐like peptide 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)), glucose‐dependent insulinotropic polypeptide (also known as [gastric inhibitory polypeptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3542)([*GIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4270), [P09681](http://www.uniprot.org/uniprot/P09681))), [GHRH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270)([*GHRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4265), [P01286](http://www.uniprot.org/uniprot/P01286)) and [secretin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643)([*SCT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10607), [P09683](http://www.uniprot.org/uniprot/P09683)). One common precursor ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191)) generates [glucagon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136)([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)), [glucagon‐like peptide 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194)([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) and [glucagon‐like peptide 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140)([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) peptides \[[827](http://www.ncbi.nlm.nih.gov/pubmed/11179772?dopt=AbstractPlus)\].

Nomenclature[GHRH receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=247)[GIP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=248)[GLP‐1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249)HGNC, UniProt[*GHRHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4266), [Q02643](http://www.uniprot.org/uniprot/Q02643)[*GIPR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4271), [P48546](http://www.uniprot.org/uniprot/P48546)[*GLP1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4324), [P43220](http://www.uniprot.org/uniprot/P43220)Endogenous agonists--[gastric inhibitory polypeptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3542) ([*GIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4270), [P09681](http://www.uniprot.org/uniprot/P09681)) (Selective) (p*K* ~d~ 8.7) \[[1961](http://www.ncbi.nlm.nih.gov/pubmed/7589426?dopt=AbstractPlus)\][glucagon‐like peptide 1‐(7‐36) amide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1132) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) (Selective) (p*K* ~i~ 9.2) \[[885](http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus)\], [glucagon‐like peptide 1‐(7‐37)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3544) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) (Selective) \[[425](http://www.ncbi.nlm.nih.gov/pubmed/8404634?dopt=AbstractPlus)\]Agonists[JI‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6523) \[[255](http://www.ncbi.nlm.nih.gov/pubmed/24373935?dopt=AbstractPlus)\], [sermorelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6998)--[liraglutide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1133) (pEC~50~ 10.2) \[[972](http://www.ncbi.nlm.nih.gov/pubmed/10794683?dopt=AbstractPlus)\], [lixisenatide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7387) (p*K* ~i~ 8.9) \[[2010](http://www.ncbi.nlm.nih.gov/pubmed/20570597?dopt=AbstractPlus)\], [WB4‐24](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8544) (pA~2~ 4.9) \[[502](http://www.ncbi.nlm.nih.gov/pubmed/25176008?dopt=AbstractPlus)\]Selective agonists[BIM28011](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3857) \[[379](http://www.ncbi.nlm.nih.gov/pubmed/8993400?dopt=AbstractPlus)\], [tesamorelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6959)--[exendin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135) (pIC~50~ 9.2) \[[1290](http://www.ncbi.nlm.nih.gov/pubmed/18412318?dopt=AbstractPlus)\], [exendin‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135) (p*K* ~i~ 8.7--9) \[[885](http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus)\], [exendin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3730) ([P20394](http://www.uniprot.org/uniprot/P20394)) \[[1564](http://www.ncbi.nlm.nih.gov/pubmed/1704369?dopt=AbstractPlus)\]Selective antagonists[JV‐1‐36](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1107) (p*K* ~i~ 10.1--10.4) \[[1662](http://www.ncbi.nlm.nih.gov/pubmed/10542394?dopt=AbstractPlus), [1947](http://www.ncbi.nlm.nih.gov/pubmed/9892695?dopt=AbstractPlus), [1948](http://www.ncbi.nlm.nih.gov/pubmed/14755056?dopt=AbstractPlus)\] -- Rat, [JV‐1‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1109) (p*K* ~i~ 10.1) \[[1662](http://www.ncbi.nlm.nih.gov/pubmed/10542394?dopt=AbstractPlus), [1947](http://www.ncbi.nlm.nih.gov/pubmed/9892695?dopt=AbstractPlus), [1948](http://www.ncbi.nlm.nih.gov/pubmed/14755056?dopt=AbstractPlus)\] -- Rat[\[Pro^3^\]GIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3847) \[[584](http://www.ncbi.nlm.nih.gov/pubmed/12627321?dopt=AbstractPlus)\] -- Mouse[exendin‐(9‐39)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1138) (p*K* ~i~ 8.1) \[[885](http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus)\], [GLP‐1‐(9‐36)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6524) (pIC~50~ 6.9) \[[1314](http://www.ncbi.nlm.nih.gov/pubmed/9261127?dopt=AbstractPlus)\] -- Rat, [T‐0632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=884) (pIC~50~ 4.7) \[[1883](http://www.ncbi.nlm.nih.gov/pubmed/11498540?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]GHRH (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3783) (Agonist) (p*K* ~d~ 7.6) \[[192](http://www.ncbi.nlm.nih.gov/pubmed/11814616?dopt=AbstractPlus)\] -- Rat[\[^125^I\]GIP (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1131) (Agonist) (p*K* ~d~ 8.6) \[[562](http://www.ncbi.nlm.nih.gov/pubmed/8795084?dopt=AbstractPlus)\] -- Rat[\[^125^I\]GLP‐1‐(7‐36)‐amide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1134) (Agonist) (p*K* ~d~ 9.3) \[[885](http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus)\], [\[^125^I\]exendin‐(9‐39)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1137) (Antagonist) (p*K* ~d~ 8.3) \[[885](http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus)\], [\[^125^I\]GLP‐1‐(7‐37) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3784) (Agonist)

Nomenclature[GLP‐2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250)[glucagon receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251)[secretin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=252)HGNC, UniProt[*GLP2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4325), [O95838](http://www.uniprot.org/uniprot/O95838)[*GCGR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4192), [P47871](http://www.uniprot.org/uniprot/P47871)[*SCTR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10608), [P47872](http://www.uniprot.org/uniprot/P47872)Endogenous agonists[glucagon‐like peptide 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) (Selective) (pIC~50~ 8.5) \[[1880](http://www.ncbi.nlm.nih.gov/pubmed/11738243?dopt=AbstractPlus)\][glucagon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275)) (Selective) (pEC~50~ 9) \[[1515](http://www.ncbi.nlm.nih.gov/pubmed/4305077?dopt=AbstractPlus)\][secretin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643) ([*SCT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10607), [P09683](http://www.uniprot.org/uniprot/P09683)) (Selective) (pEC~50~ 9.7) \[[329](http://www.ncbi.nlm.nih.gov/pubmed/7612008?dopt=AbstractPlus)\]Agonists[teduglutide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7049) \[[1248](http://www.ncbi.nlm.nih.gov/pubmed/25859983?dopt=AbstractPlus)\]----Selective antagonists--[L‐168,049](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3505) (pIC~50~ 8.4) \[[269](http://www.ncbi.nlm.nih.gov/pubmed/10085108?dopt=AbstractPlus)\], [des‐His^1^‐\[Glu^9^\]glucagon‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1150) (pA~2~ 7.2) \[[1928](http://www.ncbi.nlm.nih.gov/pubmed/3035568?dopt=AbstractPlus), [1929](http://www.ncbi.nlm.nih.gov/pubmed/2560175?dopt=AbstractPlus)\] -- Rat, [NNC 92‐1687](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3515) (p*K* ~i~ 5) \[[1170](http://www.ncbi.nlm.nih.gov/pubmed/9857085?dopt=AbstractPlus)\], [BAY27‐9955](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3491) \[[1496](http://www.ncbi.nlm.nih.gov/pubmed/11719833?dopt=AbstractPlus)\][\[(CH~2~NH)^4,5^\]secretin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3755) (p*K* ~i~ 5.3) \[[668](http://www.ncbi.nlm.nih.gov/pubmed/1702423?dopt=AbstractPlus)\]Labelled ligands--[\[^125^I\]glucagon (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3785) (Agonist)[\[^125^I\](Tyr^10^)secretin‐27 (rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3759) (Agonist) \[[1925](http://www.ncbi.nlm.nih.gov/pubmed/9843782?dopt=AbstractPlus)\] -- Rat

Comments {#bph13348-sec-0128}
--------

The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), specifically [RAMP2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52), in heterologous expression systems \[[333](http://www.ncbi.nlm.nih.gov/pubmed/12446722?dopt=AbstractPlus)\], although the physiological significance of this has yet to be established.
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[Glycoprotein hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=30) {#bph13348-sec-0130}
==========================================================================================================

Overview {#bph13348-sec-0131}
--------

Glycoprotein hormone receptors (**provisional nomenclature \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by a non‐covalent heterodimeric glycoprotein made up of a common *α* chain ([glycoprotein hormone common alpha subunit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3731) ([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885), [P01215](http://www.uniprot.org/uniprot/P01215)) [*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885), [P01215](http://www.uniprot.org/uniprot/P01215)), with a unique *β* chain that confers the biological specificity to [FSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1157)([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*FSHB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3964), [P01215](http://www.uniprot.org/uniprot/P01215) [P01225](http://www.uniprot.org/uniprot/P01225)), [LH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1159)([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*LHB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6584), [P01215](http://www.uniprot.org/uniprot/P01215) [P01229](http://www.uniprot.org/uniprot/P01229)), [hCG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1160)([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*CGB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1886), [P01215](http://www.uniprot.org/uniprot/P01215) [P01233](http://www.uniprot.org/uniprot/P01233)) or [TSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3920)([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*TSHB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12372), [P01215](http://www.uniprot.org/uniprot/P01215) [P01222](http://www.uniprot.org/uniprot/P01222)). There is binding cross‐reactivity across the endogenous agonists for each of the glycoprotein hormone receptors. The deglycosylated hormones appear to exhibit reduced efficacy at these receptors \[[1626](http://www.ncbi.nlm.nih.gov/pubmed/2542111?dopt=AbstractPlus)\].

Nomenclature[FSH receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253)[LH receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254)[TSH receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=255)HGNC, UniProt[*FSHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3969), [P23945](http://www.uniprot.org/uniprot/P23945)[*LHCGR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6585), [P22888](http://www.uniprot.org/uniprot/P22888)[*TSHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12373), [P16473](http://www.uniprot.org/uniprot/P16473)Endogenous agonists--[hCG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1160) ([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*CGB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1886), [P01215](http://www.uniprot.org/uniprot/P01215) [P01233](http://www.uniprot.org/uniprot/P01233)) (Selective) (p*K* ~d~ 9.9--11.8) \[[864](http://www.ncbi.nlm.nih.gov/pubmed/1922095?dopt=AbstractPlus), [1353](http://www.ncbi.nlm.nih.gov/pubmed/12727981?dopt=AbstractPlus)\], [LH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1159) ([*CGA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1885) [*LHB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6584), [P01215](http://www.uniprot.org/uniprot/P01215) [P01229](http://www.uniprot.org/uniprot/P01229)) (Selective) (pIC~50~ 9.9--10.9) \[[864](http://www.ncbi.nlm.nih.gov/pubmed/1922095?dopt=AbstractPlus), [1353](http://www.ncbi.nlm.nih.gov/pubmed/12727981?dopt=AbstractPlus)\]--Antagonists[FSH deglycosylated *α*/*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1158) (p*K* ~d~ 10) \[[527](http://www.ncbi.nlm.nih.gov/pubmed/8188681?dopt=AbstractPlus), 921\]----Labelled ligands[\[^125^I\]FSH (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3780) (Agonist)[\[^125^I\]LH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3793) (Agonist), [\[^125^I\]chorionic gonadotropin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3775) (Agonist)[\[^125^I\]TSH (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3806) (Agonist)CommentsAnimal follitropins are less potent than the human hormone as agonists at the human FSH receptor. Gain‐ and loss‐of‐function mutations of the FSH receptor are associated with human reproductive disorders \[[19](http://www.ncbi.nlm.nih.gov/pubmed/7553856?dopt=AbstractPlus), [109](http://www.ncbi.nlm.nih.gov/pubmed/9769327?dopt=AbstractPlus), [650](http://www.ncbi.nlm.nih.gov/pubmed/8636335?dopt=AbstractPlus), [1900](http://www.ncbi.nlm.nih.gov/pubmed/10551778?dopt=AbstractPlus)\]. The rat FSH receptor also stimulates phosphoinositide turnover through an unidentified G protein \[[1547](http://www.ncbi.nlm.nih.gov/pubmed/8132609?dopt=AbstractPlus)\].Loss‐of‐function mutations of the LH receptor are associated with Leydig cell hypoplasia and gain‐of‐function mutations are associated with male‐limited gonadotropin‐independent precocious puberty (*e.g*. \[[1044](http://www.ncbi.nlm.nih.gov/pubmed/10486313?dopt=AbstractPlus), [1720](http://www.ncbi.nlm.nih.gov/pubmed/12408104?dopt=AbstractPlus)\]) and Leydig cell tumours \[[1126](http://www.ncbi.nlm.nih.gov/pubmed/10580072?dopt=AbstractPlus)\].Autoimmune antibodies that act as agonists of the TSH receptor are found in patients with Graves\' disease (*e.g.* \[[1558](http://www.ncbi.nlm.nih.gov/pubmed/9861544?dopt=AbstractPlus)\]). Mutants of the TSH receptor exhibiting constitutive activity underlie hyperfunctioning thyroid adenomas \[[1464](http://www.ncbi.nlm.nih.gov/pubmed/8413627?dopt=AbstractPlus)\] and congenital hyperthyroidism \[[993](http://www.ncbi.nlm.nih.gov/pubmed/7800007?dopt=AbstractPlus)\]. TSH receptor loss‐of‐function mutations are associated with TSH resistance \[[1824](http://www.ncbi.nlm.nih.gov/pubmed/7528344?dopt=AbstractPlus)\].
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[Gonadotrophin‐releasing hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=31) {#bph13348-sec-0133}
=====================================================================================================================

Overview {#bph13348-sec-0134}
--------

GnRH~1~ and GnRH~2~ receptors (**provisonal nomenclature \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**, also called Type I and Type II GnRH receptor, respectively \[[1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus)\]) have been cloned from numerous species, most of which express two or three types of GnRH receptor \[[1283](http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus), [1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus), [1741](http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus)\]. [GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)) (p‐Glu‐His‐Trp‐Ser‐Tyr‐Gly‐Leu‐Arg‐Pro‐Gly‐NH2) is a hypothalamic decapeptide also known as luteinizing hormone‐releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species \[[1283](http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus), [1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus), [1741](http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus)\] including [GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164)([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) (pGlu‐His‐Trp‐Ser‐His‐Gly‐Trp‐Tyr‐Pro‐Gly‐NH~2~(which is also known as chicken GnRH‐II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals \[[1283](http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus), [1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus), [1741](http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus)\]. GnRH~1~ receptors are expressed primarily by pituitary gonadotrophs, and mediate central control of mammalian reproduction. They are selectively activated by GnRH I and all lack the COOH‐terminal tails found in other GPCRs. GnRH~2~ receptors do have COOH‐terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH~2~ receptors are expressed by some primates but are thought not to be expressed by humans because the human *GNRHR2* gene contains a frame shift and an internal stop codon \[[1325](http://www.ncbi.nlm.nih.gov/pubmed/12538601?dopt=AbstractPlus)\]. An alternative phylogenetic classification divides GnRH receptors into three classes and includes both GnRH I‐selective mammalian and GnRH II‐selective non‐mammalian GnRH receptors as GnRH~1~ receptors \[[1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus)\]. A more recent phylogenetic classification groups vertebrate GnRH receptors into five subfamilies \[[2028](http://www.ncbi.nlm.nih.gov/pubmed/25344287?dopt=AbstractPlus)\] and highlights examples of gene loss through evolution, with humans notably retaining only one ancient gene. Although thousands of peptide analogues of GnRH I have been synthesized and several (agonists and antagonists) are used therapeutically \[[934](http://www.ncbi.nlm.nih.gov/pubmed/12072036?dopt=AbstractPlus)\], the potency of most of these peptides at GnRH~2~ receptors is unknown.

Nomenclature[GnRH~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256)[GnRH~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=257)HGNC, UniProt[*GNRHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4421), [P30968](http://www.uniprot.org/uniprot/P30968)[*GNRHR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16341), [Q96P88](http://www.uniprot.org/uniprot/Q96P88)Rank order of potency[GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)) \>[GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164) ([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) \[[1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus)\][GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164) ([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) \>[GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)) (Monkey) \[[1282](http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus)\]Endogenous agonists--[GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164) ([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) (pIC~50~ 9) \[[1282](http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus)\] -- Monkey, [GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)) (pIC~50~ 7.4) \[[1282](http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus)\] -- MonkeySelective agonists[triptorelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1177) (p*K* ~i~ 9.3--9.5) \[[112](http://www.ncbi.nlm.nih.gov/pubmed/11726197?dopt=AbstractPlus)\], [leuprolide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1175) (p*K* ~i~ 8.5--9.1) \[[1807](http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus)\], [buserelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3860), [goserelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3879), [histrelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3884), [nafarelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3902)--Antagonists[iturelix](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3854) (p*K* ~i~ 9.5) \[[1591](http://www.ncbi.nlm.nih.gov/pubmed/1850267?dopt=AbstractPlus)\]--Selective antagonists[cetrorelix](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1190) (p*K* ~i~ 9.3--10) \[[113](http://www.ncbi.nlm.nih.gov/pubmed/7649152?dopt=AbstractPlus), [114](http://www.ncbi.nlm.nih.gov/pubmed/9300077?dopt=AbstractPlus), [1807](http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus)\], [abarelix](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1188) (p*K* ~i~ 9.1--9.5) \[[1807](http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus)\], [degarelix](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5585) (p*K* ~i~ 8.8) \[[1938](http://www.ncbi.nlm.nih.gov/pubmed/21188095?dopt=AbstractPlus)\], [ganirelix](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3877)[trptorelix‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3916) \[[1183](http://www.ncbi.nlm.nih.gov/pubmed/14651258?dopt=AbstractPlus)\] -- MonkeyLabelled ligands[\[^125^I\]buserelin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1167) (Agonist) (p*K* ~d~ 7.4) \[[1024](http://www.ncbi.nlm.nih.gov/pubmed/8013367?dopt=AbstractPlus)\] -- Rat, [\[^125^I\]GnRH I (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3786) (Agonist)--Comments--Probable transcribed pseudogene in man \[[1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0135}
--------

GnRH~1~ and GnRH~2~ receptors couple primarily to G~q/11~\[[653](http://www.ncbi.nlm.nih.gov/pubmed/10734055?dopt=AbstractPlus)\] but coupling to G~s~ and G~i~ is evident in some systems \[[1009](http://www.ncbi.nlm.nih.gov/pubmed/12591945?dopt=AbstractPlus), [1024](http://www.ncbi.nlm.nih.gov/pubmed/8013367?dopt=AbstractPlus)\]. GnRH~2~ receptors may also mediate (heterotrimeric) G protein‐independent signalling to protein kinases \[[276](http://www.ncbi.nlm.nih.gov/pubmed/15059960?dopt=AbstractPlus)\]. There is increasing evidence for expression of GnRH receptors on hormone‐dependent cancer cells where they can exert antiproliferative and/or proapoptotic effects and mediate effects of cytotoxins conjugated to GnRH analogues \[[309](http://www.ncbi.nlm.nih.gov/pubmed/15561800?dopt=AbstractPlus), [706](http://www.ncbi.nlm.nih.gov/pubmed/15613448?dopt=AbstractPlus), [1108](http://www.ncbi.nlm.nih.gov/pubmed/14726258?dopt=AbstractPlus), [1661](http://www.ncbi.nlm.nih.gov/pubmed/15350601?dopt=AbstractPlus)\]. In some human cancer cell models [GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164)([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) is more potent than [GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)), implying mediation by GnRH~2~ receptors \[[657](http://www.ncbi.nlm.nih.gov/pubmed/12237622?dopt=AbstractPlus)\]. However, GnRH~2~ receptors that are expressed by some primates are probably not expressed in humans because the human GNRHR~2~ gene contains a frame shift and internal stop codon \[[1325](http://www.ncbi.nlm.nih.gov/pubmed/12538601?dopt=AbstractPlus)\]. The possibility remains that this gene generates GnRH~2~ receptor‐related proteins (other than the full‐length receptor) that mediate responses to [GnRH II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164)([*GNRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4420), [O43555](http://www.uniprot.org/uniprot/O43555)) (see \[[1372](http://www.ncbi.nlm.nih.gov/pubmed/11861490?dopt=AbstractPlus)\]). Alternatively, there is evidence for multiple active GnRH receptor conformations \[[276](http://www.ncbi.nlm.nih.gov/pubmed/15059960?dopt=AbstractPlus), [277](http://www.ncbi.nlm.nih.gov/pubmed/22808094?dopt=AbstractPlus), [516](http://www.ncbi.nlm.nih.gov/pubmed/20009083?dopt=AbstractPlus), [1231](http://www.ncbi.nlm.nih.gov/pubmed/15492280?dopt=AbstractPlus), [1284](http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus)\] raising the possibility that GnRH~1~ receptor‐mediated proliferation inhibition in hormone‐dependent cancer cells is dependent upon different conformations (with different ligand specificity and ligand biased signalling) than effects on G~q/11~ in pituitary cells \[[277](http://www.ncbi.nlm.nih.gov/pubmed/22808094?dopt=AbstractPlus), [1231](http://www.ncbi.nlm.nih.gov/pubmed/15492280?dopt=AbstractPlus)\]. Loss‐of‐function mutations in the GnRH~1~ receptor and deficiency of [GnRH I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162) ([*GNRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4419), [P01148](http://www.uniprot.org/uniprot/P01148)) are associated with hypogonadotropic hypogonadism although some 'loss of function' mutations may actually prevent trafficking of 'functional' GnRH~1~ receptors to the cell surface, as evidenced by recovery of function by nonpeptide antagonists \[[1061](http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus)\]. Human GnRH~1~ receptors appear to be poorly expressed at the cell surface because of failure to meet structural quality control criteria for endoplasmic reticulum exit \[[517](http://www.ncbi.nlm.nih.gov/pubmed/19888967?dopt=AbstractPlus), [1061](http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus)\]. This may increase susceptibility to point mutations that further impair trafficking and also increase effects of non‐peptide antagonists on GnRH~1~ receptor trafficking to the plasma membrane \[[517](http://www.ncbi.nlm.nih.gov/pubmed/19888967?dopt=AbstractPlus), [1061](http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus)\]. GnRH receptor signalling may be dependent upon receptor oligomerisation \[[363](http://www.ncbi.nlm.nih.gov/pubmed/6282571?dopt=AbstractPlus), [1007](http://www.ncbi.nlm.nih.gov/pubmed/11278883?dopt=AbstractPlus)\].
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[GPR18, GPR55 and GPR119](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114) {#bph13348-sec-0137}
====================================================================================================

Overview {#bph13348-sec-0138}
--------

GPR18, GPR55 and GPR119 (**provisional nomenclature**), although showing little structural similarity to CB~1~ and CB~2~ cannabinoid receptors, respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands \[[1494](http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus)\]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be activated *in vitro* by [N‐arachidonoylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635), [lysophosphatidylinositol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028) and [N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661), respectively, there is a lack of evidence for activation by these lipid messengers *in vivo*. As such, therefore, these receptors retain their orphan status.

Nomenclature[*GPR18*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=89)[*GPR55*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=109)[*GPR119*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126)HGNC, UniProt[*GPR18*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4472), [Q14330](http://www.uniprot.org/uniprot/Q14330)[*GPR55*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4511), [Q9Y2T6](http://www.uniprot.org/uniprot/Q9Y2T6)[*GPR119*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19060), [Q8TDV5](http://www.uniprot.org/uniprot/Q8TDV5)Rank order of potency----[N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661), [N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622)\>[SEA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621) ([anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) is ineffective) \[[1452](http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus)\]Endogenous agonists[N‐arachidonoylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635) \[[980](http://www.ncbi.nlm.nih.gov/pubmed/16844083?dopt=AbstractPlus)\][lysophosphatidylinositol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028) (pEC~50~ 5.5--7.3) \[[738](http://www.ncbi.nlm.nih.gov/pubmed/20136841?dopt=AbstractPlus), [1435](http://www.ncbi.nlm.nih.gov/pubmed/17765871?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\], [2‐arachidonoylglycerolphosphoinositol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4029) (Selective) \[[1437](http://www.ncbi.nlm.nih.gov/pubmed/18845565?dopt=AbstractPlus)\][N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661) (pEC~50~ 5.4--6.3) \[[338](http://www.ncbi.nlm.nih.gov/pubmed/19901198?dopt=AbstractPlus), [1452](http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\], [N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622), [SEA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621)Selective agonists--[AM251](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317) (pEC~50~ 5--7.4) \[[738](http://www.ncbi.nlm.nih.gov/pubmed/20136841?dopt=AbstractPlus), [905](http://www.ncbi.nlm.nih.gov/pubmed/19723626?dopt=AbstractPlus), [1620](http://www.ncbi.nlm.nih.gov/pubmed/17876302?dopt=AbstractPlus)\][AS1269574](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4027) (pEC~50~ 5.6) \[[2100](http://www.ncbi.nlm.nih.gov/pubmed/20804735?dopt=AbstractPlus)\], [PSN632408](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3319) (pEC~50~ 5.3) \[[1452](http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus)\], [PSN375963](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3318) (pEC~50~ 5.1) \[[1452](http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus)\]Selective antagonists--[CID16020046](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6577) (apparent pA~2~) (pA~2~ 7.3) \[[906](http://www.ncbi.nlm.nih.gov/pubmed/23639801?dopt=AbstractPlus)\]--CommentsThe pairing of [N‐arachidonoylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635) with GPR18 was not replicated in two studies based on arrestin assays \[[1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus), [2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\]. See \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] for discussion.See reviews \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\] and \[[1732](http://www.ncbi.nlm.nih.gov/pubmed/25926795?dopt=AbstractPlus)\].In addition to those shown above, further small molecule agonists have been reported \[[687](http://www.ncbi.nlm.nih.gov/pubmed/26048791?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0139}
--------

GPR18 failed to respond to a variety of lipid‐derived agents in an *in vitro* screen \[[2093](http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus)\], but has been reported to be activated by [*Δ*^9^‐tetrahydrocannabinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424)\[[1246](http://www.ncbi.nlm.nih.gov/pubmed/21595653?dopt=AbstractPlus)\]. GPR55 responds to [AM251](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317) and [rimonabant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=743) at micromolar concentrations, compared to their nanomolar affinity as CB~1~ receptor antagonists/inverse agonists \[[1494](http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus)\]. It has been reported that [lysophosphatidylinositol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028) acts at other sites in addition to GPR55 \[[2075](http://www.ncbi.nlm.nih.gov/pubmed/23714700?dopt=AbstractPlus)\]. N‐Arachidonoylserine has been suggested to act as a low efficacy agonist/antagonist at GPR18 *in vitro*\[[1244](http://www.ncbi.nlm.nih.gov/pubmed/20346144?dopt=AbstractPlus)\]. It has also been suggested [oleoyl‐lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3623) acts, at least in part, through GPR119 \[[1400](http://www.ncbi.nlm.nih.gov/pubmed/18724386?dopt=AbstractPlus)\]. Although [PSN375963](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3318) and [PSN632408](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3319) produce GPR119‐dependent responses in heterologous expression systems, comparison with [N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661)‐mediated responses suggests additional mechanisms of action \[[1400](http://www.ncbi.nlm.nih.gov/pubmed/18724386?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0140}
---------------
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[Histamine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=33) {#bph13348-sec-0141}
===============================================================================================

Overview {#bph13348-sec-0142}
--------

Histamine receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Histamine Receptors \[** [**754**](http://www.ncbi.nlm.nih.gov/pubmed/9311023?dopt=AbstractPlus) **,** [**1459**](http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus) **\]**) are activated by the endogenous ligand [histamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204). Marked species differences exist between histamine receptor orthologues \[[754](http://www.ncbi.nlm.nih.gov/pubmed/9311023?dopt=AbstractPlus)\].

Nomenclature[H~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=262)[H~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=263)[H~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264)[H~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=265)HGNC, UniProt[*HRH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5182), [P35367](http://www.uniprot.org/uniprot/P35367)[*HRH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5183), [P25021](http://www.uniprot.org/uniprot/P25021)[*HRH3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5184), [Q9Y5N1](http://www.uniprot.org/uniprot/Q9Y5N1)[*HRH4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17383), [Q9H3N8](http://www.uniprot.org/uniprot/Q9H3N8)Selective agonists[methylhistaprodifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1205) (p*K* ~i~ 6.4) \[[1695](http://www.ncbi.nlm.nih.gov/pubmed/12626648?dopt=AbstractPlus)\], [histaprodifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4026) (p*K* ~i~ 5.7) \[[1107](http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus)\][amthamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4025) (pEC~50~ 6.4) \[[1003](http://www.ncbi.nlm.nih.gov/pubmed/19072936?dopt=AbstractPlus)\][immethridine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4024) (p*K* ~i~ 9.1) \[[963](http://www.ncbi.nlm.nih.gov/pubmed/15115383?dopt=AbstractPlus)\], [methimepip](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1254) (p*K* ~i~ 9) \[[962](http://www.ncbi.nlm.nih.gov/pubmed/15771452?dopt=AbstractPlus)\], [MK‐0249](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7346) (Inverse agonist) (p*K* ~i~ 8.8) \[[1354](http://www.ncbi.nlm.nih.gov/pubmed/18598020?dopt=AbstractPlus)\][clobenpropit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223) (Partial agonist) (p*K* ~i~ 7.4--8.3) \[[490](http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus), [1107](http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus), [1122](http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus), [1123](http://www.ncbi.nlm.nih.gov/pubmed/11561071?dopt=AbstractPlus), [1335](http://www.ncbi.nlm.nih.gov/pubmed/11181941?dopt=AbstractPlus)\], [4‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1269) (p*K* ~i~ 7.3--8.2) \[[586](http://www.ncbi.nlm.nih.gov/pubmed/16432504?dopt=AbstractPlus), [1107](http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus)\], [VUF 8430](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1274) (p*K* ~i~ 7.5) \[[1106](http://www.ncbi.nlm.nih.gov/pubmed/17154494?dopt=AbstractPlus)\]Antagonists[cyproheptadine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277) (p*K* ~i~ 10.2) \[[1298](http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus)\], [promethazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7282) (p*K* ~i~ 9.6) \[[601](http://www.ncbi.nlm.nih.gov/pubmed/16782354?dopt=AbstractPlus)\], [pyrilamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1227) (Inverse agonist) (p*K* ~i~ 8.7--9) \[[184](http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus), [1563](http://www.ncbi.nlm.nih.gov/pubmed/15206929?dopt=AbstractPlus)\], [hydroxyzine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7199) (p*K* ~i~ 8.7) \[[608](http://www.ncbi.nlm.nih.gov/pubmed/11809864?dopt=AbstractPlus)\], [ketotifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7206) (p*K* ~i~ 8.6) \[[1014](http://www.ncbi.nlm.nih.gov/pubmed/21470866?dopt=AbstractPlus)\], [cetirizine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1222) (Inverse agonist) (p*K* ~i~ 8.2) \[[1298](http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus)\], [diphenhydramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1224) (p*K* ~i~ 7.9) \[[184](http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus)\]--[iodophenpropit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1266) (p*K* ~i~ 8.2--8.7) \[[2022](http://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus), [2051](http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus)\], [thioperamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1267) (p*K* ~i~ 7.1--7.7) \[[355](http://www.ncbi.nlm.nih.gov/pubmed/11284713?dopt=AbstractPlus), [489](http://www.ncbi.nlm.nih.gov/pubmed/15294456?dopt=AbstractPlus), [490](http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus), [1104](http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus), [1145](http://www.ncbi.nlm.nih.gov/pubmed/10869375?dopt=AbstractPlus), [2022](http://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus), [2051](http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus)\]--Selective antagonists[clemastine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6063) (p*K* ~i~ 10.3) \[68\], [desloratadine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7157) (p*K* ~i~ 9) \[[1090](http://www.ncbi.nlm.nih.gov/pubmed/15482930?dopt=AbstractPlus)\], [triprolidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1228) (p*K* ~i~ 8.5--9) \[[184](http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus), [1298](http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus)\], [azelastine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7121) (p*K* ~i~ 8.9) \[[1535](http://www.ncbi.nlm.nih.gov/pubmed/21381763?dopt=AbstractPlus)\], [astemizole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2603) (p*K* ~i~ 8.5) \[[1480](http://www.ncbi.nlm.nih.gov/pubmed/12747773?dopt=AbstractPlus)\], [cyclizine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7151) (p*K* ~i~ 8.4) \[68\], [chlorpheniramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6976) (p*K* ~i~ 8.1) \[[1535](http://www.ncbi.nlm.nih.gov/pubmed/21381763?dopt=AbstractPlus)\], [fexofenadine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4819) (p*K* ~i~ 7.6) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/19660947?dopt=AbstractPlus)\], [loratadine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7216) (p*K* ~i~ 7.4) \[[850](http://www.ncbi.nlm.nih.gov/pubmed/15771458?dopt=AbstractPlus)\], [terfenadine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608) (p*K* ~i~ 7.4) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/19660947?dopt=AbstractPlus)\], [tripelennamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7318) (pIC~50~ 7.4) \[[635](http://www.ncbi.nlm.nih.gov/pubmed/14667234?dopt=AbstractPlus)\][tiotidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1235) (p*K* ~i~ 7.5) \[[145](http://www.ncbi.nlm.nih.gov/pubmed/9384502?dopt=AbstractPlus)\] -- Rat, [ranitidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234) (p*K* ~i~ 7.1) \[[1086](http://www.ncbi.nlm.nih.gov/pubmed/7921611?dopt=AbstractPlus)\], [cimetidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231) (p*K* ~i~ 6.8) \[[263](http://www.ncbi.nlm.nih.gov/pubmed/23466604?dopt=AbstractPlus)\][clobenpropit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223) (p*K* ~i~ 8.4--9.4) \[[355](http://www.ncbi.nlm.nih.gov/pubmed/11284713?dopt=AbstractPlus), [490](http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus), [1104](http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus), [1122](http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus), [1145](http://www.ncbi.nlm.nih.gov/pubmed/10869375?dopt=AbstractPlus), [2022](http://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus), [2051](http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus)\], [A331440](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4023) (p*K* ~i~ 8.5) \[[688](http://www.ncbi.nlm.nih.gov/pubmed/15033391?dopt=AbstractPlus)\][JNJ 7777120](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1278) (p*K* ~i~ 7.8--8.3) \[[1107](http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus), [1771](http://www.ncbi.nlm.nih.gov/pubmed/16854056?dopt=AbstractPlus), [1881](http://www.ncbi.nlm.nih.gov/pubmed/14722321?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]pyrilamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1220) (Antagonist, Inverse agonist) (p*K* ~d~ 8.4--9.1) \[[403](http://www.ncbi.nlm.nih.gov/pubmed/9794809?dopt=AbstractPlus), [1298](http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus), [1675](http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus), [1695](http://www.ncbi.nlm.nih.gov/pubmed/12626648?dopt=AbstractPlus)\], [\[^11^C\]doxepin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3958) (Antagonist) (p*K* ~d~ 9) \[[830](http://www.ncbi.nlm.nih.gov/pubmed/15093820?dopt=AbstractPlus)\], [\[^11^C\]pyrilamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3957) (Antagonist, Inverse agonist)[\[^125^I\]iodoaminopotentidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1230) (Antagonist) (p*K* ~d~ 8.7) \[[1029](http://www.ncbi.nlm.nih.gov/pubmed/8961278?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]tiotidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3959) (Antagonist) (p*K* ~d~ 7.7--8.7) \[[1310](http://www.ncbi.nlm.nih.gov/pubmed/12869657?dopt=AbstractPlus)\][\[^123^I\]iodoproxyfan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1264) (Antagonist) (p*K* ~d~ 10.2) \[[1104](http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus)\], [\[^125^I\]iodophenpropit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3960) (Antagonist) (p*K* ~d~ 9.2) \[[849](http://www.ncbi.nlm.nih.gov/pubmed/7834183?dopt=AbstractPlus)\] -- Rat, [\[^3^H\](*R*)‐*α*‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1237) (Agonist) (p*K* ~d~ 9.2) \[[1122](http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus)\], [*N*‐\[^3^H\]*α*‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1240) (Agonist) (p*K* ~d~ 9) \[[301](http://www.ncbi.nlm.nih.gov/pubmed/12706455?dopt=AbstractPlus)\] -- Mouse[\[^3^H\]JNJ 7777120](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1279) (Antagonist) (p*K* ~d~ 8.4) \[[1881](http://www.ncbi.nlm.nih.gov/pubmed/14722321?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0143}
--------

[histaprodifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4026) and [methylhistaprodifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1205) are reduced efficacy agonists. The H~4~ receptor appears to exhibit broadly similar pharmacology to the H~3~ receptor for imidazole‐containing ligands, although [(*R*)‐*α*‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1236) and [*N*‐*α*‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1239) are less potent, while [clobenpropit](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223) acts as a reduced efficacy agonist at the H~4~ receptor and an antagonist at the H~3~ receptor \[[1122](http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus), [1360](http://www.ncbi.nlm.nih.gov/pubmed/11118334?dopt=AbstractPlus), [1390](http://www.ncbi.nlm.nih.gov/pubmed/11179435?dopt=AbstractPlus), [1422](http://www.ncbi.nlm.nih.gov/pubmed/10973974?dopt=AbstractPlus), [2132](http://www.ncbi.nlm.nih.gov/pubmed/11179436?dopt=AbstractPlus)\]. Moreover, [4‐methylhistamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1269) is identified as a high affinity, full agonist for the human H~4~ receptor \[[1107](http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus)\]. [\[^3^H\]histamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1247) has been used to label the H~4~ receptor in heterologous expression systems.

Further Reading {#bph13348-sec-0144}
---------------
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[Hydroxycarboxylic acid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=48) {#bph13348-sec-0145}
============================================================================================================

Overview {#bph13348-sec-0146}
--------

The hydroxycarboxylic acid family of receptors ([ENSFM00500000271913](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00500000271913), **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Hydroxycarboxylic acid receptors \[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **,** [**1424**](http://www.ncbi.nlm.nih.gov/pubmed/21454438?dopt=AbstractPlus) **\]**) respond to organic acids, including the endogenous hydroxy carboxylic acids 3‐hydroxy butyric acid and [L‐lactic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932), as well as the lipid lowering agents [nicotinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588) (niacin), [acipimox](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1596) and [acifran](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1595)\[[1774](http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus), [1913](http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus), [2036](http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus)\]. These receptors were provisionally described as nicotinic acid receptors, although nicotinic acid shows submicromolar potency at HCA~2~receptors only and is unlikely to be the natural ligand \[[1913](http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus), [2036](http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus)\].

Nomenclature[HCA~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=311)[HCA~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=312)[HCA~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=313)HGNC, UniProt[*HCAR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4532), [Q9BXC0](http://www.uniprot.org/uniprot/Q9BXC0)[*HCAR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24827), [Q8TDS4](http://www.uniprot.org/uniprot/Q8TDS4)[*HCAR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16824), [P49019](http://www.uniprot.org/uniprot/P49019)Endogenous agonists[L‐lactic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932) (Selective) (pEC~50~ 1.3--2.9) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/20374963?dopt=AbstractPlus), [256](http://www.ncbi.nlm.nih.gov/pubmed/18952058?dopt=AbstractPlus), [1124](http://www.ncbi.nlm.nih.gov/pubmed/19047060?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\][*β*‐D‐hydroxybutyric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593) (pEC~50~ 3.1) \[[1838](http://www.ncbi.nlm.nih.gov/pubmed/15929991?dopt=AbstractPlus)\][3‐hydroxyoctanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2933) (pEC~50~ 5.1) \[[13](http://www.ncbi.nlm.nih.gov/pubmed/19561068?dopt=AbstractPlus)\]Agonists[compound 2 \[PMID: 24486398\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8467) (pEC~50~ 7.2) \[[1630](http://www.ncbi.nlm.nih.gov/pubmed/24486398?dopt=AbstractPlus)\], [3,5‐dihydroxybenzoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5783) (pEC~50~ 3.7) \[[1121](http://www.ncbi.nlm.nih.gov/pubmed/22434674?dopt=AbstractPlus)\][SCH 900271](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8469) (pEC~50~ 8.7) \[[1454](http://www.ncbi.nlm.nih.gov/pubmed/24900372?dopt=AbstractPlus)\], [GSK256073](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8470) (pEC~50~ 7.5) \[[1790](http://www.ncbi.nlm.nih.gov/pubmed/25773497?dopt=AbstractPlus)\]--Selective agonists--[MK 6892](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5788) (pEC~50~ 7.8) \[[1719](http://www.ncbi.nlm.nih.gov/pubmed/20184326?dopt=AbstractPlus)\], [MK 1903](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5785) (pEC~50~ 7.6) \[[163](http://www.ncbi.nlm.nih.gov/pubmed/22435740?dopt=AbstractPlus)\], [nicotinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588) (pEC~50~ 6--7.2) \[[1774](http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus), [1913](http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus), [2036](http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus)\], [acipimox](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1596) (pEC~50~ 5.2--5.6) \[[1774](http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus), [2036](http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus)\], [monomethylfumarate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5786) (pEC~50~ 5) \[[1859](http://www.ncbi.nlm.nih.gov/pubmed/18722346?dopt=AbstractPlus)\][compound 6o \[PMID: 19524438\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5800) (pEC~50~ 8.5) \[[1751](http://www.ncbi.nlm.nih.gov/pubmed/19524438?dopt=AbstractPlus)\], [IBC 293](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1597) (pEC~50~ 6.4) \[[1697](http://www.ncbi.nlm.nih.gov/pubmed/16480258?dopt=AbstractPlus)\]Labelled ligands--[\[^3^H\]nicotinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1594) (Agonist) (p*K* ~d~ 7--7.3) \[[1774](http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus), [1913](http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus), [2036](http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus)\]--

Comments {#bph13348-sec-0147}
--------

Further closely‐related GPCRs include the [5‐oxoeicosanoid receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35) ([*OXER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24884), [Q8TDS5](http://www.uniprot.org/uniprot/Q8TDS5)) and [*GPR31*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4486)([O00270](http://www.uniprot.org/uniprot/O00270)).

Further Reading {#bph13348-sec-0148}
---------------

Chapman MJ *et al*. (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacol. Ther.* **126**: 314‐45 [\[PMID:20153365\]](http://www.ncbi.nlm.nih.gov/pubmed/20153365?dopt=AbstractPlus)

Digby JE *et al*. (2012) Niacin in cardiovascular disease: recent preclinical and clinical developments. *Arterioscler. Thromb. Vasc. Biol.* **32**: 582‐8 [\[PMID:22207729\]](http://www.ncbi.nlm.nih.gov/pubmed/22207729?dopt=AbstractPlus)

Hanson J *et al*. (2012) Role of HCA_2(GPR109A) in nicotinic acid and fumaric acid ester‐induced effects on the skin. *Pharmacol. Ther.* **136**: 1‐7 [\[PMID:22743741\]](http://www.ncbi.nlm.nih.gov/pubmed/22743741?dopt=AbstractPlus)

Kamanna VS *et al*. (2013) Recent advances in niacin and lipid metabolism. *Curr. Opin. Lipidol.* **24**: 239‐45 [\[PMID:23619367\]](http://www.ncbi.nlm.nih.gov/pubmed/23619367?dopt=AbstractPlus)

Offermanns S. (2014) Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. *Annu. Rev. Pharmacol. Toxicol.* **54**: 407‐34 [\[PMID:24160702\]](http://www.ncbi.nlm.nih.gov/pubmed/24160702?dopt=AbstractPlus)

Offermanns S *et al*. (2011) International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy‐carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). *Pharmacol. Rev.* **63**: 269‐90 [\[PMID:21454438\]](http://www.ncbi.nlm.nih.gov/pubmed/21454438?dopt=AbstractPlus)

Offermanns S *et al*. (2015) Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation. *Trends Mol Med* **21**: 245‐55 [\[PMID:25766751\]](http://www.ncbi.nlm.nih.gov/pubmed/25766751?dopt=AbstractPlus)

[Kisspeptin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=34) {#bph13348-sec-0149}
===============================================================================================

Overview {#bph13348-sec-0150}
--------

The kisspeptin receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the kisspeptin receptor \[** [**958**](http://www.ncbi.nlm.nih.gov/pubmed/21079036?dopt=AbstractPlus) **\]**), like neuropeptide FF (NPFF), prolactin‐releasing peptide (PrP) and QRFP receptors (provisional nomenclature) responds to endogenous peptides with an arginine‐phenylalanine‐amide (RFamide) motif. [Kisspeptin‐54](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1288)([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341), [Q15726](http://www.uniprot.org/uniprot/Q15726)) (KP54, originally named metastin), [kisspeptin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1284)([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341), [Q15726](http://www.uniprot.org/uniprot/Q15726)) (KP13) and [kisspeptin‐10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1283)([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341)) (KP10) are biologically‐active peptides cleaved from the [*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341)([Q15726](http://www.uniprot.org/uniprot/Q15726)) gene product.

Nomenclature[kisspeptin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=266)HGNC, UniProt[*KISS1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4510), [Q969F8](http://www.uniprot.org/uniprot/Q969F8)Endogenous agonists[kisspeptin‐10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1283) ([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341)) (Selective) (p*K* ~i~ 8.6--10.4) \[[996](http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus), [1434](http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus)\], [kisspeptin‐54](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1288) ([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341), [Q15726](http://www.uniprot.org/uniprot/Q15726)) (Selective) (p*K* ~i~ 8.8--9.5) \[[996](http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus), [1434](http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus)\], [kisspeptin‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1285) ([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341), [Q15726](http://www.uniprot.org/uniprot/Q15726)) (p*K* ~i~ 8.8) \[[996](http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus)\], [kisspeptin‐13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1284) ([*KISS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6341), [Q15726](http://www.uniprot.org/uniprot/Q15726)) (Selective) (p*K* ~i~ 8.4) \[[996](http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus)\]Selective agonists[4‐fluorobenzoyl‐FGLRW‐NH2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4014) (pEC~50~ 9.2) \[[1894](http://www.ncbi.nlm.nih.gov/pubmed/18302161?dopt=AbstractPlus)\], [\[dY\]^1^KP‐10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4015) (pIC~50~ 8.4) \[[385](http://www.ncbi.nlm.nih.gov/pubmed/19934405?dopt=AbstractPlus)\] -- MouseSelective antagonists[peptide 234](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4012) \[[1600](http://www.ncbi.nlm.nih.gov/pubmed/19321788?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]Tyr^45^‐kisspeptin‐15](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1280) (Agonist) (p*K* ~d~ 10) \[[1434](http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus)\], [\[^125^I\]kisspeptin‐13 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3792) (Agonist) (p*K* ~d~ 9.7) \[[1252](http://www.ncbi.nlm.nih.gov/pubmed/17023533?dopt=AbstractPlus)\], [\[^125^I\]kisspeptin‐10 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1281) (Agonist) (p*K* ~d~ 8.7) \[[996](http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus)\], [\[^125^I\]kisspeptin‐14 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4013) (Agonist) \[[1252](http://www.ncbi.nlm.nih.gov/pubmed/17023533?dopt=AbstractPlus)\]

Further Reading {#bph13348-sec-0151}
---------------

Kanda S *et al*. (2013) Structure, synthesis, and phylogeny of kisspeptin and its receptor. *Adv. Exp. Med. Biol.* **784**: 9‐26 [\[PMID:23550000\]](http://www.ncbi.nlm.nih.gov/pubmed/23550000?dopt=AbstractPlus)

Kirby HR *et al*. (2010) International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function. *Pharmacol. Rev.* **62**: 565‐78 [\[PMID:21079036\]](http://www.ncbi.nlm.nih.gov/pubmed/21079036?dopt=AbstractPlus)

Millar RP *et al*. (2010) Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology. *Brain Res.* **1364**: 81‐9 [\[PMID:20858467\]](http://www.ncbi.nlm.nih.gov/pubmed/20858467?dopt=AbstractPlus)

Pasquier J *et al*. (2014) Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. *J. Mol. Endocrinol.* **52**: T101‐17 [\[PMID:24577719\]](http://www.ncbi.nlm.nih.gov/pubmed/24577719?dopt=AbstractPlus)

Roseweir AK *et al*. (2013) Kisspeptin antagonists. *Adv. Exp. Med. Biol.* **784**: 159‐86 [\[PMID:23550006\]](http://www.ncbi.nlm.nih.gov/pubmed/23550006?dopt=AbstractPlus)

[Leukotriene receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35) {#bph13348-sec-0152}
=================================================================================================

Overview {#bph13348-sec-0153}
--------

Leukotriene receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on Leukotriene Receptors \[** [**249**](http://www.ncbi.nlm.nih.gov/pubmed/21771892?dopt=AbstractPlus) **,** [**250**](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus) **\]**) is activated by the endogenous ligands leukotrienes (LT), synthesized from lipoxygenase metabolism of arachidonic acid.

The human BLT~1~ receptor is the high affinity LTB~4~ receptor whereas the BLT~2~ receptor in addition to being a low‐affinity LTB~4~ receptor also binds several other lipoxygenase‐products, such as [12S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404), [12S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481), [15S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401), and the thromboxane synthase product [12‐hydroxyheptadecatrienoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6159). The BLT receptors mediate chemotaxis and immunomodulation in several leukocyte populations and are in addition expressed on non‐myeloid cells, such as vascular smooth muscle and endothelial cells. In addition to BLT receptors, LTB~4~ has been reported to bind to the peroxisome proliferator activated receptor (PPAR) *α*\[[1112](http://www.ncbi.nlm.nih.gov/pubmed/9890897?dopt=AbstractPlus)\] and the vanilloid TRPV1 ligand‐gated nonselective cation channel \[[1245](http://www.ncbi.nlm.nih.gov/pubmed/16207832?dopt=AbstractPlus)\].

The receptors for the cysteinyl‐leukotrienes (*i.e.* [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354), [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) and [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352)) are termed CysLT~1~ and CysLT~2~ and exhibit distinct expression patterns in human tissues, mediating for example smooth muscle cell contraction, regulation of vascular permeability, and leukocyte activation. There is also evidence in the literature for additional CysLT receptor subtypes, derived from functional in vitro studies, radioligand binding and in mice lacking both CysLT~1~ and CysLT~2~ receptors \[[250](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus)\]. Cysteinyl‐leukotrienes have also been suggested to signal through the P2Y~12~ receptor \[[542](http://www.ncbi.nlm.nih.gov/pubmed/20702811?dopt=AbstractPlus), [1407](http://www.ncbi.nlm.nih.gov/pubmed/16185654?dopt=AbstractPlus), [1466](http://www.ncbi.nlm.nih.gov/pubmed/19822647?dopt=AbstractPlus)\], GPR17 \[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\] and GPR99 \[[900](http://www.ncbi.nlm.nih.gov/pubmed/23504326?dopt=AbstractPlus)\].

Nomenclature[BLT~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=267)[BLT~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=268)[CysLT~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=269)[CysLT~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270)HGNC, UniProt[*LTB4R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6713), [Q15722](http://www.uniprot.org/uniprot/Q15722)[*LTB4R2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19260), [Q9NPC1](http://www.uniprot.org/uniprot/Q9NPC1)[*CYSLTR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17451), [Q9Y271](http://www.uniprot.org/uniprot/Q9Y271)[*CYSLTR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18274), [Q9NS75](http://www.uniprot.org/uniprot/Q9NS75)Rank order of potency[LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487)\>[20‐hydroxy‐LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3399)≫[12R‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3405) \[[2096](http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus)\][12‐hydroxyheptadecatrienoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6159)\>[LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487)\>[12S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404) = [12S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481)\>[15S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401)\>[12R‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3405)\>[20‐hydroxy‐LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3399) \[[1442](http://www.ncbi.nlm.nih.gov/pubmed/18378794?dopt=AbstractPlus), [2096](http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus)\][LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)\>[LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354)\>[LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) \[[1157](http://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus), [1643](http://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus)\][LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354)≥[LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)≫[LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) \[[733](http://www.ncbi.nlm.nih.gov/pubmed/10851239?dopt=AbstractPlus), [1411](http://www.ncbi.nlm.nih.gov/pubmed/11093801?dopt=AbstractPlus), [1847](http://www.ncbi.nlm.nih.gov/pubmed/10913337?dopt=AbstractPlus)\]Endogenous agonists--[12S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404) (Partial agonist) (pEC~50~\<7.5) \[[2096](http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus)\]----Antagonists----[ICI198615](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3358) (‐ 8.4--8.6)[BAYu9773](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3381) (against LTC~4~ and LTD~4~ induced contraction in smooth muscle preparation) (pA~2~ 6.8--7.7) \[[1912](http://www.ncbi.nlm.nih.gov/pubmed/7698171?dopt=AbstractPlus)\] -- RatSelective antagonists[BIIL 260](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6154) (p*K* ~i~ 8.8) \[[152](http://www.ncbi.nlm.nih.gov/pubmed/11259574?dopt=AbstractPlus), [457](http://www.ncbi.nlm.nih.gov/pubmed/17170051?dopt=AbstractPlus)\], [CP105696](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3368) (pIC~50~ 8.1) \[[1735](http://www.ncbi.nlm.nih.gov/pubmed/7714764?dopt=AbstractPlus)\], [U75302](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3325) (p*K* ~i~ 6.4) \[[172](http://www.ncbi.nlm.nih.gov/pubmed/10513580?dopt=AbstractPlus)\][LY255283](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3351) (pIC~50~ 6--7.1) \[[744](http://www.ncbi.nlm.nih.gov/pubmed/1316967?dopt=AbstractPlus), [2096](http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus)\][zafirlukast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3322) (against \[^3^H\]LTD~4~ in COS‐7 or HEK‐293 cells) (pIC~50~ 8.6--8.7) \[[1157](http://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus), [1643](http://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus)\], [SR2640](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3329) (p*K* ~i~ 8.7), [montelukast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3340) (against \[^3^H\]LTD4 in COS‐7 or HEK‐293 cells) (pIC~50~ 8.3--8.6) \[[1157](http://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus), [1643](http://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus)\], [sulukast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3327) (p*K* ~i~ 8.3), [pobilukast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3334) (against \[^3^H\]LTD~4~ in HEK‐293) (pIC~50~ 7.5) \[[1643](http://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus)\][BayCysLT~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6196) (against 30‐300nM LTD~4~ *β*‐arrestin assay in C2C12 myofibroblasts) (pIC~50~ 6.6--7.3) \[[1391](http://www.ncbi.nlm.nih.gov/pubmed/21903747?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3413) (Agonist) (p*K* ~d~ 9.8) \[[2095](http://www.ncbi.nlm.nih.gov/pubmed/9177352?dopt=AbstractPlus)\], [\[^3^H\]CGS23131](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3415) (Antagonist) (p*K* ~d~ 7.9) \[[836](http://www.ncbi.nlm.nih.gov/pubmed/1320692?dopt=AbstractPlus)\][\[^3^H\]LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3413) (p*K* ~d~ 7.6--9.7)[\[^3^H\]LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3412) (Agonist) (p*K* ~d~ 8--10.7), [\[^3^H\]ICI‐198615](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3414) (Antagonist) (p*K* ~d~ 10.6) \[[1608](http://www.ncbi.nlm.nih.gov/pubmed/1329767?dopt=AbstractPlus)\][\[^3^H\]LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3412) (Agonist) (p*K* ~d~ 7.3--9.4) \[[733](http://www.ncbi.nlm.nih.gov/pubmed/10851239?dopt=AbstractPlus)\]

Nomenclature[FPR2/ALX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223)[OXE receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=271)HGNC, UniProt[*FPR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3827), [P25090](http://www.uniprot.org/uniprot/P25090)[*OXER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24884), [Q8TDS5](http://www.uniprot.org/uniprot/Q8TDS5)Rank order of potency[LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034)=[aspirin triggered lipoxin A4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933)=[ATLa2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383)\>[LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354)=[LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)≫[15‐deoxy‐LXA4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3402)≫[fMet‐Leu‐Phe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022) \[[352](http://www.ncbi.nlm.nih.gov/pubmed/10393980?dopt=AbstractPlus), [519](http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus), [521](http://www.ncbi.nlm.nih.gov/pubmed/8527441?dopt=AbstractPlus), [651](http://www.ncbi.nlm.nih.gov/pubmed/11141472?dopt=AbstractPlus), [1846](http://www.ncbi.nlm.nih.gov/pubmed/9151906?dopt=AbstractPlus)\][5‐oxo‐ETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3391), [5‐oxo‐C20:3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3392), [5‐oxo‐ODE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6164)\>[5‐oxo‐15‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6167)\>[5S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2483)\>[5S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3390) \[[784](http://www.ncbi.nlm.nih.gov/pubmed/12065583?dopt=AbstractPlus), [877](http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus), [1472](http://www.ncbi.nlm.nih.gov/pubmed/18292294?dopt=AbstractPlus)\]Endogenous agonists[LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) (Selective) (pEC~50~∼12) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\], [resolvin D1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934) (Selective) (pEC~50~∼11.9) \[[1006](http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus)\], [aspirin triggered lipoxin A4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933) (Selective)[5‐oxo‐ETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3391) (Selective) (pEC~50~ 8.3--8.5) \[[638](http://www.ncbi.nlm.nih.gov/pubmed/19450703?dopt=AbstractPlus), [1417](http://www.ncbi.nlm.nih.gov/pubmed/9829988?dopt=AbstractPlus), [1472](http://www.ncbi.nlm.nih.gov/pubmed/18292294?dopt=AbstractPlus), [1525](http://www.ncbi.nlm.nih.gov/pubmed/1326548?dopt=AbstractPlus), [1681](http://www.ncbi.nlm.nih.gov/pubmed/7797484?dopt=AbstractPlus)\]Selective agonists[ATLa2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383) \[[662](http://www.ncbi.nlm.nih.gov/pubmed/15056011?dopt=AbstractPlus)\]--Endogenous antagonists--[5‐oxo‐12‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6171) (Selective) (pIC~50~ 6.3) \[[1524](http://www.ncbi.nlm.nih.gov/pubmed/9920859?dopt=AbstractPlus)\]Antagonists----Selective antagonists----Labelled ligands[\[^3^H\]LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3411) (Agonist) (p*K* ~d~ 9.2--9.3) \[[519](http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus), [520](http://www.ncbi.nlm.nih.gov/pubmed/1322894?dopt=AbstractPlus)\][\[^3^H\]5‐oxo‐ETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3416) (Agonist) (p*K* ~d~ 8.4) \[[1417](http://www.ncbi.nlm.nih.gov/pubmed/9829988?dopt=AbstractPlus)\]CommentsThe agonist activity of the lipid mediators described has been questioned \[[697](http://www.ncbi.nlm.nih.gov/pubmed/23643932?dopt=AbstractPlus), [1513](http://www.ncbi.nlm.nih.gov/pubmed/23607720?dopt=AbstractPlus)\], which may derive from batch‐to‐batch differences, partial agonism or biased agonism. Recent results from Cooray *et al.* (2013) \[[365](http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus)\] have addressed this issue and the role of homodimers and heterodimers in the intracellular signaling .--

Comments {#bph13348-sec-0154}
--------

The FPR2/ALX receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} subcommittee on Leukotriene and Lipoxin Receptors \[** [**250**](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus) **\]**) is activated by the endogenous lipid‐derived, anti‐inflammatory ligands lipoxin A~4~([LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034)) and 15‐epi‐LXA~4~([aspirin triggered lipoxin A4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933), ATL). The FPR2/ALX receptor also interacts with endogenous peptide and protein ligands, such as MHC binding peptide \[[315](http://www.ncbi.nlm.nih.gov/pubmed/10748237?dopt=AbstractPlus)\] as well as [annexin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031) ([*ANXA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=533), [P04083](http://www.uniprot.org/uniprot/P04083)) (ANXA1) and its *N*‐terminal peptides \[[365](http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus), [1491](http://www.ncbi.nlm.nih.gov/pubmed/12368905?dopt=AbstractPlus)\]. In addition, a soluble hydrolytic product of protease action on the urokinase‐type plasminogen activator receptor has been reported to activate the FPR2/ALX receptor \[[1572](http://www.ncbi.nlm.nih.gov/pubmed/11818541?dopt=AbstractPlus)\]. Furthermore, FPR2/ALX has been suggested to act as a receptor mediating the proinflammatory actions of the acute‐phase reactant, serum amyloid A \[[1772](http://www.ncbi.nlm.nih.gov/pubmed/15171815?dopt=AbstractPlus), [1809](http://www.ncbi.nlm.nih.gov/pubmed/9892621?dopt=AbstractPlus)\]. A receptor selective for [LXB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216) has been suggested from functional studies \[[53](http://www.ncbi.nlm.nih.gov/pubmed/12794159?dopt=AbstractPlus), [1168](http://www.ncbi.nlm.nih.gov/pubmed/8551217?dopt=AbstractPlus), [1596](http://www.ncbi.nlm.nih.gov/pubmed/8757340?dopt=AbstractPlus)\]. Note that the data for FPR2/ALX are also reproduced on the [Formylpeptide receptor pages](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23).

Oxoeicosanoid receptors (**OXE, nomenclature agreed by the [NC‐IUPHAR]{.ul} subcommittee on Oxoeicosanoid Receptors \[** [**214**](http://www.ncbi.nlm.nih.gov/pubmed/15001665?dopt=AbstractPlus) **\]**) are activated by endogenous chemotactic eicosanoid ligands oxidised at the C‐5 position, with [5‐oxo‐ETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3391) the most potent agonist identified for this receptor. Initial characterization of the heterologously expressed OXE receptor suggested that polyunsaturated fatty acids, such as [docosahexaenoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051) and [EPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362), acted as receptor antagonists \[[784](http://www.ncbi.nlm.nih.gov/pubmed/12065583?dopt=AbstractPlus)\]

Further Reading {#bph13348-sec-0155}
---------------

Bäck M *et al*. (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. *Br. J. Pharmacol.* **171**: 3551‐74 [\[PMID:24588652\]](http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus)

Cooray SN *et al*. (2013) Ligand‐specific conformational change of the G‐protein‐coupled receptor ALX/FPR2 determines proresolving functional responses. *Proc. Natl. Acad. Sci. U.S.A.* **110**: 18232‐7 [\[PMID:24108355\]](http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus)

Nelson JW *et al*. (2014) ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands. *Am. J. Physiol., Cell Physiol.* **306**: C178‐85 [\[PMID:24259417\]](http://www.ncbi.nlm.nih.gov/pubmed/24259417?dopt=AbstractPlus)

Norling LV *et al*. (2012) Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor‐dependent actions. *Arterioscler. Thromb. Vasc. Biol.* **32**: 1970‐8 [\[PMID:22499990\]](http://www.ncbi.nlm.nih.gov/pubmed/22499990?dopt=AbstractPlus)

[Lysophospholipid (LPA) receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=36) {#bph13348-sec-0156}
============================================================================================================

Overview {#bph13348-sec-0157}
--------

Lysophosphatidic acid (LPA) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Lysophospholipid Receptors \[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **,** [**936**](http://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus) **\]**) are activated by the endogenous phospholipid metabolite [LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906). The first receptor, LPA~1~, was identified as *ventricular zone gene‐1* (*vzg‐1*), leading to deorphanisation of members of the endothelial differentiation gene (*edg*) family as other LPA receptors along with sphingosine 1‐phosphate (S1P) receptors. Additional LPA receptor GPCRs were later identified. Gene names have been codified as *LPAR1*, etc. to reflect the receptor function of proteins. The crystal structure of LPA~1~ was recently solved and demonstrates ligand access characteristics that allows for extracellular LPA binding \[[331](http://www.ncbi.nlm.nih.gov/pubmed/26091040?dopt=AbstractPlus)\]; these studies have also implicated cross‐talk with endocannabinoids *via* phosphorylated intermediates that can activate this receptor. The identified receptors can account for most, although not all, LPA‐induced phenomena in the literature, indicating that a majority of LPA‐dependent phenomena are receptor‐mediated. Radioligand binding has been conducted in heterologous expression systems using [\[^3^H\]LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5395)(*e.g.* \[[556](http://www.ncbi.nlm.nih.gov/pubmed/9600933?dopt=AbstractPlus)\]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding, and therefore the relationship between recombinant and endogenously expressed receptors is unclear. Targeted deletion of LPA receptors has clarified signalling pathways and identified physiological and pathophysiological roles. Independent validation by multiple groups has been reported in the peer‐reviewed literature for all six LPA receptors described in the tables, including further validation using a distinct read‐out via a novel TGF*α*"shedding" assay \[[825](http://www.ncbi.nlm.nih.gov/pubmed/22983457?dopt=AbstractPlus)\]. [LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906) has also been described as an agonist at other orphan GPCRs (PSP24, GPR87 and GPR35), as well as at the nuclear hormone PPAR*γ* receptors \[[1247](http://www.ncbi.nlm.nih.gov/pubmed/12502787?dopt=AbstractPlus), [1743](http://www.ncbi.nlm.nih.gov/pubmed/15710620?dopt=AbstractPlus)\], although the physiological significance of these observations remain unclear.

Nomenclature[LPA~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=272)[LPA~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=273)[LPA~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=274)HGNC, UniProt[*LPAR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3166), [Q92633](http://www.uniprot.org/uniprot/Q92633)[*LPAR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3168), [Q9HBW0](http://www.uniprot.org/uniprot/Q9HBW0)[*LPAR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14298), [Q9UBY5](http://www.uniprot.org/uniprot/Q9UBY5)Selective agonists--[dodecylphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4031) (pEC~50~ 6.2) \[[1958](http://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus)\], [decyl dihydrogen phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4030) (pEC~50~ 5.4) \[[1958](http://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus)\], [GRI977143](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6580) (pEC~50~ 4.5) \[[959](http://www.ncbi.nlm.nih.gov/pubmed/22968304?dopt=AbstractPlus)\][OMPT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2912) (pEC~50~ 7.2) \[[709](http://www.ncbi.nlm.nih.gov/pubmed/12554733?dopt=AbstractPlus)\]Selective antagonists[AM966](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2905) (pIC~50~ 6.7--7.8) \[[1832](http://www.ncbi.nlm.nih.gov/pubmed/20649573?dopt=AbstractPlus)\]--[dioctanoylglycerol pyrophosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2916) (p*K* ~i~ 5.5--7) \[[522](http://www.ncbi.nlm.nih.gov/pubmed/11562440?dopt=AbstractPlus), [1432](http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus)\]Comments--Virtual screening experiments have shown [H2L5186303](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6579) to be a potent antagonist of LPA~2~ \[[510](http://www.ncbi.nlm.nih.gov/pubmed/18467108?dopt=AbstractPlus)\]. [dodecylphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4031) is also an antagonist at LPA~3~ receptors \[[1958](http://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus)\].--

Nomenclature[LPA~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=94)[LPA~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=124)[LPA~6~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=163)HGNC, UniProt[*LPAR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4478), [Q99677](http://www.uniprot.org/uniprot/Q99677)[*LPAR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13307), [Q9H1C0](http://www.uniprot.org/uniprot/Q9H1C0)[*LPAR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15520), [P43657](http://www.uniprot.org/uniprot/P43657)

Comments {#bph13348-sec-0158}
--------

[Ki16425](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2907)\[[1432](http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus)\], [VPC12249](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2909)\[[735](http://www.ncbi.nlm.nih.gov/pubmed/11723223?dopt=AbstractPlus)\] and [VPC32179](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5450)\[[729](http://www.ncbi.nlm.nih.gov/pubmed/15125924?dopt=AbstractPlus)\] have antagonist activity at LPA~1~ and LPA~3~ receptors. There is growing evidence for *in vivo* efficacy of these chemical antagonists in several disorders, including fetal hydrocephalus \[[2107](http://www.ncbi.nlm.nih.gov/pubmed/21900594?dopt=AbstractPlus)\], lung fibrosis \[[1429](http://www.ncbi.nlm.nih.gov/pubmed/25959255?dopt=AbstractPlus)\], and systemic sclerosis \[[1429](http://www.ncbi.nlm.nih.gov/pubmed/25959255?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0159}
---------------
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Mutoh T *et al*. (2012) Insights into the pharmacological relevance of lysophospholipid receptors. *Br. J. Pharmacol.* **165**: 829‐44 [\[PMID:21838759\]](http://www.ncbi.nlm.nih.gov/pubmed/21838759?dopt=AbstractPlus)

Schober A *et al*. (2012) Lysophosphatidic acid in atherosclerotic diseases. *Br. J. Pharmacol.* **167**: 465‐82 [\[PMID:22568609\]](http://www.ncbi.nlm.nih.gov/pubmed/22568609?dopt=AbstractPlus)

Sheng X *et al*. (2015) Lysophosphatidic acid signalling in development. *Development* **142**: 1390‐5 [\[PMID:25852197\]](http://www.ncbi.nlm.nih.gov/pubmed/25852197?dopt=AbstractPlus)

Yung YC *et al*. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. *J. Lipid Res.* **55**: 1192‐1214 [\[PMID:24643338\]](http://www.ncbi.nlm.nih.gov/pubmed/24643338?dopt=AbstractPlus)

Yung YC *et al*. (2015) Lysophosphatidic Acid signaling in the nervous system. *Neuron* **85**: 669‐82 [\[PMID:25695267\]](http://www.ncbi.nlm.nih.gov/pubmed/25695267?dopt=AbstractPlus)

[Lysophospholipid (S1P) receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=135) {#bph13348-sec-0160}
=============================================================================================================

Overview {#bph13348-sec-0161}
--------

Sphingosine 1‐phosphate (S1P) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Lysophospholipid receptors \[** [**936**](http://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus) **\]**) are activated by the endogenous lipid [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) (S1P) and with lower apparent affinity, [sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032)(SPC). Originally cloned as orphan members of the endothelial differentiation gene (*edg*) family, deorphanisation as lysophospholipid receptors for S1P was based on sequence homology to LPA receptors. Current gene names have been codified as S1PR1, etc. to reflect the receptor function of these proteins. Most cellular phenomena ascribed to S1P can be explained by receptor‐mediated mechanisms; S1P has also been described to act at intracellular sites \[[1841](http://www.ncbi.nlm.nih.gov/pubmed/18552276?dopt=AbstractPlus)\], and awaits precise definition. Previously‐proposed SPC (or lysophophosphatidylcholine) receptors‐ G2A, TDAG8, OGR1 and GPR4 ‐ continue to lack confirmation of these roles \[[396](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus)\]. The relationship between recombinant and endogenously expressed receptors is unclear. Radioligand binding has been conducted in heterologous expression systems using [\[^32^P\]S1P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5402)(*e.g* \[[1438](http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus)\]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding. Targeted deletion of several S1P receptors and key enzymes involved in S1P biosynthesis or degradation has clarified signalling pathways and physiological roles. A crystal structure of an S1P~1~‐T4 fusion protein has been described \[[698](http://www.ncbi.nlm.nih.gov/pubmed/22344443?dopt=AbstractPlus)\].

The S1P receptor modulator, [fingolimod](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407)(FTY720, Gilenya), has received world‐wide approval as the first oral therapy for relapsing forms of multiple sclerosis. This drug has a novel mechanism of action involving modulation of S1P receptors in both the immune and nervous systems \[[325](http://www.ncbi.nlm.nih.gov/pubmed/21177428?dopt=AbstractPlus), [356](http://www.ncbi.nlm.nih.gov/pubmed/21520239?dopt=AbstractPlus), [654](http://www.ncbi.nlm.nih.gov/pubmed/23518370?dopt=AbstractPlus)\], although the precise nature of its interaction requires clarification.

Nomenclature[S1P~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275)[S1P~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=276)[S1P~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=277)[S1P~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=278)[S1P~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=279)HGNC, UniProt[*S1PR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3165), [P21453](http://www.uniprot.org/uniprot/P21453)[*S1PR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3169), [O95136](http://www.uniprot.org/uniprot/O95136)[*S1PR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3167), [Q99500](http://www.uniprot.org/uniprot/Q99500)[*S1PR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3170), [O95977](http://www.uniprot.org/uniprot/O95977)[*S1PR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14299), [Q9H228](http://www.uniprot.org/uniprot/Q9H228)Rank order of potency[sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)\>[dihydrosphingosine‐1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921)\>[sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[45](http://www.ncbi.nlm.nih.gov/pubmed/10383399?dopt=AbstractPlus), [1438](http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus)\][sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)\>[dihydrosphingosine‐1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921)\>[sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[45](http://www.ncbi.nlm.nih.gov/pubmed/10383399?dopt=AbstractPlus), [1438](http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus)\][sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)\>[dihydrosphingosine‐1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921)\>[sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[1438](http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus)\][sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)\>[dihydrosphingosine‐1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921)\>[sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[1936](http://www.ncbi.nlm.nih.gov/pubmed/10753843?dopt=AbstractPlus)\][sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)\>[dihydrosphingosine‐1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921)\>[sphingosylphosphorylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032) \[[821](http://www.ncbi.nlm.nih.gov/pubmed/10799507?dopt=AbstractPlus)\]Agonists[SEW2871](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2926) (p*K* ~i~ 5.5--7.7) \[[1640](http://www.ncbi.nlm.nih.gov/pubmed/14732717?dopt=AbstractPlus)\]--------Antagonists[VPC44116](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2930) (p*K* ~i~ 8.5) \[[533](http://www.ncbi.nlm.nih.gov/pubmed/17113298?dopt=AbstractPlus)\], [VPC23019](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3324) (p*K* ~i~ 7.9) \[[400](http://www.ncbi.nlm.nih.gov/pubmed/15590668?dopt=AbstractPlus)\]--[VPC44116](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2930) (p*K* ~i~ 6.5) \[[533](http://www.ncbi.nlm.nih.gov/pubmed/17113298?dopt=AbstractPlus)\], [VPC23019](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3324) (p*K* ~i~ 5.9) \[[400](http://www.ncbi.nlm.nih.gov/pubmed/15590668?dopt=AbstractPlus)\]----Selective antagonists[W146](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2931) (p*K* ~i~ 7.1) \[[1641](http://www.ncbi.nlm.nih.gov/pubmed/16829954?dopt=AbstractPlus)\][JTE‐013](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2917) (pIC~50~ 7.8) \[[1447](http://www.ncbi.nlm.nih.gov/pubmed/12445827?dopt=AbstractPlus)\]------Selective agonists[AUY954](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2925) (pEC~50~ 8.9) \[[1456](http://www.ncbi.nlm.nih.gov/pubmed/17114004?dopt=AbstractPlus)\]--------

Comments {#bph13348-sec-0162}
--------

The approved immunomodulator drug [fingolimod](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407) can be phosphorylated *in vivo* \[[31](http://www.ncbi.nlm.nih.gov/pubmed/16078855?dopt=AbstractPlus)\] to generate a relatively potent agonist with activity at S1P~1~, S1P~3~, S1P~4~ and S1P~5~ receptors \[[215](http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus), [1198](http://www.ncbi.nlm.nih.gov/pubmed/11923495?dopt=AbstractPlus)\], although its biological activity appears to involve an element of functional antagonism \[[339](http://www.ncbi.nlm.nih.gov/pubmed/21955849?dopt=AbstractPlus), [356](http://www.ncbi.nlm.nih.gov/pubmed/21520239?dopt=AbstractPlus), [1405](http://www.ncbi.nlm.nih.gov/pubmed/20979571?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0163}
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O\'Sullivan C *et al*. (2013) The structure and function of the S1P1 receptor. *Trends Pharmacol. Sci.* **34**: 401‐12 [\[PMID:23763867\]](http://www.ncbi.nlm.nih.gov/pubmed/23763867?dopt=AbstractPlus)

Spiegel S *et al*. (2011) The outs and the ins of sphingosine‐1‐phosphate in immunity. *Nat. Rev. Immunol.* **11**: 403‐15 [\[PMID:21546914\]](http://www.ncbi.nlm.nih.gov/pubmed/21546914?dopt=AbstractPlus)

[Melanin‐concentrating hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=37) {#bph13348-sec-0164}
===================================================================================================================

Overview {#bph13348-sec-0165}
--------

Melanin‐concentrating hormone (MCH) receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul} \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by an endogenous nonadecameric cyclic peptide identical in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor ([*PMCH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9109), [P20382](http://www.uniprot.org/uniprot/P20382)), which also produces [neuropeptide EI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5374)([*PMCH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9109), [P20382](http://www.uniprot.org/uniprot/P20382)) and [neuropeptide GE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5375) ([*PMCH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9109), [P20382](http://www.uniprot.org/uniprot/P20382)).

Nomenclature[MCH~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=280)[MCH~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=281)HGNC, UniProt[*MCHR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4479), [Q99705](http://www.uniprot.org/uniprot/Q99705)[*MCHR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20867), [Q969V1](http://www.uniprot.org/uniprot/Q969V1)Rank order of potency[melanin‐concentrating hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1298) ([*PMCH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9109), [P20382](http://www.uniprot.org/uniprot/P20382)) \>[MCH (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1301)[melanin‐concentrating hormone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1298) ([*PMCH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9109), [P20382](http://www.uniprot.org/uniprot/P20382)) = [MCH (salmon)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1301) \[[753](http://www.ncbi.nlm.nih.gov/pubmed/11274220?dopt=AbstractPlus)\]Selective antagonists[GW803430](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4033) (pIC~50~ 9.3) \[[745](http://www.ncbi.nlm.nih.gov/pubmed/16870432?dopt=AbstractPlus)\], [SNAP‐7941](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1313) (pA~2~ 9.2) \[[186](http://www.ncbi.nlm.nih.gov/pubmed/12118247?dopt=AbstractPlus)\], [T‐226296](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1314) (pIC~50~ 8.3) \[[1853](http://www.ncbi.nlm.nih.gov/pubmed/11909603?dopt=AbstractPlus)\], [ATC0175](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1305) (pIC~50~ 7.9--8.1) \[[283](http://www.ncbi.nlm.nih.gov/pubmed/15677346?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]S36057](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1317) (Antagonist) (p*K* ~d~ 9.2--9.5) \[[66](http://www.ncbi.nlm.nih.gov/pubmed/11375253?dopt=AbstractPlus)\], [\[^125^I\]\[Phe^13^,Tyr^19^\]MCH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3844) (Agonist) (p*K* ~d~ 9.2) \[[242](http://www.ncbi.nlm.nih.gov/pubmed/9434758?dopt=AbstractPlus)\], [\[^3^H\]MCH (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3827) (Agonist) \[[242](http://www.ncbi.nlm.nih.gov/pubmed/9434758?dopt=AbstractPlus)\]--

Comments {#bph13348-sec-0166}
--------

The MCH~2~ receptor appears to be a non‐functional pseudogene in rodents \[[1857](http://www.ncbi.nlm.nih.gov/pubmed/12036292?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0167}
---------------
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[Melanocortin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=38) {#bph13348-sec-0168}
==================================================================================================

Overview {#bph13348-sec-0169}
--------

Melanocortin receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by members of the melanocortin family ([*α*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320)([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [*β*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606)([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) and [*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333)([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) forms; ‐*δ* form is not found in mammals) and adrenocorticotrophin ([ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633)([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))). Endogenous antagonists include [agouti](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3609)([*ASIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=745), [P42127](http://www.uniprot.org/uniprot/P42127)) and [agouti‐related protein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1335) ([*AGRP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=330), [O00253](http://www.uniprot.org/uniprot/O00253)).

Nomenclature[MC~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=282)[MC~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=283)[MC~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=284)[MC~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285)[MC~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=286)HGNC, UniProt[*MC1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6929), [Q01726](http://www.uniprot.org/uniprot/Q01726)[*MC2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6930), [Q01718](http://www.uniprot.org/uniprot/Q01718)[*MC3R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6931), [P41968](http://www.uniprot.org/uniprot/P41968)[*MC4R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6932), [P32245](http://www.uniprot.org/uniprot/P32245)[*MC5R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6933), [P33032](http://www.uniprot.org/uniprot/P33032)Rank order of potency[*α*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[*β*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))[ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))[*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [*β*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [*α*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))[*β*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[*α*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))[*α*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[*β*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[ACTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) \>[*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189))Selective agonists--[corticotropin zinchydroxide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6967)[\[D‐Trp^8^\]*γ*‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1334) (pIC~50~ 8.2) \[[645](http://www.ncbi.nlm.nih.gov/pubmed/11150170?dopt=AbstractPlus)\][THIQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1338) (pIC~50~ 8.9) \[[1690](http://www.ncbi.nlm.nih.gov/pubmed/12361385?dopt=AbstractPlus)\]--Antagonists----[PG‐106](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6546) (pIC~50~ 6.7) \[[646](http://www.ncbi.nlm.nih.gov/pubmed/17482720?dopt=AbstractPlus)\]----Selective antagonists------[MBP10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1339) (pIC~50~ 10) \[[117](http://www.ncbi.nlm.nih.gov/pubmed/11606131?dopt=AbstractPlus)\], [HS014](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1321) (p*K* ~i~ 8.5) \[[1667](http://www.ncbi.nlm.nih.gov/pubmed/9630346?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]NDP‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326) (Agonist) (p*K* ~d~ 9.5) \[[991](http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus)\][\[^125^I\]ACTH‐(1‐24)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3767) (Agonist)[\[^125^I\]NDP‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326) (Agonist) (p*K* ~d~ 9.7) \[[991](http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus)\], [\[^125^I\]SHU9119](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804) (Antagonist) \[[1392](http://www.ncbi.nlm.nih.gov/pubmed/12604699?dopt=AbstractPlus)\][\[^125^I\]SHU9119](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804) (Antagonist) (p*K* ~d~ 9.2) \[[1392](http://www.ncbi.nlm.nih.gov/pubmed/12604699?dopt=AbstractPlus)\], [\[^125^I\]NDP‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326) (Agonist) (p*K* ~d~ 8.4--8.9) \[[991](http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus), [1665](http://www.ncbi.nlm.nih.gov/pubmed/7774675?dopt=AbstractPlus)\][\[^125^I\]NDP‐MSH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326) (Agonist) (p*K* ~d~ 8.6) \[[991](http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0170}
--------

Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor have been linked to obesity \[[282](http://www.ncbi.nlm.nih.gov/pubmed/9392003?dopt=AbstractPlus), [505](http://www.ncbi.nlm.nih.gov/pubmed/18779842?dopt=AbstractPlus)\].
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---------------
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[Melatonin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=39) {#bph13348-sec-0172}
===============================================================================================

Overview {#bph13348-sec-0173}
--------

Melatonin receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul}Subcommittee on Melatonin Receptors \[** [**446**](http://www.ncbi.nlm.nih.gov/pubmed/20605968?dopt=AbstractPlus) **\]**) are activated by the endogenous ligands [melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224) and [N‐acetylserotonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5451).

Nomenclature[MT~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=287)[MT~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288)HGNC, UniProt[*MTNR1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7463), [P48039](http://www.uniprot.org/uniprot/P48039)[*MTNR1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7464), [P49286](http://www.uniprot.org/uniprot/P49286)Endogenous agonists[melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224) (p*K* ~i~ 9.1--9.7) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [445](http://www.ncbi.nlm.nih.gov/pubmed/2991499?dopt=AbstractPlus), [447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus)\][melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224) (p*K* ~i~ 9.4--9.8) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [445](http://www.ncbi.nlm.nih.gov/pubmed/2991499?dopt=AbstractPlus), [447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus)\]Agonists[ramelteon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356) (p*K* ~i~ 10.9) \[[909](http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus)\], [agomelatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198) (p*K* ~i~ 10--10.4) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [132](http://www.ncbi.nlm.nih.gov/pubmed/9618428?dopt=AbstractPlus)\][agomelatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198) (p*K* ~i~ 9.9--10.5) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [132](http://www.ncbi.nlm.nih.gov/pubmed/9618428?dopt=AbstractPlus)\], [ramelteon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356) (p*K* ~i~ 10) \[[909](http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus), [1565](http://www.ncbi.nlm.nih.gov/pubmed/21182402?dopt=AbstractPlus)\]Selective agonists--[IIK7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1350) (p*K* ~i~ 10.3) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/10737738?dopt=AbstractPlus), [1814](http://www.ncbi.nlm.nih.gov/pubmed/10420436?dopt=AbstractPlus)\], [5‐methoxy‐luzindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1364) (Partial agonist) (p*K* ~i~ 9.6) \[[447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus)\]Selective antagonists--[4P‐PDOT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1358) (p*K* ~i~ 8.8--9.4) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus), [448](http://www.ncbi.nlm.nih.gov/pubmed/9737724?dopt=AbstractPlus)\], [K185](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1359) (p*K* ~i~ 9.3) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/10737738?dopt=AbstractPlus), [1814](http://www.ncbi.nlm.nih.gov/pubmed/10420436?dopt=AbstractPlus)\], [DH97](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3366) (p*K* ~i~ 8) \[[1865](http://www.ncbi.nlm.nih.gov/pubmed/9840420?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]SD6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770) (Agonist) (p*K* ~d~ 10.9) \[[1074](http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus)\], [2‐\[^125^I\]melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344) (Agonist) (p*K* ~d~ 9.9--10.7) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus)\], [\[^3^H\]melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357) (Agonist) (p*K* ~d~ 9.4--9.9) \[[230](http://www.ncbi.nlm.nih.gov/pubmed/10696085?dopt=AbstractPlus)\][\[^125^I\]SD6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770) (Agonist) (p*K* ~d~ 10.2) \[[1074](http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus)\], [2‐\[^125^I\]melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344) (Agonist) (p*K* ~d~ 9.7--10) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus), [447](http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus)\], [\[^125^I\]DIV880](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7771) (Agonist, Partial agonist) (p*K* ~d~ 9.7) \[[1074](http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus)\], [\[^3^H\]melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357) (Agonist) (p*K* ~d~ 9--9.6) \[[230](http://www.ncbi.nlm.nih.gov/pubmed/10696085?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0174}
--------

[melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224), [2‐iodo‐melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1343), [agomelatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198), [GR 196429](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1349), [LY 156735](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1351) and [ramelteon](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356)\[[909](http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus)\] are nonselective agonists for MT~1~ and MT~2~ receptors. (‐)‐AMMTC displays an \~400‐fold greater agonist potency than (+)‐AMMTC at rat MT~1~ receptors (see [AMMTC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3385) for structure) \[[1888](http://www.ncbi.nlm.nih.gov/pubmed/10433507?dopt=AbstractPlus)\]. [Luzindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1363) is an MT~1~/MT~2~ melatonin receptor‐selective competitive antagonist with some selectivity for the MT2 receptor \[[448](http://www.ncbi.nlm.nih.gov/pubmed/9737724?dopt=AbstractPlus)\]. MT~1~/MT~2~ heterodimers present different pharmacological profiles from MT~1~ and MT~2~ receptors \[[72](http://www.ncbi.nlm.nih.gov/pubmed/15266022?dopt=AbstractPlus)\].

The *MT~3~* binding site of hamster brain and peripheral tissues such as kidney and testis, also termed the ML~2~ receptor, binds selectively [2‐iodo‐\[^125^I\]5MCA‐NAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5396)\[[1302](http://www.ncbi.nlm.nih.gov/pubmed/8773460?dopt=AbstractPlus)\]. Pharmacological investigations of *MT~3~* binding sites have primarily been conducted in hamster tissues. At this site, [N‐acetylserotonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5451)\[[467](http://www.ncbi.nlm.nih.gov/pubmed/8246675?dopt=AbstractPlus), [1149](http://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus), [1302](http://www.ncbi.nlm.nih.gov/pubmed/8773460?dopt=AbstractPlus), [1516](http://www.ncbi.nlm.nih.gov/pubmed/7798906?dopt=AbstractPlus)\] and [5MCA‐NAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3393)\[[1516](http://www.ncbi.nlm.nih.gov/pubmed/7798906?dopt=AbstractPlus)\] appear to function as agonists, while [prazosin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503)\[[1149](http://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus)\] functions as an antagonist. The *MT~3~* binding site of hamster kidney was also identified as the hamster homologue of human quinone reductase 2 ([*NQO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7856), [P16083](http://www.uniprot.org/uniprot/P16083)\[[1408](http://www.ncbi.nlm.nih.gov/pubmed/10913150?dopt=AbstractPlus), [1409](http://www.ncbi.nlm.nih.gov/pubmed/11331072?dopt=AbstractPlus)\]). The *MT~3~* binding site activated by [5MCA‐NAT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3393) in eye ciliary body is positively coupled to adenylyl cyclase and regulates chloride secretion \[[802](http://www.ncbi.nlm.nih.gov/pubmed/25344385?dopt=AbstractPlus)\]. *Xenopus* melanophores and chick brain express a distinct receptor (x420, P49219; c346, P49288, initially termed Mel~1C~) coupled to the G~i/o~ family of G proteins, for which GPR50 has recently been suggested to be a mammalian counterpart \[[451](http://www.ncbi.nlm.nih.gov/pubmed/18400093?dopt=AbstractPlus)\] although [melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224) does not bind to GPR50 receptors.

Further Reading {#bph13348-sec-0175}
---------------
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[Metabotropic glutamate receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=40) {#bph13348-sec-0176}
============================================================================================================

Overview {#bph13348-sec-0177}
--------

Metabotropic glutamate (mGlu) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Metabotropic Glutamate Receptors \[1672\]**) are activated by the endogenous ligands [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369), [L‐serine‐O‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411), N‐acetylaspartylglutamate ([NAAG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405)) and [L‐cysteine sulphinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5447). Examples of agonists selective for mGlu receptors compared with ionotropic glutamate receptors are [(1*S*,3*R*)‐ACPD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365) and [L‐CCG‐I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1368), which show limited selectivity for Group‐II receptors. An example of an antagonist selective for mGlu receptors is [LY341495](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1378), which blocks mGlu~2~ and mGlu~3~ at low nanomolar concentrations, mGlu~8~ at high nanomolar concentrations, and mGlu~4~, mGlu~5~, and mGlu~7~ in the micromolar range \[[955](http://www.ncbi.nlm.nih.gov/pubmed/9680254?dopt=AbstractPlus)\]. Three groups of native receptors are distinguishable on the bases of similarities of agonist pharmacology, primary sequence and G protein coupling to effector: Group‐I (mGlu~1~ and mGlu~5~), Group‐II (mGlu~2~ and mGlu~3~) and Group‐III (mGlu~4~, mGlu~6~, mGlu~7~ and mGlu~8~) (see Further reading). Group‐I mGlu receptors may be activated by [3,5‐DHPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1367) and [(*S*)‐3HPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1366)\[[198](http://www.ncbi.nlm.nih.gov/pubmed/8532171?dopt=AbstractPlus)\] and antagonized by [(S)‐hexylhomoibotenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5448)\[[1171](http://www.ncbi.nlm.nih.gov/pubmed/15996690?dopt=AbstractPlus)\]. Group‐II mGlu receptors may be activated by [LY389795](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3349)\[[1311](http://www.ncbi.nlm.nih.gov/pubmed/10090786?dopt=AbstractPlus)\], [LY379268](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1394)\[[1311](http://www.ncbi.nlm.nih.gov/pubmed/10090786?dopt=AbstractPlus)\], [eglumegad](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393)\[[1673](http://www.ncbi.nlm.nih.gov/pubmed/9144636?dopt=AbstractPlus), [2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\], [DCG‐IV](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1377) and [(2*R*,3*R*)‐APDC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1392)\[[1674](http://www.ncbi.nlm.nih.gov/pubmed/9076745?dopt=AbstractPlus)\], and antagonised by [eGlu](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1400)(4.3, \[[848](http://www.ncbi.nlm.nih.gov/pubmed/9121605?dopt=AbstractPlus)\] and [LY307452](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3350)\[[491](http://www.ncbi.nlm.nih.gov/pubmed/9871538?dopt=AbstractPlus), [2009](http://www.ncbi.nlm.nih.gov/pubmed/8632404?dopt=AbstractPlus)\]. Group‐III mGlu receptors may be activated by [L‐AP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410) and [(*R,S*)‐4‐PPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1406)\[[579](http://www.ncbi.nlm.nih.gov/pubmed/10336568?dopt=AbstractPlus)\].

In addition to orthosteric ligands that directly interact with the glutamate recognition site directly, allosteric modulators have been described. Negative allosteric modulators are listed separately. The positive allosteric modulators most often act as 'potentiators' of an orthosteric agonist response, without significantly activating the receptor in the absence of agonist.

Although mGlu receptors have been thought to only form homodimers, recent studies revealed the possible formation of heterodimers between either group‐I receptors, or within and between group‐II and ‐III receptors \[[441](http://www.ncbi.nlm.nih.gov/pubmed/20826542?dopt=AbstractPlus)\]. Although well characterized in transfected cells, co‐localization and specific pharmacological properties also suggest the existence of such heterodimers in the brain \[[2094](http://www.ncbi.nlm.nih.gov/pubmed/24381270?dopt=AbstractPlus)\].

The structure of the 7 transmembrane (TM) domains of both mGlu~1~ and mGlu~5~ have been solved, and confirm a general helical organization similar to that of other GPCRs, although the helices appear more compacted \[[438](http://www.ncbi.nlm.nih.gov/pubmed/25042998?dopt=AbstractPlus), [2048](http://www.ncbi.nlm.nih.gov/pubmed/24603153?dopt=AbstractPlus)\].

Nomenclature r[mGlu~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289)[mGlu~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=290)[mGlu~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=291)[mGlu~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292)HGNC, UniProt[*GRM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4593), [Q13255](http://www.uniprot.org/uniprot/Q13255)[*GRM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4594), [Q14416](http://www.uniprot.org/uniprot/Q14416)[*GRM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4595), [Q14832](http://www.uniprot.org/uniprot/Q14832)[*GRM4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4596), [Q14833](http://www.uniprot.org/uniprot/Q14833)Endogenous agonists----[NAAG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405) (Selective) (p*K* ~i~ 4.7) \[[1679](http://www.ncbi.nlm.nih.gov/pubmed/10884552?dopt=AbstractPlus)\]--Agonists------[L‐AP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410) (pEC~50~ 6.5) \[[2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\], [L‐serine‐O‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411) (pEC~50~ 5.9) \[[2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\]Selective agonists------[LSP4‐2022](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6706) (pEC~50~ 7) \[[631](http://www.ncbi.nlm.nih.gov/pubmed/22223752?dopt=AbstractPlus)\]Antagonists[LY367385](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1379) (pIC~50~ 5.1) \[349\]----[MAP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1414) (p*K* ~i~ 4.6) \[[686](http://www.ncbi.nlm.nih.gov/pubmed/10187777?dopt=AbstractPlus)\] -- RatSelective antagonists[3‐MATIDA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3396) (pIC~50~ 5.2) \[[1333](http://www.ncbi.nlm.nih.gov/pubmed/12015200?dopt=AbstractPlus)\] -- Rat, [(S)‐(+)‐CBPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421) (pIC~50~ 4.2) \[[1200](http://www.ncbi.nlm.nih.gov/pubmed/10428410?dopt=AbstractPlus)\] -- Rat, [(S)‐TBPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3419) (pIC~50~ 4.2) \[[367](http://www.ncbi.nlm.nih.gov/pubmed/11249114?dopt=AbstractPlus)\] -- Rat, [AIDA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1376) (pA~2~ 4.2) \[[1334](http://www.ncbi.nlm.nih.gov/pubmed/9152378?dopt=AbstractPlus)\][PCCG‐4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3335) (pIC~50~ 5.1) \[[1483](http://www.ncbi.nlm.nih.gov/pubmed/8667369?dopt=AbstractPlus)\] -- Rat----Allosteric modulators[YM298198](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1389) (Negative) (pIC~50~ 7.8) \[[979](http://www.ncbi.nlm.nih.gov/pubmed/15976016?dopt=AbstractPlus)\] -- Rat[CBiPES](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3372) (Positive) (pEC~50~ 7) \[[874](http://www.ncbi.nlm.nih.gov/pubmed/15717213?dopt=AbstractPlus)\], [4‐MPPTS](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1402) (Positive) (pIC~50~ 5.8) \[[94](http://www.ncbi.nlm.nih.gov/pubmed/15149652?dopt=AbstractPlus), [873](http://www.ncbi.nlm.nih.gov/pubmed/12852748?dopt=AbstractPlus), [874](http://www.ncbi.nlm.nih.gov/pubmed/15717213?dopt=AbstractPlus), [1660](http://www.ncbi.nlm.nih.gov/pubmed/14500736?dopt=AbstractPlus)\]--[SIB‐1893](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1432) (Positive) (pEC~50~ 6.3--6.8) \[[1217](http://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus)\], [MPEP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426) (Positive) (pEC~50~ 6.3--6.6) \[[1217](http://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus)\], [PHCCC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1416) (Positive) (pEC~50~ 4.5) \[[1184](http://www.ncbi.nlm.nih.gov/pubmed/14573382?dopt=AbstractPlus)\]Selective allosteric modulators[BAY 367620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1381) (Negative) (p*K* ~i~ 9.5) \[[267](http://www.ncbi.nlm.nih.gov/pubmed/11306677?dopt=AbstractPlus)\] -- Rat, [JNJ16259685](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1385) (Negative) (pIC~50~ 8.9) \[[1047](http://www.ncbi.nlm.nih.gov/pubmed/15555631?dopt=AbstractPlus)\], [A‐841720](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3953) (Negative) (pIC~50~ 8) \[[2126](http://www.ncbi.nlm.nih.gov/pubmed/16279797?dopt=AbstractPlus)\], [Ro67‐7476](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1388) (Positive) (p*K* ~i~ 7.5--7.9) \[[971](http://www.ncbi.nlm.nih.gov/pubmed/11606768?dopt=AbstractPlus)\] -- Rat, [3,5‐dimethyl PPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3397) (Negative) (pIC~50~ 7.8) \[[1271](http://www.ncbi.nlm.nih.gov/pubmed/12470711?dopt=AbstractPlus)\] -- Rat, [EM‐TBPC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3363) (Negative) (p*K* ~i~ 7.8) \[[1191](http://www.ncbi.nlm.nih.gov/pubmed/12509432?dopt=AbstractPlus)\] -- Rat, [Ro01‐6128](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1386) (Positive) (p*K* ~i~ 7.5--7.7) \[[971](http://www.ncbi.nlm.nih.gov/pubmed/11606768?dopt=AbstractPlus)\] -- Rat, [LY456236](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3346) (Negative) (pIC~50~ 6.9) \[1094\], [CPCCOEt](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1382) (Negative) (pIC~50~ 5.2--5.8) \[[1116](http://www.ncbi.nlm.nih.gov/pubmed/10051528?dopt=AbstractPlus)\], [Ro67‐4853](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1387) (Positive) (p*K* ~i~ 5.1) \[[971](http://www.ncbi.nlm.nih.gov/pubmed/11606768?dopt=AbstractPlus)\] -- Rat, [PHCCC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1416) (Positive)[Ro64‐5229](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3955) (Negative) (pIC~50~ 7) \[[985](http://www.ncbi.nlm.nih.gov/pubmed/10465539?dopt=AbstractPlus)\] -- Rat, [biphenylindanone A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3954) (Positive) (pEC~50~ 7) \[[183](http://www.ncbi.nlm.nih.gov/pubmed/16046122?dopt=AbstractPlus)\]--[VU0361737](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3956) (Positive) (pEC~50~ 6.6) \[[480](http://www.ncbi.nlm.nih.gov/pubmed/19469556?dopt=AbstractPlus)\], [VU0155041](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3323) (Positive) (pEC~50~ 6.1) \[[1402](http://www.ncbi.nlm.nih.gov/pubmed/18664603?dopt=AbstractPlus)\]Comments------pEC50 values for MPEP and SIB‐1893 were obtained in the presence of L‐AP4 \[[1217](http://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus)\].

Nomenclature[mGlu~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293)[mGlu~6~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294)[mGlu~7~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=295)[mGlu~8~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=296)HGNC, UniProt[*GRM5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4597), [P41594](http://www.uniprot.org/uniprot/P41594)[*GRM6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4598), [O15303](http://www.uniprot.org/uniprot/O15303)[*GRM7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4599), [Q14831](http://www.uniprot.org/uniprot/Q14831)[*GRM8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4600), [O00222](http://www.uniprot.org/uniprot/O00222)Endogenous agonists------[L‐serine‐O‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411) (pIC~50~ 6.2--7.2) \[[1192](http://www.ncbi.nlm.nih.gov/pubmed/10216218?dopt=AbstractPlus), [2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\]Agonists----[LSP4‐2022](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6706) (pEC~50~ 4.9) \[[631](http://www.ncbi.nlm.nih.gov/pubmed/22223752?dopt=AbstractPlus)\], [L‐serine‐O‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411) (pEC~50~ 4.5) \[[2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\], [L‐AP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410) (pEC~50~ 3.8) \[[2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\][(*S*)‐3,4‐DCPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1407) (pEC~50~ 7.5) \[[1876](http://www.ncbi.nlm.nih.gov/pubmed/11166323?dopt=AbstractPlus)\], [L‐AP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410) (pIC~50~ 7--7.2) \[[1192](http://www.ncbi.nlm.nih.gov/pubmed/10216218?dopt=AbstractPlus)\]Selective agonists[(S)‐(+)‐CBPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421) (Partial agonist) (pEC~50~ 4.3) \[[1200](http://www.ncbi.nlm.nih.gov/pubmed/10428410?dopt=AbstractPlus)\] -- Rat, [CHPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1417) (pIC~50~ 3.4) \[[1350](http://www.ncbi.nlm.nih.gov/pubmed/11080213?dopt=AbstractPlus)\][1‐benzyl‐APDC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1436) (pEC~50~ 4.7) \[1911\] -- Rat, [homo‐AMPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3359) (pEC~50~ 4.1) \[[237](http://www.ncbi.nlm.nih.gov/pubmed/8759641?dopt=AbstractPlus)\]----Antagonists--[MAP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1414) (pIC~50~ 3.5) \[[1504](http://www.ncbi.nlm.nih.gov/pubmed/12769621?dopt=AbstractPlus)\] -- Rat, [THPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3326) \[[1879](http://www.ncbi.nlm.nih.gov/pubmed/9144637?dopt=AbstractPlus)\] -- Unknown--[MPPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1415) (pIC~50~ 4.3) \[[2050](http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus)\]Selective antagonists[ACDPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3388) (pIC~50~ 6.9) \[[182](http://www.ncbi.nlm.nih.gov/pubmed/15686941?dopt=AbstractPlus)\]------Allosteric modulators[3,3\'‐difluorobenzaldazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1424) (Positive) (pIC~50~ 5.6--8.5) \[[1415](http://www.ncbi.nlm.nih.gov/pubmed/12920211?dopt=AbstractPlus), [1416](http://www.ncbi.nlm.nih.gov/pubmed/14747613?dopt=AbstractPlus)\], [alloswitch‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8543) (Negative) (pIC~50~ 8.1) \[[1511](http://www.ncbi.nlm.nih.gov/pubmed/25173999?dopt=AbstractPlus)\] -- Rat, [CDPPB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1422) (Positive) (pEC~50~ 7.6--8) \[[956](http://www.ncbi.nlm.nih.gov/pubmed/15608073?dopt=AbstractPlus), [1114](http://www.ncbi.nlm.nih.gov/pubmed/15537338?dopt=AbstractPlus)\], [MTEP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3336) (Negative) (p*K* ~i~ 7.8) \[[223](http://www.ncbi.nlm.nih.gov/pubmed/12473093?dopt=AbstractPlus)\], [MPEP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426) (Negative) (pIC~50~ 7.4--7.7) \[[578](http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus), [580](http://www.ncbi.nlm.nih.gov/pubmed/10530811?dopt=AbstractPlus)\], [fenobam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1434) (Negative) (pIC~50~ 7.2) \[[1519](http://www.ncbi.nlm.nih.gov/pubmed/16040814?dopt=AbstractPlus)\], [SIB‐1893](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1432) (Negative) (pIC~50~ 5.9--6.5) \[[578](http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus), [1949](http://www.ncbi.nlm.nih.gov/pubmed/10381773?dopt=AbstractPlus)\], [SIB‐1757](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1431) (Negative) (pIC~50~ 6--6.4) \[[578](http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus), [1949](http://www.ncbi.nlm.nih.gov/pubmed/10381773?dopt=AbstractPlus)\], [CPPHA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1423) (Positive) (pIC~50~ 6.3) \[[1416](http://www.ncbi.nlm.nih.gov/pubmed/14747613?dopt=AbstractPlus)\]--[MMPIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3341) (Negative) (pIC~50~ 6.1--7.6) \[[1401](http://www.ncbi.nlm.nih.gov/pubmed/20026717?dopt=AbstractPlus), [1827](http://www.ncbi.nlm.nih.gov/pubmed/17609420?dopt=AbstractPlus)\] -- Rat, [AMN082](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1441) (Positive) (pEC~50~ 6.5--6.8) \[[1293](http://www.ncbi.nlm.nih.gov/pubmed/16339898?dopt=AbstractPlus)\], [XAP044](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8545) (Negative) (pIC~50~ 5.6) \[[587](http://www.ncbi.nlm.nih.gov/pubmed/24596089?dopt=AbstractPlus)\]--Selective allosteric modulators[VU‐1545](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4059) (Positive) (pEC~50~ 8) \[[2142](http://www.ncbi.nlm.nih.gov/pubmed/16722652?dopt=AbstractPlus)\]------

Comments {#bph13348-sec-0178}
--------

The activity of [NAAG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405) as an agonist at mGlu~3~ receptors was questioned on the basis of contamination with glutamate \[[327](http://www.ncbi.nlm.nih.gov/pubmed/19389924?dopt=AbstractPlus), [547](http://www.ncbi.nlm.nih.gov/pubmed/19285517?dopt=AbstractPlus)\], but this has been refuted \[[1369](http://www.ncbi.nlm.nih.gov/pubmed/21740441?dopt=AbstractPlus)\].

Radioligand binding using a variety of radioligands has been conducted on recombinant receptors (for example, [\[^3^H\]R214127](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1391)\[[1046](http://www.ncbi.nlm.nih.gov/pubmed/12695537?dopt=AbstractPlus)\] and [\[^3^H\]YM298198](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5392)\[[979](http://www.ncbi.nlm.nih.gov/pubmed/15976016?dopt=AbstractPlus)\] at mGlu~1~ receptors and [\[^3^H\]M‐MPEP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1425)\[[578](http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus)\] and [\[^3^H\]methoxymethyl‐MTEP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5394)\[[47](http://www.ncbi.nlm.nih.gov/pubmed/12438526?dopt=AbstractPlus)\] at mGlu~5~ receptors. Although a number of radioligands have been used to examine binding in native tissues, correlation with individual subtypes is limited. Many pharmacological agents have not been fully tested across all known subtypes of mGlu receptors. Potential differences linked to the species (*e.g.* human *versus* rat or mouse) of the receptors and the receptor splice variants are generally not known. The influence of receptor expression level on pharmacology and selectivity has not been controlled for in most studies, particularly those involving functional assays of receptor coupling.

[(S)‐(+)‐CBPG](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421) is an antagonist at mGlu~1~, but is an agonist (albeit of reduced efficacy) at mGlu~5~ receptors. [DCG‐IV](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1377) also exhibits agonist activity at NMDA glutamate receptors \[[1931](http://www.ncbi.nlm.nih.gov/pubmed/9106476?dopt=AbstractPlus)\], and is an antagonist at all group‐III mGluRs with an IC~50~ of 30*μ*M. A potential novel metabotropic glutamate receptor coupled to phosphoinositide turnover has been observed in rat brain; it is activated by [4‐methylhomoibotenic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5449) (ineffective as an agonist at recombinant Group I metabotropic glutamate receptors), but resistant to [LY341495](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1378)\[[341](http://www.ncbi.nlm.nih.gov/pubmed/9353394?dopt=AbstractPlus)\]. There are also reports of a distinct metabotropic glutamate receptor coupled to phospholipase D in rat brain, which does not readily fit into the current classification \[[964](http://www.ncbi.nlm.nih.gov/pubmed/9175608?dopt=AbstractPlus), [1482](http://www.ncbi.nlm.nih.gov/pubmed/8799579?dopt=AbstractPlus)\]

A related class C receptor composed of two distinct subunits, T1R1 + T1R3 is also activated by glutamate and is responsible for umami taste detection.

All selective antagonists at metabotropic glutamate receptors are competitive.

Further Reading {#bph13348-sec-0179}
---------------
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[Motilin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=41) {#bph13348-sec-0180}
============================================================================================

Overview {#bph13348-sec-0181}
--------

Motilin receptors (**provisional nomenclature**) are activated by a 22 amino‐acid peptide derived from a precursor ([*MLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7141), [P12872](http://www.uniprot.org/uniprot/P12872)), which may also generate a [motilin‐associated peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5376) ([*MLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7141), [P12872](http://www.uniprot.org/uniprot/P12872)). These receptors are also suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics (often called motilides; *e.g.* erythromycin), although for many of these molecules the evidence is sparse.

Nomenclature[motilin receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297)HGNC, UniProt[*MLNR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4495), [O43193](http://www.uniprot.org/uniprot/O43193)Endogenous agonists[motilin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1458) ([*MLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7141), [P12872](http://www.uniprot.org/uniprot/P12872)) (p*K* ~i~ 8.4--8.7) \[[372](http://www.ncbi.nlm.nih.gov/pubmed/11461914?dopt=AbstractPlus), [1223](http://www.ncbi.nlm.nih.gov/pubmed/15677347?dopt=AbstractPlus), [1224](http://www.ncbi.nlm.nih.gov/pubmed/11781320?dopt=AbstractPlus), [1225](http://www.ncbi.nlm.nih.gov/pubmed/16531413?dopt=AbstractPlus)\]Agonists[alemcinal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1444) (pIC~50~ 7.2) \[[1872](http://www.ncbi.nlm.nih.gov/pubmed/15764739?dopt=AbstractPlus)\], [erythromycin‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1456) (pIC~50~ 5.5--6.5) \[[507](http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus), [1872](http://www.ncbi.nlm.nih.gov/pubmed/15764739?dopt=AbstractPlus)\], [azithromycin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6510) (pEC~50~ 5.5) \[[220](http://www.ncbi.nlm.nih.gov/pubmed/23190027?dopt=AbstractPlus)\]Selective agonists[camicinal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4035) (pEC~50~ 7.9) \[[99](http://www.ncbi.nlm.nih.gov/pubmed/25341626?dopt=AbstractPlus), [1639](http://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus)\], [mitemcinal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3511) (pEC~50~ 7.5--7.8) \[977, [1845](http://www.ncbi.nlm.nih.gov/pubmed/17183187?dopt=AbstractPlus)\] -- RabbitSelective antagonists[MA‐2029](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4036) (pA~2~ 9.2) \[[1811](http://www.ncbi.nlm.nih.gov/pubmed/18164286?dopt=AbstractPlus)\], [GM‐109](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1466) (pIC~50~ 8) \[[701](http://www.ncbi.nlm.nih.gov/pubmed/11806718?dopt=AbstractPlus)\] -- PigLabelled ligands[\[^125^I\]motilin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3794) (Agonist) (p*K* ~d~ 10) \[[507](http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0182}
--------

In laboratory rodents, the gene encoding the motilin percursor appears to be absent, while the receptor appears to be a pseudogene \[[725](http://www.ncbi.nlm.nih.gov/pubmed/19696113?dopt=AbstractPlus), [1637](http://www.ncbi.nlm.nih.gov/pubmed/21531468?dopt=AbstractPlus)\]. Functions of [motilin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1458)([*MLN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7141), [P12872](http://www.uniprot.org/uniprot/P12872)) are not usually detected in rodents, although brain and other responses to motilin and the macrolide [alemcinal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1444) have been reported and the mechanism of these actions are obscure \[[1249](http://www.ncbi.nlm.nih.gov/pubmed/9441746?dopt=AbstractPlus), [1396](http://www.ncbi.nlm.nih.gov/pubmed/10092986?dopt=AbstractPlus)\]. Marked differences in ligand affinities for the motilin receptor in dogs and humans may be explained by significant differences in receptor structure \[[1638](http://www.ncbi.nlm.nih.gov/pubmed/23189978?dopt=AbstractPlus)\]. Note that for the complex macrolide structures, selectivity of action has often not been rigorously examined and other actions are possible (*e.g.* P2X inhibition by erythromycin; \[[2123](http://www.ncbi.nlm.nih.gov/pubmed/10749750?dopt=AbstractPlus)\]). Small molecule motilin receptor agonists are now described \[[1093](http://www.ncbi.nlm.nih.gov/pubmed/15027861?dopt=AbstractPlus), [1639](http://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus), [2013](http://www.ncbi.nlm.nih.gov/pubmed/21544957?dopt=AbstractPlus)\]. The motilin receptor does not appear to have constitutive activity \[[774](http://www.ncbi.nlm.nih.gov/pubmed/12907757?dopt=AbstractPlus)\]. Although not proven, the existence of biased agonism at the receptor has been suggested \[[1225](http://www.ncbi.nlm.nih.gov/pubmed/16531413?dopt=AbstractPlus), [1292](http://www.ncbi.nlm.nih.gov/pubmed/17074305?dopt=AbstractPlus), [1636](http://www.ncbi.nlm.nih.gov/pubmed/24438586?dopt=AbstractPlus)\]. A truncated 5‐transmembrane structure has been identified but this is without activity when transfected into a host cell \[[507](http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0183}
---------------

De Smet B *et al*. (2009) Motilin and ghrelin as prokinetic drug targets. *Pharmacol. Ther.* **123**: 207‐23 [\[PMID:19427331\]](http://www.ncbi.nlm.nih.gov/pubmed/19427331?dopt=AbstractPlus)

Foord SM *et al*. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. *Pharmacol Rev* **57**: 279‐288 [\[PMID:15914470\]](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)

Sanger GJ *et al*. (2012) Motilin: Toward a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. *Br. J. Pharmacol.* [\[PMID:23189978\]](http://www.ncbi.nlm.nih.gov/pubmed/23189978?dopt=AbstractPlus)

Takeshita E *et al*. (2006) Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. *J Gastroenterol* **41**: 223‐230 [\[PMID:16699856\]](http://www.ncbi.nlm.nih.gov/pubmed/16699856?dopt=AbstractPlus)

[Neuromedin U receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=42) {#bph13348-sec-0184}
==================================================================================================

Overview {#bph13348-sec-0185}
--------

Neuromedin U receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous 25 amino acid peptide neuromedin U ([neuromedin U‐25](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1470) ([*NMU*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7859), [P48645](http://www.uniprot.org/uniprot/P48645)), NmU‐25), a peptide originally isolated from pig spinal cord \[[1287](http://www.ncbi.nlm.nih.gov/pubmed/3839674?dopt=AbstractPlus)\]. In humans, NmU‐25 appears to be the sole product of a precursor gene ([*NMU*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7859), [P48645](http://www.uniprot.org/uniprot/P48645)) showing a broad tissue distribution, but which is expressed at highest levels in the upper gastrointestinal tract, CNS, bone marrow and fetal liver. Much shorter versions of NmU are found in some species, but not in human, and are derived at least in some instances from the proteolytic cleavage of the longer NmU. Despite species differences in NmU structure, the C‐terminal region (particularly the C‐terminal pentapeptide) is highly conserved and contains biological activity. Neuromedin S ([neuromedin S‐33](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1468) ([*NMS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32203), [Q5H8A3](http://www.uniprot.org/uniprot/Q5H8A3))) has also been identified as an endogenous agonist \[[1326](http://www.ncbi.nlm.nih.gov/pubmed/15635449?dopt=AbstractPlus)\]. NmS‐33 is, as its name suggests, a 33 amino‐acid product of a precursor protein derived from a single gene and contains an amidated C‐terminal heptapeptide identical to NmU. NmS‐33 appears to activate NMU receptors with equivalent potency to NmU‐25.

Nomenclature[NMU1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=298)[NMU2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=299)HGNC, UniProt[*NMUR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4518), [Q9HB89](http://www.uniprot.org/uniprot/Q9HB89)[*NMUR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16454), [Q9GZQ4](http://www.uniprot.org/uniprot/Q9GZQ4)Antagonists--[R‐PSOP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3524) (p*K* ~B~ 7) \[[1128](http://www.ncbi.nlm.nih.gov/pubmed/19369576?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0186}
--------

NMU1 and NMU2 couple predominantly to G~q/11~ although there is evidence of good coupling to G~i/o~\[[213](http://www.ncbi.nlm.nih.gov/pubmed/15331768?dopt=AbstractPlus), [786](http://www.ncbi.nlm.nih.gov/pubmed/10887190?dopt=AbstractPlus), [794](http://www.ncbi.nlm.nih.gov/pubmed/17652154?dopt=AbstractPlus)\]. NMU1 and NMU2 can be labelled with \[^125^I\]‐NmU and \[^125^I\]‐NmS (of various species, *e.g.* \[[1259](http://www.ncbi.nlm.nih.gov/pubmed/18358099?dopt=AbstractPlus)\]), [BODIPY^®;^ TMR‐NMU](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3858) or [Cy3B‐NMU‐8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3863)\[[213](http://www.ncbi.nlm.nih.gov/pubmed/15331768?dopt=AbstractPlus)\]. A range of radiolabelled (^125^I‐), fluorescently labelled (*e.g.* Cy3, Cy5, rhodamine and FAM) and [biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787) labelled versions of [neuromedin U‐25](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1470)([*NMU*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7859), [P48645](http://www.uniprot.org/uniprot/P48645)) and [neuromedin S‐33](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1468) ([*NMS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32203), [Q5H8A3](http://www.uniprot.org/uniprot/Q5H8A3)) are now commercially available.

Further Reading {#bph13348-sec-0187}
---------------

Brighton PJ *et al*. (2004) Neuromedin U and its receptors: structure, function, and physiological roles. *Pharmacol. Rev.* **56**: 231‐48 [\[PMID:15169928\]](http://www.ncbi.nlm.nih.gov/pubmed/15169928?dopt=AbstractPlus)

Budhiraja S *et al*. (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. *Fundam Clin Pharmacol* **23**: 149‐57 [\[PMID:19645813\]](http://www.ncbi.nlm.nih.gov/pubmed/19645813?dopt=AbstractPlus)

Foord SM *et al*. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. *Pharmacol Rev* **57**: 279‐288 [\[PMID:15914470\]](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)

Mitchell JD *et al*. (2009) Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. *Br. J. Pharmacol.* **158**: 87‐103 [\[PMID:19519756\]](http://www.ncbi.nlm.nih.gov/pubmed/19519756?dopt=AbstractPlus)

Novak CM. (2009) Neuromedin S and U. *Endocrinology* **150**: 2985‐7 [\[PMID:19549882\]](http://www.ncbi.nlm.nih.gov/pubmed/19549882?dopt=AbstractPlus)

[Neuropeptide FF/neuropeptide AF receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=43) {#bph13348-sec-0188}
=====================================================================================================================

Overview {#bph13348-sec-0189}
--------

The Neuropeptide FF receptor family contains two subtypes, NPFF1 and NPFF2 (**provisional nomenclature \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**), which exhibit high affinities for neuropeptide FF ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) and RFamide related peptides (RFRP: precursor gene symbol [NPVF](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)). NPFF1 is broadly distributed in the central nervous system with the highest levels found in the limbic system and the hypothalamus. NPFF2 is present in high density in the superficial layers of the mammalian spinal cord where it is involved in nociception and modulation of opioid functions.

Nomenclature[NPFF1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=300)[NPFF2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=301)HGNC, UniProt[*NPFFR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17425), [Q9GZQ6](http://www.uniprot.org/uniprot/Q9GZQ6)[*NPFFR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4525), [Q9Y5X5](http://www.uniprot.org/uniprot/Q9Y5X5)Rank order of potency[RFRP‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5340) ([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)) \>[RFRP‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016) ([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)) \> FMRF[neuropeptide FF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) \>[neuropeptide AF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3735) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) \>[neuropeptide SF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)), [QRFP43](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665) ([*QRFP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982), [P83859](http://www.uniprot.org/uniprot/P83859)), [PrRP‐31](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) \[[628](http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus)\][neuropeptide AF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3735) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)), [neuropeptide FF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) \>[PrRP‐31](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) \> FMRF, [QRFP43](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665) ([*QRFP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982), [P83859](http://www.uniprot.org/uniprot/P83859)) \>[neuropeptide SF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) \[[628](http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus)\]Endogenous agonists[neuropeptide FF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) (Selective) (p*K* ~i~ 8.5--9.9) \[[628](http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus), [629](http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus), [1306](http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus)\], [RFRP‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016) ([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)) (Selective) (p*K* ~i~ 9.2--9.3) \[[629](http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus), [630](http://www.ncbi.nlm.nih.gov/pubmed/17337079?dopt=AbstractPlus), [1306](http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus)\][neuropeptide FF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479) ([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)) (Selective) (p*K* ~i~ 9.7) \[[629](http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus), [1305](http://www.ncbi.nlm.nih.gov/pubmed/11325787?dopt=AbstractPlus)\]Selective agonists--[dNPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1489) (p*K* ~i~ 10.6) \[[1607](http://www.ncbi.nlm.nih.gov/pubmed/16129413?dopt=AbstractPlus)\], [AC263093](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4020) (pEC~50~ 5.2--5.9) \[[1036](http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus)\]Antagonists[RF9](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1486) (p*K* ~i~ 7.2) \[[1745](http://www.ncbi.nlm.nih.gov/pubmed/16407169?dopt=AbstractPlus)\]--Selective antagonists[AC262620](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4017) (p*K* ~i~ 7.7--8.1) \[[1036](http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus)\], [AC262970](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4018) (p*K* ~i~ 7.4--8.1) \[[1036](http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]Y‐RFRP‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1484) (Agonist) (p*K* ~d~ 9.7) \[[629](http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus)\], [\[^3^H\]NPVF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4019) (Agonist) (p*K* ~d~ 8.6) \[[1855](http://www.ncbi.nlm.nih.gov/pubmed/19682524?dopt=AbstractPlus)\], [\[^125^I\]NPFF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3797) (Agonist) \[[628](http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus)\][\[^125^I\]EYF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1488) (Agonist) (p*K* ~d~ 10.2) \[[1306](http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus)\], [\[^3^H\]EYF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4021) (Agonist) (p*K* ~d~ 9.3) \[[1855](http://www.ncbi.nlm.nih.gov/pubmed/19682524?dopt=AbstractPlus)\], [\[^125^I\]NPFF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3797) (Agonist) \[[628](http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0190}
--------

An orphan receptor [*GPR83*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4523)([Q9NYM4](http://www.uniprot.org/uniprot/Q9NYM4)) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist [RF9](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1486) is selective for NPFF receptors, but does not distinguish between the NPFF1 and NPFF2 subtypes (p*K* ~i~ 7.1 and 7.2, respectively, \[[1745](http://www.ncbi.nlm.nih.gov/pubmed/16407169?dopt=AbstractPlus)\]).

Further Reading {#bph13348-sec-0191}
---------------

Moulédous L *et al*. (2010) Opioid‐modulating properties of the neuropeptide FF system. *Biofactors* **36**: 423‐9 [\[PMID:20803521\]](http://www.ncbi.nlm.nih.gov/pubmed/20803521?dopt=AbstractPlus)

Vyas N *et al*. (2006) Structure‐activity relationships of neuropeptide FF and related peptidic and non‐peptidic derivatives. *Peptides* **27**: 990‐6 [\[PMID:16490282\]](http://www.ncbi.nlm.nih.gov/pubmed/16490282?dopt=AbstractPlus)

Yang HY *et al*. (2008) Modulatory role of neuropeptide FF system in nociception and opiate analgesia. *Neuropeptides* **42**: 1‐18 [\[PMID:17854890\]](http://www.ncbi.nlm.nih.gov/pubmed/17854890?dopt=AbstractPlus)

[Neuropeptide S receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=44) {#bph13348-sec-0192}
===================================================================================================

Overview {#bph13348-sec-0193}
--------

The neuropeptide S receptor (NPS, **provisional nomenclature \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) responds to the 20 amino‐acid peptide neuropeptide S derived from the precursor ([*NPS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=33940), [P0C0P6](http://www.uniprot.org/uniprot/P0C0P6)).

Nomenclature[NPS receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=302)HGNC, UniProt[*NPSR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23631), [Q6W5P4](http://www.uniprot.org/uniprot/Q6W5P4)Endogenous agonists[neuropeptide S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1490) ([*NPS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=33940), [P0C0P6](http://www.uniprot.org/uniprot/P0C0P6)) (pEC~50~ 8) \[[2070](http://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]Tyr^10^NPS (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1493) (Agonist) (p*K* ~d~ 9.5) \[[2070](http://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0194}
--------

Polymorphisms in the NPS receptor have been suggested to be associated with asthma \[[1953](http://www.ncbi.nlm.nih.gov/pubmed/15947423?dopt=AbstractPlus)\] and irritable bowel syndrome \[[386](http://www.ncbi.nlm.nih.gov/pubmed/17854592?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0195}
---------------

Cannella N *et al*. (2013) The role of the neuropeptide S system in addiction: focus on its interaction with the CRF and hypocretin/orexin neurotransmission. *Prog. Neurobiol.* **100**: 48‐59 [\[PMID:23041581\]](http://www.ncbi.nlm.nih.gov/pubmed/23041581?dopt=AbstractPlus)

Dal Ben D *et al*. (2011) Neuropeptide S receptor: recent updates on nonpeptide antagonist discovery. *ChemMedChem* **6**: 1163‐71 [\[PMID:21452188\]](http://www.ncbi.nlm.nih.gov/pubmed/21452188?dopt=AbstractPlus)

Foord SM *et al*. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. *Pharmacol Rev* **57**: 279‐288 [\[PMID:15914470\]](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)

Guerrini R *et al*. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. *Med Res Rev* **30**: 751‐77 [\[PMID:19824051\]](http://www.ncbi.nlm.nih.gov/pubmed/19824051?dopt=AbstractPlus)

Pape HC *et al*. (2010) Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. *Neuropharmacology* **58**: 29‐34 [\[PMID:19523478\]](http://www.ncbi.nlm.nih.gov/pubmed/19523478?dopt=AbstractPlus)

Reinscheid RK. (2008) Neuropeptide S: anatomy, pharmacology, genetics and physiological functions. *Results Probl Cell Differ* **46**: 145‐58 [\[PMID:18204825\]](http://www.ncbi.nlm.nih.gov/pubmed/18204825?dopt=AbstractPlus)

[Neuropeptide W/neuropeptide B receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=45) {#bph13348-sec-0196}
===================================================================================================================

Overview {#bph13348-sec-0197}
--------

The neuropeptide BW receptor 1 (NPBW1, **provisional nomenclature \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) is activated by two 23‐amino‐acid peptides, neuropeptide W ([neuropeptide W‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495) ([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729))) and neuropeptide B ([neuropeptide B‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41))) \[[554](http://www.ncbi.nlm.nih.gov/pubmed/12118011?dopt=AbstractPlus), [1725](http://www.ncbi.nlm.nih.gov/pubmed/12130646?dopt=AbstractPlus)\]. C‐terminally extended forms of the peptides ([neuropeptide W‐30](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496)([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729)) and [neuropeptide B‐29](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41))) also activate NPBW1 \[[211](http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus)\]. Unique to both forms of neuropeptide B is the N‐terminal bromination of the first tryptophan residue, and it is from this post‐translational modification that the nomenclature NPB is derived. These peptides were first identified from bovine hypothalamus and therefore are classed as neuropeptides. Endogenous variants of the peptides without the N‐terminal bromination, [des‐Br‐neuropeptide B‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1499)([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)) and [des‐Br‐neuropeptide B‐29](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1500) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)), were not found to be major components of bovine hypothalamic tissue extracts. The NPBW2 receptor is activated by the short and C‐terminal extended forms of neuropeptide W and neuropeptide B \[[211](http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus)\].

Nomenclature[NPBW1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=303)[NPBW2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=304)HGNC, UniProt[*NPBWR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4522), [P48145](http://www.uniprot.org/uniprot/P48145)[*NPBWR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4530), [P48146](http://www.uniprot.org/uniprot/P48146)Rank order of potency[neuropeptide B‐29](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)) \>[neuropeptide B‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)) \>[neuropeptide W‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495) ([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729)) \>[neuropeptide W‐30](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496) ([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729)) \[[211](http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus)\][neuropeptide W‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495) ([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729)) \>[neuropeptide W‐30](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496) ([*NPW*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30509), [Q8N729](http://www.uniprot.org/uniprot/Q8N729)) \>[neuropeptide B‐29](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)) \>[neuropeptide B‐23](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501) ([*NPB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30099), [Q8NG41](http://www.uniprot.org/uniprot/Q8NG41)) \[[211](http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus)\]Selective agonists[Ava3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3855) (p*K* ~i~ 9.4--9.4) \[[902](http://www.ncbi.nlm.nih.gov/pubmed/17486669?dopt=AbstractPlus)\], [Ava5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3856) (p*K* ~i~ 8.8--9) \[[902](http://www.ncbi.nlm.nih.gov/pubmed/17486669?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]NPW‐23 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1497) (Agonist) (p*K* ~d~ 9.4) \[[1747](http://www.ncbi.nlm.nih.gov/pubmed/15261118?dopt=AbstractPlus)\][\[^125^I\]NPW‐23 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1497) (Agonist) (p*K* ~d~ 7.7) \[[1725](http://www.ncbi.nlm.nih.gov/pubmed/12130646?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0198}
--------

Potency measurements were conducted with heterologously‐expressed receptors with a range of 0.14‐0.57 nM (NPBW1) and 0.98‐21 nM (NPBW2).

NPBW1^‐/‐^ mice show changes in social behavior, suggesting that the NPBW1 pathway may have an important role in the emotional responses of social interaction \[[1355](http://www.ncbi.nlm.nih.gov/pubmed/21390312?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0199}
---------------

Date Y *et al*. (2010) Neuropeptide W: an anorectic peptide regulated by leptin and metabolic state. *Endocrinology* **151**: 2200‐10 [\[PMID:20189998\]](http://www.ncbi.nlm.nih.gov/pubmed/20189998?dopt=AbstractPlus)

Hondo M *et al*. (2008) The NPB/NPW neuropeptide system and its role in regulating energy homeostasis, pain, and emotion. *Results Probl Cell Differ* **46**: 239‐56 [\[PMID:18204824\]](http://www.ncbi.nlm.nih.gov/pubmed/18204824?dopt=AbstractPlus)

Sakurai T. (2013) NPBWR1 and NPBWR2: Implications in Energy Homeostasis, Pain, and Emotion. *Front Endocrinol (Lausanne)* **4**: 23 [\[PMID:23515889\]](http://www.ncbi.nlm.nih.gov/pubmed/23515889?dopt=AbstractPlus)

Singh G *et al*. (2006) Neuropeptide B and W: neurotransmitters in an emerging G‐protein‐coupled receptor system. *Br. J. Pharmacol.* **148**: 1033‐41 [\[PMID:16847439\]](http://www.ncbi.nlm.nih.gov/pubmed/16847439?dopt=AbstractPlus)

[Neuropeptide Y receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=46) {#bph13348-sec-0200}
====================================================================================================

Overview {#bph13348-sec-0201}
--------

Neuropeptide Y (NPY) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Neuropeptide Y Receptors \[** [**1270**](http://www.ncbi.nlm.nih.gov/pubmed/9549761?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides [neuropeptide Y](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504) ([*NPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7955), [P01303](http://www.uniprot.org/uniprot/P01303)), neuropeptide Y‐(3‐36), [peptide YY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514)([*PYY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9748), [P10082](http://www.uniprot.org/uniprot/P10082)), PYY‐(3‐36) and [pancreatic polypeptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1512) ([*PPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9327), [P01298](http://www.uniprot.org/uniprot/P01298)) (PP). The receptor originally identified as the Y3 receptor has been identified as the [CXCR4 chemokine recepter](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71) (originally named LESTR, \[[1135](http://www.ncbi.nlm.nih.gov/pubmed/8276799?dopt=AbstractPlus)\]). The y6 receptor is a functional gene product in mouse, absent in rat, but contains a frame‐shift mutation in primates producing a truncated non‐functional gene \[[642](http://www.ncbi.nlm.nih.gov/pubmed/8641440?dopt=AbstractPlus)\]. Many of the agonists exhibit differing degrees of selectivity dependent on the species examined. For example, the potency of PP is greater at the rat Y~4~receptor than at the human receptor \[[485](http://www.ncbi.nlm.nih.gov/pubmed/9802391?dopt=AbstractPlus)\]. In addition, many agonists lack selectivity for individual subtypes, but can exhibit comparable potency against pairs of NPY receptor subtypes, or have not been examined for activity at all subtypes. \[^125^I\]‐PYY or \[^125^I\]‐NPY can be used to label Y~1~, Y~2~, Y~5~ and y~6~ subtypes non‐selectively, while [\[^125^I\]\[cPP(1‐7), NPY(19‐23), Ala^31^, Aib^32^, Gln^34^\]hPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3921) may be used to label Y~5~ receptors preferentially (note that cPP denotes chicken peptide sequence and hPP is the human sequence).

Nomenclature[Y~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=305)[Y~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306)[Y~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=307)[Y~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=308)[y~6~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=683)HGNC, UniProt[*NPY1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7956), [P25929](http://www.uniprot.org/uniprot/P25929)[*NPY2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7957), [P49146](http://www.uniprot.org/uniprot/P49146)[*NPY4R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9329), [P50391](http://www.uniprot.org/uniprot/P50391)[*NPY5R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7958), [Q15761](http://www.uniprot.org/uniprot/Q15761)[*NPY6R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7959), [Q99463](http://www.uniprot.org/uniprot/Q99463)Rank order of potencyneuropeptide Y \> peptide YY ≫ pancreatic polypeptideneuropeptide Y \> peptide YY ≫ pancreatic polypeptidepancreatic polypeptide \> neuropeptide Y = peptide YYneuropeptide Y \> peptide YY \> pancreatic polypeptideneuropeptide Y = peptide YY \> pancreatic polypeptideEndogenous agonists[neuropeptide Y](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504) ([*NPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7955), [P01303](http://www.uniprot.org/uniprot/P01303)), [peptide YY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514) ([*PYY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9748), [P10082](http://www.uniprot.org/uniprot/P10082))[PYY‐(3‐36)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1517) ([*PYY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9748), [P10082](http://www.uniprot.org/uniprot/P10082)) (p*K* ~i~ 9.2--9.7) \[[588](http://www.ncbi.nlm.nih.gov/pubmed/8632753?dopt=AbstractPlus), [599](http://www.ncbi.nlm.nih.gov/pubmed/7592910?dopt=AbstractPlus)\], [neuropeptide Y](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504) ([*NPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7955), [P01303](http://www.uniprot.org/uniprot/P01303)), [neuropeptide Y‐(3‐36)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3627) ([*NPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7955), [P01303](http://www.uniprot.org/uniprot/P01303)), [peptide YY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514) ([*PYY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9748), [P10082](http://www.uniprot.org/uniprot/P10082))[pancreatic polypeptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1512) ([*PPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9327), [P01298](http://www.uniprot.org/uniprot/P01298)) (p*K* ~i~ 8.7--10.9) \[[92](http://www.ncbi.nlm.nih.gov/pubmed/7592911?dopt=AbstractPlus), [1152](http://www.ncbi.nlm.nih.gov/pubmed/7493937?dopt=AbstractPlus), [1899](http://www.ncbi.nlm.nih.gov/pubmed/16807358?dopt=AbstractPlus), [2076](http://www.ncbi.nlm.nih.gov/pubmed/8643460?dopt=AbstractPlus)\]----Selective agonists[\[Leu^31^,Pro^34^\]NPY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1545) (pEC~50~ 7.1) \[[378](http://www.ncbi.nlm.nih.gov/pubmed/8590988?dopt=AbstractPlus)\], [\[Leu^31^,Pro^34^\]PYY (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1527), [\[Pro^34^\]NPY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3848), [\[Pro^34^\]PYY (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1546)----[\[Ala^31^,Aib^32^\]NPY (pig)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1522) (pIC~50~ 8.2) \[[254](http://www.ncbi.nlm.nih.gov/pubmed/12069595?dopt=AbstractPlus)\]--Selective antagonists[BIBO3304](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1528) (pIC~50~ 9.5) \[[2020](http://www.ncbi.nlm.nih.gov/pubmed/9806339?dopt=AbstractPlus)\], [BIBP3226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1485) (p*K* ~i~ 8.1--9.3) \[[436](http://www.ncbi.nlm.nih.gov/pubmed/7562541?dopt=AbstractPlus), [2021](http://www.ncbi.nlm.nih.gov/pubmed/7562543?dopt=AbstractPlus)\][BIIE0246](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1547) (pIC~50~ 8.5) \[[434](http://www.ncbi.nlm.nih.gov/pubmed/10611450?dopt=AbstractPlus)\], [JNJ‐5207787](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3504) (pIC~50~ 6.9--7.1) \[[178](http://www.ncbi.nlm.nih.gov/pubmed/14617685?dopt=AbstractPlus)\]--[L‐152,804](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1565) (p*K* ~i~ 7.6) \[[901](http://www.ncbi.nlm.nih.gov/pubmed/10872822?dopt=AbstractPlus)\]--Labelled ligands[\[^3^H\]BIBP3226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3474) (Antagonist) (p*K* ~d~ 8.7), [\[^125^I\]\[Leu^31^,Pro^34^\]NPY](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3762) (Agonist)[\[^125^I\]PYY‐(3‐36) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3802) (Agonist)[\[^125^I\]PP (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3800) (Agonist)[\[^125^I\]\[cPP(1‐7), NPY(19‐23), Ala^31^, Aib^32^, Gln^34^\]hPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3921) (Agonist) (p*K* ~d~ 9.2--9.3) \[[453](http://www.ncbi.nlm.nih.gov/pubmed/15337369?dopt=AbstractPlus)\] -- Rat--CommentsNote that Pro^34^‐containing NPY and PYY can also bind Y~4~ and Y~5~ receptors, so strictly speaking are not selective, but are the \'preferred\' agonists.------The y~6~ receptor is a pseudogene in humans, but is functional in mouse, rabbit and some other mammals.

Comments {#bph13348-sec-0202}
--------

The Y~1~ agonists indicated are selective relative to Y~2~ receptors. [BIBP3226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1485) is selective relative to Y~2~, Y~4~ and Y~5~ receptors \[[598](http://www.ncbi.nlm.nih.gov/pubmed/8700207?dopt=AbstractPlus)\]. [NPY‐(13‐36)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3903) is Y~2~ selective relative to Y~1~ and Y~5~ receptors. PYY‐(3‐36) is Y~2~ selective relative to Y~1~ receptors.

Further Reading {#bph13348-sec-0203}
---------------

Bowers ME *et al*. (2012) Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. *Physiol. Behav.* **107**: 699‐710 [\[PMID:22429904\]](http://www.ncbi.nlm.nih.gov/pubmed/22429904?dopt=AbstractPlus)

Decressac M *et al*. (2012) Neuropeptide Y and its role in CNS disease and repair. *Exp. Neurol.* **238**: 265‐72 [\[PMID:23022456\]](http://www.ncbi.nlm.nih.gov/pubmed/23022456?dopt=AbstractPlus)

Michel MC *et al*. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. *Pharmacol. Rev.* **50**: 143‐150 [\[PMID:9549761\]](http://www.ncbi.nlm.nih.gov/pubmed/9549761?dopt=AbstractPlus)

Morales‐Medina JC *et al*. (2010) A possible role of neuropeptide Y in depression and stress. *Brain Res.* **1314**: 194‐205 [\[PMID:19782662\]](http://www.ncbi.nlm.nih.gov/pubmed/19782662?dopt=AbstractPlus)

Zengin A *et al*. (2010) Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. *Trends Endocrinol. Metab.* **21**: 411‐8 [\[PMID:20202858\]](http://www.ncbi.nlm.nih.gov/pubmed/20202858?dopt=AbstractPlus)

Zhang L *et al*. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. *Pharmacol. Ther.* **131**: 91‐113 [\[PMID:21439311\]](http://www.ncbi.nlm.nih.gov/pubmed/21439311?dopt=AbstractPlus)

[Neurotensin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=47) {#bph13348-sec-0204}
=================================================================================================

Overview {#bph13348-sec-0205}
--------

Neurotensin receptors (**nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous tridecapeptide neurotensin (pGlu‐Leu‐Tyr‐Glu‐Asn‐Lys‐Pro‐Arg‐Arg‐Pro‐Tyr‐Ile‐Leu) derived from a precursor ([*NTS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8038), [30990](http://www.uniprot.org/uniprot/30990)), which also generates neuromedin N, an agonist at the NTS~2~ receptor. A nonpeptide antagonist, [SR142948A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1580), shows high affinity (pK~i~\~9) at both NTS~1~ and NTS~2~ receptors \[[664](http://www.ncbi.nlm.nih.gov/pubmed/9023294?dopt=AbstractPlus)\]. [\[^3^H\]neurotensin (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3830) and [\[^125^I\]neurotensin (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1574) may be used to label NTS~1~ and NTS~2~ receptors at 0.1‐0.3 and 3‐5 nM concentrations respectively.

Nomenclature[NTS~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309)[NTS~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=310)HGNC, UniProt[*NTSR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8039), [P30989](http://www.uniprot.org/uniprot/P30989)[*NTSR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8040), [O95665](http://www.uniprot.org/uniprot/O95665)Rank order of potency[neurotensin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579) ([*NTS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8038), [P30990](http://www.uniprot.org/uniprot/P30990)) \>[neuromedin N](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1578) {Mouse, Rat} \[[741](http://www.ncbi.nlm.nih.gov/pubmed/9283723?dopt=AbstractPlus)\][neurotensin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579) ([*NTS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8038), [P30990](http://www.uniprot.org/uniprot/P30990)) = [neuromedin N](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1578) {Mouse, Rat} \[[1235](http://www.ncbi.nlm.nih.gov/pubmed/8795617?dopt=AbstractPlus)\]Selective agonists[JMV449](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1570) (p*K* ~i~ 10) \[[1753](http://www.ncbi.nlm.nih.gov/pubmed/12869647?dopt=AbstractPlus)\] -- Rat[levocabastine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1586) (p*K* ~i~ 6.8) \[[1235](http://www.ncbi.nlm.nih.gov/pubmed/8795617?dopt=AbstractPlus), [1583](http://www.ncbi.nlm.nih.gov/pubmed/11723247?dopt=AbstractPlus)\]Antagonists[meclinertant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582) (pIC~50~ 7.5--8.2) \[[664](http://www.ncbi.nlm.nih.gov/pubmed/9023294?dopt=AbstractPlus)\]--Labelled ligands[\[^3^H\]meclinertant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1583) (Antagonist) (p*K* ~d~ 8.5) \[[1030](http://www.ncbi.nlm.nih.gov/pubmed/7746272?dopt=AbstractPlus)\] -- Rat--Comments--A splice variant of the NTS~2~ receptor bearing 5 transmembrane domains has been identified in mouse \[[191](http://www.ncbi.nlm.nih.gov/pubmed/9001400?dopt=AbstractPlus)\] and later in rat \[[1492](http://www.ncbi.nlm.nih.gov/pubmed/15637074?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0206}
--------

[neurotensin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579)([*NTS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8038), [P30990](http://www.uniprot.org/uniprot/P30990)) appears to be a low‐efficacy agonist at the NTS~2~ receptor \[[1959](http://www.ncbi.nlm.nih.gov/pubmed/9851594?dopt=AbstractPlus)\], while the NTS~1~ receptor antagonist [meclinertant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582) is an agonist at NTS~2~ receptors \[[1959](http://www.ncbi.nlm.nih.gov/pubmed/9851594?dopt=AbstractPlus)\]. An additional protein, provisionally termed NTS~3~ (also known as NTR3, gp95 and sortilin; [ENSG00000134243](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134243;r=1:109852192-109940573)), has been suggested to bind lipoprotein lipase and mediate its degradation \[[1395](http://www.ncbi.nlm.nih.gov/pubmed/10085125?dopt=AbstractPlus)\]. It has been reported to interact with the NTS~1~ receptor \[[1211](http://www.ncbi.nlm.nih.gov/pubmed/12360476?dopt=AbstractPlus)\] and has been implicated in hormone trafficking and/or neurotensin uptake.

Further Reading {#bph13348-sec-0207}
---------------
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[Opioid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=50) {#bph13348-sec-0208}
============================================================================================

Overview {#bph13348-sec-0209}
--------

Opioid and opioid‐like receptors are activated by a variety of endogenous peptides including [\[Met\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614)([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)) (met), [\[Leu\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613)([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)) (leu), [*β*‐endorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643)([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)) (*β*‐end), [*α*‐neodynorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3737)([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213)), [dynorphin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1620)([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213)) (dynA), [dynorphin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1622)([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213)) (dynB), [big dynorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3669)([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213)) (Big dyn), [nociceptin/orphanin FQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1681)([*PNOC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9163), [Q13519](http://www.uniprot.org/uniprot/Q13519)) (N/OFQ); [endomorphin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623) and [endomorphin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668) are also potential endogenous peptides. The Greek letter nomenclature for the opioid receptors, *μ*, *δ* and *κ*, is well established, and [**NC‐IUPHAR**]{.ul} considers this nomenclature most appropriate \[[376](http://www.ncbi.nlm.nih.gov/pubmed/24528283?dopt=AbstractPlus), [417](http://www.ncbi.nlm.nih.gov/pubmed/8981566?dopt=AbstractPlus), [530](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)\]. The human N/OFQ receptor is considered \'opioid‐related\' rather than opioid because while it exhibits a high degree of structural homology with the conventional opioid receptors \[[1308](http://www.ncbi.nlm.nih.gov/pubmed/8137918?dopt=AbstractPlus)\], it displays a distinct pharmacology.

Nomenclature[*δ* receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317)[*κ* receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318)[*μ* receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319)[NOP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320)HGNC, UniProt[*OPRD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8153), [P41143](http://www.uniprot.org/uniprot/P41143)[*OPRK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8154), [P41145](http://www.uniprot.org/uniprot/P41145)[*OPRM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8156), [P35372](http://www.uniprot.org/uniprot/P35372)[*OPRL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8155), [P41146](http://www.uniprot.org/uniprot/P41146)Principal endogenous agonists[*β*‐endorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [\[Leu\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)), [\[Met\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210))[big dynorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3669) ([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213)), [dynorphin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1620) ([*PDYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8820), [P01213](http://www.uniprot.org/uniprot/P01213))[*β*‐endorphin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643) ([*POMC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9201), [P01189](http://www.uniprot.org/uniprot/P01189)), [\[Met\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)), [\[Leu\]enkephalin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613) ([*PENK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8831), [P01210](http://www.uniprot.org/uniprot/P01210)), [endomorphin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623), [endomorphin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668)--Endogenous agonists----[endomorphin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668) (Selective) (p*K* ~i~ 8.5) \[[2109](http://www.ncbi.nlm.nih.gov/pubmed/9087409?dopt=AbstractPlus)\] -- Rat, [endomorphin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623) (Selective) (p*K* ~i~ 8.3) \[[622](http://www.ncbi.nlm.nih.gov/pubmed/9849897?dopt=AbstractPlus), [2109](http://www.ncbi.nlm.nih.gov/pubmed/9087409?dopt=AbstractPlus)\][nociceptin/orphanin FQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1681) ([*PNOC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9163), [Q13519](http://www.uniprot.org/uniprot/Q13519)) (Selective) (p*K* ~i~ 9.7--10.4) \[[149](http://www.ncbi.nlm.nih.gov/pubmed/12070757?dopt=AbstractPlus), [1242](http://www.ncbi.nlm.nih.gov/pubmed/12967935?dopt=AbstractPlus), [1303](http://www.ncbi.nlm.nih.gov/pubmed/22827708?dopt=AbstractPlus), [1307](http://www.ncbi.nlm.nih.gov/pubmed/8849681?dopt=AbstractPlus), [1439](http://www.ncbi.nlm.nih.gov/pubmed/10369464?dopt=AbstractPlus)\]Agonists----[levorphanol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7595) (pIC~50~ 9.9) \[[692](http://www.ncbi.nlm.nih.gov/pubmed/12502358?dopt=AbstractPlus)\], [hydromorphone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7082) (p*K* ~i~ 9.6) \[[2007](http://www.ncbi.nlm.nih.gov/pubmed/19282177?dopt=AbstractPlus)\], [fentanyl](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1626) (p*K* ~i~ 9.2) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [buprenorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1670) (Partial agonist) (p*K* ~i~ 8.8) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [methadone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5458) (pIC~50~ 8.4) \[[1523](http://www.ncbi.nlm.nih.gov/pubmed/11585443?dopt=AbstractPlus)\], [codeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1673) (p*K* ~i~ 6.9) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [tapentadol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7477) (p*K* ~i~ 6.8) \[[1916](http://www.ncbi.nlm.nih.gov/pubmed/17656655?dopt=AbstractPlus)\], [meperidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7221) (pIC~50~ 6.5) \[[1523](http://www.ncbi.nlm.nih.gov/pubmed/11585443?dopt=AbstractPlus)\]--Selective agonists[\[D‐Ala^2^\]deltorphin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3838) (p*K* ~d~ 9.4) \[[487](http://www.ncbi.nlm.nih.gov/pubmed/3071223?dopt=AbstractPlus), [1795](http://www.ncbi.nlm.nih.gov/pubmed/1329092?dopt=AbstractPlus)\], [DPDPE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1608) (p*K* ~i~ 8.8) \[[1337](http://www.ncbi.nlm.nih.gov/pubmed/6310598?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [\[D‐Ala^2^\]deltorphin II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4060) (p*K* ~i~ 8.8) \[[488](http://www.ncbi.nlm.nih.gov/pubmed/2544892?dopt=AbstractPlus)\], [SNC80](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1611) (p*K* ~i~ 7.2) \[[258](http://www.ncbi.nlm.nih.gov/pubmed/8035418?dopt=AbstractPlus), [1549](http://www.ncbi.nlm.nih.gov/pubmed/9178661?dopt=AbstractPlus)\][U50488](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1652) (p*K* ~i~ 7.8--9.7) \[[297](http://www.ncbi.nlm.nih.gov/pubmed/14718611?dopt=AbstractPlus), 1478, [1744](http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus), [1962](http://www.ncbi.nlm.nih.gov/pubmed/6129321?dopt=AbstractPlus), [2128](http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus), [2130](http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus)\], [enadoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1646) (p*K* ~i~ 9.6) \[[808](http://www.ncbi.nlm.nih.gov/pubmed/2178014?dopt=AbstractPlus), [1383](http://www.ncbi.nlm.nih.gov/pubmed/14613319?dopt=AbstractPlus)\], [U69593](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1655) (p*K* ~i~ 9.5) \[[1034](http://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [salvinorin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1666) (p*K* ~i~ 7.8--8.7) \[[251](http://www.ncbi.nlm.nih.gov/pubmed/15869877?dopt=AbstractPlus), [1603](http://www.ncbi.nlm.nih.gov/pubmed/12192085?dopt=AbstractPlus)\][sufentanil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3534) (p*K* ~i~ 9.9) \[[1960](http://www.ncbi.nlm.nih.gov/pubmed/21215785?dopt=AbstractPlus)\], [DAMGO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1647) (p*K* ~i~ 9.3) \[[691](http://www.ncbi.nlm.nih.gov/pubmed/6263640?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [loperamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7215) (p*K* ~i~ 9.3) \[[308](http://www.ncbi.nlm.nih.gov/pubmed/15454210?dopt=AbstractPlus)\], [morphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1627) (p*K* ~i~ 9) \[[620](http://www.ncbi.nlm.nih.gov/pubmed/2549383?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [PL017](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1671) (p*K* ~i~ 8.2) \[[290](http://www.ncbi.nlm.nih.gov/pubmed/6313901?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\][N/OFQ‐(1‐13)‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1682) (p*K* ~i~ 10.1--10.4) \[[149](http://www.ncbi.nlm.nih.gov/pubmed/12070757?dopt=AbstractPlus), [661](http://www.ncbi.nlm.nih.gov/pubmed/9191955?dopt=AbstractPlus), [1242](http://www.ncbi.nlm.nih.gov/pubmed/12967935?dopt=AbstractPlus), [1439](http://www.ncbi.nlm.nih.gov/pubmed/10369464?dopt=AbstractPlus)\], [Ro64‐6198](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1684) (p*K* ~i~ 9.6) \[[855](http://www.ncbi.nlm.nih.gov/pubmed/10758169?dopt=AbstractPlus)\]Antagonists[naltrexone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639) (p*K* ~i~ 8) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [naloxone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638) (p*K* ~i~ 7.2) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\][buprenorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1670) (p*K* ~i~ 9.1--10.2) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus), [2130](http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus)\], [nalmefene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628) (p*K* ~i~ 9.5) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [naltrexone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639) (p*K* ~i~ 8.4--9.4) \[1478, [1744](http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [naloxone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638) (p*K* ~i~ 7.6--8.6) \[1478, [1744](http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus), [2128](http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus), [2130](http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus)\][naltrexone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639) (p*K* ~i~ 9.7) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [nalmefene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628) (p*K* ~i~ 9.5) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [nalorphine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1629) (p*K* ~i~ 8.9) \[[1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [methylnaltrexone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7563) (p*K* ~i~ 8.7) \[[2007](http://www.ncbi.nlm.nih.gov/pubmed/19282177?dopt=AbstractPlus)\]--Selective antagonists[naltriben](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640) (p*K* ~i~ 10) \[[1773](http://www.ncbi.nlm.nih.gov/pubmed/1851833?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [naltrindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1641) (p*K* ~i~ 9.7) \[[1521](http://www.ncbi.nlm.nih.gov/pubmed/2832195?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\], [TIPP*ψ*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1637) (Inverse agonist) (p*K* ~i~ 9) \[[1664](http://www.ncbi.nlm.nih.gov/pubmed/8230106?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\][nor‐binaltorphimine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1642) (p*K* ~i~ 8.9--11) \[1478, [1520](http://www.ncbi.nlm.nih.gov/pubmed/2444704?dopt=AbstractPlus), [1744](http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus), [2128](http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus), [2130](http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus)\], [5\'‐guanidinonaltrindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1669) (p*K* ~i~ 9.7--9.9) \[[882](http://www.ncbi.nlm.nih.gov/pubmed/10822054?dopt=AbstractPlus), 1478, [1797](http://www.ncbi.nlm.nih.gov/pubmed/10893314?dopt=AbstractPlus)\][alvimopan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7471) (p*K* ~i~ 9.3) \[[1056](http://www.ncbi.nlm.nih.gov/pubmed/18313920?dopt=AbstractPlus)\], [levallorphan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7209) (p*K* ~i~ 8.8--9.3) \[[1187](http://www.ncbi.nlm.nih.gov/pubmed/21621410?dopt=AbstractPlus)\], [CTAP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1635) (p*K* ~i~ 8.6) \[[290](http://www.ncbi.nlm.nih.gov/pubmed/6313901?dopt=AbstractPlus), [1893](http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus)\][UFP‐101](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1694) (p*K* ~i~ 10.2) \[[259](http://www.ncbi.nlm.nih.gov/pubmed/12010780?dopt=AbstractPlus)\], [Banyu Compound‐24](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7361) (p*K* ~i~ 9.6) \[[523](http://www.ncbi.nlm.nih.gov/pubmed/19445927?dopt=AbstractPlus)\], [SB 612111](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1693) (p*K* ~i~ 9.5) \[[2112](http://www.ncbi.nlm.nih.gov/pubmed/14593080?dopt=AbstractPlus)\], [J‐113397](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1691) (pIC~50~ 8.3) \[[919](http://www.ncbi.nlm.nih.gov/pubmed/10602690?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]naltrindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3829) (Antagonist) (p*K* ~d~ 10.4) \[[2072](http://www.ncbi.nlm.nih.gov/pubmed/1313133?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]DPDPE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3819) (Agonist) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/2986120?dopt=AbstractPlus)\], [\[^3^H\]deltorphin II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3816) (Agonist) \[[252](http://www.ncbi.nlm.nih.gov/pubmed/1313131?dopt=AbstractPlus)\], [\[^3^H\]naltriben](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3828) (Antagonist) \[[1088](http://www.ncbi.nlm.nih.gov/pubmed/9696425?dopt=AbstractPlus)\][\[^3^H\]U69593](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1656) (Agonist) (p*K* ~d~ 8.7--8.8) \[[1034](http://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus), 1478, [1744](http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus)\], [\[^3^H\]enadoline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3475) (Agonist) \[[1746](http://www.ncbi.nlm.nih.gov/pubmed/11239918?dopt=AbstractPlus)\][\[^3^H\]DAMGO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3815) (Agonist) (p*K* ~d~ 9.2) \[[1567](http://www.ncbi.nlm.nih.gov/pubmed/8114680?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]PL017](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3832) (Agonist) \[[717](http://www.ncbi.nlm.nih.gov/pubmed/3030778?dopt=AbstractPlus)\] -- Rat[\[^3^H\]N/OFQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1688) (Agonist) (p*K* ~d~ 10.2) \[[437](http://www.ncbi.nlm.nih.gov/pubmed/8684262?dopt=AbstractPlus), [1307](http://www.ncbi.nlm.nih.gov/pubmed/8849681?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0210}
--------

Three naloxone‐sensitive opioid receptor genes have been identified in humans, and while the *μ*‐receptor in particular may be subject to extensive alternative splicing \[[1468](http://www.ncbi.nlm.nih.gov/pubmed/24076545?dopt=AbstractPlus)\], these putative isoforms have not been correlated with any of the subtypes of receptor proposed in years past. Opioid receptors may heterodimerize with each other or with other 7TM receptors \[[884](http://www.ncbi.nlm.nih.gov/pubmed/10385123?dopt=AbstractPlus)\], and give rise to complexes with a unique pharmacology, however, evidence for such heterodimers in native cells is equivocal and the consequences this heterodimerization for signalling remains largely unknown. For *μ*‐opioid receptors at least, dimerization does not seem to be required for signalling \[[1026](http://www.ncbi.nlm.nih.gov/pubmed/19542234?dopt=AbstractPlus)\]. A distinct met‐enkephalin receptor lacking structural resemblance to the opioid receptors listed has been identified ([*OGFR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15768), [9NZT2](http://www.uniprot.org/uniprot/9NZT2)) and termed an [o]{.ul}pioid [g]{.ul}rowth [f]{.ul}actor [r]{.ul}eceptor \[[2110](http://www.ncbi.nlm.nih.gov/pubmed/11890982?dopt=AbstractPlus)\].

[Endomorphin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623) and [endomorphin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668) have been identified as highly selective, putative endogenous agonists for the *μ*‐opioid receptor. At present, however, the mechanisms for endomorphin synthesis *in vivo* have not been established, and there is no gene identified that encodes for either. Thus, the status of these peptides as endogenous ligands remains unproven.

Two areas of increasing importance in defining opioid receptor function are the presence of functionally relevant single nucleotide polymorphisms in human *μ*‐receptors \[[1423](http://www.ncbi.nlm.nih.gov/pubmed/19116204?dopt=AbstractPlus)\] and the identification of biased signalling by opioid receptor ligands, in particular, compounds previously characterized as antagonists \[[231](http://www.ncbi.nlm.nih.gov/pubmed/17702750?dopt=AbstractPlus)\]. Pathway bias for agonists makes general rank orders of potency and efficacy somewhat obsolete, so these do not appear in the table. As ever, the mechanisms underlying the acute and long term regulation of opiod receptor function are the subject of intense investigation and debate.

The richness of opioid receptor pharmacology has been enhanced with the recent discovery of allosteric modulators of MOPr and DOPr, notably the positive allosteric modulators and silent allosteric \"antagonists\" outlined in \[[240](http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus), [241](http://www.ncbi.nlm.nih.gov/pubmed/25901762?dopt=AbstractPlus)\]. Negative allosteric modulation of opioid receptors has been previously suggested \[[908](http://www.ncbi.nlm.nih.gov/pubmed/16489449?dopt=AbstractPlus)\], whether all compounds are acting at a similar site remains to be established.
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[Orexin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=51) {#bph13348-sec-0212}
============================================================================================

Overview {#bph13348-sec-0213}
--------

Orexin receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Orexin receptors \[** [**627**](http://www.ncbi.nlm.nih.gov/pubmed/22759794?dopt=AbstractPlus) **\]**) are activated by the endogenous polypeptides [orexin‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697)([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612)) and [orexin‐B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699)([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612)) (also known as hypocretin‐1 and ‐2; 33 and 28 aa) derived from a common precursor, [preproorexin or orexin precursor](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), by proteolytic cleavage \[[1629](http://www.ncbi.nlm.nih.gov/pubmed/9491897?dopt=AbstractPlus)\]. Binding to both receptors may be accomplished with [\[^125^I\]orexin A (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3798) \[[773](http://www.ncbi.nlm.nih.gov/pubmed/11403934?dopt=AbstractPlus)\].

Nomenclature[OX~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=321)[OX~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=322)HGNC, UniProt[*HCRTR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4848), [O43613](http://www.uniprot.org/uniprot/O43613)[*HCRTR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4849), [O43614](http://www.uniprot.org/uniprot/O43614)Rank order of potency[orexin‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697) ([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612)) \>[orexin‐B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699) ([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612))[orexin‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697) ([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612)) = [orexin‐B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699) ([*HCRT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4847), [O43612](http://www.uniprot.org/uniprot/O43612))Selective agonists--[\[Ala^11^, D‐Leu^15^\]orexin‐B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700) (pEC~50~ 9.9) \[[62](http://www.ncbi.nlm.nih.gov/pubmed/12467628?dopt=AbstractPlus)\](Sub)family‐selective antagonists[suvorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890) (p*K* ~i~ 9.3) \[[377](http://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus)\], [SB‐649868](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4461) (p*K* ~i~ 9.1) \[[419](http://www.ncbi.nlm.nih.gov/pubmed/21831639?dopt=AbstractPlus)\], [filorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460) (p*K* ~i~ 8.6) \[[2035](http://www.ncbi.nlm.nih.gov/pubmed/22019562?dopt=AbstractPlus)\], [almorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886) (pIC~50~ 7.9) \[[216](http://www.ncbi.nlm.nih.gov/pubmed/17259994?dopt=AbstractPlus)\][filorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460) (p*K* ~i~ 9.5) \[[2035](http://www.ncbi.nlm.nih.gov/pubmed/22019562?dopt=AbstractPlus)\], [suvorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890) (p*K* ~i~ 9.5) \[[377](http://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus)\], [SB‐649868](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4461) (p*K* ~i~ 8.9) \[[419](http://www.ncbi.nlm.nih.gov/pubmed/21831639?dopt=AbstractPlus)\], [almorexant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886) (pIC~50~ 8.1) \[[216](http://www.ncbi.nlm.nih.gov/pubmed/17259994?dopt=AbstractPlus)\]Selective antagonists[SB‐408124](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1704) (p*K* ~i~ 7.2--7.6) \[[1042](http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus), [1190](http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus)\], [SB‐334867](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1703) (p*K* ~i~ 7.4--7.5) \[[1190](http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus), [1518](http://www.ncbi.nlm.nih.gov/pubmed/11459658?dopt=AbstractPlus)\][EMPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4037) (p*K* ~i~ 9) \[[1189](http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus)\], [JNJ 10397049](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1701) (p*K* ~i~ 7.9--8.6) \[[1238](http://www.ncbi.nlm.nih.gov/pubmed/15261275?dopt=AbstractPlus)\], [TCS‐OX2‐29](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4038) (p*K* ~i~ 7.4) \[[760](http://www.ncbi.nlm.nih.gov/pubmed/14643355?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]SB‐674042](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1706) (Antagonist) (p*K* ~d~ 8.3--9.1) \[[1042](http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus), [1190](http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus), [1193](http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus)\]--

Comments {#bph13348-sec-0214}
--------

The primary coupling of orexin receptors to G~q/11~ proteins is rather speculative and based on the strong activation of phospholipase C. Coupling of both receptors to G~i/o~ and G~s~ has also been reported \[1019, [1555](http://www.ncbi.nlm.nih.gov/pubmed/19460850?dopt=AbstractPlus)\]; for most cellular responses observed, the G protein pathway is unknown. The rank order of endogenous agonist potency may depend on the cellular signal transduction machinery. The synthetic [\[Ala^11^, D‐Leu^15^\]orexin‐B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700) may show poor OX~2~ receptor selectivity \[[1540](http://www.ncbi.nlm.nih.gov/pubmed/21362456?dopt=AbstractPlus)\].

Loss‐of‐function mutations in the gene encoding the OX~2~ receptor underlie canine hereditary narcolepsy \[[1111](http://www.ncbi.nlm.nih.gov/pubmed/10458611?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0215}
---------------

Boss C. (2014) Orexin receptor antagonists--a patent review (2010 to August 2014). *Expert Opin Ther Pat* **24**: 1367‐81 [\[PMID:25407283\]](http://www.ncbi.nlm.nih.gov/pubmed/25407283?dopt=AbstractPlus)

Boss C *et al*. (2009) Biomedical application of orexin/hypocretin receptor ligands in neuroscience. *J. Med. Chem.* **52**: 891‐903 [\[PMID:19199652\]](http://www.ncbi.nlm.nih.gov/pubmed/19199652?dopt=AbstractPlus)

Christopher JA. (2014) Small‐molecule antagonists of the orexin receptors. *Pharm Pat Anal* **3**: 625‐38 [\[PMID:25489915\]](http://www.ncbi.nlm.nih.gov/pubmed/25489915?dopt=AbstractPlus)

Gotter AL *et al*. (2012) International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. *Pharmacol. Rev.* **64**: 389‐420 [\[PMID:22759794\]](http://www.ncbi.nlm.nih.gov/pubmed/22759794?dopt=AbstractPlus)

Lebold TP *et al*. (2013) Selective orexin receptor antagonists. *Bioorg. Med. Chem. Lett.* **23**: 4761‐9 [\[PMID:23891187\]](http://www.ncbi.nlm.nih.gov/pubmed/23891187?dopt=AbstractPlus)

Mieda M *et al*. (2013) Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. *CNS Drugs* **27**: 83‐90 [\[PMID:23359095\]](http://www.ncbi.nlm.nih.gov/pubmed/23359095?dopt=AbstractPlus)

[Oxoglutarate receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=447) {#bph13348-sec-0216}
==================================================================================================

Overview {#bph13348-sec-0217}
--------

**Nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **\]**.

Nomenclature[oxoglutarate receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=162)HGNC, UniProt[*OXGR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4531), [Q96P68](http://www.uniprot.org/uniprot/Q96P68)Endogenous agonists[*α*‐ketoglutaric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636) (pEC~50~ 3.3--4.5) \[[728](http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]

[P2Y receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=52) {#bph13348-sec-0218}
=========================================================================================

Overview {#bph13348-sec-0219}
--------

P2Y receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on P2Y Receptors \[** [**1**](http://www.ncbi.nlm.nih.gov/pubmed/12559763?dopt=AbstractPlus) **,** [**2**](http://www.ncbi.nlm.nih.gov/pubmed/16968944?dopt=AbstractPlus) **\]**) are activated by the endogenous ligands [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713), [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712), [uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734), [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) and [UDP‐glucose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783). The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as '[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)‐preferring (or [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)‐, *etc*.) P2Y receptor' or 'P2Y~1~‐like', *etc*., until further, as yet undefined, corroborative criteria can be applied \[244, [486](http://www.ncbi.nlm.nih.gov/pubmed/21586366?dopt=AbstractPlus), [837](http://www.ncbi.nlm.nih.gov/pubmed/23597047?dopt=AbstractPlus), [2003](http://www.ncbi.nlm.nih.gov/pubmed/22963441?dopt=AbstractPlus), [2146](http://www.ncbi.nlm.nih.gov/pubmed/21586365?dopt=AbstractPlus)\].

Nomenclature[P2Y~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323)[P2Y~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=324)[P2Y~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=325)[P2Y~6~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=326)HGNC, UniProt[*P2RY1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8539), [P47900](http://www.uniprot.org/uniprot/P47900)[*P2RY2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8541), [P41231](http://www.uniprot.org/uniprot/P41231)[*P2RY4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8542), [P51582](http://www.uniprot.org/uniprot/P51582)[*P2RY6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8543), [Q15077](http://www.uniprot.org/uniprot/Q15077)Rank order of potency[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712)\>[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)=[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)\>[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) (at rat recombinant receptors, UTP = ATP)[uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749)≫[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)\>[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)Endogenous agonists------[uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) (Selective) (pEC~50~ 6.5) \[[359](http://www.ncbi.nlm.nih.gov/pubmed/8670200?dopt=AbstractPlus)\]Agonists[ADP*β*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755) (pEC~50~ 7.3) \[[1848](http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus)\], [2MeSADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1710) (pIC~50~ 5.4--7) \[[1658](http://www.ncbi.nlm.nih.gov/pubmed/9154346?dopt=AbstractPlus), [1970](http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus)\]----[Rp‐5‐OMe‐UDP*α*B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5910) (pEC~50~ 8.1) \[[611](http://www.ncbi.nlm.nih.gov/pubmed/22901672?dopt=AbstractPlus), [666](http://www.ncbi.nlm.nih.gov/pubmed/24970757?dopt=AbstractPlus)\]Selective agonists[MRS2365](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3338) (pEC~50~ 9.4) \[[314](http://www.ncbi.nlm.nih.gov/pubmed/15345752?dopt=AbstractPlus)\], [2‐Cl‐ADP(*α*‐BH~3~)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8447) (pEC~50~ 8.1) \[[73](http://www.ncbi.nlm.nih.gov/pubmed/23751098?dopt=AbstractPlus)\][2‐thioUTP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3398) (pEC~50~ 7.3) \[[470](http://www.ncbi.nlm.nih.gov/pubmed/17125260?dopt=AbstractPlus)\], [PSB1114](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5902) (EC~50~ value determined using an IP~3~ functional assay) (pEC~50~ 6.9) \[[471](http://www.ncbi.nlm.nih.gov/pubmed/21417463?dopt=AbstractPlus)\], [Ap~4~A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732) (pEC~50~ 6.1) \[[270](http://www.ncbi.nlm.nih.gov/pubmed/1393282?dopt=AbstractPlus), [1471](http://www.ncbi.nlm.nih.gov/pubmed/11711032?dopt=AbstractPlus)\], [UTP*γ*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735) (pEC~50~ 5.8) \[[1054](http://www.ncbi.nlm.nih.gov/pubmed/8564228?dopt=AbstractPlus)\], [MRS2768](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4043) (EC~50~ value determined using an IP~3~ functional assay) (pEC~50~ 5.7) \[[973](http://www.ncbi.nlm.nih.gov/pubmed/18514530?dopt=AbstractPlus)\][MRS4062](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4044) (pEC~50~ 7.6) \[[1213](http://www.ncbi.nlm.nih.gov/pubmed/21528910?dopt=AbstractPlus)\], [UTP*γ*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735) \[[1055](http://www.ncbi.nlm.nih.gov/pubmed/8825364?dopt=AbstractPlus)\] -- Unknown[MRS2957](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5903) (pEC~50~ 7.9) \[[1212](http://www.ncbi.nlm.nih.gov/pubmed/20446735?dopt=AbstractPlus)\], [MRS2693](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1747) (pEC~50~ 7.8) \[[143](http://www.ncbi.nlm.nih.gov/pubmed/16942026?dopt=AbstractPlus)\], [3‐phenacyl‐UDP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1745) (pEC~50~ 7.2) \[[470](http://www.ncbi.nlm.nih.gov/pubmed/17125260?dopt=AbstractPlus)\]Antagonists----[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) (p*K* ~d~ 6.2) \[[925](http://www.ncbi.nlm.nih.gov/pubmed/10779375?dopt=AbstractPlus)\]--Selective antagonists[MRS2500](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1724) (p*K* ~i~ 8.8--9.1) \[[274](http://www.ncbi.nlm.nih.gov/pubmed/15476670?dopt=AbstractPlus), [942](http://www.ncbi.nlm.nih.gov/pubmed/14584948?dopt=AbstractPlus)\], [BMS compound 16 \[PMID:23368907\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5808) (p*K* ~i~ 8.2) \[[295](http://www.ncbi.nlm.nih.gov/pubmed/23368907?dopt=AbstractPlus), [2115](http://www.ncbi.nlm.nih.gov/pubmed/25822790?dopt=AbstractPlus)\], [MRS2279](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1721) (p*K* ~i~ 7.9) \[[1970](http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus)\], [MRS2179](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1720) (p*K* ~i~ 7--7.1) \[[197](http://www.ncbi.nlm.nih.gov/pubmed/8913364?dopt=AbstractPlus), [1970](http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus)\], [2,2\'‐pyridylisatogen tosylate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1729) (p*K* ~i~ 6.8) \[[570](http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus)\][AR‐C118925XX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5907) (pIC~50~∼6) \[[924](http://www.ncbi.nlm.nih.gov/pubmed/15231488?dopt=AbstractPlus)\]--[MRS2578](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1753) (pIC~50~ 7.4) \[[1196](http://www.ncbi.nlm.nih.gov/pubmed/15081875?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]MRS2279](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1727) (Antagonist) (p*K* ~d~ 8.1) \[[1970](http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus)\], [\[^3^H\]2MeSADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763) (Agonist) (p*K* ~d~ 7.3) \[[1848](http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus)\], [\[^35^S\]ADP*β*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3408) (Agonist) -- Unknown------

Nomenclature[P2Y~11~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=327)[P2Y~12~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328)[P2Y~13~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=329)[P2Y~14~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=330)HGNC, UniProt[*P2RY11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8540), [Q96G91](http://www.uniprot.org/uniprot/Q96G91)[*P2RY12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18124), [Q9H244](http://www.uniprot.org/uniprot/Q9H244)[*P2RY13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4537), [Q9BPV8](http://www.uniprot.org/uniprot/Q9BPV8)[*P2RY14*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16442), [Q15391](http://www.uniprot.org/uniprot/Q15391)Rank order of potency[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)\>[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)--[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712)≫[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)--Rank order of potency Human------[uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749)≥[UDP‐glucose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783)Endogenous agonists--[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712) (Selective) (p*K* ~i~ 5.9) \[[740](http://www.ncbi.nlm.nih.gov/pubmed/15199474?dopt=AbstractPlus)\]----Agonists--[2MeSADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1710) (p*K* ~i~ 9.2) \[[740](http://www.ncbi.nlm.nih.gov/pubmed/15199474?dopt=AbstractPlus)\]--[MRS2690](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3337) (pEC~50~ 6.6--7.3) \[[571](http://www.ncbi.nlm.nih.gov/pubmed/22825617?dopt=AbstractPlus), [974](http://www.ncbi.nlm.nih.gov/pubmed/17407275?dopt=AbstractPlus)\]Selective agonists[AR‐C67085](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1756) (pEC~50~ 8.5) \[[88](http://www.ncbi.nlm.nih.gov/pubmed/15893764?dopt=AbstractPlus), [360](http://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus)\], [NF546](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4046) (pEC~50~ 6.3) \[[1255](http://www.ncbi.nlm.nih.gov/pubmed/19815812?dopt=AbstractPlus)\], [NAADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2450) \[[1322](http://www.ncbi.nlm.nih.gov/pubmed/17707504?dopt=AbstractPlus)\], [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) \[[1323](http://www.ncbi.nlm.nih.gov/pubmed/16926152?dopt=AbstractPlus)\]------Antagonists[NF340](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1762) (pIC~50~ 6.4--7.1) \[[1255](http://www.ncbi.nlm.nih.gov/pubmed/19815812?dopt=AbstractPlus)\][PSB‐0739](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5904) (p*K* ~i~ 7.6) \[[91](http://www.ncbi.nlm.nih.gov/pubmed/19463000?dopt=AbstractPlus)\]----Selective antagonists[NF157](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1761) (p*K* ~i~ 7.3) \[[1923](http://www.ncbi.nlm.nih.gov/pubmed/16250663?dopt=AbstractPlus)\][AZD1283](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7360) (p*K* ~i~ 8) \[[76](http://www.ncbi.nlm.nih.gov/pubmed/24215345?dopt=AbstractPlus), [2116](http://www.ncbi.nlm.nih.gov/pubmed/24670650?dopt=AbstractPlus)\], [ARL66096](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3384) (pIC~50~ 7.9) \[[806](http://www.ncbi.nlm.nih.gov/pubmed/7582510?dopt=AbstractPlus), [807](http://www.ncbi.nlm.nih.gov/pubmed/7858849?dopt=AbstractPlus)\], [ticagrelor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1765) (p*K* ~i~ 7.8) \[[2113](http://www.ncbi.nlm.nih.gov/pubmed/22984835?dopt=AbstractPlus)\][MRS2211](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1777) (pIC~50~ 6) \[[950](http://www.ncbi.nlm.nih.gov/pubmed/15913566?dopt=AbstractPlus)\][PPTN](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5802) (p*K* ~i~ 10.1) \[[96](http://www.ncbi.nlm.nih.gov/pubmed/23592514?dopt=AbstractPlus)\]Labelled ligands--[\[^3^H\]2MeSADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763) (Agonist) (pIC~50~ 7.5--9.6) \[[1848](http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus)\], [\[^3^H\]PSB‐0413](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6147) (Antagonist) (p*K* ~d~ 8.3--8.5) \[[469](http://www.ncbi.nlm.nih.gov/pubmed/16213725?dopt=AbstractPlus), [1431](http://www.ncbi.nlm.nih.gov/pubmed/22892887?dopt=AbstractPlus)\]----

Comments {#bph13348-sec-0220}
--------

[cangrelor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1776) shows selectivity for P2Y~12~ and P2Y~13~ receptors compared with other P2Y receptors \[[1209](http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus), [1848](http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus)\]. [NF157](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1761) also has antagonist activity at P2X~1~ receptors \[[1923](http://www.ncbi.nlm.nih.gov/pubmed/16250663?dopt=AbstractPlus)\]. [Uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) has been reported to be an antagonist at the P2Y~14~ receptor \[[548](http://www.ncbi.nlm.nih.gov/pubmed/18252808?dopt=AbstractPlus)\]. [\[^35^S\]ATP*α*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3407) has been used to label P2Y receptors in rat synaptosomal membranes \[[1682](http://www.ncbi.nlm.nih.gov/pubmed/9222547?dopt=AbstractPlus), [1683](http://www.ncbi.nlm.nih.gov/pubmed/10372917?dopt=AbstractPlus)\].

An orphan GPCR suggested to be a 'P2Y~15~' receptor \[[823](http://www.ncbi.nlm.nih.gov/pubmed/15001573?dopt=AbstractPlus)\] appears not to be a genuine nucleotide receptor \[[2](http://www.ncbi.nlm.nih.gov/pubmed/16968944?dopt=AbstractPlus)\], but rather responds to dicarboxylic acids \[[728](http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus)\]. Further P2Y‐like receptors have been cloned from non‐mammalian sources; a clone from chick brain, termed a p2y~3~ receptor ([ENSGALG00000017327](http://www.ensembl.org/Gallus_gallus/Gene/Summary?g=ENSGALG00000017327;r=1:200242851-200244013;t=ENSGALT00000028001)), couples to the G~q/11~ family of G proteins and shows the rank order of potency [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712)\>[uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734)\>[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) = [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) \[[1998](http://www.ncbi.nlm.nih.gov/pubmed/8700132?dopt=AbstractPlus)\]. In addition, human sources have yielded a clone with a preliminary identification of p2y5 ([*LPAR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15520), [P43657](http://www.uniprot.org/uniprot/P43657)) and contradictory evidence of responses to [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)\[[954](http://www.ncbi.nlm.nih.gov/pubmed/10869716?dopt=AbstractPlus), [1999](http://www.ncbi.nlm.nih.gov/pubmed/8619790?dopt=AbstractPlus)\]. This protein is now classified as [LPA~6~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=36#show_object_163), a receptor for lysophosphatidic acid ([LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906)) \[[1467](http://www.ncbi.nlm.nih.gov/pubmed/18297070?dopt=AbstractPlus), [2079](http://www.ncbi.nlm.nih.gov/pubmed/19386608?dopt=AbstractPlus)\]. The clone termed p2y9 ([*LPAR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4478), [Q99677](http://www.uniprot.org/uniprot/Q99677)) is also a receptor for lysophosphatidic acid, [LPA~4~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=36#show_object_94)\[[1406](http://www.ncbi.nlm.nih.gov/pubmed/12724320?dopt=AbstractPlus)\]. The clone p2y7 ([*NOP9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19826), [Q86U38](http://www.uniprot.org/uniprot/Q86U38)), originally suggested to be a P2Y receptor \[[22](http://www.ncbi.nlm.nih.gov/pubmed/8702478?dopt=AbstractPlus)\], has been shown to encode a leukotriene receptor \[[2095](http://www.ncbi.nlm.nih.gov/pubmed/9177352?dopt=AbstractPlus)\]. A P2Y receptor that was initially termed a p2y8 receptor ([P79928](http://www.uniprot.org/uniprot/P79928)) has been cloned from *Xenopus laevis*; it shows the rank order of potency [ADP*β*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755)\>[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) = [uridine triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734) = [guanosine‐5\'‐triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742)= [CTP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1741) = [TTP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5505) = [ITP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1743)\>[ATP*γ*S](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1714) and elicits a Ca^2+^‐dependent Cl^‐^ current in *Xenopus* oocytes \[[169](http://www.ncbi.nlm.nih.gov/pubmed/9139711?dopt=AbstractPlus)\]. The p2y10 clone ([*P2RY10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19906), [O00398](http://www.uniprot.org/uniprot/O00398)) lacks functional data. Diadenosine polyphosphates also have effects on as yet uncloned P2Y‐like receptors with the rank order of potency of [Ap~4~A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732)\>[Ap5a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5453)\>[Ap3a](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5454), coupling via G~q/11~\[[270](http://www.ncbi.nlm.nih.gov/pubmed/1393282?dopt=AbstractPlus)\]. P2Y‐like receptors have recently been described on mitochondria \[[126](http://www.ncbi.nlm.nih.gov/pubmed/15258927?dopt=AbstractPlus)\]. CysLT1 and CysLT2 leukotriene receptors respond to nanomolar concentrations of [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749), although they are activated principally by leukotrienes [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354) and [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353)\[[1257](http://www.ncbi.nlm.nih.gov/pubmed/13679572?dopt=AbstractPlus), [1258](http://www.ncbi.nlm.nih.gov/pubmed/11438743?dopt=AbstractPlus)\]. Human [GPR17](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4471) ([13304](http://www.uniprot.org/uniprot/13304)) and rat GPR17, which are structurally related to CysLT and P2Y receptors, are also activated by leukotrienes \[[1542](http://www.ncbi.nlm.nih.gov/pubmed/23908386?dopt=AbstractPlus)\] as well as [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) and [UDP‐glucose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783)\[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus), [540](http://www.ncbi.nlm.nih.gov/pubmed/23288840?dopt=AbstractPlus)\]. Activity at the rat GPR17 is inhibited by submicromolar concentrations of [MRS2179](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1720) and [cangrelor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1776)\[[344](http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0221}
---------------
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Burnstock G. (2007) Purine and pyrimidine receptors. *Cell. Mol. Life Sci.* **64**: 1471‐83 [\[PMID:17375261\]](http://www.ncbi.nlm.nih.gov/pubmed/17375261?dopt=AbstractPlus)
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Jacobson KA *et al*. (2009) Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signalling* **5**: 75‐89 [\[PMID:18600475\]](http://www.ncbi.nlm.nih.gov/pubmed/18600475?dopt=AbstractPlus)

Weisman GA *et al*. (2012) P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential. *CNS Neurol Disord Drug Targets* **11**: 722‐38 [\[PMID:22963441\]](http://www.ncbi.nlm.nih.gov/pubmed/22963441?dopt=AbstractPlus)

von Kügelgen I *et al*. (2011) Molecular pharmacology, physiology, and structure of the P2Y receptors. *Adv. Pharmacol.* **61**: 373‐415 [\[PMID:21586365\]](http://www.ncbi.nlm.nih.gov/pubmed/21586365?dopt=AbstractPlus)

[Parathyroid hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=53) {#bph13348-sec-0222}
=========================================================================================================

Overview {#bph13348-sec-0223}
--------

The parathyroid hormone receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Parathyroid Hormone Receptors \[** [**575**](http://www.ncbi.nlm.nih.gov/pubmed/25713287?dopt=AbstractPlus) **\]**) are family B G protein‐coupled receptors. The parathyroid hormone (PTH)/parathyroid hormone‐related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor‐derived peptides: [PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785)([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270)) (84 amino acids), and [PTHrP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738)([*PTHLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9607), [P12272](http://www.uniprot.org/uniprot/P12272)) (141 amino‐acids) and related peptides (PTH‐(1‐34), [PTHrP‐(1‐36)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1790)([*PTHLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9607), [P12272](http://www.uniprot.org/uniprot/P12272))). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor‐derived peptide [TIP39](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815)([*PTH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30828), [Q96A98](http://www.uniprot.org/uniprot/Q96A98)) (39 amino acids). \[^125^I\]PTH may be used to label both PTH1 and PTH2 receptors.

Nomenclature[PTH1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=331)[PTH2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332)HGNC, UniProt[*PTH1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9608), [Q03431](http://www.uniprot.org/uniprot/Q03431)[*PTH2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9609), [P49190](http://www.uniprot.org/uniprot/P49190)Rank order of potency[PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785) ([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270)) = [PTHrP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738) ([*PTHLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9607), [P12272](http://www.uniprot.org/uniprot/P12272))[TIP39](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815) ([*PTH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30828), [Q96A98](http://www.uniprot.org/uniprot/Q96A98)), [PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785) ([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270)) ≫[PTHrP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738) ([*PTHLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9607), [P12272](http://www.uniprot.org/uniprot/P12272))Endogenous agonists--[TIP39](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815) ([*PTH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30828), [Q96A98](http://www.uniprot.org/uniprot/Q96A98)) (pIC~50~ 7.6--9.2) \[[626](http://www.ncbi.nlm.nih.gov/pubmed/11602681?dopt=AbstractPlus), [766](http://www.ncbi.nlm.nih.gov/pubmed/10854439?dopt=AbstractPlus)\]Agonists[teriparatide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4448) (pIC~50~ 7.4) \[[573](http://www.ncbi.nlm.nih.gov/pubmed/8702701?dopt=AbstractPlus)\]--Selective agonists[PTHrP‐(1‐34) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1822) (pIC~50~ 7.8--8.1) \[[574](http://www.ncbi.nlm.nih.gov/pubmed/7896796?dopt=AbstractPlus)\] -- Rat--

Comments {#bph13348-sec-0224}
--------

Although [PTH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785)([*PTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9606), [P01270](http://www.uniprot.org/uniprot/P01270)) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. [TIP39](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815)([*PTH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30828), [Q96A98](http://www.uniprot.org/uniprot/Q96A98)) is a weak antagonist at PTH1 receptors \[[883](http://www.ncbi.nlm.nih.gov/pubmed/11159842?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0225}
---------------

Cheloha RW *et al*. (2015) Signal transduction at type‐1 parathyroid hormone receptor. *Nat Rev Endo.*

Datta NS *et al*. (2009) PTH and PTHrP signaling in osteoblasts. *Cell. Signal.* **21**: 1245‐54 [\[PMID:19249350\]](http://www.ncbi.nlm.nih.gov/pubmed/19249350?dopt=AbstractPlus)

Gardella TJ *et al*. (2015) International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid Hormone Receptors‐Family B G Protein‐Coupled Receptors. *Pharmacol. Rev.* **67**: 310‐37 [\[PMID:25713287\]](http://www.ncbi.nlm.nih.gov/pubmed/25713287?dopt=AbstractPlus)

Kraenzlin ME *et al*. (2011) Parathyroid hormone analogues in the treatment of osteoporosis. *Nat Rev Endocrinol* [\[PMID:21750510\]](http://www.ncbi.nlm.nih.gov/pubmed/21750510?dopt=AbstractPlus)

Vilardaga JP *et al*. (2014) Endosomal generation of cAMP in GPCR signaling. *Nat. Chem. Biol.* **10**: 700‐6 [\[PMID:25271346\]](http://www.ncbi.nlm.nih.gov/pubmed/25271346?dopt=AbstractPlus)

[Platelet‐activating factor receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=55) {#bph13348-sec-0226}
===============================================================================================================

Overview {#bph13348-sec-0227}
--------

Platelet‐activating factor ([PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1831), 1‐*O*‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF receptor (**provisional nomenclature recommended by [NC‐IUPHAR]{.ul} \[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) is activated by [PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1831) and other suggested endogenous ligands are oxidized phosphatidylcholine \[[1204](http://www.ncbi.nlm.nih.gov/pubmed/10497200?dopt=AbstractPlus)\] and [lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508)\[[1425](http://www.ncbi.nlm.nih.gov/pubmed/9038918?dopt=AbstractPlus)\]. It may also be activated by bacterial lipopolysaccharide \[[1358](http://www.ncbi.nlm.nih.gov/pubmed/1333988?dopt=AbstractPlus)\].

Nomenclature[PAF receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=334)HGNC, UniProt[*PTAFR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9582), [P25105](http://www.uniprot.org/uniprot/P25105)Selective agonists[methylcarbamyl PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3427) -- UnknownSelective antagonists[foropafant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1856) (p*K* ~i~ 10.3) \[[739](http://www.ncbi.nlm.nih.gov/pubmed/8395255?dopt=AbstractPlus)\], [ABT‐491](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1850) (p*K* ~i~ 9.2) \[[30](http://www.ncbi.nlm.nih.gov/pubmed/9151941?dopt=AbstractPlus)\], [CV‐6209](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1852) (pIC~50~ 8.1--8.3) \[[619](http://www.ncbi.nlm.nih.gov/pubmed/15922596?dopt=AbstractPlus), [1357](http://www.ncbi.nlm.nih.gov/pubmed/1657923?dopt=AbstractPlus)\], [L659989](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3426) (p*K* ~i~ 7.8) \[[811](http://www.ncbi.nlm.nih.gov/pubmed/2841449?dopt=AbstractPlus)\], [apafant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1860) (p*K* ~i~ 5.2--7.5) \[[1460](http://www.ncbi.nlm.nih.gov/pubmed/8798529?dopt=AbstractPlus), [1831](http://www.ncbi.nlm.nih.gov/pubmed/8380690?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1833) (Agonist) (p*K* ~d~ 8.8--8.9) \[[555](http://www.ncbi.nlm.nih.gov/pubmed/11560941?dopt=AbstractPlus), [1357](http://www.ncbi.nlm.nih.gov/pubmed/1657923?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0228}
--------

Note that a previously recommended radioligand ([\[^3^H\]apafant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1859); K~d~44.6 nM) is currently unavailable.

Further Reading {#bph13348-sec-0229}
---------------

Foord SM *et al*. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. *Pharmacol Rev* **57**: 279‐288 [\[PMID:15914470\]](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus)

Ishii S *et al*. (2000) Platelet‐activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. *Prog. Lipid Res.* **39**: 41‐82 [\[PMID:10729607\]](http://www.ncbi.nlm.nih.gov/pubmed/10729607?dopt=AbstractPlus)

Montrucchio G *et al*. (2000) Role of platelet‐activating factor in cardiovascular pathophysiology. *Physiol. Rev.* **80**: 1669‐99 [\[PMID:11015622\]](http://www.ncbi.nlm.nih.gov/pubmed/11015622?dopt=AbstractPlus)

Prescott SM *et al*. (2000) Platelet‐activating factor and related lipid mediators. *Annu. Rev. Biochem.* **69**: 419‐45 [\[PMID:10966465\]](http://www.ncbi.nlm.nih.gov/pubmed/10966465?dopt=AbstractPlus)

Shimizu T. (2009) Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. *Annu. Rev. Pharmacol. Toxicol.* **49**: 123‐50 [\[PMID:18834304\]](http://www.ncbi.nlm.nih.gov/pubmed/18834304?dopt=AbstractPlus)

Summers JB *et al*. (1995) Platelet activating factor antagonists. *Adv Pharmacol* **32**: 67‐168 [\[PMID:7748804\]](http://www.ncbi.nlm.nih.gov/pubmed/7748804?dopt=AbstractPlus)

[Prokineticin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=56) {#bph13348-sec-0230}
==================================================================================================

Overview {#bph13348-sec-0231}
--------

Prokineticin receptors, PKR~1~ and PKR~2~(**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) respond to the cysteine‐rich 81‐86 amino‐acid peptides [prokineticin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866)([*PROK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18454), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (also known as endocrine gland‐derived vascular endothelial growth factor, mambakine) and [prokineticin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867)([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (protein Bv8 homologue). An orthologue of PROK1 from black mamba (*Dendroaspis polylepi*s) venom, mamba intestinal toxin 1 ([MIT1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865), \[[1678](http://www.ncbi.nlm.nih.gov/pubmed/10567694?dopt=AbstractPlus)\]) is a potent, non‐selective agonist at prokineticin receptors \[[1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\], while [Bv8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5362), an orthologue of PROK2 from amphibians (*Bombina sp.*, \[[1304](http://www.ncbi.nlm.nih.gov/pubmed/10422759?dopt=AbstractPlus)\]), is equipotent at recombinant PKR~1~ and PKR~2~\[[1371](http://www.ncbi.nlm.nih.gov/pubmed/16113687?dopt=AbstractPlus)\], and has high potency in macrophage chemotaxis assays, which are lost in PKR~1~‐null mice.

Nomenclature[PKR~1~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=335)[PKR~2~](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=336)HGNC, UniProt[*PROKR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4524), [Q8TCW9](http://www.uniprot.org/uniprot/Q8TCW9)[*PROKR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15836), [Q8NFJ6](http://www.uniprot.org/uniprot/Q8NFJ6)Rank order of potency[prokineticin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) \>[prokineticin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866) ([*PROK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18454), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) \>[prokineticin‐2*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455)) \[[1109](http://www.ncbi.nlm.nih.gov/pubmed/11886876?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus), [1775](http://www.ncbi.nlm.nih.gov/pubmed/12427552?dopt=AbstractPlus)\][prokineticin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) \>[prokineticin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866) ([*PROK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18454), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) \>[prokineticin‐2*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455)) \[[1109](http://www.ncbi.nlm.nih.gov/pubmed/11886876?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus), [1775](http://www.ncbi.nlm.nih.gov/pubmed/12427552?dopt=AbstractPlus)\]Endogenous agonists[prokineticin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (pIC~50~ 8.2--8.4) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\], [prokineticin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866) ([*PROK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18454), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (pIC~50~ 6.6--7.6) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\], [prokineticin‐2*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455)) (pIC~50~ 7.5) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus)\][prokineticin‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (pIC~50~ 8.1--8.2) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\], [prokineticin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866) ([*PROK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18454), [Q9HC23](http://www.uniprot.org/uniprot/Q9HC23)) (pIC~50~ 7.1--7.3) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus), [1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\], [prokineticin‐2*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868) ([*PROK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18455)) (pIC~50~\<6) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus)\]Agonists[MIT1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865) (pIC~50~ 8.4) \[[1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\][MIT1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865) (pIC~50~ 9.2) \[[1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\]Selective agonists[IS20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8518) (pEC~50~ 7.4) \[[581](http://www.ncbi.nlm.nih.gov/pubmed/25831128?dopt=AbstractPlus)\], [IS1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8517) (pEC~50~ 5.6) \[[581](http://www.ncbi.nlm.nih.gov/pubmed/25831128?dopt=AbstractPlus)\]--Selective antagonists[triazine compound PC1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6064) (p*K* ~i~ 7.7) \[[87](http://www.ncbi.nlm.nih.gov/pubmed/19006379?dopt=AbstractPlus)\], [triazine compound PC7](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6431) (pIC~50~ 7.5) \[[842](http://www.ncbi.nlm.nih.gov/pubmed/21421710?dopt=AbstractPlus), [1552](http://www.ncbi.nlm.nih.gov/pubmed/19375913?dopt=AbstractPlus)\], [triazine compound PC10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6433) (pIC~50~ 7) \[[842](http://www.ncbi.nlm.nih.gov/pubmed/21421710?dopt=AbstractPlus)\][PKR‐A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6066) (pIC~50~ 7.3--7.4) \[[312](http://www.ncbi.nlm.nih.gov/pubmed/22431614?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]BH‐MIT1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8522) (Agonist) (pIC~50~ 8.4) \[[1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\][\[^125^I\]BH‐MIT1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8522) (Agonist) (pIC~50~ 9.2) \[[1215](http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0232}
--------

Genetic mutations in *PROKR1* are associated with Hirschsprung\'s disease \[[1614](http://www.ncbi.nlm.nih.gov/pubmed/21858136?dopt=AbstractPlus)\], while genetic mutations in *PROKR2* are associated with hypogonadotropic hypogonadism with anosmia \[[430](http://www.ncbi.nlm.nih.gov/pubmed/23596439?dopt=AbstractPlus)\], hypopituitarism with pituitary stalk interruption \[[1575](http://www.ncbi.nlm.nih.gov/pubmed/22466334?dopt=AbstractPlus)\] and Hirschsprung\'s disease \[[1614](http://www.ncbi.nlm.nih.gov/pubmed/21858136?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0233}
---------------
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Martin C *et al*. (2011) The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations. *Endocr. Rev.* **32**: 225‐46 [\[PMID:21037178\]](http://www.ncbi.nlm.nih.gov/pubmed/21037178?dopt=AbstractPlus)

Monnier J *et al*. (2010) Prokineticins in angiogenesis and cancer. *Cancer Lett.* **296**: 144‐9 [\[PMID:20633984\]](http://www.ncbi.nlm.nih.gov/pubmed/20633984?dopt=AbstractPlus)

Negri L *et al*. (2012) Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. *Curr Opin Pharmacol* **12**: 62‐6 [\[PMID:22136937\]](http://www.ncbi.nlm.nih.gov/pubmed/22136937?dopt=AbstractPlus)

Negri L *et al*. (2007) Bv8/Prokineticin proteins and their receptors. *Life Sci.* **81**: 1103‐16 [\[PMID:17881008\]](http://www.ncbi.nlm.nih.gov/pubmed/17881008?dopt=AbstractPlus)

Ngan ES *et al*. (2008) Prokineticin‐signaling pathway. *Int. J. Biochem. Cell Biol.* **40**: 1679‐84 [\[PMID:18440852\]](http://www.ncbi.nlm.nih.gov/pubmed/18440852?dopt=AbstractPlus)

[Prolactin‐releasing peptide receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=57) {#bph13348-sec-0234}
================================================================================================================

Overview {#bph13348-sec-0235}
--------

The precursor ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) for PrRP generates 31 and 20‐amino‐acid versions. [QRFP43](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665)([*QRFP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982), [P83859](http://www.uniprot.org/uniprot/P83859)) (named after a pyroglutamylated arginine‐phenylalanine‐amide peptide) is a 43 amino acid peptide derived from [QRFP](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982)([P83859](http://www.uniprot.org/uniprot/P83859)) and is also known as P518 or 26RFa. RFRP is an RF amide‐related peptide \[[756](http://www.ncbi.nlm.nih.gov/pubmed/11025660?dopt=AbstractPlus)\] derived from a FMRFamide‐related peptide precursor ([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)), which is cleaved to generate [neuropeptide SF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736)([*NPFF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7901), [O15130](http://www.uniprot.org/uniprot/O15130)), neuropeptide [RFRP‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5340)([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)), neuropeptide [RFRP‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5373)([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)) and neuropeptide [RFRP‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016)([*NPVF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13782), [Q9HCQ7](http://www.uniprot.org/uniprot/Q9HCQ7)) (neuropeptide NPVF).

Nomenclature[PrRP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=337)HGNC, UniProt[*PRLHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4464), [P49683](http://www.uniprot.org/uniprot/P49683)Rank order of potency[PrRP‐20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1871) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)), [PrRP‐31](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) \[[1043](http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus)\]Endogenous agonists[PrRP‐20](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1871) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) (Selective) (p*K* ~i~ 9--9.6) \[[481](http://www.ncbi.nlm.nih.gov/pubmed/12606605?dopt=AbstractPlus), [1043](http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus)\], [PrRP‐31](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873) ([*PRLH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17945), [P81277](http://www.uniprot.org/uniprot/P81277)) (Selective) (p*K* ~i~ 9--9.2) \[[481](http://www.ncbi.nlm.nih.gov/pubmed/12606605?dopt=AbstractPlus), [1043](http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus)\]Endogenous antagonists[neuropeptide Y](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504) ([*NPY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7955), [P01303](http://www.uniprot.org/uniprot/P01303)) (Selective) (p*K* ~i~ 5.4) \[[1032](http://www.ncbi.nlm.nih.gov/pubmed/15885496?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]PrRP‐20 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1875) (Agonist) (p*K* ~d~ 9.2--10.6) \[[1043](http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus)\], [\[^125^I\]PrRP31](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4022) (Agonist) \[[473](http://www.ncbi.nlm.nih.gov/pubmed/15752583?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0236}
--------

The orphan receptor [*GPR83*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4523)([Q9NYM4](http://www.uniprot.org/uniprot/Q9NYM4)) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.

Further Reading {#bph13348-sec-0237}
---------------

Samson WK *et al*. (2006) Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth. *Peptides* **27**: 1099‐103 [\[PMID:16500730\]](http://www.ncbi.nlm.nih.gov/pubmed/16500730?dopt=AbstractPlus)

Takayanagi Y *et al*. (2010) Roles of prolactin‐releasing peptide and RFamide related peptides in the control of stress and food intake. *FEBS J.* **277**: 4998‐5005 [\[PMID:21126313\]](http://www.ncbi.nlm.nih.gov/pubmed/21126313?dopt=AbstractPlus)

[Prostanoid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=58) {#bph13348-sec-0238}
================================================================================================

Overview {#bph13348-sec-0239}
--------

Prostanoid receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Prostanoid Receptors \[** [**2043**](http://www.ncbi.nlm.nih.gov/pubmed/21752876?dopt=AbstractPlus) **\]**) are activated by the endogenous ligands prostaglandins [PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883) , [PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483), prostacyclin \[[PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)\] and [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482). Measurement of the potency of [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915) and [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482) is hampered by their instability in physiological salt solution; they are often replaced by [cicaprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917) and [U46619](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1888), respectively, in receptor characterization studies.

Nomenclature[DP~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338)[DP~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339)[IP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345)[FP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344)[TP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=346)HGNC, UniProt[*PTGDR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9591), [Q13258](http://www.uniprot.org/uniprot/Q13258)[*PTGDR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4502), [Q9Y5Y4](http://www.uniprot.org/uniprot/Q9Y5Y4)[*PTGIR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9602), [P43119](http://www.uniprot.org/uniprot/P43119)[*PTGFR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9600), [P43088](http://www.uniprot.org/uniprot/P43088)[*TBXA2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11608), [P21731](http://www.uniprot.org/uniprot/P21731)Rank order of potency[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)≫[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884)\>[PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)--[PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)≫[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883), [PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884)\>[thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884)\>[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)\>[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482) = [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483)≫[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883), [PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)Rank order of potency--[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)≫[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)Agonists--[13,14‐dihydro‐15‐keto‐PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1900) (p*K* ~i~ 7.4--8.5) \[[712](http://www.ncbi.nlm.nih.gov/pubmed/12721327?dopt=AbstractPlus), [1656](http://www.ncbi.nlm.nih.gov/pubmed/12466225?dopt=AbstractPlus), [1815](http://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus)\][iloprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895) (p*K* ~i~ 7.5--8) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\], [treprostinil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820) (p*K* ~i~ 7.5) \[[2019](http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus)\][bimatoprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1958) (pIC~50~ 5.3) \[[2044](http://www.ncbi.nlm.nih.gov/pubmed/12606640?dopt=AbstractPlus)\]--Selective agonists[BW 245C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1878) (p*K* ~i~ 8.4--9.4) \[[171](http://www.ncbi.nlm.nih.gov/pubmed/7642548?dopt=AbstractPlus), [2045](http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus), [2046](http://www.ncbi.nlm.nih.gov/pubmed/10448933?dopt=AbstractPlus)\], [L‐644,698](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1879) (p*K* ~i~ 9--9.3) \[[2045](http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus), [2046](http://www.ncbi.nlm.nih.gov/pubmed/10448933?dopt=AbstractPlus)\], [SQ‐27986](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1887) (p*K* ~i~ 8) \[[1712](http://www.ncbi.nlm.nih.gov/pubmed/10772998?dopt=AbstractPlus)\], [RS 93520](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1886) (Partial agonist) (p*K* ~i~ 7.5) \[[1712](http://www.ncbi.nlm.nih.gov/pubmed/10772998?dopt=AbstractPlus)\], [ZK118182](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1890) (p*K* ~i~ 7.3) \[[1712](http://www.ncbi.nlm.nih.gov/pubmed/10772998?dopt=AbstractPlus)\][15(*R*)‐15‐methyl‐PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1902) (p*K* ~i~ 8.9) \[[712](http://www.ncbi.nlm.nih.gov/pubmed/12721327?dopt=AbstractPlus), [1312](http://www.ncbi.nlm.nih.gov/pubmed/12490611?dopt=AbstractPlus), [1815](http://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus)\][AFP‐07](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1962) (pIC~50~ 8.5) \[[288](http://www.ncbi.nlm.nih.gov/pubmed/9112287?dopt=AbstractPlus)\], [BMY 45778](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1963) (pIC~50~ 8) \[[881](http://www.ncbi.nlm.nih.gov/pubmed/9156364?dopt=AbstractPlus)\], [esuberaprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8314) (p*K* ~d~ 7.9) \[[892](http://www.ncbi.nlm.nih.gov/pubmed/2665758?dopt=AbstractPlus)\], [cicaprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917) (p*K* ~i~ 7.8) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\][fluprostenol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1940) (p*K* ~i~ 8.6) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\], [latanoprost (free acid form)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1960) (p*K* ~i~ 8.6) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\], [AL12180](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3386) (pEC~50~ 7.7--7.9) \[[1714](http://www.ncbi.nlm.nih.gov/pubmed/17076623?dopt=AbstractPlus)\], [tafluprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7451) \[[1843](http://www.ncbi.nlm.nih.gov/pubmed/15037111?dopt=AbstractPlus)\][I‐BOP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1938) (p*K* ~d~ 8.9--9.3) \[[1233](http://www.ncbi.nlm.nih.gov/pubmed/1830308?dopt=AbstractPlus)\], [U46619](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1888) (p*K* ~i~ 7.5) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\], [STA~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1939) (pIC~50~ 6.4--7.1) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus)\]Antagonists--[ramatroban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911) (p*K* ~i~ 7.4) \[[1815](http://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus)\]----[ramatroban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911) (p*K* ~i~ 8) \[[1869](http://www.ncbi.nlm.nih.gov/pubmed/1387312?dopt=AbstractPlus)\]Selective antagonists[laropiprant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3356) (p*K* ~i~ 10.1) \[[1808](http://www.ncbi.nlm.nih.gov/pubmed/17300164?dopt=AbstractPlus)\] -- Unknown, [BWA868C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1897) (p*K* ~i~ 8.6--9.3) \[[171](http://www.ncbi.nlm.nih.gov/pubmed/7642548?dopt=AbstractPlus), [606](http://www.ncbi.nlm.nih.gov/pubmed/2924081?dopt=AbstractPlus), [2045](http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus)\], [S‐5751](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1898) (p*K* ~i~ 8.8) \[[54](http://www.ncbi.nlm.nih.gov/pubmed/11454901?dopt=AbstractPlus)\], [ONO‐AE3‐237](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8537) (p*K* ~i~ 7.7) \[[758](http://www.ncbi.nlm.nih.gov/pubmed/21819041?dopt=AbstractPlus), [1895](http://www.ncbi.nlm.nih.gov/pubmed/15388164?dopt=AbstractPlus), [1897](http://www.ncbi.nlm.nih.gov/pubmed/18178816?dopt=AbstractPlus)\][CAY 10471](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1905) (pIC~50~ 8.9) \[[1610](http://www.ncbi.nlm.nih.gov/pubmed/17714552?dopt=AbstractPlus), [1927](http://www.ncbi.nlm.nih.gov/pubmed/15715457?dopt=AbstractPlus)\], [AZD1981](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7680) (pIC~50~ 8.4) \[[1150](http://www.ncbi.nlm.nih.gov/pubmed/21944852?dopt=AbstractPlus)\][RO1138452](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1969) (p*K* ~i~ 8.7) \[[158](http://www.ncbi.nlm.nih.gov/pubmed/16331286?dopt=AbstractPlus)\], [RO3244794](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4042) (pA~2~ 8.5) \[[158](http://www.ncbi.nlm.nih.gov/pubmed/16331286?dopt=AbstractPlus)\][AS604872](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3424) (p*K* ~i~ 7.5) \[[346](http://www.ncbi.nlm.nih.gov/pubmed/17618756?dopt=AbstractPlus)\][ifetroban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1987) (p*K* ~i~ 8.4--10) \[[1426](http://www.ncbi.nlm.nih.gov/pubmed/8437108?dopt=AbstractPlus)\], [vapiprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1976) (p*K* ~i~ 8.3--9.4) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus), [1151](http://www.ncbi.nlm.nih.gov/pubmed/2527074?dopt=AbstractPlus)\], [SQ‐29548](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1980) (p*K* ~i~ 8.1--9.1) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [1834](http://www.ncbi.nlm.nih.gov/pubmed/2975605?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\], [ONO‐3708](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1978) (p*K* ~i~ 7.4--8.9) \[[910](http://www.ncbi.nlm.nih.gov/pubmed/3008368?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1891) (Agonist) (p*K* ~d~ 7.9--9.5) \[[2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus), [2045](http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus)\][\[^3^H\]PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1891) (Agonist) (p*K* ~d~ 7.8--8.2) \[[1216](http://www.ncbi.nlm.nih.gov/pubmed/16418339?dopt=AbstractPlus), [1723](http://www.ncbi.nlm.nih.gov/pubmed/12975488?dopt=AbstractPlus)\][\[^3^H\]iloprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1966) (Agonist) (p*K* ~d~ 7.7--9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [170](http://www.ncbi.nlm.nih.gov/pubmed/7512962?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\][\[^3^H\]PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1957) (Agonist) (p*K* ~d~ 8.1--9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [8](http://www.ncbi.nlm.nih.gov/pubmed/8300593?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\], [\[^3^H\](+)‐fluprostenol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3417) (Agonist) (p*K* ~d~ 7.5) -- Unknown[\[^125^I\]SAP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1982) (Antagonist) (p*K* ~d~ 7.7--9.3) \[[1356](http://www.ncbi.nlm.nih.gov/pubmed/1386885?dopt=AbstractPlus)\], [\[^125^I\]BOP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1973) (Agonist) (p*K* ~d~ 8.7) \[[1328](http://www.ncbi.nlm.nih.gov/pubmed/2530338?dopt=AbstractPlus)\], [\[^3^H\]SQ‐29548](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1985) (Antagonist) (p*K* ~d~ 7.4--8.2) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\]

Nomenclature[EP~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=340)[EP~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341)[EP~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342)[EP~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343)HGNC, UniProt[*PTGER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9593), [P34995](http://www.uniprot.org/uniprot/P34995)[*PTGER2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9594), [P43116](http://www.uniprot.org/uniprot/P43116)[*PTGER3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9595), [P43115](http://www.uniprot.org/uniprot/P43115)[*PTGER4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9596), [P35408](http://www.uniprot.org/uniprot/P35408)Rank order of potency[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)\>[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)\>[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)\>[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)\>[PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884), [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)\>[PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881), [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)Endogenous agonists[PGE~1~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882) (p*K* ~i~ 6.8) \[[1713](http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus)\], [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915) (p*K* ~i~ 4.8) \[[1713](http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus)\][PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883) (p*K* ~i~ 7.5--8.3) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [1799](http://www.ncbi.nlm.nih.gov/pubmed/10462542?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\]--Agonists[17‐phenyl‐*ω*‐trinor‐PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1912) (p*K* ~i~ 8.1) \[[1713](http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus)\][evatanepag](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1929) (pIC~50~ 7.3) \[[260](http://www.ncbi.nlm.nih.gov/pubmed/19250823?dopt=AbstractPlus)\] -- Rat[misoprostol (methyl ester)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1936) (EP~3~‐III isoform) (p*K* ~i~ 6.5) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\]--Selective agonists[ONO‐DI‐004](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1914) (p*K* ~i~ 6.8) \[[1826](http://www.ncbi.nlm.nih.gov/pubmed/10746663?dopt=AbstractPlus)\] -- Mouse[ONO‐AE1‐259](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1932) (p*K* ~i~ 8.5) \[[1826](http://www.ncbi.nlm.nih.gov/pubmed/10746663?dopt=AbstractPlus)\] -- Mouse, [butaprost (free acid form)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1892) (p*K* ~i~ 5.9--7) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [1799](http://www.ncbi.nlm.nih.gov/pubmed/10462542?dopt=AbstractPlus)\][SC46275](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3331) (pEC~50~ 10.4) \[[1655](http://www.ncbi.nlm.nih.gov/pubmed/8140121?dopt=AbstractPlus)\] -- Guinea pig, [MB‐28767](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1913) (EP~3~‐III isoform) (p*K* ~i~ 9.9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\], [ONO‐AE‐248](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1931) (pEC~50~ 5.6--6.7) \[[534](http://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus), [1140](http://www.ncbi.nlm.nih.gov/pubmed/22342278?dopt=AbstractPlus)\][L902688](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3357) (pEC~50~ 8.1--10.3) \[[535](http://www.ncbi.nlm.nih.gov/pubmed/18516068?dopt=AbstractPlus), [1064](http://www.ncbi.nlm.nih.gov/pubmed/19584306?dopt=AbstractPlus)\], [ONO‐AE1‐437](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8541) (p*K* ~i~ 9.1) \[[1294](http://www.ncbi.nlm.nih.gov/pubmed/12954235?dopt=AbstractPlus)\] -- Mouse, [CP734432](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4039) (pIC~50~ 8.7) \[[1529](http://www.ncbi.nlm.nih.gov/pubmed/19445930?dopt=AbstractPlus)\], [ONO‐AE1‐329](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1933) (pEC~50~ 7.7--7.8) \[[534](http://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus), [535](http://www.ncbi.nlm.nih.gov/pubmed/18516068?dopt=AbstractPlus)\]Antagonists------[evatanepag](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1929) (p*K* ~i~ 8.6) \[[1345](http://www.ncbi.nlm.nih.gov/pubmed/18155068?dopt=AbstractPlus)\],Selective antagonists[ONO‐8711](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1920) (p*K* ~i~ 9.2) \[[1992](http://www.ncbi.nlm.nih.gov/pubmed/10537280?dopt=AbstractPlus)\], [GW848687X](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3360) (pIC~50~ 8.6) \[[605](http://www.ncbi.nlm.nih.gov/pubmed/17084082?dopt=AbstractPlus)\], [SC‐51322](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1924) (p*K* ~i~ 7.9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\][TG4‐155](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5818) (TG4‐155 also has affinity for the human DP1 receptor (p*K* ~b~ = 7.8)) (p*K* ~B~ 8.6) \[[865](http://www.ncbi.nlm.nih.gov/pubmed/22323596?dopt=AbstractPlus)\], [TG7‐171](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8546) (p*K* ~B~ 8.6) \[[567](http://www.ncbi.nlm.nih.gov/pubmed/24937185?dopt=AbstractPlus)\], [PF‐04852946](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8538) (p*K* ~B~ 8.4--8.5) \[[920](http://www.ncbi.nlm.nih.gov/pubmed/23786281?dopt=AbstractPlus)\], [PF‐04418948](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5817) (PF‐04418948 has weaker affinity at the EP2‐receptor in guinea‐pigs) (p*K* ~B~ 8.3) \[[153](http://www.ncbi.nlm.nih.gov/pubmed/22747912?dopt=AbstractPlus), [2136](http://www.ncbi.nlm.nih.gov/pubmed/21595651?dopt=AbstractPlus)\][L‐798,106](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1941) (EP~3~‐III isoform) (p*K* ~i~ 7.8--9.7) \[[888](http://www.ncbi.nlm.nih.gov/pubmed/19486006?dopt=AbstractPlus), [890](http://www.ncbi.nlm.nih.gov/pubmed/11504634?dopt=AbstractPlus), [1810](http://www.ncbi.nlm.nih.gov/pubmed/18632791?dopt=AbstractPlus)\], [L‐826266](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5844) (EP~3~‐III isoform (pK~i~=8.04 in the presence of HSA)) (p*K* ~i~ 9.1) \[[890](http://www.ncbi.nlm.nih.gov/pubmed/11504634?dopt=AbstractPlus)\], [ONO‐AE3‐240](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1943) (pIC~50~ 8.8) \[[38](http://www.ncbi.nlm.nih.gov/pubmed/12538661?dopt=AbstractPlus)\] -- Mouse, [DG‐041](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5822) (p*K* ~i~ 8.4) \[[888](http://www.ncbi.nlm.nih.gov/pubmed/19486006?dopt=AbstractPlus)\][MK‐2894](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4041) (p*K* ~i~ 9.2) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [161](http://www.ncbi.nlm.nih.gov/pubmed/20163116?dopt=AbstractPlus), [350](http://www.ncbi.nlm.nih.gov/pubmed/18287210?dopt=AbstractPlus)\], [ONO‐AE3‐208](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1942) (p*K* ~i~ 8.5), [BGC201531](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3380) (p*K* ~i~ 7.9) \[[1230](http://www.ncbi.nlm.nih.gov/pubmed/19154437?dopt=AbstractPlus)\], [ER819762](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4040) (pIC~50~ 7.2) \[[304](http://www.ncbi.nlm.nih.gov/pubmed/20423341?dopt=AbstractPlus)\], [GW 627368](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1953) (p*K* ~i~ 7--7.1) \[[2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus), [2031](http://www.ncbi.nlm.nih.gov/pubmed/15655509?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916) (Agonist) (p*K* ~d~ 7.6--7.9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [1713](http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\][\[^3^H\]PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916) (Agonist) (p*K* ~d~ 7.7--7.9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\][\[^3^H\]PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916) (Agonist) (p*K* ~d~ 8.2--9.5) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\][\[^3^H\]PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916) (Agonist) (p*K* ~d~ 7.6--9.5) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus), [401](http://www.ncbi.nlm.nih.gov/pubmed/10952683?dopt=AbstractPlus), [2019](http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus), [2030](http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0240}
--------

[ramatroban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911) is an antagonist at both DP~2~ and TP receptors. Whilst [cicaprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917) is selective for IP receptors, it does exhibit moderate agonist potency at EP~4~ receptors \[[7](http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus)\]. Apart from IP receptors, [iloprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895) also binds to other prostanoid receptors such as EP~1~ receptors. The TP receptor exists in *α* and *β* isoforms due to alternative splicing of the cytoplasmic tail \[[1566](http://www.ncbi.nlm.nih.gov/pubmed/8034687?dopt=AbstractPlus)\]. The IP receptor agonist [treprostinil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820) binds also to human EP~2~ and DP~1~ receptors with high affinity (p*K* ~i~ 8.44 and 8.36, respectively).

The EP~1~ agonist [17‐phenyl‐*ω*‐trinor‐PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1912) also shows agonist activity at EP~3~ receptors. [Butaprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3379) and [SC46275](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3331) may require de‐esterification within tissues to attain full agonist potency. There is evidence for subtypes of FP \[[1105](http://www.ncbi.nlm.nih.gov/pubmed/7830272?dopt=AbstractPlus)\], IP \[[1851](http://www.ncbi.nlm.nih.gov/pubmed/8621463?dopt=AbstractPlus), [2037](http://www.ncbi.nlm.nih.gov/pubmed/7589166?dopt=AbstractPlus)\] and TP \[[1005](http://www.ncbi.nlm.nih.gov/pubmed/8882612?dopt=AbstractPlus)\] receptors. mRNA for the EP~1~ and EP~3~ receptors undergo alternative splicing to produce two \[[1441](http://www.ncbi.nlm.nih.gov/pubmed/8940129?dopt=AbstractPlus)\] and at least six variants, respectively, which can interfere with signalling \[[1441](http://www.ncbi.nlm.nih.gov/pubmed/8940129?dopt=AbstractPlus)\] or generate complex patterns of G‐protein (G~i/o~, G~q/11~, G~s~ and G~12,13~) coupling (*e.g.* \[[997](http://www.ncbi.nlm.nih.gov/pubmed/7476918?dopt=AbstractPlus), [1370](http://www.ncbi.nlm.nih.gov/pubmed/7608175?dopt=AbstractPlus)\]). The number of EP~3~ receptor (protein) variants are variable depending on species, with five in human, three in rat and three in mouse. The possibility of additional receptors for the isoprostanes has been suggested \[[1531](http://www.ncbi.nlm.nih.gov/pubmed/8663015?dopt=AbstractPlus)\]. Putative receptor(s) for prostamide F (which as yet lack molecular correlates) and which preferentially recognize [PGF2‐1‐ethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5456) and its analogues (*e.g*. [Bimatoprost](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1958)) have been identified, together with moderate‐potency antagonists (*e.g.* [AGN 211334](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5455)) \[[2042](http://www.ncbi.nlm.nih.gov/pubmed/18700152?dopt=AbstractPlus)\].

The free acid form of AL‐12182, [AL12180](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3386), used in *in vitro* studies, has a EC~50~ value of 15nM which is the concentration of the compound giving half‐maximal stimulation of inositol phosphate turnover in HEK‐293 cells expressing the human FP receptor \[[1714](http://www.ncbi.nlm.nih.gov/pubmed/17076623?dopt=AbstractPlus)\].

References given alongside the TP receptor agonists I‐BOP \[[1233](http://www.ncbi.nlm.nih.gov/pubmed/1830308?dopt=AbstractPlus)\] and STA~2~\[[59](http://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus)\] use human platelets as the source of TP receptors for competition radio‐ligand binding assays to determine the indicated activity values.

Pharmacological evidence for a second IP receptor, denoted IP~2~, in the central nervous system \[[1851](http://www.ncbi.nlm.nih.gov/pubmed/8621463?dopt=AbstractPlus), [1994](http://www.ncbi.nlm.nih.gov/pubmed/10349870?dopt=AbstractPlus)\] and in the BEAS‐2B human airway epithelial cell line \[[2033](http://www.ncbi.nlm.nih.gov/pubmed/21173040?dopt=AbstractPlus)\] is available. This receptor is selectively activated by 15R‐17,18,19,20‐tetranor‐16‐m‐tolyl‐isocarbacyclin ([15R‐TIC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5864)) and 15R‐Deoxy 17,18,19,20‐tetranor‐16‐m‐tolyl‐isocarbacyclin ([15‐deoxy‐TIC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5865)). However, molecular biological evidence for the IP~2~ subtype is currently lacking.
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---------------
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[Proteinase‐activated receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=59) {#bph13348-sec-0242}
==========================================================================================================

Overview {#bph13348-sec-0243}
--------

Proteinase‐activated receptors (PARs, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Proteinase‐activated Receptors \[** [**770**](http://www.ncbi.nlm.nih.gov/pubmed/12037136?dopt=AbstractPlus) **\]**) are unique members of the GPCR superfamily activated by proteolytic cleavage of their amino terminal exodomains. Agonist proteinase‐induced hydrolysis unmasks a tethered ligand (TL) at the exposed amino terminus, which acts intramolecularly at the binding site in the body of the receptor to effect transmembrane signalling. TL sequences at human PAR1‐4 are [SFLLRN‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5361), [SLIGKV‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3740), [TFRGAP‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5360) and [GYPGQV‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3739), respectively. With the exception of PAR3, these synthetic peptide sequences (as carboxyl terminal amides) are able to act as agonists at their respective receptors. Several proteinases, including neutrophil elastase, cathepsin G and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such that they cleave the exodomain of the receptor without inducing activation of G*α*q‐coupled calcium signalling, thereby preventing activation by activating proteinases but not by agonist peptides. Neutrophil elastase cleavage of PAR2 can however activate MAP kinase signaling by exposing a TL that is different from the one revealed by trypsin \[[1553](http://www.ncbi.nlm.nih.gov/pubmed/22212680?dopt=AbstractPlus)\]. The role of such an action *in vivo* is unclear.

Nomenclature[PAR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=347)[PAR2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=348)[PAR3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=349)[PAR4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=350)HGNC, UniProt[*F2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3537), [P25116](http://www.uniprot.org/uniprot/P25116)[*F2RL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3538), [P55085](http://www.uniprot.org/uniprot/P55085)[*F2RL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3539), [O00254](http://www.uniprot.org/uniprot/O00254)[*F2RL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3540), [Q96RI0](http://www.uniprot.org/uniprot/Q96RI0)Agonist proteases[thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453) ([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)), activated [protein C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4473) ([*PROC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9451), [P04070](http://www.uniprot.org/uniprot/P04070)), [matrix metalloproteinase 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6655) ([*MMP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7155), [P45452](http://www.uniprot.org/uniprot/P45452)), [matrix metalloproteinase 13](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6656) ([*MMP13*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7159), [P45452](http://www.uniprot.org/uniprot/P45452)) \[[70](http://www.ncbi.nlm.nih.gov/pubmed/23086754?dopt=AbstractPlus)\]Trypsin, tryptase, TF/VIIa, Xa[thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453) ([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734))[thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453) ([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)), trypsin, [cathepsin G](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570) ([*CTSG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2532), [P08311](http://www.uniprot.org/uniprot/P08311))Selective agonists[TFLLR‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3742) (pEC~50~ 5.4) \[[340](http://www.ncbi.nlm.nih.gov/pubmed/11877318?dopt=AbstractPlus)\][GB110](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6657) (pEC~50~ 6.5) \[[98](http://www.ncbi.nlm.nih.gov/pubmed/20873792?dopt=AbstractPlus)\], [2‐furoyl‐LIGRLO‐amide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3851) (p*K* ~i~ 5.4) \[[1243](http://www.ncbi.nlm.nih.gov/pubmed/14976230?dopt=AbstractPlus)\], [SLIGKV‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3740) \[[1069](http://www.ncbi.nlm.nih.gov/pubmed/18179608?dopt=AbstractPlus)\], [SLIGRL‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3741) \[[1069](http://www.ncbi.nlm.nih.gov/pubmed/18179608?dopt=AbstractPlus)\]--[AYPGKF‐NH2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4061), [GYPGKF‐NH2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3883), [GYPGQV‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3739)Selective antagonists[vorapaxar](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4047) (p*K* ~i~ 8.1) \[[281](http://www.ncbi.nlm.nih.gov/pubmed/18447380?dopt=AbstractPlus)\], [atopaxar](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4048) (pIC~50~ 7.7) \[[978](http://www.ncbi.nlm.nih.gov/pubmed/21300059?dopt=AbstractPlus)\], [RWJ‐56110](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3525) (pIC~50~ 6.4) \[[48](http://www.ncbi.nlm.nih.gov/pubmed/10535908?dopt=AbstractPlus)\][GB88](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6658) (pIC~50~ 5.7) \[[1813](http://www.ncbi.nlm.nih.gov/pubmed/21806599?dopt=AbstractPlus)\], [P2pal18s](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6659) \[[1705](http://www.ncbi.nlm.nih.gov/pubmed/21536878?dopt=AbstractPlus)\]----Labelled ligands[\[^3^H\]haTRAP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3823) (Agonist) (p*K* ~d~ 7.8) \[[15](http://www.ncbi.nlm.nih.gov/pubmed/9203642?dopt=AbstractPlus)\][2‐furoyl‐LIGRL\[N‐(Alexa Fluor 594)‐O\]‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4050) (Agonist) \[[771](http://www.ncbi.nlm.nih.gov/pubmed/18477767?dopt=AbstractPlus)\], [2‐furoyl‐LIGRL\[N\[^3^H\]propionyl\]‐O‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4049) (Agonist) \[[771](http://www.ncbi.nlm.nih.gov/pubmed/18477767?dopt=AbstractPlus)\], [\[^3^H\]2‐furoyl‐LIGRL‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6660) (Selective Agonist) \[[903](http://www.ncbi.nlm.nih.gov/pubmed/15765104?dopt=AbstractPlus)\], [trans‐cinnamoyl‐LIGRLO \[N‐\[^3^H\]propionyl\]‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3914) (Agonist) \[[28](http://www.ncbi.nlm.nih.gov/pubmed/10411588?dopt=AbstractPlus)\]----Comments[TFLLR‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3742) is selective relative to the PAR~2~ receptor \[[155](http://www.ncbi.nlm.nih.gov/pubmed/8663335?dopt=AbstractPlus), [915](http://www.ncbi.nlm.nih.gov/pubmed/9862790?dopt=AbstractPlus)\].2‐Furoyl‐LIGRLO‐NH~2~ activity was measured via calcium mobilisation in HEK 293 cells which constitutively coexpress human PAR~1~ and PAR~2~.----

Comments {#bph13348-sec-0244}
--------

[thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453)([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)) is inactive at the PAR~2~ receptor.

Endogenous serine proteases (EC 3.4.21.) active at the proteinase‐activated receptors include: [thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453)([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)), generated by the action of Factor X ([*F10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3528), [P00742](http://www.uniprot.org/uniprot/P00742)) on liver‐derived prothrombin ([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)); trypsin, generated by the action of enterokinase ([*TMPRSS15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9490), [P98073](http://www.uniprot.org/uniprot/P98073)) on pancreatic‐derived trypsinogen ([*PRSS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9475), [P07477](http://www.uniprot.org/uniprot/P07477)); tryptase, a family of enzymes (*α*/*β*1 [*TPSAB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12019), [Q15661](http://www.uniprot.org/uniprot/Q15661) ; *γ*1 [*TPSG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14134), [Q9NRR2](http://www.uniprot.org/uniprot/Q9NRR2); *δ*1 [*TPSD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14118), [Q9BZJ3](http://www.uniprot.org/uniprot/Q9BZJ3)) secreted from mast cells; cathepsin G ([*CTSG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2532), [P08311](http://www.uniprot.org/uniprot/P08311)) generated from leukocytes; liver‐derived protein C ([*PROC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9451), [P04070](http://www.uniprot.org/uniprot/P04070)) generated in plasma by [thrombin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453)([*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)) and [matrix metalloproteinase 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6655) ([*MMP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7155), [P45452](http://www.uniprot.org/uniprot/P45452)).

Further Reading {#bph13348-sec-0245}
---------------
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Canto I *et al*. (2012) Allosteric modulation of protease‐activated receptor signaling. *Mini Rev Med Chem* **12**: 804‐11 [\[PMID:22681248\]](http://www.ncbi.nlm.nih.gov/pubmed/22681248?dopt=AbstractPlus)
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Soh UJ *et al*. (2010) Signal transduction by protease‐activated receptors. *Br. J. Pharmacol.* **160**: 191‐203 [\[PMID:20423334\]](http://www.ncbi.nlm.nih.gov/pubmed/20423334?dopt=AbstractPlus)
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[QRFP receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=54) {#bph13348-sec-0246}
=========================================================================================

Overview {#bph13348-sec-0247}
--------

The human gene encoding the QRFP receptor (QRFPR, also known as the peptide P518 receptor), previously designated as an orphan GPCR receptor was identified in 2001 by Lee *et al.* from a hypothalamus cDNA library \[[1066](http://www.ncbi.nlm.nih.gov/pubmed/11574155?dopt=AbstractPlus)\]. However, the reported cDNA (AF411117) is a chimera with bases 1‐127 derived from chromosome 1 and bases 155‐1368 derived from chromosome 4. When corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These include neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin GalR1 (35%) receptors.

Nomenclature[QRFP receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=333)HGNC, UniProt[*QRFPR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15565), [Q96P65](http://www.uniprot.org/uniprot/Q96P65)Endogenous agonists[QRFP43](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665) ([*QRFP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982), [P83859](http://www.uniprot.org/uniprot/P83859)) (pIC~50~ 7.8--9.3) \[[557](http://www.ncbi.nlm.nih.gov/pubmed/12960173?dopt=AbstractPlus), [1850](http://www.ncbi.nlm.nih.gov/pubmed/16648250?dopt=AbstractPlus)\] -- Rat, [QRFP26](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5895) ([*QRFP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29982)) (pEC~50~ 8.2) \[[867](http://www.ncbi.nlm.nih.gov/pubmed/12714592?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]QRFP43 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3803) (Agonist) (p*K* ~d~ 7.8--10.3) \[[557](http://www.ncbi.nlm.nih.gov/pubmed/12960173?dopt=AbstractPlus), 1017, [1850](http://www.ncbi.nlm.nih.gov/pubmed/16648250?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0248}
--------

The orphan receptor [*GPR83*](http://www.guidetopharmacology.org/GRAC/)([9NYM4](http://www.uniprot.org/uniprot/9NYM4)) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.

Further Reading {#bph13348-sec-0249}
---------------

Fukusumi S *et al*. (2006) Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. *Peptides* **27**: 1073‐86 [\[PMID:16500002\]](http://www.ncbi.nlm.nih.gov/pubmed/16500002?dopt=AbstractPlus)

[Relaxin family peptide receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=60) {#bph13348-sec-0250}
============================================================================================================

Overview {#bph13348-sec-0251}
--------

Relaxin family peptide receptors (RXFP, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Relaxin family peptide receptors \[** [**105**](http://www.ncbi.nlm.nih.gov/pubmed/16507880?dopt=AbstractPlus) **,** [**677**](http://www.ncbi.nlm.nih.gov/pubmed/25761609?dopt=AbstractPlus) **\]**) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists at these receptors are a number of heterodimeric peptide hormones analogous to insulin: [relaxin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1988)([*RLN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10026), [P04808](http://www.uniprot.org/uniprot/P04808)), [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)), [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) (also known as INSL7), insulin‐like peptide 3 ([INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995)([*INSL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6086), [P51460](http://www.uniprot.org/uniprot/P51460))) and [INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000)([*INSL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6088), [Q9Y5Q6](http://www.uniprot.org/uniprot/Q9Y5Q6)).

Species homologues of relaxin have distinct pharmacology ‐ [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) interacts with RXFP1, RXFP2 and RXFP3, whereas mouse and rat relaxin selectively bind to and activate RXFP1 \[[1686](http://www.ncbi.nlm.nih.gov/pubmed/15956680?dopt=AbstractPlus)\] and porcine [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1992) may have a higher efficacy than human [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) \[[678](http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus)\]. [Relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) has differential affinity for RXFP2 receptors between species; mouse and rat RXFP2 have a higher affinity for [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \[[1685](http://www.ncbi.nlm.nih.gov/pubmed/15956681?dopt=AbstractPlus)\]. At least two binding sites have been identified on the RXFP1 and RXFP2 receptors: a high‐affinity site in the leucine‐rich repeat region of the ectodomain and a somewhat lower‐affinity site located in the surface loops of the transmembrane domain \[[678](http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus), [1812](http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus)\]. The unique N‐terminal LDLa module of RXFP1 and RXFP2 is essential for receptor signalling \[[1687](http://www.ncbi.nlm.nih.gov/pubmed/16963451?dopt=AbstractPlus)\].

Nomenclature[RXFP1 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=351)[RXFP2 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=352)[RXFP3 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=353)[RXFP4 receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=354)HGNC, UniProt[*RXFP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19718), [Q9HBX9](http://www.uniprot.org/uniprot/Q9HBX9)[*RXFP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17318), [Q8WXD0](http://www.uniprot.org/uniprot/Q8WXD0)[*RXFP3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24883), [Q9NSD7](http://www.uniprot.org/uniprot/Q9NSD7)[*RXFP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14666), [Q8TDU9](http://www.uniprot.org/uniprot/Q8TDU9)Rank order of potency[relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989) ([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) = [relaxin‐1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1988) ([*RLN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10026), [P04808](http://www.uniprot.org/uniprot/P04808)) \>[relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \[[1812](http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus)\][INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995) ([*INSL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6086), [P51460](http://www.uniprot.org/uniprot/P51460)) \>[relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989) ([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) ≫[relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \[[1022](http://www.ncbi.nlm.nih.gov/pubmed/12114498?dopt=AbstractPlus), [1812](http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus)\][relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \>[relaxin‐3 (B chain)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1997) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \>[relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989) ([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) \[[1119](http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus)\][INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000) ([*INSL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6088), [Q9Y5Q6](http://www.uniprot.org/uniprot/Q9Y5Q6)) = [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \>[relaxin‐3 (B chain)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1997) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) \[[1117](http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus), [1118](http://www.ncbi.nlm.nih.gov/pubmed/14522967?dopt=AbstractPlus)\]Endogenous antagonists----[INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000) ([*INSL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6088), [Q9Y5Q6](http://www.uniprot.org/uniprot/Q9Y5Q6)) (p*K* ~i~ 7) \[[2129](http://www.ncbi.nlm.nih.gov/pubmed/18582868?dopt=AbstractPlus)\]--Antagonists[B‐R13/17K H2 relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4371) (pEC~50~ 5.7--6.7) \[[788](http://www.ncbi.nlm.nih.gov/pubmed/20043231?dopt=AbstractPlus), [1382](http://www.ncbi.nlm.nih.gov/pubmed/24812057?dopt=AbstractPlus)\], [LGR7‐truncate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3893) \[[1687](http://www.ncbi.nlm.nih.gov/pubmed/16963451?dopt=AbstractPlus)\]--[R3(B*Δ*23‐27)R/I5 chimeric peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3907) (pIC~50~ 9.2) \[[1018](http://www.ncbi.nlm.nih.gov/pubmed/17606621?dopt=AbstractPlus)\][R3(B*Δ*23‐27)R/I5 chimeric peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3907) (pIC~50~ 8--8.6) \[[714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus), [1018](http://www.ncbi.nlm.nih.gov/pubmed/17606621?dopt=AbstractPlus)\]Selective antagonists--[A(9‐26)INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8329) (p*K* ~i~ 9.1) \[[787](http://www.ncbi.nlm.nih.gov/pubmed/18434306?dopt=AbstractPlus)\], [A(10‐24)INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8330) (p*K* ~i~ 8.7) \[[787](http://www.ncbi.nlm.nih.gov/pubmed/18434306?dopt=AbstractPlus)\], [A(C10/15S)INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8331) (p*K* ~i~ 8.6) \[[2118](http://www.ncbi.nlm.nih.gov/pubmed/20570702?dopt=AbstractPlus)\], [INSL3 B chain dimer analogue 8](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4372) (p*K* ~i~ 8.5) \[[1710](http://www.ncbi.nlm.nih.gov/pubmed/20560146?dopt=AbstractPlus)\], [A(*Δ*10/15C)INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8332) (p*K* ~i~ 8.3) \[[2118](http://www.ncbi.nlm.nih.gov/pubmed/20570702?dopt=AbstractPlus)\], [cyclic INSL3 B‐chain analogue 6](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8333) (p*K* ~i~ 6.7) \[[1708](http://www.ncbi.nlm.nih.gov/pubmed/17120268?dopt=AbstractPlus)\], [INSL3 B‐chain analogue](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3885) (p*K* ~i~ 5.1) \[[411](http://www.ncbi.nlm.nih.gov/pubmed/16547350?dopt=AbstractPlus)\], [(des 1‐8) A‐chain INSL3 analogue](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3754) \[[253](http://www.ncbi.nlm.nih.gov/pubmed/15708846?dopt=AbstractPlus)\][minimised relaxin‐3 analogue 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8326) (p*K* ~i~ 7.6) \[[1706](http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus)\], [R3‐B1‐22R](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4373) (pIC~50~ 7.4) \[[714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus)\][minimised relaxin‐3 analogue 3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8326) (pIC~50~ 6.6) \[[1706](http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus)\]Selective allosteric modulators[ML290](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8322) (Agonist) (pEC~50~ 7) \[[2057](http://www.ncbi.nlm.nih.gov/pubmed/23905199?dopt=AbstractPlus), [2060](http://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus)\]------Labelled ligands[\[^33^P\]relaxin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1991) (Agonist) (p*K* ~d~ 9.3--9.7) \[[678](http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus), [1812](http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus)\], [\[^125^I\]relaxin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5398) (Agonist)[\[^125^I\]INSL3 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1996) (Agonist) (p*K* ~d~ 10) \[[1340](http://www.ncbi.nlm.nih.gov/pubmed/16051677?dopt=AbstractPlus)\], [\[^33^P\]relaxin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1991) (Agonist) (p*K* ~d~ 9--9.2) \[[678](http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus), [1812](http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus)\][\[^125^I\]relaxin‐3 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1999) (Agonist) (p*K* ~d~ 9.5) \[[1119](http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus)\], [\[^125^I\]relaxin‐3‐B/INSL5 A chimera](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3789) (Agonist) (p*K* ~d~ 9.3) \[[1117](http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus)\][\[^125^I\]relaxin‐3 (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1999) (Agonist) (p*K* ~d~ 8.7--9.7) \[[1118](http://www.ncbi.nlm.nih.gov/pubmed/14522967?dopt=AbstractPlus)\], [\[^125^I\]relaxin‐3‐B/INSL5 A chimera](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3789) (Agonist) (p*K* ~d~ 8.9) \[[1117](http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus)\], [europium‐labelled INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4375) (p*K* ~d~ 8.3) \[[714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus)\]Comments[europium‐labelled relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3874) is a fluorescent ligand for this receptor (*K* ~d~=0.5nM) \[[1707](http://www.ncbi.nlm.nih.gov/pubmed/22425984?dopt=AbstractPlus)\].[europium‐labelled INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3875) is a fluorescent ligand for this receptor (*K* ~d~=1nM) \[[1709](http://www.ncbi.nlm.nih.gov/pubmed/18529069?dopt=AbstractPlus)\].[europium‐labelled relaxin‐3‐B/INSL5 A chimera](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4374) and [R3‐B1‐22R](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4373) are fluorescent ligands for this receptor (*K* ~d~=5nM and 28nM) \[[714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus), [715](http://www.ncbi.nlm.nih.gov/pubmed/25792111?dopt=AbstractPlus)\].[europium‐labelled relaxin‐3‐B/INSL5 A chimera](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4374) is a fluorescent probe at this receptor (*K* ~d~=5nM) \[[714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus)\]. [europium‐labelled mouse INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6522) is a fluorescent ligand at this receptor (*K* ~d~=5nM) \[[120](http://www.ncbi.nlm.nih.gov/pubmed/21866895?dopt=AbstractPlus)\].

Comments {#bph13348-sec-0252}
--------

Relaxin has recently successfully completed a Phase III clinical trial for the treatment of acute heart failure. 48 hr infusion of relaxin reduced dyspnoea and 180 day mortality \[[1262](http://www.ncbi.nlm.nih.gov/pubmed/23273292?dopt=AbstractPlus)\]. Small molecule agonists active at RXFP1 receptors have been developed \[[1718](http://www.ncbi.nlm.nih.gov/pubmed/18854305?dopt=AbstractPlus), [2060](http://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus)\], and one of these ([ML290](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8322)) is an allosteric agonist at RXFP1 \[[2060](http://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus)\]. The antifibrotic actions of relaxin are dependent on the angiotensin receptor AT~2~, are absent in AT~2~ knockout mice, and are associated with heterodimer formation between RXFP1 and AT~2~\[[330](http://www.ncbi.nlm.nih.gov/pubmed/24429402?dopt=AbstractPlus)\]. Mutations in *INSL3* and *LGR8* (RXFP2) have been reported in populations of patients with cryptorchidism \[[512](http://www.ncbi.nlm.nih.gov/pubmed/12970298?dopt=AbstractPlus)\]. Numerous splice variants of the human RXFP1 and RXFP2 receptors have been identified, most of which do not bind relaxin family peptides \[[1340](http://www.ncbi.nlm.nih.gov/pubmed/16051677?dopt=AbstractPlus)\]. Splice variants of RXFP1 encoding the N‐terminal LDLa module act as antagonists of RXFP1 signalling \[[1685](http://www.ncbi.nlm.nih.gov/pubmed/15956681?dopt=AbstractPlus), [1687](http://www.ncbi.nlm.nih.gov/pubmed/16963451?dopt=AbstractPlus)\]. cAMP elevation appears to be a major signalling pathway for RXFP1 and RXFP2 \[[795](http://www.ncbi.nlm.nih.gov/pubmed/10935549?dopt=AbstractPlus), [796](http://www.ncbi.nlm.nih.gov/pubmed/11809971?dopt=AbstractPlus)\], but RXFP1 also activates MAP kinases, nitric oxide signalling, tyrosine kinase phosphorylation and relaxin can interact with glucocorticoid receptors \[[681](http://www.ncbi.nlm.nih.gov/pubmed/17293890?dopt=AbstractPlus)\]. RXFP1 signalling involves lipid rafts, residues in the C‐terminus of the receptor and activation of phosphatidylinositol‐3‐kinase \[[682](http://www.ncbi.nlm.nih.gov/pubmed/19029286?dopt=AbstractPlus)\]. More recent studies provide evidence that RXFP1 is pre‐assembled in signalosomes with other signalling proteins including G*α* ~s~, G*β* *γ* and adenylyl cyclase 2 that display constitutive activity and are exquisitely sensitive to sub‐picomolar concentrations of relaxin \[[679](http://www.ncbi.nlm.nih.gov/pubmed/20664520?dopt=AbstractPlus)\]. The [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) signalling pattern is highly dependent on the cell type in which RXFP1 is expressed \[[680](http://www.ncbi.nlm.nih.gov/pubmed/19416169?dopt=AbstractPlus)\].

The receptor expression profiles suggested that RXFP3 was a neuropeptide receptor and RXFP4 a gut hormone receptor. Studies in rats and mice (including wildtype, and relaxin‐3 and RXFP3 gene‐deletion strains \[[671](http://www.ncbi.nlm.nih.gov/pubmed/26023064?dopt=AbstractPlus), [782](http://www.ncbi.nlm.nih.gov/pubmed/25257104?dopt=AbstractPlus), [1759](http://www.ncbi.nlm.nih.gov/pubmed/24681162?dopt=AbstractPlus), [1971](http://www.ncbi.nlm.nih.gov/pubmed/25849482?dopt=AbstractPlus)\] have revealed putative roles for the relaxin‐3/RXFP3 system in the modulation of feeding \[[564](http://www.ncbi.nlm.nih.gov/pubmed/23135160?dopt=AbstractPlus), [566](http://www.ncbi.nlm.nih.gov/pubmed/22854307?dopt=AbstractPlus), [714](http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus), [1706](http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus), [1760](http://www.ncbi.nlm.nih.gov/pubmed/21899720?dopt=AbstractPlus)\], anxiety \[[1618](http://www.ncbi.nlm.nih.gov/pubmed/23380674?dopt=AbstractPlus), [2114](http://www.ncbi.nlm.nih.gov/pubmed/26057358?dopt=AbstractPlus)\], and reward and motivated, goal‐directed behaviours \[[782](http://www.ncbi.nlm.nih.gov/pubmed/25257104?dopt=AbstractPlus), [1619](http://www.ncbi.nlm.nih.gov/pubmed/24297931?dopt=AbstractPlus), [1971](http://www.ncbi.nlm.nih.gov/pubmed/25849482?dopt=AbstractPlus)\], particularly in relation to the integration of stress and corticotrophin‐releasing factor signalling \[[1162](http://www.ncbi.nlm.nih.gov/pubmed/23671163?dopt=AbstractPlus)\], with implications for the therapeutic treatment of clinical anxiety, depression, eating disorders and addiction (see \[[565](http://www.ncbi.nlm.nih.gov/pubmed/24065955?dopt=AbstractPlus), [1761](http://www.ncbi.nlm.nih.gov/pubmed/24711793?dopt=AbstractPlus)\] for review). [Relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) acts as an agonist at both RXFP3 and RXFP4 whereas [INSL5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000)([*INSL5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6088), [Q9Y5Q6](http://www.uniprot.org/uniprot/Q9Y5Q6)) is an agonist at RXFP4 and a weak antagonist at RXFP3. Unlike RXFP1 and RXFP2 both RXFP3 and RXFP4 are encoded by a single exon and therefore no splice variants exist. The rat RXFP3 sequence has two potential start codons that encode RXFP3L and RXFP3S with the longer variant having an additional 7 amino‐acids at the N‐terminus. It is not known which variant is expressed. Rat and dog RXFP4 sequences are pseudogenes \[[2027](http://www.ncbi.nlm.nih.gov/pubmed/15707501?dopt=AbstractPlus)\]. Recent studies suggest that INSL5 is an incretin secreted from enteroendocrine L cells and that the INSL5/RXFP4 system has roles in controlling food intake and glucose homeostasis \[[652](http://www.ncbi.nlm.nih.gov/pubmed/25028498?dopt=AbstractPlus)\]. RXFP3 couples to G~i/o~ and inhibits adenylyl cyclase \[[1119](http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus), [2144](http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus)\], and also causes Erk1/2 phosphorylation \[[2144](http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus)\]. Relatively little is known about RXFP4 signalling but like RXFP3 it couples to inhibitory G~i/o~ G‐proteins \[[1120](http://www.ncbi.nlm.nih.gov/pubmed/15525639?dopt=AbstractPlus)\]. Recent studies suggest that [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) also interacts with RXFP3 to cause a pattern of activation of signalling pathways that are a subset of those activated by [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)). The two patterns of signaling observed in several cell types expressing RXFP3 are strong inhibition of [forskolin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190)‐stimulated [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) accumulation, ERK1/2 activation and nuclear factor NF*κ*‐B reporter gene activation with [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)), and weaker activity with [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)), porcine [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1992), or insulin‐like peptide 3 ([INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995)([*INSL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6086), [P51460](http://www.uniprot.org/uniprot/P51460))) and a strong stimulation of activator protein (AP)‐1 reporter genes with [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)), and weaker activation with [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) or porcine [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1992)\[[2144](http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus)\]. Thus at RXFP3, [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)) is a biased ligand compared to the cognate ligand [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)). Two pharmacologically distinct ligand binding sites were also identified on RXFP3‐expressing cells using [\[^125^I\]relaxin‐3‐B/INSL5 A chimera](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3789) which binds with high affinity and displays competition by [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) or a [relaxin‐3 (B chain)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1997) ([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)) peptide, and [\[^125^I\]relaxin (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5398) which displays competition by [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989)([*RLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10027), [P04090](http://www.uniprot.org/uniprot/P04090)), [relaxin‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990)([*RLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17135), [Q8WXF3](http://www.uniprot.org/uniprot/Q8WXF3)), or [INSL3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995)([*INSL3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6086), [P51460](http://www.uniprot.org/uniprot/P51460)) and weakly by porcine [relaxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1992).
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[Somatostatin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61) {#bph13348-sec-0254}
==================================================================================================

Overview {#bph13348-sec-0255}
--------

Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (sst~1~‐sst~5~; **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Somatostatin Receptors \[790\]**). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. The relationship of the cloned receptors to endogenously expressed receptors is not yet well established in some cases. Endogenous ligands for these receptors are somatostatin‐14 ([SRIF‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2019)([*SST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11329), [P61278](http://www.uniprot.org/uniprot/P61278))) and somatostatin‐28 ([SRIF‐28](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2020)([*SST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11329), [P61278](http://www.uniprot.org/uniprot/P61278))). [Cortistatin‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2007){Mouse, Rat} has also been suggested to be an endogenous ligand for somatostatin receptors \[[404](http://www.ncbi.nlm.nih.gov/pubmed/8622767?dopt=AbstractPlus)\].

Nomenclature[sst~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355)[sst~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356)[sst~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357)[sst~4~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=358)[sst~5~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359)HGNC, UniProt[*SSTR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11330), [P30872](http://www.uniprot.org/uniprot/P30872)[*SSTR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11331), [P30874](http://www.uniprot.org/uniprot/P30874)[*SSTR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11332), [P32745](http://www.uniprot.org/uniprot/P32745)[*SSTR4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11333), [P31391](http://www.uniprot.org/uniprot/P31391)[*SSTR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11334), [P35346](http://www.uniprot.org/uniprot/P35346)Agonists[pasireotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018) (pIC~50~ 8) \[[1669](http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus)\][vapreotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2054) (p*K* ~i~ 8.3--10.1) \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus), [1474](http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus)\], [pasireotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018) (pIC~50~ 9) \[[1669](http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus)\][pasireotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018) (pIC~50~ 8.8) \[[1669](http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus)\], [vapreotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2054) (p*K* ~i~ 7.4--7.9) \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus), [1474](http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus), [1738](http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus)\][NNC269100](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3513) (p*K* ~i~ 8.2) \[[1132](http://www.ncbi.nlm.nih.gov/pubmed/9822540?dopt=AbstractPlus)\][pasireotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018) (pIC~50~ 9.8) \[[1669](http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus)\], [vapreotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2054) (p*K* ~i~ 7.3--9.2) \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus), [1265](http://www.ncbi.nlm.nih.gov/pubmed/9600011?dopt=AbstractPlus), [1474](http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus), [1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus), [1738](http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus)\]Selective agonists[L‐797,591](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2015) (p*K* ~i~ 8.8) \[[1595](http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus)\], [Des‐Ala^1,2,5^‐\[D‐Trp^8^,IAmp^9^\]SRIF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2010) (pIC~50~ 7.5) \[[484](http://www.ncbi.nlm.nih.gov/pubmed/15658864?dopt=AbstractPlus)\][L‐054,522](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2046) (p*K* ~i~ 11) \[[2084](http://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus)\], [BIM 23027](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2033) (pIC~50~ 10.9) \[[271](http://www.ncbi.nlm.nih.gov/pubmed/8646408?dopt=AbstractPlus)\], [seglitide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2051) (p*K* ~i~ 8.8--10.3) \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus), [1474](http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus), [1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus), [1738](http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus), [2084](http://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus)\], [octreotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2055) (p*K* ~i~ 8.7--9.9) \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus), [1474](http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus), [1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus), [1738](http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus), [2084](http://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus)\][L‐796,778](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2073) (p*K* ~i~ 7.6) \[[1595](http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus)\][L‐803,087](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2082) (p*K* ~i~ 9.2) \[[1595](http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus)\][BIM 23052](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2004) (p*K* ~i~ 7.4--9.6) \[[1265](http://www.ncbi.nlm.nih.gov/pubmed/9600011?dopt=AbstractPlus), [1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus), [1738](http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus)\], [L‐817,818](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2016) (p*K* ~i~ 9.4) \[[1595](http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus)\], [BIM 23268](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2083) (p*K* ~i~ 8.7) \[[1265](http://www.ncbi.nlm.nih.gov/pubmed/9600011?dopt=AbstractPlus)\]Selective antagonists[SRA880](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2030) (p*K* ~d~ 8--8.1) \[[792](http://www.ncbi.nlm.nih.gov/pubmed/15135911?dopt=AbstractPlus)\][\[D‐Tyr^8^\]CYN 154806](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2028) (p*K* ~d~ 8.1--8.9) \[[1412](http://www.ncbi.nlm.nih.gov/pubmed/12616335?dopt=AbstractPlus)\][NVP ACQ090](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2076) (p*K* ~i~ 7.9) \[793\]----Labelled ligands--[\[^125^I\]Tyr^3^ SMS 201‐995](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2062) (Agonist) (p*K* ~d~ 9.9) \[[1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus)\], [\[^125^I\]BIM23027](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3772) (Agonist) (pIC~50~ 9.7) \[[772](http://www.ncbi.nlm.nih.gov/pubmed/9121614?dopt=AbstractPlus)\] -- Rat----[\[^125^I\]Tyr^3^ SMS 201‐995](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2062) (Agonist) (p*K* ~d~ 9.6) \[[1736](http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus), [1737](http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus)\]Comments----Troxler *et al.* (2010) describe the identification of non‐peptidic, subtype‐selective sst~3~ receptor antagonists \[[1907](http://www.ncbi.nlm.nih.gov/pubmed/20137944?dopt=AbstractPlus)\].----

Comments {#bph13348-sec-0256}
--------

[\[^125^I\]Tyr^11^‐SRIF‐14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2060), [\[^125^I\]LTT‐SRIF‐28](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2023), [\[^125^I\]CGP 23996](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2022) and [\[^125^I\]Tyr^10^‐CST14](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2024) may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype‐selective agonists have been synthesised \[[1595](http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus)\]. A novel peptide somatostatin analogue, [somatoprim](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8487), has affinity for sst~2~, sst~4~ and sst~5~ receptors and is a potent inhibitor of GH secretion \[[1514](http://www.ncbi.nlm.nih.gov/pubmed/22065857?dopt=AbstractPlus), [1726](http://www.ncbi.nlm.nih.gov/pubmed/15636423?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0257}
---------------

Ben‐Shlomo A *et al*. (2010) Pituitary somatostatin receptor signaling. *Trends Endocrinol. Metab.* **21**: 123‐33 [\[PMID:20149677\]](http://www.ncbi.nlm.nih.gov/pubmed/20149677?dopt=AbstractPlus)

Colao A *et al*. (2011) Resistance to somatostatin analogs in acromegaly. *Endocr. Rev.* **32**: 247‐71 [\[PMID:21123741\]](http://www.ncbi.nlm.nih.gov/pubmed/21123741?dopt=AbstractPlus)

Csaba Z *et al*. (2012) Molecular mechanisms of somatostatin receptor trafficking. *J. Mol. Endocrinol.* **48**: R1‐12 [\[PMID:22159161\]](http://www.ncbi.nlm.nih.gov/pubmed/22159161?dopt=AbstractPlus)

Hoyer D *et al*. (2000) Somatostatin receptors. *In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn.* Edited by Watson SP, Girdlestone D: IUPHAR Media: 354‐364

Schulz S *et al*. (2014) Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5. *Br. J. Pharmacol.* **171**: 1591‐9 [\[PMID:24328848\]](http://www.ncbi.nlm.nih.gov/pubmed/24328848?dopt=AbstractPlus)

Zatelli MC *et al*. (2009) The significance of new somatostatin analogs as therapeutic agents. *Curr Opin Investig Drugs* **10**: 1025‐31 [\[PMID:19777390\]](http://www.ncbi.nlm.nih.gov/pubmed/19777390?dopt=AbstractPlus)

[Succinate receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=446) {#bph13348-sec-0258}
===============================================================================================

Overview {#bph13348-sec-0259}
--------

**Nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**396**](http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus) **\]**.

Nomenclature[succinate receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=166)HGNC, UniProt[*SUCNR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4542), [Q9BXA5](http://www.uniprot.org/uniprot/Q9BXA5)Endogenous agonists[succinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637) (pEC~50~ 3.1--4.7) \[[728](http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus), [1785](http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus)\]

[Tachykinin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=62) {#bph13348-sec-0260}
================================================================================================

Overview {#bph13348-sec-0261}
--------

Tachykinin receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides [substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098)([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) (SP), [neurokinin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) (NKA; previously known as substance K, neurokinin *α*, neuromedin L), [neurokinin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090) ([*TAC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11521), [Q9UHF0](http://www.uniprot.org/uniprot/Q9UHF0)) (NKB; previously known as neurokinin *β*, neuromedin K), [neuropeptide K](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2091)([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) and [neuropeptide *γ*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3667)([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) (N‐terminally extended forms of neurokinin A). The neurokinins (A and B) are mammalian members of the tachykinin family, which includes peptides of mammalian and nonmammalian origin containing the consensus sequence: Phe‐x‐Gly‐Leu‐Met. Marked species differences in *in vitro* pharmacology exist for all three receptors, in the context of nonpeptide ligands.

Nomenclature[NK~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360)[NK~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=361)[NK~3~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=362)HGNC, UniProt[*TACR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11526), [P25103](http://www.uniprot.org/uniprot/P25103)[*TACR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11527), [P21452](http://www.uniprot.org/uniprot/P21452)[*TACR3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11528), [P29371](http://www.uniprot.org/uniprot/P29371)Rank order of potency[substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) \>[neurokinin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) \>[neurokinin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090) ([*TAC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11521), [Q9UHF0](http://www.uniprot.org/uniprot/Q9UHF0))[neurokinin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) \>[neurokinin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090) ([*TAC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11521), [Q9UHF0](http://www.uniprot.org/uniprot/Q9UHF0)) ≫[substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366))[neurokinin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090) ([*TAC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11521), [Q9UHF0](http://www.uniprot.org/uniprot/Q9UHF0)) \>[neurokinin A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) \>[substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098) ([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366))Agonists[substance P‐OMe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2101) (pIC~50~ 7.4--7.5) \[[1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\]----Selective agonists[\[Sar^9^,Met(O~2~)^11^\]SP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3850) (pIC~50~ 9.7--9.9) \[[1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\], [septide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2095) (p*K* ~i~ 7--9.3) \[[125](http://www.ncbi.nlm.nih.gov/pubmed/11786503?dopt=AbstractPlus), [711](http://www.ncbi.nlm.nih.gov/pubmed/8985159?dopt=AbstractPlus)\], [\[Pro^9^\]SP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3849) (pIC~50~ 8.6) \[[1896](http://www.ncbi.nlm.nih.gov/pubmed/9243521?dopt=AbstractPlus)\] -- Rat[\[Lys^5^,Me‐Leu^9^,Nle^10^\]NKA‐(4‐10)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3843) (pIC~50~ 8.8--9.4) \[[1229](http://www.ncbi.nlm.nih.gov/pubmed/9718274?dopt=AbstractPlus)\] -- Rat, [GR64349](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3881) (pEC~50~ 8.4) \[[407](http://www.ncbi.nlm.nih.gov/pubmed/1331460?dopt=AbstractPlus)\] -- Rat, [\[*β*Ala^8^\]neurokinin A‐(4‐10)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2112) (p*K* ~d~ 6) \[[477](http://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus)\][\[Phe(Me)^7^\]neurokinin B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2113) (p*K* ~i~ 8.7--9.6) \[[1644](http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus)\], [senktide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2127) (p*K* ~i~ 7.1--8.6) \[[1644](http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus), [1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\]Selective antagonists[aprepitant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3490) (p*K* ~i~ 10.1) \[[673](http://www.ncbi.nlm.nih.gov/pubmed/10737756?dopt=AbstractPlus), [674](http://www.ncbi.nlm.nih.gov/pubmed/9804700?dopt=AbstractPlus)\], [lanepitant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3510) (p*K* ~i~ 9.8--10) \[[613](http://www.ncbi.nlm.nih.gov/pubmed/7473161?dopt=AbstractPlus)\], [lanepitant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3510) (pIC~50~ 9.8) \[[798](http://www.ncbi.nlm.nih.gov/pubmed/20533894?dopt=AbstractPlus)\], [CP 99994](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2102) (p*K* ~i~ 9.3--9.7) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus)\], [casopitant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5758) (p*K* ~i~ 9.4) \[[798](http://www.ncbi.nlm.nih.gov/pubmed/20533894?dopt=AbstractPlus), [1905](http://www.ncbi.nlm.nih.gov/pubmed/24106886?dopt=AbstractPlus)\], [vestipitant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5757) (p*K* ~i~ 9.4) \[[221](http://www.ncbi.nlm.nih.gov/pubmed/18657401?dopt=AbstractPlus), [418](http://www.ncbi.nlm.nih.gov/pubmed/19388677?dopt=AbstractPlus)\], [nolpitantium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2107) (pIC~50~ 8.9--9) \[[1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\], [RP67580](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3522) (pIC~50~ 7.7) \[[528](http://www.ncbi.nlm.nih.gov/pubmed/1281470?dopt=AbstractPlus)\][GR94800](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3882) (p*K* ~i~ 9.8) \[[200](http://www.ncbi.nlm.nih.gov/pubmed/8027981?dopt=AbstractPlus)\], [saredutant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2111) (p*K* ~i~ 9.4--9.7) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus), [477](http://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus)\], [GR 159897](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2115) (p*K* ~d~ 7.8--9.5) \[[133](http://www.ncbi.nlm.nih.gov/pubmed/7713168?dopt=AbstractPlus), [477](http://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus), [1770](http://www.ncbi.nlm.nih.gov/pubmed/7562907?dopt=AbstractPlus)\], [MEN10627](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3901) (p*K* ~i~ 9.2) \[[603](http://www.ncbi.nlm.nih.gov/pubmed/11063600?dopt=AbstractPlus)\], [nepadutant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2123) (p*K* ~i~ 8.5--8.7) \[[272](http://www.ncbi.nlm.nih.gov/pubmed/9484857?dopt=AbstractPlus), [343](http://www.ncbi.nlm.nih.gov/pubmed/16979621?dopt=AbstractPlus)\][osanetant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2110) (p*K* ~i~ 8.4--9.7) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus), [110](http://www.ncbi.nlm.nih.gov/pubmed/9042606?dopt=AbstractPlus), [342](http://www.ncbi.nlm.nih.gov/pubmed/7476898?dopt=AbstractPlus), [476](http://www.ncbi.nlm.nih.gov/pubmed/7830490?dopt=AbstractPlus), [898](http://www.ncbi.nlm.nih.gov/pubmed/11757797?dopt=AbstractPlus), [1450](http://www.ncbi.nlm.nih.gov/pubmed/7616392?dopt=AbstractPlus), [1644](http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus), [1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\], [talnetant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2132) (p*K* ~i~ 7.4--9) \[[129](http://www.ncbi.nlm.nih.gov/pubmed/15265501?dopt=AbstractPlus), [604](http://www.ncbi.nlm.nih.gov/pubmed/8691422?dopt=AbstractPlus), [1644](http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus), [1645](http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus)\], [PD157672](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2125) (pIC~50~ 7.8--7.9) \[[165](http://www.ncbi.nlm.nih.gov/pubmed/8648606?dopt=AbstractPlus), [1882](http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]L703,606](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3471) (Antagonist) (p*K* ~d~ 9.5) \[[537](http://www.ncbi.nlm.nih.gov/pubmed/8287060?dopt=AbstractPlus)\], [\[^125^I\]BH‐\[Sar^9^,Met(O~2~)^11^\]SP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3769) (Agonist) (p*K* ~d~ 9) \[[1901](http://www.ncbi.nlm.nih.gov/pubmed/1705465?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]BH‐\[Sar^9^,Met(O~2~)^11^\]SP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3811) (Agonist) (p*K* ~d~ 8.7) \[[1902](http://www.ncbi.nlm.nih.gov/pubmed/1722129?dopt=AbstractPlus)\] -- Rat, [\[^3^H\]SP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3835) (Agonist) (p*K* ~d~ 8.6) \[[80](http://www.ncbi.nlm.nih.gov/pubmed/2410593?dopt=AbstractPlus)\], [\[^125^I\]SP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3805) (Agonist), [\[^18^F\]SPA‐RQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3473) (Antagonist) \[317\][\[^3^H\]saredutant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3481) (Antagonist) (p*K* ~d~ 9.7) \[[649](http://www.ncbi.nlm.nih.gov/pubmed/7719707?dopt=AbstractPlus)\] -- Rat, [\[^125^I\]NKA (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3795) (Agonist) (p*K* ~d~ 9.3) \[[1990](http://www.ncbi.nlm.nih.gov/pubmed/10455255?dopt=AbstractPlus)\], [\[^3^H\]GR100679](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3822) (Antagonist) (p*K* ~d~ 9.2) \[[669](http://www.ncbi.nlm.nih.gov/pubmed/8210508?dopt=AbstractPlus)\][\[^3^H\]osanetant](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3480) (Antagonist) (p*K* ~d~ 9.9), [\[^3^H\]senktide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3834) (Agonist) (p*K* ~d~ 8.1--8.7) \[[660](http://www.ncbi.nlm.nih.gov/pubmed/1694464?dopt=AbstractPlus)\] -- Guinea pig, [\[^125^I\]\[MePhe^7^\]NKB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3763) (Agonist)

Comments {#bph13348-sec-0262}
--------

The NK~1~ receptor has also been described to couple to other G proteins \[[1606](http://www.ncbi.nlm.nih.gov/pubmed/9654151?dopt=AbstractPlus)\]. The hexapeptide agonist septide appears to bind to an overlapping but non‐identical site to [substance P](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098)([*TAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11517), [P20366](http://www.uniprot.org/uniprot/P20366)) on the NK~1~ receptor. There are suggestions for additional subtypes of tachykinin receptor; an orphan receptor (SwissProt [P30098](http://www.ncbi.nlm.nih.gov/protein/266702/)) with structural similarities to the NK~3~ receptor was found to respond to NKB when expressed in *Xenopus* oocytes or Chinese hamster ovary cells \[[433](http://www.ncbi.nlm.nih.gov/pubmed/8947459?dopt=AbstractPlus), [1004](http://www.ncbi.nlm.nih.gov/pubmed/8990205?dopt=AbstractPlus)\].
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Rojas C *et al*. (2012) Pharmacological mechanisms of 5‐HT_3 and tachykinin NK_1 receptor antagonism to prevent chemotherapy‐induced nausea and vomiting. *Eur. J. Pharmacol.* **684**: 1‐7 [\[PMID:22425650\]](http://www.ncbi.nlm.nih.gov/pubmed/22425650?dopt=AbstractPlus)
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[Thyrotropin‐releasing hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=63) {#bph13348-sec-0264}
===================================================================================================================

Overview {#bph13348-sec-0265}
--------

Thyrotropin‐releasing hormone (TRH) receptors (**provisional nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous tripeptide [TRH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2139)([*TRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12298), [P20396](http://www.uniprot.org/uniprot/P20396)) (pGlu‐His‐ProNH2). [TRH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2139)([*TRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12298), [P20396](http://www.uniprot.org/uniprot/P20396)) and TRH analogues fail to distinguish TRH~1~ and TRH~2~ receptors \[[1822](http://www.ncbi.nlm.nih.gov/pubmed/12683933?dopt=AbstractPlus)\]. [\[^3^H\]TRH (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3836) is able to label both TRH~1~ and TRH~2~ receptors with K~d~ values of 13 and 9 nM respectively.

Nomenclature[TRH~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=363)[TRH~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=754)HGNC, UniProt[*TRHR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12299), [P34981](http://www.uniprot.org/uniprot/P34981)--Antagonists[diazepam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364) (p*K* ~i~ 5.2) \[[444](http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus)\] -- Rat--Selective antagonists[midazolam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3342) (p*K* ~i~ 5.5) \[[444](http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus)\] -- Rat, [chlordiazepoxide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3370) (p*K* ~i~ 4.8) \[[444](http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus)\] -- Rat, [chlordiazepoxide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3370) (p*K* ~i~ 4.7) \[[1804](http://www.ncbi.nlm.nih.gov/pubmed/2175902?dopt=AbstractPlus)\] -- Mouse--Comments--A class A G protein‐coupled receptor: not present in man

Further Reading {#bph13348-sec-0266}
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[Trace amine receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=64) {#bph13348-sec-0267}
================================================================================================

Overview {#bph13348-sec-0268}
--------

Trace amine‐associated receptors were initially discovered as a result of a search for novel 5‐HT receptors \[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\], where 15 mammalian orthologues were identified and divided into two families. The TA~1~ receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee for the Trace amine receptor \[** [**1181**](http://www.ncbi.nlm.nih.gov/pubmed/19325074?dopt=AbstractPlus) **\]**) has been shown to have affinity for the endogenous trace amines [tyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150), [*β*‐phenylethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144) and [octopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2149) in addition to the classical amine [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940)\[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\]. Emerging evidence suggests that TA~1~ is a modulator of monoaminergic activity in the brain \[[2062](http://www.ncbi.nlm.nih.gov/pubmed/19482011?dopt=AbstractPlus)\] with TA~1~ and dopamine D~2~ receptors shown to form constitutive heterodimers when co‐expressed \[[492](http://www.ncbi.nlm.nih.gov/pubmed/21670104?dopt=AbstractPlus)\]. In addition to trace amines, receptors can be activated by amphetamine‐like psychostimulants, and endogenous thyronamines such as thyronamine and 3‐iodothyronamine.

Nomenclature[TA~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=364)HGNC, UniProt[*TAAR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17734), [Q96RJ0](http://www.uniprot.org/uniprot/Q96RJ0)Rank order of potency[tyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150)\>[*β*‐phenylethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144)\>[octopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2149) = [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) \[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\]Agonists[RO5166017](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5862) (pEC~50~ 7.3) \[[1574](http://www.ncbi.nlm.nih.gov/pubmed/21525407?dopt=AbstractPlus)\]Antagonists[EPPTB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5457) (Inverse agonist) (pIC~50~ 5.1) \[[199](http://www.ncbi.nlm.nih.gov/pubmed/19892733?dopt=AbstractPlus)\]Labelled ligands[\[^3^H\]tyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2148) (Agonist) (p*K* ~d~ 7.7) \[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0269}
--------

In addition to TA~1~, analysis has shown that in man there are up to 5 functional TAAR genes (TAAR2,5,6,8,9). See \[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\] for detailed discussion. The product of the gene TAAR2 (also known as GPR58) appears to respond to [*β*‐phenylethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144)\>[tyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150) and to couple through G~s~\[[185](http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus)\].

[*TAAR3*](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_168), in some individuals, and [*TAAR4*](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_169) are pseudogenes in man, although functional in rodents. The signalling characteristics and pharmacology of [TAA~5~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_170)(PNR, Putative Neurotransmitter Receptor: [*TAAR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30236), [O14804](http://www.uniprot.org/uniprot/O14804)), [TAA~6~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_171)(Trace amine receptor 4, TaR‐4: [*TAAR6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20978), [96RI8](http://www.uniprot.org/uniprot/96RI8)), [TAA~8~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_172)(Trace amine receptor 5, GPR102: [*TAAR8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14964), [Q969N4](http://www.uniprot.org/uniprot/Q969N4)) and [TAA~9~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_173)(trace amine associated receptor 9: [TAAR9](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20977), [96RI9](http://www.uniprot.org/uniprot/96RI9)) are lacking. The thyronamines, endogenous derivatives of thyroid hormone, have been shown to have affinity for rodent cloned trace amine receptors, including TA~1~\[[1657](http://www.ncbi.nlm.nih.gov/pubmed/15146179?dopt=AbstractPlus)\]. An antagonist [EPPTB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5457) has recently been described that has a *p*K~i~ of 9.1 at the mouse TA~1~ but less than 5.3 for human TA~1~\[[1792](http://www.ncbi.nlm.nih.gov/pubmed/21237643?dopt=AbstractPlus)\].

Further Reading {#bph13348-sec-0270}
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[Urotensin receptor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=65) {#bph13348-sec-0271}
==============================================================================================

Overview {#bph13348-sec-0272}
--------

The urotensin‐II (U‐II) receptor (UT, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on the Urotensin receptor \[439,** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **,** [**1952**](http://www.ncbi.nlm.nih.gov/pubmed/25535277?dopt=AbstractPlus) **\]**) is activated by the endogenous dodecapeptide [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153)([*UTS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12636), [O95399](http://www.uniprot.org/uniprot/O95399)), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish \[[134](http://www.ncbi.nlm.nih.gov/pubmed/2864726?dopt=AbstractPlus)\]. Several structural forms of U‐II exist in fish and amphibians. The Goby orthologue was used to identify U‐II as the cognate ligand for the predicted receptor encoded by the rat gene *gpr14* \[[375](http://www.ncbi.nlm.nih.gov/pubmed/9861051?dopt=AbstractPlus), [1130](http://www.ncbi.nlm.nih.gov/pubmed/10581185?dopt=AbstractPlus), [1327](http://www.ncbi.nlm.nih.gov/pubmed/10548501?dopt=AbstractPlus), [1410](http://www.ncbi.nlm.nih.gov/pubmed/10559967?dopt=AbstractPlus)\]. Human [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153)([*UTS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12636), [O95399](http://www.uniprot.org/uniprot/O95399)), an 11‐amino‐acid peptide \[[375](http://www.ncbi.nlm.nih.gov/pubmed/9861051?dopt=AbstractPlus)\], retains the cyclohexapeptide sequence of goby U‐II that is thought to be important in ligand binding \[[219](http://www.ncbi.nlm.nih.gov/pubmed/12807997?dopt=AbstractPlus), [957](http://www.ncbi.nlm.nih.gov/pubmed/12203418?dopt=AbstractPlus)\]. This sequence is also conserved in the deduced amino‐acid sequence of rat [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2155) {Rat} (14 amino‐acids) and mouse [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2154){Mouse} (14 amino‐acids), although the N‐terminal is more divergent from the human sequence \[[374](http://www.ncbi.nlm.nih.gov/pubmed/10486557?dopt=AbstractPlus)\]. A second endogenous ligand for UT has been discovered in rat \[[1816](http://www.ncbi.nlm.nih.gov/pubmed/17628210?dopt=AbstractPlus)\]. This is the [urotensin II‐related peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156) ([*UTS2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30894), [Q765I0](http://www.uniprot.org/uniprot/Q765I0)), an octapeptide that is derived from a different gene, but shares the C‐terminal sequence (CFWKYCV) common to U‐II from other species. Identical sequences to rat [urotensin II‐related peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156) ([*UTS2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30894), [Q765I0](http://www.uniprot.org/uniprot/Q765I0)) are predicted for the mature mouse and human peptides.

Nomenclature[UT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=365)HGNC, UniProt[*UTS2R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4468), [Q9UKP6](http://www.uniprot.org/uniprot/Q9UKP6)Endogenous agonists[urotensin II‐related peptide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156) ([*UTS2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30894), [Q765I0](http://www.uniprot.org/uniprot/Q765I0)) (p*K* ~d~ 9.6) \[[1179](http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus)\], [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153) ([*UTS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12636), [O95399](http://www.uniprot.org/uniprot/O95399)) (p*K* ~i~ 8.6) \[[440](http://www.ncbi.nlm.nih.gov/pubmed/15852036?dopt=AbstractPlus), [475](http://www.ncbi.nlm.nih.gov/pubmed/11976263?dopt=AbstractPlus), [647](http://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus)\]Selective agonists[\[Pen5\]‐U (4‐11) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2160) (p*K* ~i~ 9.7) \[[647](http://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus)\], [U‐II‐(4‐11) (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2152) (p*K* ~i~ 9.6) \[[647](http://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus)\], [FL104](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3501) (pEC~50~ 5.8--7.5) \[[1075](http://www.ncbi.nlm.nih.gov/pubmed/19481466?dopt=AbstractPlus), [1077](http://www.ncbi.nlm.nih.gov/pubmed/17112638?dopt=AbstractPlus)\], [AC‐7954](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2151) (p*K* ~i~ 6.6) \[[382](http://www.ncbi.nlm.nih.gov/pubmed/12408704?dopt=AbstractPlus), [1076](http://www.ncbi.nlm.nih.gov/pubmed/15781415?dopt=AbstractPlus)\]Selective antagonists[urantide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2167) (p*K* ~i~ 8.3) \[[1469](http://www.ncbi.nlm.nih.gov/pubmed/14645137?dopt=AbstractPlus)\], [SB‐706375](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2165) (p*K* ~i~ 8) \[[440](http://www.ncbi.nlm.nih.gov/pubmed/15852036?dopt=AbstractPlus)\], [palosuran](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3516) (pIC~50~ 7.1) \[[353](http://www.ncbi.nlm.nih.gov/pubmed/15146030?dopt=AbstractPlus)\], [SB‐611812](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3531) (p*K* ~i~ 6.6) \[[1550](http://www.ncbi.nlm.nih.gov/pubmed/16171813?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]U‐II (human)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2158) (Agonist) (p*K* ~d~ 9.4--9.6) \[[42](http://www.ncbi.nlm.nih.gov/pubmed/10499587?dopt=AbstractPlus), [1179](http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0273}
--------

In human vasculature, human [urotensin‐II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153)([*UTS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12636), [O95399](http://www.uniprot.org/uniprot/O95399)) elicits both vasoconstrictor (p*D* ~2~ 9.3‐10.1, \[[1179](http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus)\]) and vasodilator (pIC~50~ 10.3‐10.4, \[[1800](http://www.ncbi.nlm.nih.gov/pubmed/11158995?dopt=AbstractPlus)\]) responses.
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[Vasopressin and oxytocin receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=66) {#bph13348-sec-0275}
==============================================================================================================

Overview {#bph13348-sec-0276}
--------

Vasopressin (AVP) and oxytocin (OT) receptors (**nomenclature as recommended by [NC‐IUPHAR]{.ul}\[** [**530**](http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus) **\]**) are activated by the endogenous cyclic nonapeptides [vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168)([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) and [oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174)([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178)). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin).

Nomenclature[V~1A~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=366)[V~1B~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=367)[V~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368)[OT receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369)HGNC, UniProt[*AVPR1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=895), [P37288](http://www.uniprot.org/uniprot/P37288)[*AVPR1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=896), [P47901](http://www.uniprot.org/uniprot/P47901)[*AVPR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=897), [P30518](http://www.uniprot.org/uniprot/P30518)[*OXTR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8529), [P30559](http://www.uniprot.org/uniprot/P30559)Rank order of potency[vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) \>[oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174) ([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178))[vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) \>[oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174) ([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178))[vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) \>[oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174) ([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178))[oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174) ([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178)) \>[vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185))Endogenous agonists[vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) (p*K* ~i~ 8.5--9.3) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [311](http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [415](http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1501](http://www.ncbi.nlm.nih.gov/pubmed/9334232?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1870](http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\][vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) (p*K* ~i~ 9--9.5) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [311](http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus), [415](http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus), [648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\][vasopressin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168) ([*AVP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=894), [P01185](http://www.uniprot.org/uniprot/P01185)) (p*K* ~i~ 7.9--9.1) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [311](http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus), [319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [415](http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\][oxytocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174) ([*OXT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8528), [P01178](http://www.uniprot.org/uniprot/P01178)) (p*K* ~i~ 8.2--9.6) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [320](http://www.ncbi.nlm.nih.gov/pubmed/8955347?dopt=AbstractPlus), [345](http://www.ncbi.nlm.nih.gov/pubmed/12660315?dopt=AbstractPlus), [648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus), [853](http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus)\]Selective agonists[F180](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2171) (p*K* ~d~ 7.9--8.3) \[[49](http://www.ncbi.nlm.nih.gov/pubmed/11934825?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus)\][d\[Leu^4^\]LVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2191) (p*K* ~i~ 9.8) \[[1485](http://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus)\], [d\[Cha^4^\]AVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2187) (p*K* ~i~ 9--9.7) \[[415](http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus), [648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus)\][VNA932](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3537) (pIC~50~ 7.1) \[[501](http://www.ncbi.nlm.nih.gov/pubmed/16297621?dopt=AbstractPlus)\], [OPC‐51803](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2173) (p*K* ~i~ 7) \[[1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus)\], [d\[Val^4^,DArg^8^\]VP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3869)[\[Thr^4^,Gly^7^\]OT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2179) (p*K* ~i~ 8.2--8.4) \[[320](http://www.ncbi.nlm.nih.gov/pubmed/8955347?dopt=AbstractPlus), [472](http://www.ncbi.nlm.nih.gov/pubmed/2827511?dopt=AbstractPlus), [853](http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus)\]Antagonists[conivaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2203) (p*K* ~i~ 8.2--8.4) \[[1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus)\][nelivaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2202) (p*K* ~i~ 8.4--9.3) \[[644](http://www.ncbi.nlm.nih.gov/pubmed/11959912?dopt=AbstractPlus), [648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus), [1702](http://www.ncbi.nlm.nih.gov/pubmed/11861823?dopt=AbstractPlus)\]--[L‐371,257](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2252) (p*K* ~i~ 8.8) \[[648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus)\]Selective antagonists[relcovaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200) (p*K* ~i~ 8.1--9.3) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [648](http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus), [1501](http://www.ncbi.nlm.nih.gov/pubmed/9334232?dopt=AbstractPlus), [1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1870](http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [1910](http://www.ncbi.nlm.nih.gov/pubmed/11429400?dopt=AbstractPlus)\], [d(CH~2~)~5~\[Tyr(Me)^2^,Arg^8^\]VP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3867) (p*K* ~i~ 9)--[conivaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2203) (p*K* ~i~ 9.4) \[[381](http://www.ncbi.nlm.nih.gov/pubmed/20471258?dopt=AbstractPlus)\], [tolvaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2226) (p*K* ~i~ 9.4) \[[2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\], [satavaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2199) (p*K* ~i~ 8.4--9.3) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1699](http://www.ncbi.nlm.nih.gov/pubmed/8981918?dopt=AbstractPlus), [1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1910](http://www.ncbi.nlm.nih.gov/pubmed/11429400?dopt=AbstractPlus)\], [lixivaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2238) (Inverse agonist) (p*K* ~i~ 8.9--9.2) \[[33](http://www.ncbi.nlm.nih.gov/pubmed/9651149?dopt=AbstractPlus), [1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus)\], [d(CH~2~)~5~\[D‐Ile^2^,Ile^4^\]AVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2236) (p*K* ~i~ 6.9--8.4) \[[1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus)\], [mozavaptan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197) (Inverse agonist) (p*K* ~i~ 7.4--8.1) \[[370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1700](http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus), [2074](http://www.ncbi.nlm.nih.gov/pubmed/1387020?dopt=AbstractPlus)\][SSR126768A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2201) (p*K* ~i~ 8.8--9.1) \[[1701](http://www.ncbi.nlm.nih.gov/pubmed/14722330?dopt=AbstractPlus)\], [desGlyNH~2~‐d(CH~2~)~5~\[Tyr(Me)^2^,Thr^4^,Orn^8^\]OT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3870) (p*K* ~i~ 8.5), [L‐372662](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2253) (p*K* ~i~ 8.4) \[[121](http://www.ncbi.nlm.nih.gov/pubmed/9622556?dopt=AbstractPlus)\]Labelled ligands[\[^125^I\]OH‐LVA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2207) (Antagonist) (p*K* ~d~ 10.3--10.4) \[[319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [1501](http://www.ncbi.nlm.nih.gov/pubmed/9334232?dopt=AbstractPlus)\], [\[^3^H\]AVP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) (p*K* ~d~ 8.6--10.2) \[[208](http://www.ncbi.nlm.nih.gov/pubmed/11337500?dopt=AbstractPlus), [319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1501](http://www.ncbi.nlm.nih.gov/pubmed/9334232?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1870](http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [1910](http://www.ncbi.nlm.nih.gov/pubmed/11429400?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\], [\[^3^H\]d(CH~2~)~5~\[Tyr(Me)^2^\]AVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3813) (Antagonist) (p*K* ~d~ 9)[\[^3^H\]AVP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) (p*K* ~d~ 8.6--9.6) \[[208](http://www.ncbi.nlm.nih.gov/pubmed/11337500?dopt=AbstractPlus), [319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1501](http://www.ncbi.nlm.nih.gov/pubmed/9334232?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1870](http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [1910](http://www.ncbi.nlm.nih.gov/pubmed/11429400?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\][\[^3^H\]AVP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) (p*K* ~d~ 8.4--9.4) \[[319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [369](http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus), [370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1359](http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus), [1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus), [1839](http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus), [1840](http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus), [1910](http://www.ncbi.nlm.nih.gov/pubmed/11429400?dopt=AbstractPlus), [2073](http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus)\], [\[^3^H\]dDAVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2228) (Agonist) (p*K* ~d~ 7.2--9.1) \[[319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [370](http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus), [1871](http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus)\], [\[^3^H\]desGly‐NH~2~\[D‐Ile^2^,Ile^4^\]VP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3817) (p*K* ~d~ 8.6)[\[^125^I\]d(CH~2~)~5~\[Tyr(Me)^2^,Thr^4^,Orn^8^,Tyr‐NH~2~^9^\]OVT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3778) (Antagonist) (p*K* ~d~ 10), [\[^3^H\]OT (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2176) (Agonist) (p*K* ~d~ 8.2--9.5) \[[319](http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus), [553](http://www.ncbi.nlm.nih.gov/pubmed/6278592?dopt=AbstractPlus), [853](http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus), [952](http://www.ncbi.nlm.nih.gov/pubmed/7921228?dopt=AbstractPlus)\], [\[^111^In\]DOTA‐dLVT](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3756) (p*K* ~d~ 8.3) \[[318](http://www.ncbi.nlm.nih.gov/pubmed/12942128?dopt=AbstractPlus)\]

Comments {#bph13348-sec-0277}
--------

The V~2~ receptor exhibits marked species differences, such that many ligands ([d(CH~2~)~5~\[D‐Ile^2^,Ile^4^\]AVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2236) and [\[^3^H\]desGly‐NH~2~\[D‐Ile^2^,Ile^4^\]VP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3817)) exhibit low affinity at human V~2~ receptors \[[29](http://www.ncbi.nlm.nih.gov/pubmed/9773787?dopt=AbstractPlus)\]. Similarly, [\[^3^H\]d\[D‐Arg^8^\]VP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5403) is V~2~ selective in the rat, not in the human \[[1627](http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus)\]. The gene encoding the V~2~ receptor is polymorphic in man, underlying nephrogenic diabetes insipidus \[[148](http://www.ncbi.nlm.nih.gov/pubmed/9756088?dopt=AbstractPlus)\]. [D\[Cha^4^\]AVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2187) is selective only for the human and bovine V~1b~ receptors \[[415](http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus)\], while [d\[Leu^4^\]LVP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2191) has high affinity for the rat V~1b~ receptor \[[1485](http://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus)\].
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[VIP and PACAP receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=67) {#bph13348-sec-0279}
===================================================================================================

Overview {#bph13348-sec-0280}
--------

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase‐activating peptide (PACAP) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Vasoactive Intestinal Peptide Receptors \[** [**704**](http://www.ncbi.nlm.nih.gov/pubmed/9647867?dopt=AbstractPlus) **,** [**705**](http://www.ncbi.nlm.nih.gov/pubmed/22289055?dopt=AbstractPlus) **\]**) are activated by the endogenous peptides [VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)), [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), peptide histidine isoleucineamide ([PHI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4397) {Mouse, Rat}), peptide histidine methionineamide ([PHM](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2274)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282))) and peptide histidine valine ([PHV](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3706)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282))). VPAC~1~ and VPAC~2~ receptors display comparable affinity for the PACAP peptides, [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) and [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), and [VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)), whereas [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) and [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) are \>100 fold more potent than [VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)) as agonists of most isoforms of the PAC~1~ receptor. However, one splice variant of the human PAC~1~ receptor has been reported to respond to [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) and [VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)) with comparable affinity \[[393](http://www.ncbi.nlm.nih.gov/pubmed/10583729?dopt=AbstractPlus)\]. [PG 99‐465](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2272)\[[1320](http://www.ncbi.nlm.nih.gov/pubmed/11068102?dopt=AbstractPlus)\] has been used as a selective VPAC~2~receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC~1~ and PAC~1~ receptors \[[422](http://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus)\]. The selective PAC~1~ receptor agonist [maxadilan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264), was extracted from the salivary glands of sand flies (*Lutzomyia longipalpis*) and has no sequence homology to [VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152)([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)) or the PACAP peptides \[[1330](http://www.ncbi.nlm.nih.gov/pubmed/8995389?dopt=AbstractPlus)\]. Two deletion variants of [maxadilan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264), [M65](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3305)\[[1918](http://www.ncbi.nlm.nih.gov/pubmed/9928019?dopt=AbstractPlus)\] and [Max.d.4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2265)\[[1331](http://www.ncbi.nlm.nih.gov/pubmed/10438479?dopt=AbstractPlus)\] have been reported to be PAC~1~ receptor antagonists, but these peptides have not been extensively characterised.

Nomenclature[PAC~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=370)[VPAC~1~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=371)[VPAC~2~ receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=372)HGNC, UniProt[*ADCYAP1R1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=242), [P41586](http://www.uniprot.org/uniprot/P41586)[*VIPR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12694), [P32241](http://www.uniprot.org/uniprot/P32241)[*VIPR2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12695), [P41587](http://www.uniprot.org/uniprot/P41587)Rank order of potency[PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) ≫[VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) ([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282))[VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) ([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)), [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) ≫[GHRH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270) ([*GHRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4265), [P01286](http://www.uniprot.org/uniprot/P01286)), [PHI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2273) {Pig}, [secretin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643) ([*SCT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10607), [P09683](http://www.uniprot.org/uniprot/P09683))[VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) ([*VIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12693), [P01282](http://www.uniprot.org/uniprot/P01282)), [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)), [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257) ([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) \>[PHI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2273) {Pig} ≫[GHRH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270) ([*GHRH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4265), [P01286](http://www.uniprot.org/uniprot/P01286)), [secretin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643) ([*SCT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10607), [P09683](http://www.uniprot.org/uniprot/P09683))Selective agonists[maxadilan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264) (pEC~50~ 10.3) \[[422](http://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus)\], [maxadilan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264) (pEC~50~ 6.2) \[[422](http://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus)\][\[Lys^15^,Arg^16^,Leu^27^\]VIP‐(1‐7)/GRF‐(8‐27)‐NH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3842) (pEC~50~ 8.3) \[[1315](http://www.ncbi.nlm.nih.gov/pubmed/11931347?dopt=AbstractPlus)\], [\[Ala^11,22,28^\]VIP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2278) (p*K* ~i~ 8.1) \[[1393](http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus)\][Ro 25‐1553](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2259) (pIC~50~ 7.8--9.5) \[[634](http://www.ncbi.nlm.nih.gov/pubmed/9145428?dopt=AbstractPlus), [887](http://www.ncbi.nlm.nih.gov/pubmed/10570056?dopt=AbstractPlus), [1315](http://www.ncbi.nlm.nih.gov/pubmed/11931347?dopt=AbstractPlus)\], [Ro 25‐1392](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2276) (p*K* ~i~ 8) \[[2056](http://www.ncbi.nlm.nih.gov/pubmed/9152366?dopt=AbstractPlus)\]Selective antagonists--[PG 97‐269](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2268) (pIC~50~ 8.7) \[[633](http://www.ncbi.nlm.nih.gov/pubmed/9437716?dopt=AbstractPlus), [887](http://www.ncbi.nlm.nih.gov/pubmed/10570056?dopt=AbstractPlus)\]--Labelled ligands[\[^125^I\]PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261) (Agonist) (p*K* ~d~ 9.1) \[[1509](http://www.ncbi.nlm.nih.gov/pubmed/11193823?dopt=AbstractPlus)\][\[^125^I\]VIP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2277) (Agonist) (p*K* ~d~ 9.4) \[[1393](http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus)\], [\[^125^I\]PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261) (Agonist)[\[^125^I\]VIP (human, mouse, rat)](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2277) (Agonist) (p*K* ~d~ 9.2) \[[1393](http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus)\], [\[^125^I\]PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261) (Agonist)

Comments {#bph13348-sec-0281}
--------

Subtypes of PAC~1~ receptors have been proposed based on tissue differences in the potencies of [PACAP‐27](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)) and [PACAP‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258)([*ADCYAP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=241), [P18509](http://www.uniprot.org/uniprot/P18509)); these might result from differences in G protein coupling and second messenger mechanisms \[[1939](http://www.ncbi.nlm.nih.gov/pubmed/8967982?dopt=AbstractPlus)\], or from alternative splicing of PAC~1~ receptor mRNA \[[1788](http://www.ncbi.nlm.nih.gov/pubmed/8396727?dopt=AbstractPlus)\].
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